
<html lang="en"     class="pb-page"  data-request-id="7593492b-8af8-464b-b776-e8ad5a1fe23a"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/acs.jmedchem.0c01100;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2020.63.issue-20;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Antibacterial Spiropyrimidinetriones with N-Linked Azole Substituents on a Benzisoxazole Scaffold Targeting DNA Gyrase" /></meta><meta name="dc.Creator" content="Gregory S.  Basarab" /></meta><meta name="dc.Creator" content="Peter  Doig" /></meta><meta name="dc.Creator" content="Charles J.  Eyermann" /></meta><meta name="dc.Creator" content="Vincent  Galullo" /></meta><meta name="dc.Creator" content="Gunther  Kern" /></meta><meta name="dc.Creator" content="Amy  Kimzey" /></meta><meta name="dc.Creator" content="Amy  Kutschke" /></meta><meta name="dc.Creator" content="Marshall  Morningstar" /></meta><meta name="dc.Creator" content="Virna  Schuck" /></meta><meta name="dc.Creator" content="Karthick  Vishwanathan" /></meta><meta name="dc.Creator" content="Fei  Zhou" /></meta><meta name="dc.Creator" content="Madhusudhan  Gowravaram" /></meta><meta name="dc.Creator" content="Sheila  Hauck" /></meta><meta name="dc.Description" content="Herein, we report spiropyrimidinetriones (SPTs) incorporating N-linked azole substituents on a benzisoxazole scaffold with improved Gram-positive antibacterial activity relative to previously descr..." /></meta><meta name="Description" content="Herein, we report spiropyrimidinetriones (SPTs) incorporating N-linked azole substituents on a benzisoxazole scaffold with improved Gram-positive antibacterial activity relative to previously descr..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="September 11, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01100" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01100" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01100" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01100" /></link>
        
    
    

<title>Antibacterial Spiropyrimidinetriones with N-Linked Azole Substituents on a Benzisoxazole Scaffold Targeting DNA Gyrase | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01100" /></meta><meta property="og:title" content="Antibacterial Spiropyrimidinetriones with N-Linked Azole Substituents on a Benzisoxazole Scaffold Targeting DNA Gyrase" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/large/jm0c01100_0017.jpeg" /></meta><meta property="og:description" content="Herein, we report spiropyrimidinetriones (SPTs) incorporating N-linked azole substituents on a benzisoxazole scaffold with improved Gram-positive antibacterial activity relative to previously described analogues. SPTs have an unusual spirocyclic architecture and represent a new antibacterial class of bacterial DNA gyrase and topoisomerase IV inhibitors. They are not cross-resistant to fluoroquinolones and other DNA gyrase/topoisomerase IV inhibitors used clinically. The activity of the SPTs was assessed for DNA gyrase inhibition, and the antibacterial activity across Gram-positive and Gram-negative pathogens with N-linked 1,2,4-triazoles substituted on the 5-position provides the most worthwhile profile. Directed nucleophilic and electrophilic chemistry was developed to vary this 5-position with carbon, nitrogen, or oxygen substituents and explore structure–activity relationships including those around a target binding model. Compounds with favorable pharmacokinetic parameters were identified, and two compounds demonstrated cidality in a mouse model of Staphylococcus aureus infection." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01100"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01100">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01100&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01100&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01100&amp;href=/doi/10.1021/acs.jmedchem.0c01100" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 20</span><span class="cit-fg-pageRange">, 11882-11901</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/20" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01076" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c01152" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Antibacterial Spiropyrimidinetriones with N-Linked Azole Substituents on a Benzisoxazole Scaffold Targeting DNA Gyrase</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Gregory S. Basarab</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gregory S. Basarab</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemistry, Infection Innovative Medicines, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#d4b3a6b1b3fab6b5a7b5a6b5b694a1b7a0fab5b7faaeb5"><span class="__cf_email__" data-cfemail="a5c2d7c0c28bc7c4d6c4d7c4c7e5d0c6d18bc4c68bdfc4">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gregory+S.++Basarab">Gregory S. Basarab</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5684-6046" title="Orcid link">http://orcid.org/0000-0001-5684-6046</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Peter Doig</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Peter Doig</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biosciences, Infection Innovative Medicines, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Peter++Doig">Peter Doig</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Charles J. Eyermann</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Charles J. Eyermann</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemistry, Infection Innovative Medicines, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Charles+J.++Eyermann">Charles J. Eyermann</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Vincent Galullo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Vincent Galullo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemistry, Infection Innovative Medicines, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Vincent++Galullo">Vincent Galullo</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gunther Kern</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gunther Kern</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biosciences, Infection Innovative Medicines, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gunther++Kern">Gunther Kern</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Amy Kimzey</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Amy Kimzey</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Discovery Safety, Infection Innovative Medicines, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Amy++Kimzey">Amy Kimzey</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Amy Kutschke</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Amy Kutschke</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemistry, Infection Innovative Medicines, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Amy++Kutschke">Amy Kutschke</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Marshall Morningstar</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Marshall Morningstar</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemistry, Infection Innovative Medicines, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Marshall++Morningstar">Marshall Morningstar</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Virna Schuck</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Virna Schuck</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Safety and Metabolism, Infection Innovative Medicines, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Virna++Schuck">Virna Schuck</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Karthick Vishwanathan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Karthick Vishwanathan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Safety and Metabolism, Infection Innovative Medicines, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Karthick++Vishwanathan">Karthick Vishwanathan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Fei Zhou</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Fei Zhou</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemistry, Infection Innovative Medicines, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Fei++Zhou">Fei Zhou</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Madhusudhan Gowravaram</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Madhusudhan Gowravaram</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemistry, Infection Innovative Medicines, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Madhusudhan++Gowravaram">Madhusudhan Gowravaram</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Sheila Hauck</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sheila Hauck</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemistry, Infection Innovative Medicines, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sheila++Hauck">Sheila Hauck</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01100&amp;href=/doi/10.1021%2Facs.jmedchem.0c01100" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 20</span><span class="cit-pageRange">, 11882–11901</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">September 11, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>2 July 2020</li><li><span class="item_label"><b>Published</b> online</span>11 September 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 22 October 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01100" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01100</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D11882%26pageCount%3D20%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DGregory%2BS.%2BBasarab%252C%2BPeter%2BDoig%252C%2BCharles%2BJ.%2BEyermann%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D20%26contentID%3Dacs.jmedchem.0c01100%26title%3DAntibacterial%2BSpiropyrimidinetriones%2Bwith%2BN-Linked%2BAzole%2BSubstituents%2Bon%2Ba%2BBenzisoxazole%2BScaffold%2BTargeting%2BDNA%2BGyrase%26numPages%3D20%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D11901%26publicationDate%3DOctober%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01100"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">676</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">1</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01100" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Antibacterial Spiropyrimidinetriones with N-Linked Azole Substituents on a Benzisoxazole Scaffold Targeting DNA Gyrase&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Gregory&quot;,&quot;last_name&quot;:&quot;S. Basarab&quot;},{&quot;first_name&quot;:&quot;Peter&quot;,&quot;last_name&quot;:&quot;Doig&quot;},{&quot;first_name&quot;:&quot;Charles&quot;,&quot;last_name&quot;:&quot;J. Eyermann&quot;},{&quot;first_name&quot;:&quot;Vincent&quot;,&quot;last_name&quot;:&quot;Galullo&quot;},{&quot;first_name&quot;:&quot;Gunther&quot;,&quot;last_name&quot;:&quot;Kern&quot;},{&quot;first_name&quot;:&quot;Amy&quot;,&quot;last_name&quot;:&quot;Kimzey&quot;},{&quot;first_name&quot;:&quot;Amy&quot;,&quot;last_name&quot;:&quot;Kutschke&quot;},{&quot;first_name&quot;:&quot;Marshall&quot;,&quot;last_name&quot;:&quot;Morningstar&quot;},{&quot;first_name&quot;:&quot;Virna&quot;,&quot;last_name&quot;:&quot;Schuck&quot;},{&quot;first_name&quot;:&quot;Karthick&quot;,&quot;last_name&quot;:&quot;Vishwanathan&quot;},{&quot;first_name&quot;:&quot;Fei&quot;,&quot;last_name&quot;:&quot;Zhou&quot;},{&quot;first_name&quot;:&quot;Madhusudhan&quot;,&quot;last_name&quot;:&quot;Gowravaram&quot;},{&quot;first_name&quot;:&quot;Sheila&quot;,&quot;last_name&quot;:&quot;Hauck&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;09&quot;,&quot;day&quot;:&quot;11&quot;,&quot;issue&quot;:&quot;20&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;11882-11901&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01100&quot;},&quot;abstract&quot;:&quot;Herein, we report spiropyrimidinetriones (SPTs) incorporating N-linked azole substituents on a benzisoxazole scaffold with improved Gram-positive antibacterial activity relative to previously described analogues. SPTs have an unusual spirocyclic architecture and represent a new antibacterial class of bacterial DNA gyrase and topoisomerase IV inhibitors. They are not cross-resistant to fluoroquinolones and other DNA gyrase/topoisomerase IV inhibitors used clinically. The activity of the SPTs was assessed for DNA gyrase inhibition, and the antibacterial activity across Gram-positive and Gram-negative pathogens with N-linked 1,2,4-triazoles substituted on the 5-position provides the most worthwhile profile. Directed nucleophilic and electrophilic chemistry was developed to vary this 5-position with carbon, nitrogen, or oxygen substituents and explore structure–activity relationships including those around a target binding model. Compounds with favorable pharmacokinetic parameters were identified, and two compoun&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01100&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01100" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01100&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01100" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01100&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01100" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01100&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01100&amp;href=/doi/10.1021/acs.jmedchem.0c01100" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01100" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01100" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01100%26sid%3Dliteratum%253Aachs%26pmid%3D32914979%26genre%3Darticle%26aulast%3DBasarab%26date%3D2020%26atitle%3DAntibacterial%2BSpiropyrimidinetriones%2Bwith%2BN-Linked%2BAzole%2BSubstituents%2Bon%2Ba%2BBenzisoxazole%2BScaffold%2BTargeting%2BDNA%2BGyrase%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D20%26spage%3D11882%26epage%3D11901%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (4)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291783" title="Triazole">Triazole</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a>,</li><li><a href="/action/doSearch?ConceptID=290676" title="Substituents">Substituents</a>,</li><li><a href="/action/doSearch?ConceptID=292444" title="Molecular structure">Molecular structure</a>,</li><li><a href="/action/doSearch?ConceptID=291676" title="Antibacterial activity">Antibacterial activity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/20" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/jmcmar.2020.63.issue-20/20201022/jmcmar.2020.63.issue-20.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/medium/jm0c01100_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/large/jm0c01100_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01100&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Herein, we report spiropyrimidinetriones (SPTs) incorporating N-linked azole substituents on a benzisoxazole scaffold with improved Gram-positive antibacterial activity relative to previously described analogues. SPTs have an unusual spirocyclic architecture and represent a new antibacterial class of bacterial DNA gyrase and topoisomerase IV inhibitors. They are not cross-resistant to fluoroquinolones and other DNA gyrase/topoisomerase IV inhibitors used clinically. The activity of the SPTs was assessed for DNA gyrase inhibition, and the antibacterial activity across Gram-positive and Gram-negative pathogens with N-linked 1,2,4-triazoles substituted on the 5-position provides the most worthwhile profile. Directed nucleophilic and electrophilic chemistry was developed to vary this 5-position with carbon, nitrogen, or oxygen substituents and explore structure–activity relationships including those around a target binding model. Compounds with favorable pharmacokinetic parameters were identified, and two compounds demonstrated cidality in a mouse model of <i>Staphylococcus aureus</i> infection.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17712" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17712" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Because of the rapid spread of resistance against established antibacterial agents, there is a need for new medicines for a variety of infectious disease indications that are not adequately responding to the current regimens.<a onclick="showRef(event, 'ref1 ref2 ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref4">(1−4)</a> As part of a call to action to keep this situation from further deteriorating, the World Health Organization (WHO) published in 2017 a list of the most problematic resistant-variant bacterial pathogens that ought to be prioritized for focused drug discovery and development research.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Among these pathogens are resistant varieties of <i>Staphylococcus aureus</i>, <i>Streptococcus pneumoniae,</i> and <i>Neisseria gonorrhoeae</i>, which are susceptible to a new class of antibacterial agents called spiropyrimidinetriones (SPTs). SPTs operate by inhibition of the bacterial type II topoisomerases, DNA gyrase, and topoisomerase IV (TopoIV) via a differentiated mechanism from the one established for fluoroquinolone (FQ) and aminocoumarin (AC) topoisomerase inhibitors and, therefore, are not cross-resistant.<a onclick="showRef(event, 'ref6 ref7 ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref8 ref9">(6−9)</a> The clinically most advanced member of the SPT class, zoliflodacin (<b>1</b>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), has recently demonstrated human proof of concept in a phase 2 clinical trial against gonorrhea and the causative agent <i>N. gonorrhoeae</i> and is now being evaluated in phase 3.<a onclick="showRef(event, 'ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref10 ref11">(10,11)</a> It was derived via medicinal chemistry optimization that followed QPT-1 (<b>2</b>), a compound identified by phenotypic screening against <i>S. aureus</i> and <i>Escherichia coli</i> and shown not to be cross-resistant with other antibacterials.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> This observation was important as since the 1980s, there have been only three new mode-of-action antibacterials that have entered the antibacterial marketplace, namely, daptomycin<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> and linezolid (<b>3</b>)<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> for Gram-positive infections and bedaquiline for tuberculosis.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Zoliflodacin <b>1</b> shows antibacterial activity across an array of fastidious Gram-negative pathogens including <i>N. gonorrhoeae</i>, <i>Haemophilus influenzae,</i> and <i>Moraxella catarrhalis</i> and Gram-positive pathogens including <i>Staphylococcus</i> spp. and <i>Streptococcus</i> spp. Numerous antibacterial surveillance studies have shown that <b>1</b> does not suffer from cross-resistance with FQs such as ciprofloxacin <b>4</b>.<a onclick="showRef(event, 'ref16 ref17 ref18 ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18 ref19 ref20">(16−20)</a> The spirocyclic chemotype of <b>1</b> and analogues fuse a dimethylmorpholine ring having a (2<i>R</i>,4a<i>S</i>,4a<i>S</i>)-configuration with benzisoxazole through a six-membered ring that displays a pyrimidinetrione spirocyclic. The 3-position of benzisoxazole can accommodate a large variety of substituents that maintain antibacterial activity including oxazolidinones (as with <b>1</b>), carboxamides, and aromatic heterocycles.<a onclick="showRef(event, 'ref6 ref7 ref21'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref21">(6,7,21)</a> Herein, we expand on a subset of aromatic heterocycles, namely, those with an N-linked azole substituent that imparts improved Gram-positive antibacterial activity relative to <b>1</b> and previously described analogues in the SPT class. Importantly, versatile chemistry was developed to introduce both electrophiles and nucleophiles onto the more optimal triazole 5-position as described herein. Here, we set out to understand the structure–activity relationships (SAR) and structure–property relationships associated with this subset of SPTs with favorable activity and pharmacological parameters to support efficacy in the in vivo setting.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/medium/jm0c01100_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/large/jm0c01100_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of zoliflodacin <b>1</b>, QPT-1 <b>2</b>, linezolid <b>3</b>, and ciprofloxacin <b>4</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/large/jm0c01100_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01100&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61115" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61115" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p"><a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> shows the synthesis route utilized for most of the N-linked azole SPT analogues, wherein nucleophilic displacement with azole anions (pyrazoles, imidazoles, and triazoles) on the previously described chiral chlorobenzisoxazoles <b>5a</b>, <b>5b</b>, and <b>5c</b><a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> leads to <b>6</b>. Generally, the chemistry proceeded in higher yields using the protected 1,3-dioxolanes <b>5b</b> and <b>5c</b> rather than the free aldehyde <b>5a</b>. Subsequently, the key tertiary amino effect reaction (T-reaction) was carried out to afford compounds <b>7–11</b>. In the course of the T-reaction, a minor (10%) diastereomeric byproduct <b>7′–11′</b> is seen as previously described<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> and is routinely removed during purification. In addition to the unsubstituted pyrazole <b>8a</b>, pyrazoles <b>8b</b> and <b>8c</b> are included in this study as they probe a space not thought to be accessible with 1,2,4-triazoles that ultimately generated the most interest (see below). The displacement with triazoles (either 1,2,3- or 1,2,4-triazole) to form <b>6</b> can lead to two isomeric products. In line with precedence for S<sub>N</sub>Ar reactions,<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> 1,2,3-triazole led to a 2:1 ratio of isomers that were separated and each converted to compounds <b>9</b> and <b>10</b>. Also in line with precedence,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> 1,2,4-triazole led predominately to a single isomer (>95%) that was converted to <b>11a</b> without any symmetrical 4<i>H</i>-1,2,4-triazole <b>12</b> (see below) being detected. The conversion of compounds <b>6</b> to final products via the T-reaction to assemble the spirocyclic architecture could lead theoretically to four possible diastereomers around the morpholine ring. Only the two pictured diastereomers are seen under the reaction conditions with the major (2<i>R</i>,4a<i>S</i>,4a<i>S</i>)-configuration predominating over the minor in a 9:1 ratio.<a onclick="showRef(event, 'ref21 ref24'); return false;" href="javascript:void(0);" class="ref ref21 ref24">(21,24)</a> It has been well demonstrated that the major diastereomer showed considerably more activity than the minor.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> As the minor diastereomer slowly isomerizes to the major diastereomer at room temperature (rt), it has therefore not been isolated and characterized herein for any of the analogues. The two diastereomers are favored thermodynamically, while the other two possible diastereomers are considerably higher in energy because of the unfavorable 1,3-diaxial interactions around the morpholine ring, accounting for their not being detected under the reaction conditions.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> The reaction cascade from <b>6</b> encompasses hydrolysis of those compounds containing the acetal to the corresponding aldehyde, followed by a Knövenagel condensation with barbituric acid, a [1,5]-hydride migration, and a Mannich ring closure, all occurring with a single mixing and heating of reagents. Notably, by using the chiral <i>R</i>,<i>R</i>-dimethylmorpholine isomer in the reaction sequence, the final products are chiral. In a couple of instances, the achiral meso <i>R</i>,<i>S</i>-dimethylmorpholine diastereomer was utilized via slightly modified conditions (see the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>) to afford the racemic final products of <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/medium/jm0c01100_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/large/jm0c01100_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Route for the Synthesis of SPTs with a Variety of Azole Substituents</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/large/jm0c01100_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01100&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Azole Heterocycle Influence on DNA Gyrase Inhibitory Potency, MIC, and PPB</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/medium/jm0c01100_0011.gif" alt="" id="GRAPHIC-d7e591-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/medium/jm0c01100_0012.gif" alt="" id="gr10" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">± denotes racemic compounds, otherwise chiral with absolute configurations as diagrammed.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Methicillin-sensitive <i>S. aureus</i>.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">Methicillin-resistant, quinolone-resistant <i>S. aureus</i>.</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last"><i>E. coli.</i></p></div></div><div></div></div><div class="NLM_p">An alternative sequence was followed to synthesize symmetrical triazole <b>12</b>, wherein <b>13</b><a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> was condensed with 1,2,4-triazole to afford <b>14a</b> and <b>14b</b>, with the latter minor product being continued through the reaction sequence (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). Toward this end, the ketal of <b>14a</b> was hydrolyzed, the dimethylmorpholine was introduced by S<sub>N</sub>Ar reaction, and the T-reaction was carried out with barbituric acid.</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/medium/jm0c01100_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/large/jm0c01100_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. : Synthesis of Symmetrical 1,2,4-Triazole Derivative <b>12</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/large/jm0c01100_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01100&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) DIPEA, POCl<sub>3</sub>, 1,2,4-triazole, and reflux; (b) HCl, H<sub>2</sub>O, CH<sub>3</sub>CN, and 85 °C; (c) K<sub>2</sub>CO<sub>3</sub>, (2<i>R</i>,6<i>R</i>)-2,6-dimethylmorpholine CH<sub>3</sub>CN, and reflux; and (d) barbituric acid; 90% aqueous EtOH, AcOH, 120 °C, and 2 h.</p></p></figure><div class="NLM_p">Because the asymmetrical 1<i>H</i>-1,2,4-triazole proved most interesting (see below), methods were developed for selectively incorporating substituents on either the triazole 3- or 5-position using either intermediate <b>5b</b> or <b>5d</b><a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). In line with steric considerations, the S<sub>N</sub>Ar reaction of the sodium salts of mono-substituted 1,2,4-triazoles with intermediates <b>5a</b> and <b>5b</b> afforded compounds <b>6</b> with the substituent residing at the distal R<sub>3</sub>-position and no evidence of the isomer having the substituent at the R<sub>5</sub>-position. To engineer substitution at the R<sub>5</sub>-triazole position, selective lithiation was carried out on the unsubstituted triazole <b>6</b> (R<sub>3</sub> = H) affording compounds <b>6a</b> on reaction with electrophiles. In three examples (leading to <b>11g</b>, <b>11h</b>, and <b>11i</b>), the R<sub>5</sub> substituent was transformed from one entity to another, designated in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a> as <b>6a</b> (R<sub>5</sub> substituent) being transformed to <b>6b</b> (R<sub class="stack">5</sub><sup class="stack">′</sup> substituent). Alternatively, chlorination of the lithium anion of <b>6</b> when R<sub>3</sub> = H formed <b>6c</b>, enabling a subsequent nucleophilic displacement of the chloride to afford compounds <b>6d</b>. For the syntheses of <b>11u</b> and <b>11w</b> (each a pair of diastereomers), the R<sub>5</sub> substituent was also transformed from one entity to another, designated in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a> as <b>6d</b> (R<sub>5</sub> substituent) being transformed to <b>6b</b> (R<sub class="stack">5</sub><sup class="stack">′</sup> substituent). Only a few examples exist in the literature for the chlorination of triazole 5-position anions<a onclick="showRef(event, 'ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref27 ref28">(27,28)</a> and for the nucleophilic displacement of similarly positioned 5-chlorotriazoles.<a onclick="showRef(event, 'ref29 ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref29 ref30 ref31">(29−31)</a> The intermediates <b>6a–d</b> were converted to <b>11a–w</b> by heating with barbituric acid under aqueous acid conditions, during which deprotection of the ketal occurred in situ, releasing the aldehyde for the T-reaction. Overall, the versatility of the sequences in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a> permitted the selective substitution at either 3- or 5-position of the triazole. The facile introduction of either electrophiles or nucleophiles on the biologically more active 5-position enabled the diverse incorporation of substituents important for establishing SAR.</div><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/medium/jm0c01100_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/large/jm0c01100_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds with N-Linked Triazole Benzisoxazole Substituents<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/large/jm0c01100_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01100&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaH, DMF, rt, and 16 h; (b) LDA or <i>n</i>-BuLi, THF, E<sup>+</sup>, and −70 °C; (c) LDA, THF, Cl<sub>3</sub>CCCl<sub>3</sub>, and −70 °C; (d) functional group transformations on R<sub>5</sub>; (e) Nuc-H, base, and rt; and (f) AcOH, H<sub>2</sub>O, 120 °C, and 1 h.</p></p></figure><div class="NLM_p">The focus of this study is on variations of the azole substituents on the benzisoxazole scaffold. Previous SPT analogue work has demonstrated that variations around the pyrimidinetrione spirocycle led to loss of activity. Though this was determined empirically through the extensive analogue work, a recent crystal structure of DNA gyrase from the <i>S. aureus</i> in complex with a 20-mer DNA duplex and QPT-1 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CDM">5CDM</a>)<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> well explains the tight SAR by delineating a snug fit for the enzyme around the pyrimidinetrione with an array of hydrogen bond donors and bridging water molecules (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A). Similarly, there is little room for maneuvering around the SPT morpholine ring. Most notably, the relative and absolute stereochemistry is required for activity, enabling the morpholine ring to maintain a relatively flat chair conformation that positions both methyl groups in equatorial orientations. Again, the X-ray structure explains the reason for this quite well as the binding region is sandwiched above and below the morpholine ring by two DNA bases limiting the fit of alternative conformations or stereochemistries. By contrast, the region where the nitro group of QPT-1 lies is more spacious and can accommodate a large variety of functionalities. Hence, there is a robust capability to retain biological activity by building in the benzisoxazole ring fusion and appending a variety of azole substituents.</div><figure id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/medium/jm0c01100_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/large/jm0c01100_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Views of QPT-1 from <i>S. aureus</i> crystal structure (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CDM">5CDM</a>) (A). Hydrogen bond array and bridging water molecules surrounding pyrimidinetrione. (B) Morpholine chair conformation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/large/jm0c01100_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01100&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p"><a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>–<named-content content-type="anchor" rid="tbl2" type="simple"></named-content><named-content content-type="anchor" rid="tbl3" type="simple"></named-content><a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a> show key physicochemical properties and biological activity comparisons determined for <i>N</i>-linked pyrazoles, imidazoles, and triazoles. Solubility measurements were designed to approximate the thermodynamic (vs kinetic) state and were measured in high-throughput mode after removal of dimethyl sulfoxide (DMSO) from stock solutions by vacuum centrifugation. As is well recognized, the drug development process is significantly facilitated by higher solubility, especially for antibacterial drugs where doses are generally high. Antibacterial activities against <i>S. aureus</i> and <i>E. coli</i> are reported as the minimum inhibitory concentration (MIC) or the minimum concentration to inhibit visible bacterial growth in microtiter plate format. Both a methicillin- and quinolone-susceptible <i>S. aureus</i> strain (MSSA MIC = 0.78 μM for ciprofloxacin) and a methicillin- and quinolone-resistant <i>S. aureus</i> strain (MRQR, MIC > 50 μM for ciprofloxacin) are included in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, demonstrating that SPTs are not cross-resistant with FQs despite both inhibiting the shared targets. The differentiation between SPTs and FQs relative to resistance involves a mode of inhibition, wherein it was demonstrated that SPTs, in contrast to FQs, do not use Mg<sup>2+</sup> for binding.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Primary mutations of DNA gyrase or TopoIV imparting resistance to FQs involve residues that bridge to the FQ keto-acid pharmacophore via a Mg<sup>2+</sup> hydrate as delineated in various crystal structure determinations.<a onclick="showRef(event, 'ref32 ref33 ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref32 ref33 ref34 ref35">(32−35)</a> Inhibitory potencies (IC<sub>50</sub>’s) were measured for DNA gyrase using the <i>E. coli</i> isozyme in a fluorescence-based anisotropic assay that detects inhibition of DNA supercoiling and serves to correlate with the cellular MIC. The enzyme assay was developed for the <i>E. coli</i> isozyme but not from the (herein more relevant) <i>S. aureus</i>, for which only low-throughput gel-based assays have been developed.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Hence, the assay serves only a rough surrogate for correlating with MIC values that were seen against <i>S. aureus</i>. Plotting the <i>E. coli</i> pIC<sub>50</sub> against the pMICs for <i>E. coli</i> and <i>S. aureus</i> (Figure S1, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01100/suppl_file/jm0c01100_si_001.pdf" class="ext-link">Supporting Informatio</a>n) both show poor correlations (<i>R</i><sup>2</sup> values <0.3), which can been attributed to variable compound lipophilicity that affects compound permeability through the bacterial cell envelop, as has been demonstrated for other SPT analogues.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> MIC values against <i>E. coli</i> were relatively high and represents the difficulty of permeation through the bacterial cell envelop. By contrast, MIC values against an efflux pump debilitated <i>E. coli</i> strain (<i>tolC</i><sup>–</sup>) were greater than 2 orders of magnitude lower (data not shown), in line with low permeability compromising the antibacterial activity. The IC<sub>50</sub>’s seen in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> were similar (within 3-fold) among the azole variations, while the MIC values varied considerably more. As mentioned, SPTs also inhibit TopoIV conceivably accounting for the disparate correlation; however, mutational analyses have pointed to DNA gyrase as the primary mode of action of the SPT class.<a onclick="showRef(event, 'ref6 ref7 ref37'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref37">(6,7,37)</a> The poor correlation between IC<sub>50</sub> and MIC is better attributed to differential membrane permeability and susceptibility to bacterial efflux.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> As would be anticipated, more polar compounds (lower log <i>D</i>) generally showed higher solubility and lower plasma protein binding (PPB, or higher fraction unbound, <i>f</i><sub>u</sub>, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>–<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a> and <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>), important parameters for optimizing in vivo compound parameters. However, higher polarity also correlated with lower antibacterial activity in line with lower permeability across the bacterial cell envelope. This was best exemplified by the symmetrical 1,2,4-triazole <b>12</b> that displayed weaker antibacterial activity attributable to its lower log <i>D</i> despite having a comparable IC<sub>50</sub> to the other compounds of <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>. Conversely, the more lipophilic pyrazole <b>8a</b> showed higher antibacterial activity, but its solubility was low (29 μM) and the <i>f</i><sub>u</sub> was lower than the limit of detection (<1% free). In line with the trend in <i>f</i><sub>u</sub>, more lipophilic compounds showed higher shifts in MIC values against MSSA on addition of 50% human serum serving to indicate the PPB influence on antibacterial activity. Hence, <b>12</b> and <b>8a</b>, with higher and lower <i>f</i><sub>u</sub> values, showed serum shifts of 2× and 8×, respectively. Compounds <b>8a</b> and <b>12</b> bracketed the extremes between low and high polarity (log <i>D</i>) within the set. Both led to a less-favorable (higher) MIC/<i>f</i><sub>u</sub> ratio, values shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> for the MRQR <i>S. aureus</i> strain. Compounds <b>8b</b> and <b>8c</b> substituted on the pyrazole 4-position with increasingly larger cyano and sulfonamide groups displayed sub-micromolar inhibitory potencies, indicating considerable leeway associated with the surrounding DNA gyrase binding domain. The imidazole <b>7</b>, 1,2,3-triazoles <b>9</b> and <b>10</b> and the asymmetrical 1,2,4-triazole <b>11a</b> also offered possibilities for more extended analogue optimization. Further work concentrated on expanding the range of substituents on <b>11a</b> that showed the lowest MIC/<i>f</i><sub>u</sub> ratio in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, higher solubility and favorable in vivo pharmacokinetics (PK) (see below). Moreover, the triazole moiety was amenable to robust synthetic variation of substituents as described above and led to robust SAR correlations as described next.</div><figure id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/medium/jm0c01100_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/large/jm0c01100_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Correlation between PPB and log <i>D</i>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/large/jm0c01100_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01100&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Influence of Triazole Substitution Pattern on DNA Gyrase Inhibitory Potency, Solubility, log <i>D</i>, PPB, and MIC<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a><sup>,</sup><a class="ref internalNav" href="#t2fn4" aria-label="d">d</a><sup>,</sup><a class="ref internalNav" href="#t2fn5" aria-label="e">e</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/medium/jm0c01100_0013.gif" alt="" id="GRAPHIC-d7e1147-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="7" align="center">MICs (μM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cmpd</th><th class="colsep0 rowsep0" align="center">X</th><th class="colsep0 rowsep0" align="center">R<sub>3</sub></th><th class="colsep0 rowsep0" align="center">R<sub>5</sub></th><th class="colsep0 rowsep0" align="center" char=".">Eco IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center" char=".">log <i>D</i></th><th class="colsep0 rowsep0" align="center" char=".">solubility (μM)</th><th class="colsep0 rowsep0" align="center">human PPB (% <i>f</i><sub>u</sub>)</th><th class="colsep0 rowsep0" align="center">MSSA<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">MSSA + serum</th><th class="colsep0 rowsep0" align="center">MRQR Sau<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">Spn</th><th class="colsep0 rowsep0" align="center" char=".">Spy<a class="ref internalNav" href="#t2fn6" aria-label="f">f</a></th><th class="colsep0 rowsep0" align="center" char=".">Hin</th><th class="colsep0 rowsep0" align="center" char=".">Eco</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11a</b></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">0.22</td><td class="colsep0 rowsep0" align="char" char=".">1.7</td><td class="colsep0 rowsep0" align="char" char=".">250</td><td class="colsep0 rowsep0" align="left">13.9</td><td class="colsep0 rowsep0" align="left">0.049</td><td class="colsep0 rowsep0" align="left"><0.2</td><td class="colsep0 rowsep0" align="left">0.20</td><td class="colsep0 rowsep0" align="char" char=".">0.39</td><td class="colsep0 rowsep0" align="char" char=".">0.39</td><td class="colsep0 rowsep0" align="char" char=".">0.39</td><td class="colsep0 rowsep0" align="char" char=".">14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11b</b></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">0.12</td><td class="colsep0 rowsep0" align="char" char=".">2.0</td><td class="colsep0 rowsep0" align="char" char=".">420</td><td class="colsep0 rowsep0" align="left">7.4</td><td class="colsep0 rowsep0" align="left"><0.2</td><td class="colsep0 rowsep0" align="left">0.39</td><td class="colsep0 rowsep0" align="left">0.39</td><td class="colsep0 rowsep0" align="char" char=".">0.39</td><td class="colsep0 rowsep0" align="char" char=".">0.39</td><td class="colsep0 rowsep0" align="char" char=".">0.78</td><td class="colsep0 rowsep0" align="char" char=".">12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11c</b></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">1.0</td><td class="colsep0 rowsep0" align="char" char=".">1.9</td><td class="colsep0 rowsep0" align="char" char=".">29</td><td class="colsep0 rowsep0" align="left">5.3</td><td class="colsep0 rowsep0" align="left">0.20</td><td class="colsep0 rowsep0" align="left">0.78</td><td class="colsep0 rowsep0" align="left">0.78</td><td class="colsep0 rowsep0" align="char" char=".">3.1</td><td class="colsep0 rowsep0" align="char" char=".">0.78</td><td class="colsep0 rowsep0" align="char" char=".">1.6</td><td class="colsep0 rowsep0" align="char" char=".">100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11d</b></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">CN</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">1.3</td><td class="colsep0 rowsep0" align="char" char=".">2.0</td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">0.20</td><td class="colsep0 rowsep0" align="left">3.1</td><td class="colsep0 rowsep0" align="left">0.39</td><td class="colsep0 rowsep0" align="char" char=".">1.6</td><td class="colsep0 rowsep0" align="char" char=".">0.8</td><td class="colsep0 rowsep0" align="char" char=".">3.1</td><td class="colsep0 rowsep0" align="char" char=".">100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11e</b></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">0.34</td><td class="colsep0 rowsep0" align="char" char=".">2.1</td><td class="colsep0 rowsep0" align="char" char=".">22</td><td class="colsep0 rowsep0" align="left">9.8</td><td class="colsep0 rowsep0" align="left">0.20</td><td class="colsep0 rowsep0" align="left">0.39</td><td class="colsep0 rowsep0" align="left">0.39</td><td class="colsep0 rowsep0" align="char" char=".">0.78</td><td class="colsep0 rowsep0" align="char" char=".">0.55</td><td class="colsep0 rowsep0" align="char" char=".">1.6</td><td class="colsep0 rowsep0" align="char" char=".">50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11f</b></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CN</td><td class="colsep0 rowsep0" align="char" char=".">0.32</td><td class="colsep0 rowsep0" align="char" char=".">2.0</td><td class="colsep0 rowsep0" align="char" char=".">560</td><td class="colsep0 rowsep0" align="left">7.6</td><td class="colsep0 rowsep0" align="left"><0.2</td><td class="colsep0 rowsep0" align="left">0.39</td><td class="colsep0 rowsep0" align="left"><0.2</td><td class="colsep0 rowsep0" align="char" char=".">0.39</td><td class="colsep0 rowsep0" align="char" char=".">0.39</td><td class="colsep0 rowsep0" align="char" char=".">0.39</td><td class="colsep0 rowsep0" align="char" char=".">6.2</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Methicillin-sensitive <i>S. aureus</i>.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Methicillin-resistant, quinolone-resistant <i>S. aureus</i>.</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last"><i>S. pneumoniae</i>.</p></div><div class="footnote" id="t2fn4"><sup><sup>d</sup></sup><p class="last"><i>Streptococcus pyogenes</i>.</p></div><div class="footnote" id="t2fn5"><sup><sup>e</sup></sup><p class="last"><i>H. influenzae</i>.</p></div><div class="footnote" id="t2fn6"><sup><sup>f</sup></sup><p class="last"><i>E. coli.</i></p></div></div></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Influence of R<sub>5</sub>-Triazole Substituents on DNA Gyrase Inhibitory Potency, Solubility, log <i>D</i>, PPB, and MIC<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a><sup>,</sup><a class="ref internalNav" href="#t3fn2" aria-label="b">b</a><sup>,</sup><a class="ref internalNav" href="#t3fn5" aria-label="e">e</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/medium/jm0c01100_0014.gif" alt="" id="GRAPHIC-d7e1497-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="rowsep1 colsep0" colspan="7" align="center">MICs (μM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cmpd</th><th class="colsep0 rowsep0" align="center">R<sub>5</sub></th><th class="colsep0 rowsep0" align="center" char=".">Eco IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center" char=".">log <i>D</i></th><th class="colsep0 rowsep0" align="center">solubility (μM)</th><th class="colsep0 rowsep0" align="center" char=".">human PPB (% <i>f</i><sub>u</sub>)</th><th class="colsep0 rowsep0" align="center">MSSA<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">MSSA + serum</th><th class="colsep0 rowsep0" align="center">MRQR Sau<a class="ref internalNav" href="#t3fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center">Spn</th><th class="colsep0 rowsep0" align="center">Spy<a class="ref internalNav" href="#t3fn6" aria-label="f">f</a></th><th class="colsep0 rowsep0" align="center" char=".">Hin</th><th class="colsep0 rowsep0" align="center" char=".">Eco</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11g</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="char" char=".">0.19</td><td class="colsep0 rowsep0" align="char" char=".">1.4</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="char" char=".">17</td><td class="colsep0 rowsep0" align="left">0.31</td><td class="colsep0 rowsep0" align="left">0.49</td><td class="colsep0 rowsep0" align="left">1.6</td><td class="colsep0 rowsep0" align="left">0.39</td><td class="colsep0 rowsep0" align="left">0.78</td><td class="colsep0 rowsep0" align="char" char=".">0.78</td><td class="colsep0 rowsep0" align="char" char=".">50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11h</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">1.1</td><td class="colsep0 rowsep0" align="char" char=".">1.7</td><td class="colsep0 rowsep0" align="left">890</td><td class="colsep0 rowsep0" align="char" char=".">14</td><td class="colsep0 rowsep0" align="left"><0.2</td><td class="colsep0 rowsep0" align="left">0.39</td><td class="colsep0 rowsep0" align="left">0.39</td><td class="colsep0 rowsep0" align="left">0.78</td><td class="colsep0 rowsep0" align="left">0.78</td><td class="colsep0 rowsep0" align="char" char=".">0.78</td><td class="colsep0 rowsep0" align="char" char=".">70</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11i</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>N(CH<sub>3</sub>)<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">0.59</td><td class="colsep0 rowsep0" align="char" char=".">0.93</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="char" char=".">18</td><td class="colsep0 rowsep0" align="left"><0.2</td><td class="colsep0 rowsep0" align="left">0.39</td><td class="colsep0 rowsep0" align="left">0.78</td><td class="colsep0 rowsep0" align="left">1.6</td><td class="colsep0 rowsep0" align="left">1.6</td><td class="colsep0 rowsep0" align="char" char=".">1.6</td><td class="colsep0 rowsep0" align="char" char=".">50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11j</b></td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">0.32</td><td class="colsep0 rowsep0" align="char" char=".">1.7</td><td class="colsep0 rowsep0" align="left">900</td><td class="colsep0 rowsep0" align="char" char=".">14</td><td class="colsep0 rowsep0" align="left">0.098</td><td class="colsep0 rowsep0" align="left">0.39</td><td class="colsep0 rowsep0" align="left">0.39</td><td class="colsep0 rowsep0" align="left">0.39</td><td class="colsep0 rowsep0" align="left">0.39</td><td class="colsep0 rowsep0" align="char" char=".">0.78</td><td class="colsep0 rowsep0" align="char" char=".">30</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11k</b></td><td class="colsep0 rowsep0" align="left">OCH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">0.32</td><td class="colsep0 rowsep0" align="char" char=".">1.7</td><td class="colsep0 rowsep0" align="left">640</td><td class="colsep0 rowsep0" align="char" char=".">12</td><td class="colsep0 rowsep0" align="left">0.39</td><td class="colsep0 rowsep0" align="left">1.6</td><td class="colsep0 rowsep0" align="left">1.6</td><td class="colsep0 rowsep0" align="left"><0.2</td><td class="colsep0 rowsep0" align="left"><0.2</td><td class="colsep0 rowsep0" align="char" char=".">0.39</td><td class="colsep0 rowsep0" align="char" char=".">100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11l</b></td><td class="colsep0 rowsep0" align="left">N(CH<sub>3</sub>)<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">0.67</td><td class="colsep0 rowsep0" align="char" char=".">1.7</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="char" char=".">13</td><td class="colsep0 rowsep0" align="left">0.39</td><td class="colsep0 rowsep0" align="left">1.6</td><td class="colsep0 rowsep0" align="left">0.78</td><td class="colsep0 rowsep0" align="left">1.6</td><td class="colsep0 rowsep0" align="left">0.78</td><td class="colsep0 rowsep0" align="char" char=".">1.6</td><td class="colsep0 rowsep0" align="char" char=".">100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11m</b></td><td class="colsep0 rowsep0" align="left">-morpholine</td><td class="colsep0 rowsep0" align="char" char=".">0.66</td><td class="colsep0 rowsep0" align="char" char=".">1.6</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="char" char=".">17</td><td class="colsep0 rowsep0" align="left">0.39</td><td class="colsep0 rowsep0" align="left">0.78</td><td class="colsep0 rowsep0" align="left">0.98</td><td class="colsep0 rowsep0" align="left">1.6</td><td class="colsep0 rowsep0" align="left">0.78</td><td class="colsep0 rowsep0" align="char" char=".">1.6</td><td class="colsep0 rowsep0" align="char" char=".">200</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11n</b></td><td class="colsep0 rowsep0" align="left">NH<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">0.075</td><td class="colsep0 rowsep0" align="char" char=".">1.9</td><td class="colsep0 rowsep0" align="left">460</td><td class="colsep0 rowsep0" align="char" char=".">11</td><td class="colsep0 rowsep0" align="left">0.049</td><td class="colsep0 rowsep0" align="left"><0.2</td><td class="colsep0 rowsep0" align="left"><0.2</td><td class="colsep0 rowsep0" align="left">0.098</td><td class="colsep0 rowsep0" align="left">0.098</td><td class="colsep0 rowsep0" align="char" char=".">0.39</td><td class="colsep0 rowsep0" align="char" char=".">12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11o</b></td><td class="colsep0 rowsep0" align="left">NHCH<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">0.071</td><td class="colsep0 rowsep0" align="char" char=".">2.1</td><td class="colsep0 rowsep0" align="left">280</td><td class="colsep0 rowsep0" align="char" char=".">8.0</td><td class="colsep0 rowsep0" align="left">0.049</td><td class="colsep0 rowsep0" align="left"><0.2</td><td class="colsep0 rowsep0" align="left">0.20</td><td class="colsep0 rowsep0" align="left">0.19</td><td class="colsep0 rowsep0" align="left">0.19</td><td class="colsep0 rowsep0" align="char" char=".">0.39</td><td class="colsep0 rowsep0" align="char" char=".">16</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11p</b></td><td class="colsep0 rowsep0" align="left">NHCH<sub>2</sub>CH<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">0.097</td><td class="colsep0 rowsep0" align="char" char=".">2.2</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="char" char=".">3.7</td><td class="colsep0 rowsep0" align="left">0.049</td><td class="colsep0 rowsep0" align="left"><0.2</td><td class="colsep0 rowsep0" align="left">0.098</td><td class="colsep0 rowsep0" align="left"><0.2</td><td class="colsep0 rowsep0" align="left"><0.2</td><td class="colsep0 rowsep0" align="char" char=".">0.39</td><td class="colsep0 rowsep0" align="char" char=".">12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11q</b></td><td class="colsep0 rowsep0" align="left">NHCH<sub>2</sub>CH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="char" char=".">0.27</td><td class="colsep0 rowsep0" align="char" char=".">1.6</td><td class="colsep0 rowsep0" align="left">625</td><td class="colsep0 rowsep0" align="char" char=".">14</td><td class="colsep0 rowsep0" align="left">0.39</td><td class="colsep0 rowsep0" align="left"><0.2</td><td class="colsep0 rowsep0" align="left">0.78</td><td class="colsep0 rowsep0" align="left">0.39</td><td class="colsep0 rowsep0" align="left">0.39</td><td class="colsep0 rowsep0" align="char" char=".">0.39</td><td class="colsep0 rowsep0" align="char" char=".">25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11r</b></td><td class="colsep0 rowsep0" align="left">NHCH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">0.038</td><td class="colsep0 rowsep0" align="char" char=".">2.2</td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="char" char=".">7.7</td><td class="colsep0 rowsep0" align="left">0.039</td><td class="colsep0 rowsep0" align="left"><0.2</td><td class="colsep0 rowsep0" align="left">0.098</td><td class="colsep0 rowsep0" align="left"><0.2</td><td class="colsep0 rowsep0" align="left"><0.2</td><td class="colsep0 rowsep0" align="char" char=".">0.39</td><td class="colsep0 rowsep0" align="char" char=".">25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11s</b></td><td class="colsep0 rowsep0" align="left">NHCH<sub>2</sub>CH<sub>2</sub>N(CH<sub>3</sub>)<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">0.15</td><td class="colsep0 rowsep0" align="char" char=".">1.4</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="char" char=".">53</td><td class="colsep0 rowsep0" align="left">0.78</td><td class="colsep0 rowsep0" align="left">0.78</td><td class="colsep0 rowsep0" align="left">6.2</td><td class="colsep0 rowsep0" align="left">0.39</td><td class="colsep0 rowsep0" align="left">0.39</td><td class="colsep0 rowsep0" align="char" char=".">1.6</td><td class="colsep0 rowsep0" align="char" char=".">50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11t</b></td><td class="colsep0 rowsep0" align="left">NHCH<sub>2</sub>CH<sub>2</sub>-morpholine</td><td class="colsep0 rowsep0" align="char" char=".">0.31</td><td class="colsep0 rowsep0" align="char" char=".">2.1</td><td class="colsep0 rowsep0" align="left">150</td><td class="colsep0 rowsep0" align="char" char=".">11</td><td class="colsep0 rowsep0" align="left"><0.2</td><td class="colsep0 rowsep0" align="left">0.78</td><td class="colsep0 rowsep0" align="left">3.5</td><td class="colsep0 rowsep0" align="left">0.39</td><td class="colsep0 rowsep0" align="left">0.39</td><td class="colsep0 rowsep0" align="char" char=".">1.6</td><td class="colsep0 rowsep0" align="char" char=".">100</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Methicillin-sensitive <i>S. aureus</i>.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">Methicillin-resistant, quinolone-resistant <i>S. aureus</i>.</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last"><i>S. pneumoniae</i>.</p></div><div class="footnote" id="t3fn4"><sup><sup>d</sup></sup><p class="last"><i>S. pyogenes</i>.</p></div><div class="footnote" id="t3fn5"><sup><sup>e</sup></sup><p class="last"><i>H. influenzae</i>.</p></div><div class="footnote" id="t3fn6"><sup><sup>f</sup></sup><p class="last"><i>E. coli</i>.</p></div></div></div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Influence of R<sub>5</sub> Chirality on DNA Gyrase Inhibitory Potency, Solubility, LogD, PPB, and MIC<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a><sup>,</sup><a class="ref internalNav" href="#t4fn2" aria-label="b">b</a><sup>,</sup><a class="ref internalNav" href="#t4fn5" aria-label="e">e</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/medium/jm0c01100_0015.gif" alt="" id="GRAPHIC-d7e2112-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/medium/jm0c01100_0016.gif" alt="" id="gr11" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Methicillin-sensitive <i>S. aureus</i>.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">Methicillin-resistant, quinolone-resistant <i>S. aureus</i>.</p></div><div class="footnote" id="t4fn3"><sup><sup>c</sup></sup><p class="last"><i>S. pneumoniae</i>.</p></div><div class="footnote" id="t4fn4"><sup><sup>d</sup></sup><p class="last"><i>S. pyogenes</i>.</p></div><div class="footnote" id="t4fn5"><sup><sup>e</sup></sup><p class="last"><i>H. influenzae</i>.</p></div><div class="footnote" id="t4fn6"><sup><sup>f</sup></sup><p class="last"><i>E. coli.</i></p></div></div><div></div></div><div class="NLM_p">Matched pairs of analogues with either an electron-withdrawing cyano or an electron-donating CH<sub>3</sub> group on the triazole ring showed that the 5-position was favored over the 3-position for inhibitory potency and antibacterial activity. Compare <b>11c</b> with <b>11e</b> and <b>11d</b> with <b>11f</b> (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). For the more active CN isomer <b>11f</b>, the activity was approximately equal to the unsubstituted <b>11a</b>, and the solubility was higher. However, <b>11f</b> suffered from very high in vivo plasma clearance (Cl<sub>p</sub>) out of line with compounds otherwise (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Finally, <b>11a</b> with the Cl atom on benzisoxazole retained the antibacterial activity relative to <b>11b</b> with an F atom while modestly raising the log <i>D</i> and lowering <i>f</i><sub>u</sub>, observations in line with those for other analogues.<a onclick="showRef(event, 'ref6 ref21'); return false;" href="javascript:void(0);" class="ref ref6 ref21">(6,21)</a></div><div class="NLM_p">Subsequent analogue analyses hereafter will focus on varying substituents at the more favorable 5-triazole position. Analogues with a primary or unsubstituted amine substituent (<b>11n–11w</b>, <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Tables <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>) generally displaced higher inhibitory potencies relative to <b>11a</b>, which correlates with the capacity for intramolecular hydrogen bonding that brings the triazole and benzisoxazole rings into coplanarity (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). Clear evidence for the intramolecular H-bond was provided by NMR <i>A</i>-values, calculated via the equation <i>A</i> = 0.0065 + 0.133[δ(DMSO) – δ(CDCl<sub>3</sub>)] and representing the solvent effect on chemical shifts for an NH resonance.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> In this empirically derived correlation, <i>A</i>-values ≤0.05 indicate intramolecular H-bonding. As an example, <b>11o</b> with a methylamine substituent showed an <i>A</i>-value of −0.0055 indicative of the intramolecular H-bond. Conversely, as an internal negative control, the two pyrimidinetrione NH resonances for <b>11o</b> showed <i>A</i>-values of 0.52 and 0.53, well above the <i>A</i>-value >0.16 associated with no internal H-bonding. Though the coplanarity between the triazole and benzisoxazole rings appears favorable for binding, the DNA gyrase inhibitory potency and antibacterial activities are retained (albeit 8- to 10-fold higher) for <b>11l</b> and <b>11m</b> with secondary amines that preclude such coplanarity. The secondary amine substituents also lowered the log <i>D</i>, increased the solubility, and raised the <i>f</i><sub>u</sub>. Compare <b>11l</b> with <b>11o</b>. Because the intramolecular H-bond increased the lipophilicity and lowered the solubility, more polar primary amines (as with <b>11q–11w</b>) were incorporated at R<sub>5</sub>, leading to a lower IC<sub>50</sub>, lower log <i>D</i>, and higher solubility. The extensive leeway relative to inhibitor potency for incorporating larger amine substituents at the 5-position suggests an open region of the binding site. However, the more polar functionality, including those such as <b>11s</b>, <b>11t</b>, and <b>11w</b> (both diastereomers) that might be charged at physiological pH, led to lower antibacterial activity, presumably because of diminished bacterial membrane permeability in line with the observations mentioned previously. Alkyl ethers for R<sub>5</sub> (as in <b>11j</b> and <b>11k</b>) were also well tolerated for activity as were carbon substituents (compounds <b>11g–11i</b>). Overall, there was considerable leeway for DNA gyrase inhibitory potency with the various 5-position substituents as electron-withdrawing and -donating groups, larger and smaller groups, and lipophilic and polar groups were well tolerated. Pairs of <i>R</i>- and <i>S</i>-substituents for R<sub>5</sub> (pairs of compounds <b>11u</b>, <b>11v</b>, and <b>11w</b>, <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>) made to probe the specificity of the seemingly open region of the binding site showed a modest (less than 2.5-fold) differentiation in IC<sub>50</sub>.</div><figure id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/medium/jm0c01100_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/large/jm0c01100_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Intramolecular hydrogen bond from the triazole amine substituent to the benzisoxazole nitrogen.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/large/jm0c01100_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01100&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To corroborate the SAR findings relative to inhibitor potencies, a binding model was built using <b>11r</b> and <b>11l</b> from the X-ray structure determined for DNA gyrase from <i>S. aureus</i>.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Though DNA gyrase inhibitor potencies were measured against the <i>E. coli</i> rather than the <i>S. aureus</i> isozyme used for X-ray crystallography, the residues surrounding the triazole binding region are similar in hydrogen bonding capability based on sequence alignment. A side chain of the key (non-nucleic acid) arginine/lysine residue is positioned alongside the SPT azole-benzisoxazole bond and is embedded within a conserved GyrB PL (R478/K447 <i>S. aureus</i>/<i>E. coli</i>) GK motif that has a catalytic function for topoisomerases.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> There is also a GyrB pentapeptide sequence <i>S. aureus</i> 476–480/<i>E. coli</i> 465–469, positioning the side chains of three residues (N476/Q465, E477/E466, and N480/T469) toward the distal SPT triazole. The residues of these two regions are embedded in an extended highly homologous stretch of GyrB across isozymes without additions or deletions (S2 and S3, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01100/suppl_file/jm0c01100_si_001.pdf" class="ext-link">Supporting Informatio</a>n). The binding region otherwise well accounts for the broad tolerability of the 5-position triazole substituents. The 4-position triazole nitrogen of <b>11r</b> was aligned as an H-bond acceptor from the side chain carboxamide of GyrB Asn476, and the pendant amine substituent extended into a trough lined by GyrB Asn476 on one side and a DNA deoxyribose unit on the other and was otherwise exposed to solvent (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A). Additionally, the binding model accounts for the operability of the cyano and sulfonamide substituent of pyrazoles <b>8a</b> and <b>8b</b>, which are proposed to partially overlap the region occupied by the extended side chain of <b>11r</b>. Substituents on the triazole 3-position (as for <b>11c</b> and <b>11d</b>) appear to bump unfavorably against Glu477 of the enzyme; however, the substituents can be accommodated via a 180° degree torsional rotation of the triazole relative to benzisoxazole. Compound <b>11l</b> and similar substituents at the triazole 5-position that preclude coplanarity were accommodated by skewing the triazole relative to the benzisoxazole, placing the substituents accessible to the solvent channel (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B). This orientation maintained an opportunity for an H-bond between Ans476 and the triazole 4-position nitrogen. Overall, the binding region for the triazole, and by extension other benzisoxazole substituents, extends partly into the solvent and likely has a measure of flexibility accounting for the broad SAR scope. This region also encompasses the piperazine of ciprofloxacin as seen in its cocrystal structure with the <i>S. aureus</i> DNA gyrase.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> The variety of substituents that have been incorporated in place of piperazine for FQ drugs can be inferred to support the broad tolerability for the binding region.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a></div><figure id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/medium/jm0c01100_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/large/jm0c01100_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Models derived from the DNA gyrase crystal structure of <i>S. aureus</i> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CDM">5CDM</a>) showing the triazoles of <b>11r</b> (<b>A</b>) and <b>11l</b> (<b>B</b>) attached to the SPT scaffold that is intercalated between stacking DNA bases.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/large/jm0c01100_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01100&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compounds with a higher in vitro antibacterial activity profile had their PK profiles determined in rats following intravenous (iv) administration. As <i>f</i><sub>u</sub> is associated with drug levels available for clearance mechanisms in vivo,<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> the Cl<sub>p</sub> was adjusted for <i>f</i><sub>u</sub> to estimate an unbound clearance (Cl<sub>u</sub>, <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>).<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Human and rat <i>f</i><sub>u</sub> values have shown only modest variations for SPTs in general<a onclick="showRef(event, 'ref6 ref7 ref21'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref21">(6,7,21)</a> and for the examples of <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>, and hence, the more accessible human <i>f</i><sub>u</sub> values were used for the calculation of Cl<sub>u</sub>. Historical rat and mouse clearances for zoliflodacin <b>1</b> are included in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Tables <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a> for comparison. Except for <b>11d</b>, the Cl<sub>u</sub> values held to a favorable range of 70–220 μL/min/kg, in line with that seen for zoliflodacin <b>1</b>. The high clearance seen for <b>11d</b> well exceeded the hepatic blood flow (80 mL/min/kg) in rats<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> and indicates that an extra-hepatic clearance mechanism must be occurring relative to the other compounds of <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Rat Plasma (Cl<sub>p</sub>) and Unbound (Cl<sub>u</sub>) Clearances (μL/min/kg)</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"><b>11a</b></th><th class="colsep0 rowsep0" align="center"><b>11b</b></th><th class="colsep0 rowsep0" align="center"><b>11d</b></th><th class="colsep0 rowsep0" align="center"><b>11g</b></th><th class="colsep0 rowsep0" align="center"><b>11h</b></th><th class="colsep0 rowsep0" align="center"><b>11i</b></th><th class="colsep0 rowsep0" align="center"><b>11j</b></th><th class="colsep0 rowsep0" align="center"><b>11o</b></th><th class="colsep0 rowsep0" align="center"><b>11p</b></th><th class="colsep0 rowsep0" align="center"><b>1</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">R<sub>5</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CN</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">CH(OH)CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">NH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">NHCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">X</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">F</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Cl<sub>p</sub></td><td class="colsep0 rowsep0" align="left">9.1</td><td class="colsep0 rowsep0" align="left">11.6</td><td class="colsep0 rowsep0" align="left">200</td><td class="colsep0 rowsep0" align="left">37</td><td class="colsep0 rowsep0" align="left">17</td><td class="colsep0 rowsep0" align="left">23</td><td class="colsep0 rowsep0" align="left">13</td><td class="colsep0 rowsep0" align="left">32</td><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0" align="left">22</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Cl<sub>u</sub></td><td class="colsep0 rowsep0" align="left">70</td><td class="colsep0 rowsep0" align="left">156</td><td class="colsep0 rowsep0" align="left">2600</td><td class="colsep0 rowsep0" align="left">220</td><td class="colsep0 rowsep0" align="left">120</td><td class="colsep0 rowsep0" align="left">110</td><td class="colsep0 rowsep0" align="left">93</td><td class="colsep0 rowsep0" align="left">190</td><td class="colsep0 rowsep0" align="left">130</td><td class="colsep0 rowsep0" align="left">130</td></tr></tbody></table></div></div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. PK Properties in Mouse and Rat</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col /></col><col /></col><col /></col><col /></col><col /></col><col /></col><col /></col><col /></col><col /></col><col /></col><col /></col><col /></col><col /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">PPB (<i>f</i><sub>u</sub>)<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" colspan="2" align="center">in vivo Cl<sub>p</sub><a class="ref internalNav" href="#t6fn2" aria-label="b">b</a> (iv)</th><th class="rowsep1 colsep0" colspan="2" align="center">in vivo Cl<sub>u</sub><a class="ref internalNav" href="#t6fn3" aria-label="c">c</a> (iv)</th><th class="rowsep1 colsep0" colspan="2" align="center">in vivo <i>V</i><sub>ss</sub><a class="ref internalNav" href="#t6fn4" aria-label="d">d</a> (iv)</th><th class="rowsep1 colsep0" colspan="2" align="center">in vivo <i>t</i><sub>1/2</sub><a class="ref internalNav" href="#t6fn5" aria-label="e">e</a> (iv)</th><th class="rowsep1 colsep0" colspan="2" align="center">in vivo <i>F</i><a class="ref internalNav" href="#t6fn6" aria-label="f">f</a> (PO)</th></tr><tr valign="top" class="colsep0"><th class="rowsep1 colsep0" align="center">cmpd</th><th class="rowsep1 colsep0" align="center">mouse</th><th class="rowsep1 colsep0" align="center">rat</th><th class="rowsep1 colsep0" align="center">mouse</th><th class="rowsep1 colsep0" align="center">rat</th><th class="rowsep1 colsep0" align="center">mouse</th><th class="rowsep1 colsep0" align="center">rat</th><th class="rowsep1 colsep0" align="center">mouse</th><th class="rowsep1 colsep0" align="center">rat</th><th class="rowsep1 colsep0" align="center">mouse</th><th class="rowsep1 colsep0" align="center">rat</th><th class="rowsep1 colsep0" align="center">mouse</th><th class="rowsep1 colsep0" align="center">rat</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>11a</b></td><td class="colsep0 rowsep0">12</td><td class="colsep0 rowsep0">10</td><td class="colsep0 rowsep0">21</td><td class="colsep0 rowsep0">9.1</td><td class="colsep0 rowsep0">175</td><td class="colsep0 rowsep0">91</td><td class="colsep0 rowsep0"> </td><td class="colsep0 rowsep0">1.9</td><td class="colsep0 rowsep0"> </td><td class="colsep0 rowsep0">2.41</td><td class="colsep0 rowsep0">37</td><td class="colsep0 rowsep0">62</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>11j</b></td><td class="colsep0 rowsep0">20</td><td class="colsep0 rowsep0">13</td><td class="colsep0 rowsep0">11</td><td class="colsep0 rowsep0">13</td><td class="colsep0 rowsep0">55</td><td class="colsep0 rowsep0">100</td><td class="colsep0 rowsep0">2.4</td><td class="colsep0 rowsep0">1.9</td><td class="colsep0 rowsep0">2.52</td><td class="colsep0 rowsep0">1.69</td><td class="colsep0 rowsep0">62</td><td class="colsep0 rowsep0">48</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>1</b></td><td class="colsep0 rowsep0">17</td><td class="colsep0 rowsep0">13</td><td class="colsep0 rowsep0">57</td><td class="colsep0 rowsep0">22</td><td class="colsep0 rowsep0">335</td><td class="colsep0 rowsep0">169</td><td class="colsep0 rowsep0">3.0</td><td class="colsep0 rowsep0">1.5</td><td class="colsep0 rowsep0">0.61</td><td class="colsep0 rowsep0">0.79</td><td class="colsep0 rowsep0">43.5</td><td class="colsep0 rowsep0">31</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last"><i>f</i><sub>u</sub>, fraction unbound (%).</p></div><div class="footnote" id="t6fn2"><sup><sup>b</sup></sup><p class="last">Plasma clearance (mL/min/kg).</p></div><div class="footnote" id="t6fn3"><sup><sup>c</sup></sup><p class="last">Unbound plasma clearance (mL/min/kg).</p></div><div class="footnote" id="t6fn4"><sup><sup>d</sup></sup><p class="last">Steady-state volume of distribution (L/kg).</p></div><div class="footnote" id="t6fn5"><sup><sup>e</sup></sup><p class="last">Half-life (h).</p></div><div class="footnote" id="t6fn6"><sup><sup>f</sup></sup><p class="last">Bioavailability (%).</p></div></div></div><div class="NLM_p">Compounds <b>11a</b> and <b>11j</b>, selected for further in vivo evaluation, showed sufficiently favorable mouse PK (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>) and antibacterial activity to support administration in a neutropenic murine <i>S. aureus</i> model of infection. In both cases, iv PK in the mouse showed that Cl<sub>u</sub> values were lower and the half-lives longer than those for zoliflodacin <b>1</b>. As well, both compounds showed lower Cl<sub>u</sub> in the rat relative to zoliflodacin, suggesting that PK in humans might be improved. In fact, the short half-life for zoliflodacin called for the its coadministration with the broad-spectrum cytochrome P450 inhibitor 1-aminobenzotriazole (ABT) to increase the exposure and demonstrate the efficacy in the mouse infection model.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> An ascending single-dose experiment with <b>11j</b> (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>) was carried out in a neutropenic mouse thigh <i>S. aureus</i> infection model via intraperitoneal (IP) administration of 25, 50, and 150 mg/kg doses while measuring the bacterial load (colony-forming units, CFUs) at various time points over 24 h. At 12 h for all three doses, a 1-log reduction in CFU count was seen relative to the bacterial level at the beginning of the treatment. There was some regrowth for the lower two doses that correlates with drug being cleared from plasma, and the highest dose achieved over a 2-log reduction in CFU counts versus the bacterial load at the beginning of the treatment and a 4.5-log reduction relative to the untreated control at 24 h. Ascending single (UID) doses with <b>11a</b> in the infection model also showed cidality with a 4-log reduction of CFU count or more at 50 and 75 mg/kg relative to the untreated control and greater than 2 log reduction relative to the initial inoculum at the beginning of the treatment. Stasis activity was seen between 10 and 25 mg/kg UID dosing relative to the initial inoculum. This efficacy was comparable or somewhat better to that seen for zoliflodacin plus ABT in the same model, where 1.8 log reduction at 100 mg/kg and stasis at 20 mg/kg (total dose from BID administration) were seen relative to the initial inoculum. Variability at the 100 mg/kg dose may be related to solubility limitations of the formulated compound and its potential impact on dosing. Overall, both <b>11a</b> and <b>11j</b> showed quite promising activity in the mouse model.</div><figure id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/medium/jm0c01100_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/large/jm0c01100_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Neutropenic mouse thigh models of <i>S. aureus</i> infection. Left: CFU time course dosing <b>11j</b>; right: CFU counts after 24 h postdose of <b>11a</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/large/jm0c01100_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01100&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Despite the quite favorable efficacy data, the triazole compounds herein were not progressed as drug candidates because of the chromosomal micronucleation aberrations observed in an in vitro mouse lymphoma micronucleation assay (MLMA).<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> This genotoxicity was reported previously for <b>11a</b>,<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> but the data herein (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>) showed it to be a broad effect with triazole benzisoxazole substituents. The exception in the triazole series is that of <b>11s</b> that did not have micronucleation aberrations at the highest concentration (400 μM) tested. However, its antibacterial activity against the MRQR strain was not sufficiently high to progress the compound. Nonetheless, the data offers the possibility that genotoxicity could be abrogated in the triazole series given the high 0.15 μM target potency of <b>11s</b>. The observed genotoxicity in the MLMA could be mechanism-related because of inhibition of mammalian type II topoisomerases in a loose association that was previously described.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Gemifloxacin was shown to be a low micromolar inhibitor of both human topoisomerase IIα and human topoisomerase IIβ and to induce aberrations in the MLMA assay at 6 μM. Zoliflodacin did not show mutagenicity in the MLMA at the highest concentration tested, which supported its progression to clinical trials.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Mouse Lymphoma Micronucleation Assay</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cmpd</th><th class="colsep0 rowsep0" align="center">NOEL<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a> (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11a</b></td><td class="colsep0 rowsep0" align="left"><6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11b</b></td><td class="colsep0 rowsep0" align="left"><6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11d</b></td><td class="colsep0 rowsep0" align="left"><6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11g</b></td><td class="colsep0 rowsep0" align="left">12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11h</b></td><td class="colsep0 rowsep0" align="left">12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11v-<i>R</i></b></td><td class="colsep0 rowsep0" align="left">12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11j</b></td><td class="colsep0 rowsep0" align="left">25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11n</b></td><td class="colsep0 rowsep0" align="left">6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11o</b></td><td class="colsep0 rowsep0" align="left">3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11s</b></td><td class="colsep0 rowsep0" align="left">>400</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11w-<i>S</i></b></td><td class="colsep0 rowsep0" align="left">12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">>400</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>gemifloxacin</b></td><td class="colsep0 rowsep0" align="left">3</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">No observable effect level.</p></div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00274" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00274" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Several valuable SAR findings were delineated through the work described herein. Attachment of an N-linked triazole on the SPT benzisoxazole scaffold was demonstrated to be a worthy synthon for analogue optimization with trends favoring substitution on the triazole 5-position. Enabling chemistry to introduce either nucleophiles or electrophiles was developed to incorporate a wide array of substituents at this 5-position, which, being adjacent to scaffold linkage, would have been difficult to achieve otherwise. Coplanarity for the triazole relative to the benzisoxazole ring was enhanced via an intramolecular H-bond when an N–H substituent resided on the 5-position, leading to higher inhibitory potency against the target DNA gyrase. A binding model to DNA gyrase was derived accounting for the higher inhibitory potency with such N–H substituents including those that are appended with larger groups. However, compounds do retain worthwhile enzyme inhibitory potency and antibacterial activity when the triazole is forced out of coplanarity by introduction of nonhydrogen bonding substituents at the 5-position. There was not a direct correlation between inhibitor potency and antibacterial activity for the analogues herein likely because of the differential bacterial permeability. In general, compounds with a higher log <i>D</i> registered higher antibacterial activity in line with apparent higher permeability. The caveat, of course, is that higher lipophilicity led to lower solubility and higher PPB, the latter associated with an upward shift in MIC values in the presence of blood plasma serum. Higher logD compounds also showed lower in vivo PK clearance values, likely related to the higher PPB. As with any drug, a balance between target potency, physical properties, and PK properties is needed to ultimately identify a worthwhile compound for drug development. With this, two compounds <b>11a</b> and <b>11j</b> demonstrated high cidal activity in the neutropenic mouse thigh model of <i>S. aureus</i> infection. Compound <b>11a</b> would predict a lower human dose than zoliflodacin because of its somewhat improved efficacy in the model and lower unbound clearances across the species. However, genotoxicity associated with both compounds as well as with the analogue series more broadly prevented further considerations for clinical development. Whether this genotoxicity is associated with human topoisomerase inhibition has not been conclusively established. The phase 3 development candidate zoliflodacin <b>1</b> was not genotoxic both in vitro and in vivo at high concentrations/exposures and was a less potent inhibitor of human TopoIIα and TopoIIβ relative to the triazole series.<a onclick="showRef(event, 'ref7 ref21'); return false;" href="javascript:void(0);" class="ref ref7 ref21">(7,21)</a> These results represent only a circumstantial set of data, and a much broader set of investigations would need to be carried out to confirm the correlation. The work herein does, however, offer considerations that there is room for improvement for DNA gyrase inhibitory potency and antibacterial activity with the SPT chemotype and offers guidance for future drug optimization.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01888" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01888" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> General Considerations</h3><div class="NLM_p last">All of the solvents and reagents used were obtained commercially and used as such unless noted otherwise. All final compounds were determined to be greater than 95% pure via analysis by reversed-phase chromatography and NMR. The <sup>1</sup>H NMR spectra were recorded in CDCl<sub>3</sub> or DMSO-<i>d</i><sub>6</sub> solutions at 300 K using a Bruker UltraShield 300 MHz instrument or a Bruker UltraShield 400 MHz instrument. The <sup>13</sup>C NMR spectra were recorded in DMSO-<i>d</i><sub>6</sub> solutions at 300 K and 126 MHz using a Bruker DRX-500 500 MHz instrument with a QNP cryoprobe or at 101 MHz using a Bruker UltraShield 400 MHz instrument or at 75.5 MHz using a Bruker UltraShield 300 MHz instrument. The <sup>19</sup>F NMR spectra were recorded at 282 MHz in CDCl<sub>3</sub> or DMSO-<i>d</i><sub>6</sub> solutions at 300 K using a Bruker UltraShield 300 MHz instrument. Chemical shifts are reported as parts per million relative to TMS (0.00) for <sup>1</sup>H and <sup>13</sup>C NMR and CFCl<sub>3</sub> for <sup>19</sup>F NMR. High-resolution mass spectra (HRMS) were obtained using a hybrid quadrupole time-of-flight mass spectrometer (microTOFq II, Bruker Daltonics) in ESI<sup>+</sup> mode. Silica gel chromatographies were performed on an ISCO CombiFlash Companion Instruments using ISCO RediSep Flash Cartridges (particle size: 35–70 μm) or Silicycle SiliaSep Flash Cartridges (particle size: 40–63 μm). Preparative reverse-phase high-performance liquid chromatography (HPLC) was carried out using YMC Pack ODS-AQ (100 × 20 mm ID, S-5 μ particle size, 12 nm pore size) on Agilent instruments. When not indicated, compound intermediates and reagents were purchased from chemical supply houses. All final compounds were analyzed by reversed-phase ultra performance liquid chromatography mass spectroscopy (UPLC-MS) (retention times, rt, in minutes) with a Waters Acquity UPLC instrument with DAD and ELSD and a UPLC HSS T3, 2.1 × 30 mm, 1.8 μm column and a gradient of 2–98% acetonitrile in water with 0.1% formic acid over 2.0 min at 1 mL/min. Injection volume was 1 μL and the column temperature was 30 °C. Detection was based on electrospray ionization (ESI) in positive and negative polarity using a Waters ZQ mass spectrometer (Milford, MA, USA), a diode array UV detector from 210 to 400 nm, and an evaporative light-scattering detector (Sedex 75, Sedere, Alfortville Cedex, France). The synthesis of <b>11a</b> has been previously described.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Reference ciprofloxacin was obtained from the MP Biomedicals (Santa Ana, CA). The syntheses of intermediates <b>5a</b>, <b>5b</b>, <b>5c</b>, and <b>5d</b> have been previously reported.<a onclick="showRef(event, 'ref6 ref21'); return false;" href="javascript:void(0);" class="ref ref6 ref21">(6,21)</a></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> General Procedure for Carrying Out the T-Reaction</h3><div class="NLM_p last">Unless otherwise delineated, the conversion of aldehyde or protected aldehyde substrates to final SPT compounds were carried out as follows: a mixture of the substrate and 1.1 equivalent of pyrimidine-2,4,6(1<i>H</i>,3<i>H</i>,5<i>H</i>)-trione was heated in 4:1 AcOH–water at 120 °C for 1 h in a microwave reactor. The solvent was removed, and the residue was purified by chromatography as indicated for each individual compound.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> [(2<i>R</i>,6<i>S</i>)-2,6-Dimethylmorpholin-4-yl]-7-fluoro-3-(1<i>H</i>-imidazol-1-yl)-1,2-benzoxazole-5-carbaldehyde (<b>6</b>, Azole = N-Linked Imidazole, X = F, Y = CHO)</h3><div class="NLM_p last">A mixture of DBU (0.19 mL, 1.28 mmol), imidazole (53 mg, 0.76 mmol), and 3-chloro-6-[(2<i>R</i>,6<i>S</i>)-2,6-dimethylmorpholin-4-yl]-7-fluoro-l,2-benzoxazole-5-carbaldehyde<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> (0.2 g, 0.68 mmol) in acetonitrile was heated at 100 °C for 12 h. The solvent was removed, and the residue was purified by silica gel column chromatography using EtOAc in petroleum ether to afford 35 mg (16%) of the title product. MS (ES): MH<sup>+</sup> 345.2 for C<sub>17</sub>H<sub>17</sub>FN<sub>4</sub>O<sub>3</sub>.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> <i>rel</i>-(2<i>R</i>,4<i>S</i>,4a<i>S</i>)-11-Fluoro-8-(1<i>H</i>-imidazol-1-yl)-2,4-dimethyl-1,2,4,4a-tetrahydro-2′<i>H</i>,6<i>H</i>-spiro[1,4-oxazino[4,3-<i>a</i>][1,2]oxazolo[4,5-<i>g</i>]quinoline-5,5′-pyrimidine]-2′,4′,6′(1′<i>H</i>,3′<i>H</i>)-trione (<b>7</b>)</h3><div class="NLM_p last">A stirred solution of the preceding compound (34 mg, 0.098 mmol) and pyrimidine-2,4,6(1<i>H</i>,3<i>H</i>,5<i>H</i>)-trione (14 mg, 0.11 mmol) in isopropanol (5 mL) was heated for 16 h at 80 °C in a microwave reactor. The solvent was removed, and the residue was purified on silica gel (30–50% EtOAc in hexanes) to afford the product as a white solid (40 mg, 71%). LC–MS (ES): MH<sup>+</sup> 455 for C<sub>21</sub>H<sub>19</sub>FN<sub>6</sub>O<sub>5</sub>; <sup>1</sup>HNMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 0.9 (d, 3H), 1.15 (d, 3H), 3.0 (d, 1H), 3.2 (t, 1H), 3.55 (d, 1H), 3.7 (m, 1H), 3.8 (m, 1H), 4.0 (d, 1H), 4.1 (d, 1H), 7.3 (s, 1H), 7.65 (s, 1H), 7.9 (s, 1H), 8.5 (s, 1H), 11.6 (s, 1H), 11.9 (s, 1H).</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> 6-((2<i>R</i>,6<i>S</i>)-2,6-Dimethylmorpholino)-7-fluoro-3-(1<i>H</i>-pyrazol-1-yl)benzo[<i>d</i>]isoxazole-5-carbaldehyde (<b>6</b>, Azole = Pyrazole, X = F, Y = CHO)</h3><div class="NLM_p last">A mixture of <b>5a</b> (0.2 g, 0.68 mmol), DBU (0.19 mL, 1.28 mmol), and pyrazole (0.053 g, 0.76 mmol) was heated at 100 °C for 12 h in a microwave reactor. The reaction mixture was concentrated, and the residue was purified by silica gel column chromatography using EtOAc in petroleum ether to afford 135 mg (58%) of the title product.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> <i>rel</i>-(2<i>R</i>,4<i>S</i>,4a<i>S</i>)-11-Fluoro-2,4-dimethyl-8-(1<i>H</i>-pyrazol-1-yl)-2,4,4a,6-tetrahydro-1<i>H</i>,1′<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-2′,4′,6′(3′<i>H</i>)-trione (<b>8a</b>)</h3><div class="NLM_p last">A mixture of 130 mg (0.38 mmol) of the preceding compound and 53 mg (0.41 mmol) of pyrimidine-2,4,6(1<i>H</i>,3<i>H</i>,5<i>H</i>)-trione in 10 mL of isopropanol was heated at reflux overnight. The solvent was removed, and the residue was purified by silica gel column chromatography using EtOAc in CH<sub>2</sub>Cl<sub>2</sub> to afford 43 mg (25%). UPLC rt = 1.02 min, (ES): MH<sup>+</sup> 455.0 for C<sub>21</sub>H<sub>20</sub>FN<sub>6</sub>O<sub>5</sub>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.90 (s, 1H), 11.54 (s, 1H), 8.57 (d, <i>J</i> = 2.8 Hz, 1H), 8.06 (d, <i>J</i> = 1.8 Hz, 1H), 7.75 (s, 1H), 6.77 (dd, <i>J</i> = 1.8, 2.8 Hz, 1H), 4.19 (d, <i>J</i> = 12.8 Hz, 1H), 4.03 (d, <i>J</i> = 8.8 Hz, 1H), 3.81–3.93 (m, 2H), 3.65–3.80 (m, 1H), 3.13–3.28 (m, 1H), 2.98 (d, <i>J</i> = 13.8 Hz, 1H), 1.21 (d, <i>J</i> = 6.0 Hz, 3H), 0.96 (d, <i>J</i> = 6.5 Hz, 3H); <sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>): δ −157.39; <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 170.8, 167.7, 153.6, 153.5, 149.4, 143.5, 135.6, 133.4 (d, <i>J</i><sub>CF</sub> = 240.0 Hz), 129.5, 124.4, 116.8, 109.3, 105.9, 72.1, 71.7, 64.5, 56.3 (d, <i>J</i><sub>CF</sub> = 9.5 Hz), 53.0, 38.3, 18.2, 18.1; HRMS: (ES) MH<sup>+</sup> calcd for C<sub>21</sub>H<sub>20</sub>FN<sub>6</sub>O<sub>5</sub>, 455.1474; found, 455.1490.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> 1-(6-((2<i>R</i>,6<i>S</i>)-2,6-Dimethylmorpholino)-7-fluoro-5-formylbenzo[<i>d</i>]isoxazol-3-yl)-1<i>H</i>-pyrazole-4-carbonitrile (<b>6</b>, Azole = 4-Cyanopyrazole, X = F, Y = CHO)</h3><div class="NLM_p last">A mixture of <b>5a</b> (0.2 g, 0.68 mmol), DBU (0.19 mL, 1.28 mmol), and 4-cyanopyrazole (71 mg, 0.76 mmol) was heated at 100 °C for 12 h in a microwave reactor. The reaction mixture was concentrated, and the residue was purified by silica gel column chromatography using EtOAc in petroleum ether to afford 120 mg (32%) of the title product.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> 1-((2<i>R</i>,4<i>S</i>,4a<i>S</i>)-11-Fluoro-2,4-dimethyl-2′,4′,6′-trioxo-2,2′,3′,4,4a,4′,6,6′-octahydro-1<i>H</i>,1′<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-8-yl)-1<i>H</i>-pyrazole-4-carbonitrile (<b>8b</b>)</h3><div class="NLM_p last">A mixture of the preceding compound (115 mg, 0.30 mmol) and pyrimidine-2,4,6(1<i>H</i>,3<i>H</i>,5<i>H</i>)-trione (38 mg, 0.30 mmol) in isopropanol (5 mL) was heated for 16 h at 80 °C in a microwave reactor. The solvent was removed, and the residue was purified to separate enantiomers separated by SFC, a Chiralpak IB column, and 25% MeOH in CO<sub>2</sub> to afford 49 mg (34%) of the title compound as a white solid (40 mg, 71%). LC = MS rt = 2.56 min, (ES): MH<sup>+</sup> 480.1 for C<sub>22</sub>H<sub>19</sub>FN<sub>7</sub>O<sub>5</sub>; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 0.89 (d, <i>J</i> = 6.22 Hz, 3 H) 1.15 (d, <i>J</i> = 6.22 Hz, 3 H) 2.82–3.22 (m, 2 H) 3.58–4.31 (m, 5 H) 7.61 (s, 1 H) 9.44 (s, 1 H) 11.64 (s, 2 H). [α] −181 (<i>c</i> = 0.1 in DMF).</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> 1-((2<i>R</i>,4<i>S</i>,4a<i>S</i>)-11-Fluoro-2,4-dimethyl-2′,4′,6′-trioxo-2,2′,3′,4,4a,4′,6,6′-octahydro-1<i>H</i>,1′<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-8-yl)-<i>N</i>-methyl-1<i>H</i>-pyrazole-4-sulfonamide (<b>8c</b>)</h3><div class="NLM_p last">A mixture of <b>5a</b> (0.2 g, 0.68 mmol), DBU (0.19 mL, 1.28 mmol), and <i>N</i>-methyl-1<i>H</i>-pyrazole-4-sulfonamide (122 mg, 0.76 mmol) was heated at 100 °C for 12 h in a microwave reactor. The reaction mixture was concentrated, and the residue was taken up in acetic acid (3.00 mL) and water (0.5 mL). Pyrimidine-2,4,6(1<i>H</i>,3<i>H</i>,5<i>H</i>)-trione (91 mg, 0.71 mmol) was added and the mixture was heated at 120 °C for 1 h. The solvent was removed and the residue was purified by SFC, a Chiralpak IC column, 35% <i>i</i>-PrOH in CO<sub>2</sub> to afford 114 mg (33%) of the title compound as well as 61 mg of the corresponding enantiomer. LCMS rt = 2.38 min, (ES): MH<sup>+</sup> 547.9 for C<sub>22</sub>H<sub>23</sub>FN<sub>7</sub>O<sub>7</sub>S; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.92 (br s, 1H), 11.57 (br s, 1H), 9.00 (s, 1H), 8.37 (s, 1H), 7.72 (s, 1H), 7.61 (q, <i>J</i> = 5.09 Hz, 1H), 4.24 (d, <i>J</i> = 13.0 Hz, 1H), 4.08 (d, <i>J</i> = 8.85 Hz, 1H), 3.71–3.97 (m, 3H), 3.19–3.32 (m, 1H), 3.04 (d, <i>J</i> = 14.1 Hz, 1H), 2.64 (d, <i>J</i> = 4.9 Hz, 3H), 1.25 (d, <i>J</i> = 6.2 Hz, 3H), 1.00 (d, <i>J</i> = 6.2 Hz, 3H); <sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>): δ −157.30; <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 170.8, 167.7, 153.8 (d, <i>J</i><sub>CF</sub> = 13.7 Hz), 153.0, 149.5, 141.4, 135.9, 133.3 (d, <i>J</i><sub>CF</sub> = 240.1 Hz), 130.7, 125.0, 124.9, 116.2, 105.6, 72.1, 71.7, 64.5, 56.3 (d, <i>J</i><sub>CF</sub> = 9.2 Hz), 52.9, 38.2, 28.8, 18.2, 18.1; HRMS (ES): MH<sup>+</sup> calcd for C<sub>22</sub>H<sub>23</sub>FN<sub>7</sub>O<sub>7</sub>S, 548.1358; found, 548.1353; [α]<sub class="stack">D</sub><sup class="stack">20</sup> −159 (<i>c</i> 0.1; DMF).</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> 6-((2<i>R</i>,6<i>R</i>)-2,6-Dimethylmorpholino)-5-(1,3-dioxolan-2-yl)-7-fluoro-3-(2<i>H</i>-1,2,3-triazol-2-yl)benzo[<i>d</i>]isoxazole (<b>6</b>, X = 2<i>H</i>-1,2,3-Triazole, Y = CHO) and 6-((2<i>R</i>,6<i>R</i>)-2,6-Dimethylmorpholino)-5-(1,3-dioxolan-2-yl)-7-fluoro-3-(1<i>H</i>-1,2,3-triazol-1-yl)benzo[<i>d</i>]isoxazole (<b>6</b>, X = 1<i>H</i>-1,2,3-Triazole, Y = CHO)</h3><div class="NLM_p last">A mixture of 3-chloro-6-[(2<i>R</i>,6<i>S</i>)-2,6-dimethylmorpholin-4-yl]-7-fluoro-l,2-benzoxazole-5-carbaldehyde <b>5a</b> (0.7 g, 1.96 mmol), 1<i>H</i>-1,2,3-triazole (0.203 g, 2.94 mmol), and K<sub>2</sub>CO<sub>3</sub> (0.407 g, 2.94 mmol) was heated at 80 °C for 16 h. The solvent was removed. The residue was taken up in Et<sub>2</sub>O, which was washed three times with water. The combined aqueous layers were extracted with additional Et<sub>2</sub>O, which was washed twice more with water. The combined Et<sub>2</sub>O layers were dried (MgSO<sub>4</sub>) and concentrated to afford an oil that was chromatographed on silica gel (0–40% gradient of EtOAc in CH<sub>2</sub>Cl<sub>2</sub>). Two materials were isolated as white solids. The first eluting material (185 mg, 24%) was consistent with the first title compound. UPLC rt = 1.20 min, (ES): MH<sup>+</sup> 390.0 for C<sub>18</sub>H<sub>21</sub>FN<sub>5</sub>O<sub>4</sub>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.39 (d, <i>J</i> = 0.94 Hz, 1H), 8.06 (s, 2H), 6.35 (s, 1H), 4.16–4.35 (m, 4H), 3.95–4.14 (m, 2H), 3.36 (br s, 2H), 3.03 (dd, <i>J</i> = 5.37, 11.21 Hz, 2H), 1.36 (d, <i>J</i> = 5.65 Hz, 6H); <sup>19</sup>F NMR (282 MHz, CDCl<sub>3</sub>): δ −142.62. The second eluting material (309 mg, 40%) was consistent with the second title compound. UPLC rt = 1.17 min, (ES): MH<sup>+</sup> 390.0 for C<sub>18</sub>H<sub>21</sub>FN<sub>5</sub>O<sub>4</sub>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.50 (d, <i>J</i> = 1.32 Hz, 1H), 8.47 (d, <i>J</i> = 0.75 Hz, 1H), 7.96 (d, <i>J</i> = 1.32 Hz, 1H), 6.35 (s, 1H), 4.16–4.29 (m, 4H), 4.03–4.13 (m, 2H), 3.36 (br s, 2H), 3.03 (dd, <i>J</i> = 5.65, 11.11 Hz, 2H), 1.36 (d, <i>J</i> = 6.03 Hz, 6H); <sup>19</sup>F NMR (282 MHz, CDCl<sub>3</sub>): δ −142.90.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> (2<i>R</i>,4<i>S</i>,4a<i>S</i>)-211-Fluoro-2,4-dimethyl-8-(2<i>H</i>-1,2,3-triazol-1-yl)-2,4,4a,6-tetrahydro-1<i>H</i>,1′<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-2′,4′,6′(3′<i>H</i>)-trione (<b>9</b>)</h3><div class="NLM_p last">The general T-reaction procedure was used with 299 mg (0.77 mmol) of 6-((2<i>R</i>,6<i>R</i>)-2,6-dimethylmorpholino)-5-(1,3-dioxolan-2-yl)-7-fluoro-3-(2<i>H</i>-1,2,3-triazol-1-yl)benzo[<i>d</i>]isoxazole (<b>6</b>, X = 1<i>H</i>-1,2,3-triazole, Y = CHO). Purification by SFC, an (S,S)-Whelk-O1 column, and a gradient of 0–35% EtOH in CO<sub>2</sub> affords 97 mg (58%) of the title compound. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.67 (br s, 2H), 8.97 (d, <i>J</i> = 1.5 Hz, 1H), 8.15 (d, <i>J</i> = 1.5 Hz, 1H), 7.68 (s, 1H), 4.14 (d, <i>J</i> = 12.8 Hz, 1H), 4.00 (d, <i>J</i> = 9.0 Hz, 1H), 3.78–3.85 (m, 2H), 3.64–3.75 (m, 1H), 3.10–3.20 (m, 1H), 2.92 (d, <i>J</i> = 13.55 Hz, 1H), 1.16 (d, <i>J</i> = 6.3 Hz, 3H), 0.91 (d, <i>J</i> = 6.3 Hz, 3H); <sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>): δ −157.25; <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 170.9, 167.7, 153.9 (d, <i>J</i><sub>CF</sub> = 13.2 Hz), 151.5 (d, <i>J</i><sub>CF</sub> = 2.9 Hz), 149.5, 136.0, 134.7, 133.2 (d, <i>J</i><sub>CF</sub> = 240.8 Hz), 125.3, 124.0, 105.3, 72.1, 71.7, 64.5, 56.3 (d, <i>J</i><sub>CF</sub> = 9.5 Hz), 52.8, 38.2, 18.2, 18.1; HRMS (ES): MH<sup>+</sup> calcd for C<sub>20</sub>H<sub>19</sub>FN<sub>7</sub>O<sub>5</sub>, 456.1426; found, 456.1416; [α]<sub class="stack">D</sub><sup class="stack">20</sup> −192 (<i>c</i> 1; MeOH).</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> (2<i>R</i>,4<i>S</i>,4a<i>S</i>)-11-Fluoro-2,4-dimethyl-8-(2<i>H</i>-1,2,3-triazol-2-yl)-2,4,4a,6-tetrahydro-1<i>H</i>,1′<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-2′,4′,6′(3′<i>H</i>)-trione (<b>10</b>)</h3><div class="NLM_p last">The general T-reaction procedure was used with 144 mg (0.37 mmol) of 6-((2<i>R</i>,6<i>R</i>)-2,6-dimethylmorpholino)-5-(1,3-dioxolan-2-yl)-7-fluoro-3-(2<i>H</i>-1,2,3-triazol-2-yl)benzo[<i>d</i>]isoxazole (<b>6</b>, X = 2<i>H</i>-1,2,3-triazole, Y = CHO) and 47.4 mg (0.37 mmol) of pyrimidine-2,4,6(1<i>H</i>,3<i>H</i>,5<i>H</i>)-trione. Purification by SFC, an (S,S)-Whelk-O1 column, and a gradient of 0–35% EtOH in CO<sub>2</sub> affords 97 mg (58%) of the title compound. UPLC rt = 0.95 min, (ES): MH<sup>+</sup> 456.0 for C<sub>20</sub>H<sub>19</sub>FN<sub>7</sub>O<sub>5</sub>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.59 (br s, 2H), 8.32 (s, 2H), 7.59 (s, 1H), 4.07 (d, <i>J</i> = 12.8 Hz, 1H), 3.91 (d, <i>J</i> = 8.8 Hz, 1H), 3.68–3.80 (m, 2H), 3.62 (qd, <i>J</i> = 6.3, 8.85 Hz, 1H), 3.00–3.17 (m, 1H), 2.86 (d, <i>J</i> = 13.8 Hz, 1H), 1.09 (d, <i>J</i> = 6.3 Hz, 3H), 0.83 (d, <i>J</i> = 6.3 Hz, 3H); <sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>): δ −157.22; <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 170.8, 167.7, 153.7 (d, <i>J</i><sub>CF</sub> = 13.2 Hz), 153.0 (d, <i>J</i><sub>CF</sub> = 2.2 Hz), 149.4, 138.6, 135.8, 133.3 (d, <i>J</i><sub>CF</sub> = 240.0 Hz), 125.0, 116.1, 105.3, 72.1, 71.7, 64.5, 56.3 (d, <i>J</i><sub>CF</sub> = 9.5 Hz), 52.9, 38.2, 18.2, 18.1; HRMS: (ES) MH<sup>+</sup> calcd for C<sub>20</sub>H<sub>19</sub>FN<sub>7</sub>O<sub>5</sub>, 456.1426; found, 456.1404; [α]<sub class="stack">D</sub><sup class="stack">20</sup> −150 (<i>c</i> 1; MeOH).</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> 7-Chloro-6-((2<i>S</i>,6<i>R</i>)-2,6-dimethylmorpholino)-5-(1,3-dioxolan-2-yl)-3-(1<i>H</i>-1,2,4-triazol-1-yl)benzo[<i>d</i>]isoxazole (<b>6</b>, Azole = 1<i>H</i>-1,2,4-Triazole, X = Cl, Y = 1,3-Dioxolanyl)</h3><div class="NLM_p last">NaH (60% dispersion in oil, 870 mg, 21.7 mmol) was added portionwise to a solution of 1.5 g (21.7 mmol) of 1,2,4-triazole in 100 mL of dimethylformamide (DMF) at rt. After stirring for 20 min, 4 g (10.7 mmol) of <b>5c</b> was added, and the mixture was heated at 60 °C for 24 h. After cooling to rt and quenching with saturated aqueous NH<sub>4</sub>Cl, the solvent was removed. The residue was partitioned between water and EtOAc, and the EtOAc was separated and washed with brine. Drying (Na<sub>2</sub>SO<sub>4</sub>) of the organic extract and removal of the solvent afforded a residue that was chromatographed on silica gel (20% EtOAc in hexanes) to afford 2.51 g (57%) of the title compound.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> (2<i>R</i>,4<i>S</i>,4a<i>S</i>)-11-Chloro-2,4-dimethyl-8-(1<i>H</i>-1,2,4-triazol-1-yl)-2,4,4a,6-tetrahydro-1<i>H</i>,1′<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-2′,4′,6′(3′<i>H</i>)-trione (<b>11b</b>)</h3><div class="NLM_p last">A mixture of 2.5 g (6.16 mmol) of the preceding compound and 790 mg (6.17 mmol) pyrimidine-2,4,6(1H,3<i>H</i>,5<i>H</i>)-trione in 100 mL of IPA was heated at reflux overnight. The solvent was removed, and the residue was purified by SFC, a Chiralpak IC column, and 30% EtOH in CO<sub>2</sub> to afford 768 mg (26%) of the title compound as well as 770 mg (26%) of the corresponding enantiomer. LC–MS rt = 2.26 min, (ES): MH<sup>+</sup> 472.0 for C<sub>20</sub>H<sub>19</sub>ClN<sub>7</sub>O<sub>5</sub>; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.74 (br s, 1H), 11.41 (br s, 1H), 9.35 (s, 1H), 8.43 (s, 1H), 7.62 (s, 1H), 4.34–4.72 (m, 1H), 3.97 (d, <i>J</i> = 8.69 Hz, 1H), 3.84–3.95 (m, 1H), 3.70 (d, <i>J</i> = 14.5 Hz, 1H), 3.52–3.66 (m, 1H), 3.02 (dd, <i>J</i> = 10.1, 14.1 Hz, 1H), 2.83–2.96 (m, 1H), 1.11 (d, <i>J</i> = 6.2 Hz, 3H), 0.84 (d, <i>J</i> = 6.4 Hz, 3H); <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): δ 170.6, 167.6, 162.5, 153.7, 151.6, 149.4, 145.4, 144.2, 124.7, 118.7, 104.7, 97.4, 72.5, 65.9, 56.3, 52.6, 18.1, 18.1; HRMS: (ES) MH<sup>+</sup> calcd for C<sub>21</sub>H<sub>19</sub>ClN<sub>7</sub>O<sub>5</sub>, 472.1131; found, 472.1142; [α]<sub class="stack">D</sub><sup class="stack">20</sup> −300 (<i>c</i> 1; MeOH). Corresponding enantiomer: (2<i>S</i>,4<i>R</i>,4a<i>R</i>)-11-chloro-2,4-dimethyl-8-(1<i>H</i>-1,2,4-triazol-1-yl)-2,4,4a,6-tetrahydro-1<i>H</i>,1′<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-2′,4′,6′(3′<i>H</i>)-trione. LC–MS rt = 2.25 min, (ES): MH<sup>+</sup> 472.1 for C<sub>20</sub>H<sub>19</sub>ClN<sub>7</sub>O<sub>5</sub>; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.74 (br s, 1H), 11.41 (br s, 1H), 9.35 (s, 1H), 8.43 (s, 1H), 7.62 (s, 1H), 4.34–4.72 (m, 1H), 3.97 (d, <i>J</i> = 8.69 Hz, 1H), 3.84–3.95 (m, 1H), 3.70 (d, <i>J</i> = 14.5 Hz, 1H), 3.52–3.66 (m, 1H), 3.02 (dd, <i>J</i> = 10.1, 14.1 Hz, 1H), 2.83–2.96 (m, 1H), 1.11 (d, <i>J</i> = 6.2 Hz, 3H), 0.84 (d, <i>J</i> = 6.4 Hz, 3H); [α]<sub class="stack">D</sub><sup class="stack">20</sup> +271 (<i>c</i> 1; MeOH).</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> 6-((2<i>R</i>,6<i>R</i>)-2,6-Dimethylmorpholino)-5-(1,3-dioxolan-2-yl)-7-fluoro-3-(3-methyl-1<i>H</i>-1,2,4-triazol-1-yl)benzo[<i>d</i>]isoxazole (<b>6</b>, R<sub>3</sub> = CH<sub>3</sub>, Y = 1,3-Dioxolanyl)</h3><div class="NLM_p last">A solution of 200 mg (0.56 mmol) of <b>5b</b>, 51 mg (0.62 mmol) of 3-methyl-1<i>H</i>-1,2,4-triazole, and 85 mg (1.50.62 mmol) of K<sub>2</sub>CO<sub>3</sub> in 10 mL of CH<sub>3</sub>CN was heated at reflux overnight. The solvent was removed, and the residue was partitioned between water and EtOAc. The EtOAc was separated and washed with brine. Drying (Na<sub>2</sub>SO<sub>4</sub>) of the organic extract and removal of the solvent afforded a residue that was chromatographed on silica gel (10% EtOAc in hexanes) to afford 74 mg (33%) of the title compound. UPLC (ES): MH<sup>+</sup> 404.0 for C<sub>19</sub>H<sub>23</sub>FN<sub>5</sub>O<sub>4</sub>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.91 (s, 1H), 8.29 (d, <i>J</i> = 0.75 Hz, 1H), 6.33 (s, 1H), 4.22–4.28 (m, 2H), 4.13–4.21 (m, 2H), 4.02–4.14 (m, 2H), 3.35 (br s, 2H), 3.03 (dd, <i>J</i> = 5.6, 10.8 Hz, 2H), 2.61 (s, 3H), 1.36 (d, <i>J</i> = 5.8 Hz, 6H); <sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>): δ −142.70.</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> (2<i>R</i>,4<i>S</i>,4a<i>S</i>)-11-Fluoro-2,4-dimethyl-8-(3-methyl-1<i>H</i>-1,2,4-triazol-1-yl)-2,4,4a,6-tetrahydro-1<i>H</i>,1′<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-2′,4′,6′(3′<i>H</i>)-trione (<b>11c</b>)</h3><div class="NLM_p last">The general T-reaction procedure was used with 71 mg (0.18 mmol) of the preceding compound. Purification by SFC, an (S,S)-Whelk-O1 column, and a gradient of 0–30% MeOH in CO<sub>2</sub> affords 58 mg (70%) of the title compound. UPLC rt = 0.91 min, (ES): MH<sup>+</sup> 470.0 for C<sub>21</sub>H<sub>21</sub>FN<sub>7</sub>O<sub>5</sub>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.66 (br s, 2H), 9.26 (s, 1H), 7.56 (s, 1H), 4.12 (d, <i>J</i> = 13.30 Hz, 1H), 3.98 (d, <i>J</i> = 8.78 Hz, 1H), 3.73–3.87 (m, 2H), 3.63–3.73 (m, 1H), 3.13 (t, <i>J</i> = 12.05 Hz, 1H), 2.92 (d, <i>J</i> = 14.31 Hz, 1H), 2.45 (s, 3H), 1.16 (d, <i>J</i> = 6.27 Hz, 3H), 0.90 (d, <i>J</i> = 6.27 Hz, 3H); <sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>): δ −157.30; <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 170.9, 167.7, 162.6, 154.8, 153.5 153.5 (d, <i>J</i><sub>CF</sub> = 12.4 Hz), 152.6, 151.2 (d, <i>J</i><sub>CF</sub> = 2.2 Hz), 149.6, 144.5, 135.8, 133.2 (d, <i>J</i><sub>CF</sub> = 240.8 Hz), 124.8, 115.9, 72.1, 71.7, 64.5, 56.3 (d, <i>J</i><sub>CF</sub> = 9.5 Hz), 52.9, 38.2, 18.1, 18.1, 13.6; HRMS: (ES) MH<sup>+</sup> calcd for C<sub>21</sub>H<sub>21</sub>FN<sub>7</sub>O<sub>5</sub>, 470.1583; found, 470.1593; [α]<sub class="stack">D</sub><sup class="stack">20</sup> −150 (<i>c</i> 1; MeOH).</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> 1-(6-((2<i>R</i>,6<i>R</i>)-2,6-Dimethylmorpholino)-5-(1,3-dioxolan-2-yl)-7-fluorobenzo[<i>d</i>]isoxazol-3-yl)-1<i>H</i>-1,2,4-triazole-3-carbonitrile (<b>6</b>, R<sub>3</sub> = CN, Y = 1,3-Dioxolanyl)</h3><div class="NLM_p last">NaH (60% dispersion in oil, 61.4 mg, 0.54 mmol) was added portionwise to a solution of 144 mg (1.54 mmol) of 1<i>H</i>-1,2,4-triazole-3-carbonitrile in 5 mL of DMF at rt. After stirring for 20 min, 274 mg (0.77 mmol) of <b>5b</b> was added, and the mixture was heated at 60 °C for 24 h. After cooling to rt and quenching with saturated aqueous NH<sub>4</sub>Cl, the solvent was removed. The residue was partitioned between water and EtOAc, and the EtOAc was separated and washed with brine. Drying (Na<sub>2</sub>SO<sub>4</sub>) of the organic extract and removal of the solvent afforded a residue that was chromatographed on silica gel (20% EtOAc in hexanes) to afford 135 mg (42%) of the title compound. UPLC (ES): MH<sup>+</sup> 415.0 for C<sub>19</sub>H<sub>20</sub>FN<sub>6</sub>O<sub>4</sub>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 9.11 (s, 1H), 8.24 (d, <i>J</i> = 0.9 Hz, 1H), 6.31 (s, 1H), 4.26–4.32 (m, 2H), 4.17–4.24 (m, 2H), 4.07–4.15 (m, 2H), 3.38 (d, <i>J</i> = 10.55 Hz, 2H), 3.04 (dd, <i>J</i> = 5.5, 11.5 Hz, 2H), 1.36 (d, <i>J</i> = 6.2 Hz, 6H); <sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>): δ −142.28.</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> 1-((2<i>R</i>,4<i>S</i>,4a<i>S</i>)-11-Fluoro-2,4-dimethyl-2′,4′,6′-trioxo-2,2′,3′,4,4a,4′,6,6′-octahydro-1<i>H</i>,1′<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidin]-8-yl)-1<i>H</i>-1,2,4-triazole-3-carbonitrile (<b>11d</b>)</h3><div class="NLM_p last">The general T-reaction procedure was used with 132 mg (0.32 mmol) of the preceding compound. Purification by SFC, an (S,S)-Whelk-O1 column, and a gradient of 0–30% MeOH in CO<sub>2</sub> affords 101 mg (66%) of the title compound. UPLC rt = 1.03 min, (ES): MH<sup>+</sup> 480.9 for C<sub>21</sub>H<sub>18</sub>FN<sub>8</sub>O<sub>5</sub>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.67 (br s, 2H), 9.83 (s, 1H), 7.58 (s, 1H), 4.15 (d, <i>J</i> = 12.80 Hz, 1H), 4.00 (d, <i>J</i> = 8.78 Hz, 1H), 3.76–3.90 (m, 2H), 3.61–3.76 (m, 1H), 3.06–3.24 (m, 1H), 2.93 (d, <i>J</i> = 13.80 Hz, 1H), 1.17 (d, <i>J</i> = 6.02 Hz, 3H), 0.91 (d, <i>J</i> = 6.27 Hz, 3H); <sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>): δ −157.16; <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 170.8, 167.6, 153.8 (d, <i>J</i><sub>CF</sub> = 13.2 Hz), 150.9 (d, <i>J</i><sub>CF</sub> = 2.9 Hz), 149.5, 146.6, 139.9, 136.2, 133.1 (d, <i>J</i><sub>CF</sub> = 240.8 Hz), 125.6, 111.7, 104.9, 72.1, 71.7, 64.5, 52.8, 38.0, 18.2, 18.1; HRMS (ES): MH<sup>+</sup> calcd for C<sub>21</sub>H<sub>18</sub>FN<sub>8</sub>O<sub>5</sub>, 481.1379; found, 481.1392; [α]<sub class="stack">D</sub><sup class="stack">20</sup> −126 (<i>c</i> 1; MeOH).</div></div><div id="sec4_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> 6-((2<i>R</i>,6<i>R</i>)-2,6-Dimethylmorpholino)-5-(1,3-dioxolan-2-yl)-7-fluoro-3-(1<i>H</i>-1,2,4-triazol-1-yl)benzo[<i>d</i>]isoxazole (<b>6</b>, Azole = 1<i>H</i>-1,2,4-Triazole, X = F, Y = 1,3-Dioxolanyl)</h3><div class="NLM_p last">NaH (1.62 g of a 60% dispersion in oil, 85.6 mmol) was added portionwise over 5 min at rt to 1<i>H</i>-1,2,4-triazole (2.77 g, 40.1 mmol) dissolved in 2 mL of DMF (gas evolution). The mixture was stirred at rt for 10 min before adding <b>5b</b> (14 g, 39.2 mmol) in 30 mL of DMF and heating at 100 °C for 3 h. After cooling to rt, the mixture was quenched with saturated aqueous NH<sub>4</sub>Cl and extracted with EtOAc. The EtOAc was washed with aqueous NaHCO<sub>3</sub> and brine before being dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated. The residue was chromatographed on silica gel (1:2 EtOAc–hexanes) to afford 11.3 g (74%) of the title compound as a white solid. LC–MS (ES): MH<sup>+</sup> 391.9 for C<sub>18</sub>H<sub>23</sub>FN<sub>5</sub>O<sub>4</sub>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 9.02 (s, 1H), 8.32 (s, 1H), 8.30 (s, 1H), 6.33 (s, 1H), 4.0–4.3 (m, 7H), 3.35 (br s, 2H), 3.03 (dd, <i>J</i> = 10.8, 5.4 Hz, 2H), 1.35 (br s, 6H).</div></div><div id="sec4_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> 3-(5-Chloro-1<i>H</i>-1,2,4-triazol-1-yl)-6-((2<i>R</i>,6<i>R</i>)-2,6-dimethylmorpholino)-5-(1,3-dioxolan-2-yl)-7-fluorobenzo[<i>d</i>]isoxazole (<b>6c</b>, Y = 1,3-Dioxolanyl)</h3><div class="NLM_p last">A solution of 2.5 M <i>n</i>-BuLi (18 mL, 45 mmol) in hexanes was added over 10 min to a solution of the previous compound (11.3 g, 29 mmol) in 200 mL of tetrahydrofuran (THF) cooled to −78 °C. After stirring at −78 for 20 min, hexachloroethane (10.6 g, 44.8 mmol) in 50 mL of THF was added over 5 min. The solution was stirred at −78 °C for 20 min and warmed to −20 °C before being quenched with saturated aqueous NH<sub>4</sub>Cl. After warming to rt, the mixture was extracted twice with EtOAc, which was washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated. The residue was chromatographed on silica gel (1:2 EtOAc/hexanes gradient) to afford 10.6 g (86%) of the title compound as a white solid. UPLC (ES): MH<sup>+</sup> 424.0 for C<sub>18</sub>H<sub>20</sub>ClFN<sub>5</sub>O<sub>4</sub>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.19 (s, 1H), 8.13 (s, 1H), 6.31 (s, 1 H), 4.1–4.3 (m, 4H), 4.0–4.1 (m, 2H), 3.35 (br s, 2H), 3.03 (dd, <i>J</i> = 11.0, 5.4 Hz, 2H), 1.35 (d, <i>J</i> = 6 Hz, 6H); <sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>): δ −142.45.</div></div><div id="sec4_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> 3-(5-Chloro-1<i>H</i>-1,2,4-triazol-1-yl)-5-(dimethoxymethyl)-6-((2<i>R</i>,6R)-2,6-dimethylmorpholino)-7-fluorobenzo[<i>d</i>]isoxazole (<b>6c</b>, Y = Dimethoxymethyl)</h3><div class="NLM_p last">A solution of 2.5 M <i>n</i>-BuLi (6.1 mL, 15 mmol) in hexanes was added over 10 min to a solution of <b>5d</b> in 100 mL of THF cooled to −78 °C. After stirring at −78 for 20 min, hexachloroethane (4.54 g, 19 mmol) in 30 mL of THF was added over 5 min. The solution was stirred at −78 °C for 20 min and warmed to −20 °C before being quenched with saturated aqueous NH<sub>4</sub>Cl. After warming to rt, the mixture was extracted twice with EtOAc, which was washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated. The residue was chromatographed on silica gel (10–35% EtOAc gradient in hexanes) to afford 4.6 g (85%) of the title compound as a white solid. LC–MS (ES): MH<sup>+</sup> 426.3 for C<sub>18</sub>H<sub>22</sub>ClFN<sub>5</sub>O<sub>4</sub>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.18 (s, 1H), 8.09 (s, 1H), 5.86 (s, 1H), 4.21 (dt, <i>J</i> = 3.39, 6.03 Hz, 2H), 3.39 (d, <i>J</i> = 3.20 Hz, 6H), 2.93 (dd, <i>J</i> = 5.56, 11.21 Hz, 2H), 1.36 (d, <i>J</i> = 5.27 Hz, 6H)<sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>): δ −141.93.</div></div><div id="sec4_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> 6-((2<i>R</i>,6<i>R</i>)-2,6-Dimethylmorpholino)-5-(1,3-dioxolan-2-yl)-7-fluoro-3-(5-methyl-1<i>H</i>-1,2,4-triazol-1-yl)benzo[<i>d</i>]isoxazole (<b>6a</b>, R<sub>3</sub> = CH<sub>3</sub>, Y = 1,3-Dioxolanyl)</h3><div class="NLM_p last">A solution of 300 mg (0.77 mmol) of 6-((2<i>R</i>,6<i>R</i>)-2,6-dimethylmorpholino)-5-(1,3-dioxolan-2-yl)-7-fluoro-3-(1<i>H</i>-1,2,4-triazol-1-yl)benzo[<i>d</i>]isoxazole (<b>6</b>, azole = 1<i>H</i>-1,2,4-triazole, X = F, Y = 1,3-dioxolanyl) in 5 mL of THF was cooled to below −70 °C. A solution of <i>n</i>-butyllithium (2.0 M in cyclohexane, 0.462 mL, 0.92 mmol) was added slowly over 5 min to maintain a temperature below −70 °C. The mixture was stirred 5 min before CH<sub>3</sub>I (0.096 mL, 1.54 mmol) was added and the mixture was warmed to rt. The mixture was quenched with aqueous NH<sub>4</sub>Cl and partitioned between water and EtOAc. The EtOAc was separated and washed with brine. The combined aqueous layers were extracted with EtOAc, which was washed with brine. Drying (MgSO<sub>4</sub>) and removal of the solvent from the combined EtOAc layers afforded 298 mg (96%) of the title compound as a solid. LC–MS (ES): MH<sup>+</sup> 404.3 for C<sub>19</sub>H<sub>23</sub>FN<sub>5</sub>O<sub>4</sub>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.22 (d, <i>J</i> = 0.9 Hz, 1H), 8.03 (s, 1H), 7.19 (s, 1H), 6.23 (s, 1H), 4.04–4.18 (m, 4H), 3.94–4.03 (m, 2H), 3.25 (br s, 2H), 2.93 (dd, <i>J</i> = 5.6, 11.2 Hz, 2H), 2.83 (s, 3H), 1.26 (br s, 6H); <sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>): δ −143.06.</div></div><div id="sec4_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> (2<i>R</i>,4<i>S</i>,4a<i>S</i>)-11-Fluoro-2,4-dimethyl-8-(5-methyl-1<i>H</i>-1,2,4-triazol-1-yl)-2,4,4a,6-tetrahydro-1<i>H</i>,1′<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-2′,4′,6′(3′<i>H</i>)-trione (<b>11e</b>)</h3><div class="NLM_p last">The general T-reaction procedure was used with 243 mg (0.60 mmol) of the preceding compound. Solids precipitated from the solution on cooling to rt. The solids were filtered off, and the filtrate was concentrated. The residue from the filtrate was chromatographed on silica gel (0–80% EtOAc gradient in CH<sub>2</sub>Cl<sub>2</sub>) to afford 140 mg (50%) of the title compound. LC–MS rt = 2.38 min, (ES): MH<sup>+</sup> 470.2 for C<sub>21</sub>H<sub>21</sub>FN<sub>7</sub>O<sub>5</sub>; <sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>): δ −157.45; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.82 (br s, 1H), 11.46 (br s, 1H), 8.30 (s, 1H), 7.58 (s, 1H), 4.14 (d, <i>J</i> = 13.0 Hz, 1H), 3.98 (d, <i>J</i> = 8.9 Hz, 1H), 3.73–3.86 (m, 2H), 3.62–3.73 (m, 1H), 3.15 (t, <i>J</i> = 12.9 Hz, 1H), 2.94 (d, <i>J</i> = 14.0 Hz, 1H), 2.76 (s, 3H), 1.16 (d, <i>J</i> = 6.0 Hz, 3H), 0.90 (d, <i>J</i> = 6.4 Hz, 3H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 170.8, 167.7, 154.8, 153.1 (d, <i>J</i><sub>CF</sub> = 12.8 Hz), 152.6, 152.4, 149.5, 135.8, 133.2 (d, <i>J</i><sub>CF</sub> = 240.1 Hz), 124.7, 116.6, 106.6, 72.1, 71.7, 64.5, 56.3 (d, <i>J</i><sub>CF</sub> = 9.2 Hz), 52.9, 38.2, 18.2, 18.1, 14.1; HRMS (ES): MH<sup>+</sup> calcd for C<sub>21</sub>H<sub>21</sub>FN<sub>7</sub>O<sub>5</sub>, 470.1583; found, 470.1597; [α]<sub class="stack">D</sub><sup class="stack">20</sup> −226 (<i>c</i> 0.1; DMSO).</div></div><div id="sec4_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> 1-(6-((2<i>R</i>,6<i>R</i>)-2,6-Dimethylmorpholino)-5-(1,3-dioxolan-2-yl)-7-fluorobenzo[<i>d</i>]isoxazol-3-yl)-1<i>H</i>-1,2,4-triazole-5-carbonitrile (<b>6d</b>, R<sub>5</sub> = −CN, Y = 1,3-Dioxolanyl)</h3><div class="NLM_p last">A mixture of 300 mg (0.71 mmol) of 3-(5-chloro-1<i>H</i>-1,2,4-triazol-1-yl)-5-(dimethoxymethyl)-6-((2<i>R</i>,6R)-2,6-dimethylmorpholino)-7-fluorobenzo[<i>d</i>]isoxazole (<b>6c</b>, Y = dimethoxymethyl) and 55.3 mg (0.85 mmol) of KCN in 3 mL of DMF was heated at 90 °C for 1 h in a microwave reactor. The mixture was poured into 1:1 aqueous NH<sub>4</sub>Cl/MeOH. The solids were collected and rinsed with water before being dried in vacuo. The solids were dissolved in 10 mL of hot 4:1 EtOH/water. Cooling to rt over 3 h afforded a white precipitate that was collected, rinsed with 4:1 EtOH/water, and dried in vacuo to afford 156 mg (53%) of the title compound. UPLC (ES): MH<sup>+</sup> 415.0 for C<sub>19</sub>H<sub>20</sub>FN<sub>6</sub>O<sub>4</sub>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.92 (s, 1H), 8.10 (s, 1H), 6.19 (s, 1H), 3.92–4.19 (m, 6H), 3.23–3.36 (m, 3H), 2.96 (dd, <i>J</i> = 5.27, 10.74 Hz, 2H), 1.24 (d, <i>J</i> = 6.40 Hz, 6H); <sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>): δ −143.69.</div></div><div id="sec4_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> 1-((2<i>R</i>,4<i>S</i>,4a<i>S</i>)-11-Fluoro-2,4-dimethyl-2′,4′,6′-trioxo-2,2′,3′,4,4a,4′,6,6′-octahydro-1<i>H</i>,1′<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidin]-8-yl)-1<i>H</i>-1,2,4-triazole-5-carbonitrile (<b>11f</b>)</h3><div class="NLM_p last">The general T-reaction procedure was used with 155 mg (0.37 mmol) of the preceding compound. Purification by SFC, an (S,S)-Whelk-O1 column, and a gradient of 0–30% <i>i</i>-PrOH in CO<sub>2</sub> affords 80 mg (45%) of the title compound. UPLC rt = 1.04 min, (ES): MH<sup>+</sup> 480.9 for C<sub>21</sub>H<sub>18</sub>FN<sub>8</sub>O<sub>5</sub>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.87 (br s, 1H), 11.50 (br s, 1H), 8.84 (s, 1H), 7.54 (s, 1H), 4.16 (d, <i>J</i> = 12.80 Hz, 1H), 4.00 (d, <i>J</i> = 9.03 Hz, 1H), 3.82 (d, <i>J</i> = 14.56 Hz, 2H), 3.60–3.75 (m, 1H), 3.17 (t, <i>J</i> = 12.80 Hz, 1H), 2.95 (d, <i>J</i> = 14.05 Hz, 1H), 1.17 (d, <i>J</i> = 6.27 Hz, 3H), 0.91 (d, <i>J</i> = 6.27 Hz, 3H); <sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>): δ −157.11; <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 170.8, 167.6, 154.0, 153.7 (d, <i>J</i><sub>CF</sub> = 13.2 Hz), 151.0, 149.4, 136.2, 133.1 (d, <i>J</i><sub>CF</sub> = 240.8 Hz), 129.6, 125.6, 115.7, 109.0, 105.3, 72.1, 71.7, 64.6, 56.3 (d, <i>J</i><sub>CF</sub> = 8.8 Hz), 52.7, 38.1, 18.2, 18.1; HRMS (ES): MH<sup>+</sup> calcd for C<sub>21</sub>H<sub>18</sub>FN<sub>8</sub>O<sub>5</sub>, 481.1379; found, 481.1388; [α]<sub class="stack">D</sub><sup class="stack">20</sup> −198 (<i>c</i> 1; MeOH).</div></div><div id="sec4_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> (1-(6-((2<i>R</i>,6<i>R</i>)-2,6-Dimethylmorpholino)-5-(1,3-dioxolan-2-yl)-7-fluorobenzo[<i>d</i>]isoxazol-3-yl)-1<i>H</i>-1,2,4-triazol-5-yl)methanol (<b>6b</b>, R<sub>5</sub> = CH<sub>2</sub>OH, Y = 1,3-Dioxolanyl)</h3><div class="NLM_p last">NaBH<sub>4</sub> (0.50 g, 13.2 mmol) was added portionwise to a solution of 1-(6-((2<i>R</i>,6<i>R</i>)-2,6-dimethylmorpholino)-5-(1,3-dioxolan-2-yl)-7-fluorobenzo[<i>d</i>]isoxazol-3-yl)-1<i>H</i>-1,2,4-triazole-5-carbaldehyde (5.53 g, 13.2 mmol) in EtOH (40 mL) cooled in an ice–water bath. After 2 h of stirring, the mixture was treated with 1 N HCl (1 mL) and diluted with water and EtOAc. The EtOAc was separated and washed with brine. The combined aqueous layers were extracted with EtOAc, which was washed with brine. The combined EtOAc layers were dried (MgSO<sub>4</sub>) and concentrated. The residue was chromatographed on silica gel (0–50% EtOAc gradient in CH<sub>2</sub>Cl<sub>2</sub>) to afford 2.85 g (51%) of the title compound as the major eluting component. LC–MS (ES): MH<sup>+</sup> 420.1 for C<sub>19</sub>H<sub>23</sub>FN<sub>5</sub>O<sub>5</sub>; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.48 (s, 1H), 8.13 (s, 1H), 6.18 (s, 1H), 5.67 (t, <i>J</i> = 6.1 Hz, 1H), 4.95 (d, <i>J</i> = 6.0 Hz, 2H), 3.9–4.2 (m, 8H), 3.2 (m, 2H), 2.9 (dd, <i>J</i> = 10.8, 5.5 Hz, 2H) 1.23 (d, <i>J</i> = 6.2 Hz, 6H); <sup>19</sup>F NMR (282 MHz, CDCl<sub>3</sub>): δ −144.12.</div></div><div id="sec4_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> (2<i>R</i>,4<i>S</i>,4a<i>S</i>)-11-Fluoro-8-(5-(hydroxymethyl)-1<i>H</i>-1,2,4-triazol-1-yl)-2,4-dimethyl-2,4,4a,6-tetrahydro-1<i>H</i>,1′<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-2′,4′,6′(3′<i>H</i>)-trione (<b>11g</b>)</h3><div class="NLM_p last">The general T-reaction procedure was used with 1.0 g (2.38 mmol) of the preceding compound. Purification by SFC, an Chiralpak AC column, and 35% CH<sub>3</sub>CN/MeOH (85:15) in CO<sub>2</sub> affords 630 mg (54%) of the title compound. LC–MS rt = 2.08 min, (ES): MH<sup>+</sup> 486.1 for C<sub>21</sub>H<sub>21</sub>FN<sub>7</sub>O<sub>6</sub>; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.83 (br s, 1H), 11.47 (br s, 1H), 8.39 (s, 1H), 7.54 (s, 1H), 5.82 (t, <i>J</i> = 6.0 Hz, 1H), 4.91 (d, <i>J</i> = 6.0 Hz, 2H), 4.15 (d, <i>J</i> = 13.4 Hz, 1H), 3.99 (d, <i>J</i> = 8.9 Hz, 1H), 3.6–3.9 (m, 3H), 3.1–3.2 (m, 1H), 2.94 (d, <i>J</i> = 14.4 Hz, 1H), 1.16 (d, <i>J</i> = 6.2 Hz, 3H), 0.90 (d, <i>J</i> = 6.4 Hz, 3H); <sup>19</sup>F NMR (282 MHz, CDCl<sub>3</sub>): δ −157.36; HRMS (ES): MH<sup>+</sup> calcd for C<sub>21</sub>H<sub>21</sub>FN<sub>7</sub>O<sub>6</sub>, 486.1532; found, 486.1522; [α]<sub class="stack">D</sub><sup class="stack">20</sup> −242 (<i>c</i> 0.1; DMSO).</div></div><div id="sec4_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> 6-((2<i>R</i>,6<i>R</i>)-2,6-Dimethylmorpholino)-5-(1,3-dioxolan-2-yl)-7-fluoro-3-(5-(methoxymethyl)-1<i>H</i>-1,2,4-triazol-1-yl)benzo[<i>d</i>]isoxazole (<b>6b</b>, R<sub>5</sub> = CH<sub>2</sub>OCH<sub>3</sub>, Y = 1,3-Dioxolanyl)</h3><div class="NLM_p last">NaH (60% dispersion, 0.157 g, 3.93 mmol) was added to a solution of (1-(6-((2<i>R</i>,6<i>R</i>)-2,6-dimethylmorpholino)-5-(1,3-dioxolan-2-yl)-7-fluorobenzo[<i>d</i>]isoxazol-3-yl)-1<i>H</i>-1,2,4-triazol-5-yl)methanol (1.1 g, 2.62 mmol) and CH<sub>3</sub>I (0.49 mL, 7.9 mmol) in 5 mL of DMF at rt. After stirring overnight, additional CH<sub>3</sub>I (100 μL) and NaH (30 mg) were added sequentially, and the mixture was stirred at rt for 4 h. The mixture was quenched with 5% aqueous NH<sub>4</sub>Cl and the solvent was removed. The residue was taken up in EtOAc and washed with water and brine. The EtOAc was dried (MgSO<sub>4</sub>) and concentrated, and the residue was chromatographed on silica gel (0–40% EtOAc gradient in CH<sub>2</sub>Cl<sub>2</sub>) to afford the title compound. LC–MS (ES): MH<sup>+</sup> 434.3 for C<sub>20</sub>H<sub>25</sub>FN<sub>5</sub>O<sub>5</sub>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.27 (d, <i>J</i> = 0.9 Hz, 1H), 8.20 (s, 1H), 6.31 (s, 1H), 5.04 (s, 2H), 4.14–4.25 (m, 4H), 4.03–4.11 (m, 2H), 3.54 (s, 3H), 3.26–3.40 (m, 2H), 3.01 (dd, <i>J</i> = 5.5, 11.1 Hz, 2H), 1.34 (d, <i>J</i> = 6.4 Hz, 6H); <sup>19</sup>F NMR (282 MHz, CDCl<sub>3</sub>): δ −144.95.</div></div><div id="sec4_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> (2<i>R</i>,4<i>S</i>,4a<i>S</i>)-11-Fluoro-8-(5-(methoxymethyl)-1<i>H</i>-1,2,4-triazol-1-yl)-2,4-dimethyl-2,4,4a,6-tetrahydro-1<i>H</i>,1′<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-2′,4′,6′(3′<i>H</i>)-trione (<b>11h</b>)</h3><div class="NLM_p last">The general T-reaction procedure was used with 918 mg (2.12 mmol) of the preceding compound. Purification by SFC, an Chiralpak AC column, and 30% EtOH in CO<sub>2</sub> affords 388 mg (37%) of the title compound. LC–MS rt = 2.30 min, (ES): MH<sup>+</sup> 500.1 for C<sub>22</sub>H<sub>23</sub>FN<sub>7</sub>O<sub>6</sub>; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.82 (br s, 1H), 11.47 (br s, 1H), 8.44 (s, 1H), 7.55 (s, 1H), 4.91 (s, 2H), 4.15 (d, <i>J</i> = 13.22 Hz, 1H), 3.99 (d, <i>J</i> = 8.88 Hz, 1H), 3.62–3.90 (m, 3H), 3.37 (s, 3H), 3.15 (t, <i>J</i> = 12.09 Hz, 1H), 2.94 (d, <i>J</i> = 13.97 Hz, 1H), 1.16 (d, <i>J</i> = 6.23 Hz, 3H), 0.90 (d, <i>J</i> = 6.42 Hz, 3H); <sup>19</sup>F NMR (282 MHz, CDCl<sub>3</sub>): δ −157.35; <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 170.8, 167.6, 154.7, 153.2 (d, <i>J</i><sub>CF</sub> = 12.8 Hz), 152.8, 152.0, 149.4, 135.9, 133.2 (d, <i>J</i><sub>CF</sub> = 240.1 Hz), 124.9, 116.2, 106.5, 72.1, 71.7, 65.0, 64.5, 58.4, 56.3 (d, <i>J</i><sub>CF</sub> = 9.2 Hz), 52.9, 38.2, 18.2, 18.1; HRMS (ES): MH<sup>+</sup> calcd for C<sub>22</sub>H<sub>23</sub>FN<sub>7</sub>O<sub>6</sub>, 500.1688; found, 500.1684; [α]<sub class="stack">D</sub><sup class="stack">20</sup> −235 (<i>c</i> 0.1; DMSO).</div></div><div id="sec4_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> 1-(6-((2<i>R</i>,6<i>R</i>)-2,6-Dimethylmorpholino)-5-(1,3-dioxolan-2-yl)-7-fluorobenzo[<i>d</i>]isoxazol-3-yl)-1<i>H</i>-1,2,4-triazole-5-carbaldehyde (<b>6a</b>, R<sub>5</sub> = CHO, Y = 1,3-Dioxolanyl)</h3><div class="NLM_p last">LDA (1.8 M in heptane/THF/ethylbenzene) (3.21 mL, 5.78 mmol) was added over 10 min to a solution of 1.5 g (3.85 mmol) of 6-((2<i>R</i>,6<i>R</i>)-2,6-dimethylmorpholino)-5-(1,3-dioxolan-2-yl)-7-fluoro-3-(1<i>H</i>-1,2,4-triazol-1-yl)benzo[<i>d</i>]isoxazole (<b>6</b>, azole = 1<i>H</i>-1,2,4-triazole, X = F, Y = 1,3-dioxolanyl) dissolved in THF (20 mL) at −78 °C. After stirring for 20 min, morpholine-4-carbaldehyde (0.532 g, 4.62 mmol) was added, and stirring was continued for 1 h at −78 °C. The mixture was quenched with saturated aqueous NH<sub>4</sub>Cl before warming to rt and extracting with EtOAc. The EtOAc was washed with brine, dried (Na<sub>2</sub>CO<sub>4</sub>), and concentrated. The residue was chromatographed on silica gel (0–40% EtOAc gradient in CH<sub>2</sub>Cl<sub>2</sub>) to afford 1.48 g (92%) of the title compound. LC–MS (ES): MH<sup>+</sup> 418.1 for C<sub>19</sub>H<sub>21</sub>FN<sub>5</sub>O<sub>5</sub>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 10.47 (s, 1H), 8.39 (s, 1H), 8.04 (d, <i>J</i> = 0.76 Hz, 1H), 6.28 (s, 1H), 5.30 (s, 1H), 4.11–4.25 (m, 4H), 4.01–4.09 (m, 2H), 3.34 (br s, 2H), 2.92–3.07 (m, 2H), 1.34 (d, <i>J</i> = 5.85 Hz, 6H); <sup>19</sup>F NMR (282 MHz, CDCl<sub>3</sub>): δ −142.23.</div></div><div id="sec4_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> 1-(1-(6-((2<i>R</i>,6<i>R</i>)-2,6-Dimethylmorpholino)-5-(1,3-dioxolan-2-yl)-7-fluorobenzo[<i>d</i>]isoxazol-3-yl)-1<i>H</i>-1,2,4-triazol-5-yl)-<i>N</i>,<i>N</i>-dimethylmethanamine (<b>6b</b>, R<sub>5</sub> = CH<sub>2</sub>N(CH<sub>3</sub>)<sub>2</sub>, Y = 1,3-Dioxolanyl)</h3><div class="NLM_p last">Dimethylamine (2 M in THF, 0.180 mL, 0.36 mmol), acetic acid (0.021 mL, 0.36 mmol), and sodium triacetoxyborohydride (112 mg, 0.53 mmol) were sequentially added to a solution of the preceding compound (100 mg, 0.24 mmol) in 5 mL of CH<sub>2</sub>Cl<sub>2</sub> at rt, and the mixture was stirred at rt overnight. After quenching with saturated aqueous Na<sub>2</sub>CO<sub>4</sub>, the mixture was extracted with EtOAc, which was washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated. The residue was purified by reverse-phase HPLC [10–50% gradient of CH<sub>3</sub>CN in water with 0.1% trifluoroacetyl (TFA)] to afford 75 mg (78%). LC–MS (ES): MH<sup>+</sup> 403.1 for C<sub>21</sub>H<sub>28</sub>FN<sub>6</sub>O<sub>4</sub>.</div></div><div id="sec4_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> (2<i>R</i>,4<i>S</i>,4a<i>S</i>)-8-(5-((Dimethylamino)methyl)-1<i>H</i>-1,2,4-triazol-1-yl)-11-fluoro-2,4-dimethyl-2,4,4a,6-tetrahydro-1<i>H</i>,1′<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-2′,4′,6′(3′<i>H</i>)-trione (<b>11i</b>)</h3><div class="NLM_p last">The general T-reaction procedure was used with 98 mg (0.24 mmol) of the preceding compound. Purification by reverse-phase HPLC and 10–35% CH<sub>3</sub>CN gradient in water with 0.1% TFA buffer affords 51 mg (42%) of the title compound as the TFA salt. LC–MS rt = 1.6 min, (ES): MH<sup>+</sup> 513.3 for C<sub>23</sub>H<sub>26</sub>FN<sub>8</sub>O<sub>5</sub>; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.61 (br s, 2H), 8.38 (s, 1H), 7.52 (s, 1H), 4.08–4.21 (m, 1H), 3.95–4.02 (m, 3H), 3.62–3.87 (m, 3H), 3.09–3.20 (m, 2H), 2.93 (d, <i>J</i> = 14.0 Hz, 1H), 2.22 (s, 6H), 1.16 (d, <i>J</i> = 6.0 Hz, 3H), 0.90 (d, <i>J</i> = 6.4 Hz, 3H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 170.8, 167.6, 157.9 (q, <i>J</i><sub>CF</sub> = 32.7 Hz, TFA), 155.4, 152.6 (d, <i>J</i><sub>CF</sub> = 12.8 Hz), 152.1, 151.8, 149.5, 135.9, 133.3 (d, <i>J</i><sub>CF</sub> = 240.1 Hz), 124.4, 116.9, 116.6 (q, <i>J</i><sub>CF</sub> = 319.8 Hz, TFA), 106.0, 72.1, 71.7, 64.5, 63.3, 56.3 (d, <i>J</i><sub>CF</sub> = 9.2 Hz), 55.3, 52.9, 51.4, 38.2, 37.9, 18.2, 18.1; <sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>): δ −157.43; HRMS (ES) MH<sup>+</sup> calcd for C<sub>23</sub>H<sub>26</sub>FN<sub>8</sub>O<sub>5</sub>, 513.2005; found, 513.2024; [α]<sub class="stack">D</sub><sup class="stack">20</sup> −212 (<i>c</i> 0.1; DMSO).</div></div><div id="sec4_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> 5-(Dimethoxymethyl)-6-((2<i>R</i>,6<i>R</i>)-2,6-dimethylmorpholino)-7-fluoro-3-(5-methoxy-1<i>H</i>-1,2,4-triazol-1-yl)benzo[<i>d</i>]isoxazole</h3><div class="NLM_p last">NaOMe (0.578 g, 10.71 mmol) was added portionwise over 5 min to a solution of 3.8 g (8.92 mmol) of 3-(5-chloro-1<i>H</i>-1,2,4-triazol-1-yl)-5-(dimethoxymethyl)-6-((2<i>R</i>,6<i>R</i>)-2,6-dimethylmorpholino)-7-fluorobenzo[<i>d</i>]isoxazole (<b>6c</b>, Y = dimethoxymethyl) in 50 mL of DMF at rt. After stirring for 90 min, the mixture was partitioned between EtOAc and water. The EtOAc was separated, washed with brine, dried (MgSO<sub>4</sub>), and concentrated. The residue was chromatographed on silica gel (10–30% EtOAc gradient in hexanes) to afford 2.89 g (77%) of the title compound as a white solid. LCMS (ES): MH<sup>+</sup> 422.2 for C<sub>19</sub>H<sub>24</sub>FN<sub>5</sub>O<sub>5</sub>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.13 (s, 1H), 7.74 (s, 1H), 5.79 (s, 1H), 4.24 (s, 3H), 4.00–4.20 (m, 2H), 3.30 (d, <i>J</i> = 1.32 Hz, 6H), 2.74–2.96 (m, 2H), 1.18–1.38 (m, 6H); <sup>19</sup>F NMR (282 MHz, CDCl<sub>3</sub>): δ −142.34.</div></div><div id="sec4_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> (2<i>R</i>,4<i>S</i>,4a<i>S</i>)-11-Fluoro-8-(5-methoxy-1<i>H</i>-1,2,4-triazol-1-yl)-2,4-dimethyl-2,4,4a,6-tetrahydro-1<i>H</i>,1′<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-2′,4′,6′(3′<i>H</i>)-trione (<b>11j</b>)</h3><div class="NLM_p last">The general T-reaction procedure was used with 2.24 g (5.55 mmol) of the preceding compound. Purification by SFC, a Chiralpak IA column, and a gradient of 60% EtOH in CO<sub>2</sub> affords 1.72 g (64%) of the title compound. UPLC rt = 0.87 min, (ES): MH<sup>+</sup> 486.2 for C<sub>21</sub>H<sub>21</sub>ClN<sub>7</sub>O<sub>6</sub>; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.80 (br s, 1H), 11.47 (br s, 1H), 8.06 (s, 1H), 7.51 (s, 1H), 4.19 (s, 3H), 4.13 (d, <i>J</i> = 13.0 Hz, 1H), 3.97 (d, <i>J</i> = 8.9 Hz, 1H), 3.82 (d, <i>J</i> = 8.9 Hz, 1H), 3.75 (d, <i>J</i> = 14.5 Hz, 1H), 3.68 (dd, <i>J</i> = 6.42, 8.9 Hz, 1H), 3.08–3.19 (m, 1H), 2.93 (d, <i>J</i> = 14.2 Hz, 1H), 1.15 (d, <i>J</i> = 6.2 Hz, 3H), 0.90 (d, <i>J</i> = 6.2 Hz, 3H); <sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>): δ −157.39; <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): δ 170.8, 167.6, 159.9, 151.0, 149.4, 135.6, 133.3 (d, <i>J</i><sub>CF</sub> = 241.5 Hz), 124.4, 116.3, 106.6, 72.1, 71.7, 64.5, 59.4, 56.4, 52.9, 38.3, 18.1, 18.1; HRMS (ES) MH<sup>+</sup> calcd for C<sub>21</sub>H<sub>21</sub>FN<sub>7</sub>O<sub>6</sub>, 486.1532; found, 486.1531; [α]<sub class="stack">D</sub><sup class="stack">20</sup> −251 (<i>c</i> 0.1; DMSO).</div></div><div id="sec4_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> 6-((2<i>R</i>,6<i>R</i>)-2,6-Dimethylmorpholino)-5-(1,3-dioxolan-2-yl)-7-fluoro-3-(5-(2-methoxyethoxy)-1<i>H</i>-1,2,4-triazol-1-yl)benzo[<i>d</i>]isoxazole (<b>6d</b>, R<sub>3</sub> = −OCH<sub>2</sub>CH<sub>2</sub>–OCH<sub>3</sub>, Y = 1,3-Dioxolanyl)</h3><div class="NLM_p last">NaH (60% in oil, 32.5 mg, 0.81 mmol) was added to a solution of 2-methoxyethanol (0.058 mL, 0.74 mmol) in 3 mL of DMF at rt. After stirring for 15 min, a solution of 313 mg (0.74 mmol) of 3-(5-chloro-1<i>H</i>-1,2,4-triazol-1-yl)-6-((2<i>R</i>,6<i>R</i>)-2,6-dimethylmorpholino)-5-(1,3-dioxolan-2-yl)-7-fluorobenzo[<i>d</i>]isoxazole (<b>6c</b>, Y = 1,3-dioxolanyl) in 4 mL of DMF was added, and the mixture was stirred at rt for 20 min. The mixture was partitioned between EtOAc and water. The phases were separated, and the aqueous layer was extracted with EtOAc. The combined EtOAc extracts were washed with brine, dried (MgSO<sub>4</sub>), and concentrated. The residue was chromatographed on silica gel (10–40% EtOAc gradient in hexanes) to afford the title compound (182 mg, 53%) as a white solid. LCMS (ES) MH<sup>+</sup>: 464.1 for C<sub>21</sub>H<sub>27</sub>FN<sub>5</sub>O<sub>6</sub>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.20 (d, <i>J</i> = 0.94 Hz, 1H), 7.80 (s, 1H), 7.27 (s, 1H), 6.30 (s, 1H), 4.72–4.84 (m, 2H), 4.10–4.24 (m, 4H), 3.99–4.09 (m, 2H), 3.80–3.91 (m, 2H), 3.44 (s, 3H), 3.32 (br s, 1H), 3.01 (d, <i>J</i> = 5.46 Hz, 2H), 1.26–1.47 (m, 6H); <sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>): δ −143.06.</div></div><div id="sec4_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> (2<i>R</i>,4<i>S</i>,4a<i>S</i>)-11-Fluoro-8-(5-(2-methoxyethoxy)-1<i>H</i>-1,2,4-triazol-1-yl)-2,4-dimethyl-2,4,4a,6-tetrahydro-1<i>H</i>,1′<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-2′,4′,6′(3′<i>H</i>)-trione (<b>11k</b>)</h3><div class="NLM_p last">The general T-reaction procedure was used with 182 mg (0.39 mmol) of the preceding compound. Purification by chromatography on silica gel (10–50% EtOAc gradient in CH<sub>2</sub>Cl<sub>2</sub>) affords 40 mg (19%) of the title compound. LC–MS rt = 2.19 min, (ES): MH<sup>+</sup> 530.2 for C<sub>23</sub>H<sub>25</sub>FN<sub>7</sub>O<sub>7</sub>; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.76 (s, 1H), 11.40 (s, 1H), 7.98 (s, 1H), 7.43 (s, 1H), 4.48–4.84 (m, 2H), 4.06 (d, <i>J</i> = 13.0 Hz, 1H), 3.90 (d, <i>J</i> = 8.9 Hz, 1H), 3.69–3.83 (m, 1H), 3.64–3.69 (m, 2H), 3.56–3.63 (m, 1H), 3.23 (s, 3H), 3.06 (t, <i>J</i> = 12.9 Hz, 1H), 2.87 (d, <i>J</i> = 14.2 Hz, 1H), 1.08 (d, <i>J</i> = 6.2 Hz, 3H), 0.83 (d, <i>J</i> = 6.4 Hz, 3H); <sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>): δ −157.38; <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): δ 170.8, 167.6, 159.3, 153.0 (d, <i>J</i><sub>CF</sub> = 13.2 Hz), 150.9, 150.8, 149.4, 135.6, 133.3 (d, <i>J</i><sub>CF</sub> = 239.9 Hz), 124.4, 116.2, 106.6, 72.1, 71.9, 71.7, 69.5, 64.5, 58.2, 56.3 (d, <i>J</i><sub>CF</sub> = 10.5 Hz), 52.9, 38.3, 18.2, 18.1; HRMS (ES): MH<sup>+</sup> calcd for C<sub>23</sub>H<sub>25</sub>FN<sub>7</sub>O<sub>7</sub>, 530.1794; found, 530.1814; [α]<sub class="stack">D</sub><sup class="stack">20</sup> −213 (<i>c</i> 0.1; DMSO).</div></div><div id="sec4_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> 1-(5-(Dimethoxymethyl)-6-((2<i>R</i>,6<i>R</i>)-2,6-dimethylmorpholino)-7-fluorobenzo[<i>d</i>]isoxazol-3-yl)-<i>N</i>,<i>N</i>-dimethyl-1<i>H</i>-1,2,4-triazol-5-amine (<b>6d</b>, R<sub>3</sub> = −N(CH<sub>3</sub>)<sub>2</sub>, Y = 1,3-Dioxolanyl)</h3><div class="NLM_p last">A mixture of 0.30 g (0.70 mmol) of 3-(5-chloro-1<i>H</i>-1,2,4-triazol-1-yl)-5-(dimethoxymethyl)-6-((2<i>R</i>,6R)-2,6-dimethylmorpholino)-7-fluorobenzo[<i>d</i>]isoxazole (<b>6c</b>, Y = dimethoxymethyl) in 4 mL of THF and 2.0 M dimethylamine in THF (0.7 mL, 1.4 mmol) was heated in a microwave at 100 °C for 60 min. The reaction mixture was diluted with EtOAc and washed with aqueous NaHCO<sub>3</sub> and brine. The organic solution was dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated. The residue was chromatographed on silica gel (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford 240 mg (78%) of the title compound as a white solid. LCMS (ES) MH<sup>+</sup>: 435.0 for C<sub>20</sub>H<sub>28</sub>FN<sub>6</sub>O<sub>4</sub>; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.01 (s, 1H), 7.98 (s, 1H), 5.78 (s, 1H), 4.0–4.2 (m, 2H), 3.33 (s, 3H), 3.29 (s, 3H), 3.15–3.3 (br s, 2H), 2.96 (s, 6H), 2.84 (dd, <i>J</i> = 11.1, 5.7 Hz, 2H) 1.25 (br s, 6H); <sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>): δ −143.79.</div></div><div id="sec4_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> (2<i>R</i>,4<i>S</i>,4a<i>S</i>)-8-(5-(Dimethylamino)-1<i>H</i>-1,2,4-triazol-1-yl)-11-fluoro-2,4-dimethyl-2,4,4a,6-tetrahydro-1<i>H</i>,1′<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-2′,4′,6′(3′<i>H</i>)-trione (<b>11l</b>)</h3><div class="NLM_p last">The general T-reaction procedure was used with 210 mg (0.48 mmol) of the preceding. Purification by SFC, a Chiralpak IA column, and a gradient of 25% <i>i</i>-PrOH in CO<sub>2</sub> affords 119 mg (49%) of the title compound. LCMS rt = 2.26 min, (ES): MH<sup>+</sup> 499.0 for C<sub>22</sub>H<sub>24</sub>FN<sub>8</sub>O<sub>5</sub>; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.76 (br s, 1H), 11.42 (br s, 1H), 7.85 (s, 1H), 7.33 (s, 1H), 4.06 (d, <i>J</i> = 12.8 Hz, 1H), 3.90 (d, <i>J</i> = 8.85 Hz, 1H), 3.55–3.78 (m, 3H), 2.99–3.14 (m, 1H), 2.85 (s, 6H); 2.8–2.9 (m, 1H), 1.08 (d, <i>J</i> = 6.0 Hz, 3H), 0.83 (d, <i>J</i> = 6.4 Hz, 3H); <sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>): δ −157.38; <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 170.8, 167.7, 159.6, 153.0 (d, <i>J</i><sub>CF</sub> = 12.8 Hz), 152.7 (d, <i>J</i><sub>CF</sub> = 1.8 Hz), 151.7, 149.4, 133.3 (d, <i>J</i><sub>CF</sub> = 240.1 Hz), 115.9, 107.8, 72.1, 71.7, 64.5, 56.3 (d, <i>J</i><sub>CF</sub> = 9.2 Hz), 52.9, 40.7, 38.2, 18.2, 18.1; HRMS (ES): MH<sup>+</sup> calcd for C<sub>21</sub>H<sub>22</sub>FN<sub>8</sub>O<sub>5</sub>, 485.1692; found, 485.1711; [α]<sub class="stack">D</sub><sup class="stack">20</sup> −244 (<i>c</i> 1; DMSO).</div></div><div id="sec4_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> 5-(Dimethoxymethyl)-6-((2<i>R</i>,6<i>R</i>)-2,6-dimethylmorpholino)-7-fluoro-3-(5-morpholino-1<i>H</i>-1,2,4-triazol-1-yl)benzo[<i>d</i>]isoxazole (<b>6d</b>, R<sub>3</sub> = Morpholinyl, Y = Dimethoxymethyl)</h3><div class="NLM_p last">A mixture of 178 mg (0.42 mmol) of 3-(5-chloro-1<i>H</i>-1,2,4-triazol-1-yl)-6-((2<i>R</i>,6<i>R</i>)-2,6-dimethylmorpholino)-5-(1,3-dioxolan-2-yl)-7-fluorobenzo[<i>d</i>]isoxazole (<b>6c</b>, Y = dimethoxymethyl), Et<sub>3</sub>N (0.76 mL, 5.4 mmol), and morpholine (89 mg, 1.02 mmol) in THF (40 mL) was heated at 70 °C for 6 h. After cooling to rt and quenching with saturated aqueous NH<sub>4</sub>Cl, the mixture was extracted twice with EtOAc. The combined EtOAc extracts were washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated to afford a residue that was chromatographed on silica gel (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford 122 mg (61%) of the title compound. LC–MS (ES): MH<sup>+</sup> 477.1 for C<sub>22</sub>H<sub>30</sub>FN<sub>6</sub>O<sub>5</sub>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.16 (s, 1H), 7.80 (s, 1H), 5.79 (s, 1H), 4.12 (dt, <i>J</i> = 3.6, 5.8 Hz, 2H), 3.75–3.84 (m, 4H), 3.35–3.41 (m, 4H), 2.84 (dd, <i>J</i> = 5.4, 10.8 Hz, 2H), 1.27 (br s, 6H); <sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>): δ −142.65.</div></div><div id="sec4_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> (2<i>R</i>,4<i>S</i>,4a<i>S</i>)-11-Fluoro-2,4-dimethyl-8-(5-morpholino-1<i>H</i>-1,2,4-triazol-1-yl)-2,4,4a,6-tetrahydro-1<i>H</i>,1′<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-2′,4′,6′(3′H)-trione (<b>11m</b>)</h3><div class="NLM_p last">The general T-reaction procedure was used with 110 mg (0.23 mmol) of the preceding compound. Purification by SFC, an (S,S) Whelk-O1 column, and 25% EtOH in CO<sub>2</sub> affords 179 mg (66%) of the title compound. LC–MS rt = 2.16 min, (ES): MH<sup>+</sup> 540.9 for C<sub>24</sub>H<sub>26</sub>FN<sub>8</sub>O<sub>6</sub>; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.76 (br s, 1H), 11.42 (br s, 1H), 7.98 (s, 1H), 7.44 (s, 1H), 4.06 (d, <i>J</i> = 13.0 Hz, 1H), 3.90 (d, <i>J</i> = 8.85 Hz, 1H), 3.67–3.81 (m, 2H), 3.57–3.66 (m, 6H), 3.00–3.13 (m, 1H), 2.86 (d, <i>J</i> = 14.1 Hz, 1H), 1.09 (d, <i>J</i> = 6.2 Hz, 3H), 0.83 (d, <i>J</i> = 6.4 Hz, 3H); <sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>): δ −157.51; <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 170.8, 167.7, 158.9, 153.0, 152.3, 151.8, 149.4, 135.6, 133.2, 124.4, 116.4, 107.1, 72.1, 71.7, 65.3, 64.5, 56.3, 52.9, 49.1, 38.2, 18.2, 18.1; HRMS (ES): MH<sup>+</sup> calcd for C<sub>24</sub>H<sub>26</sub>FN<sub>8</sub>O<sub>6</sub>, 541.1954; found, 541.1960; [α]<sub class="stack">D</sub><sup class="stack">20</sup> −219 (<i>c</i> 0.1; DMSO).</div></div><div id="sec4_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> 1-(5-(Dimethoxymethyl)-6-((2<i>R</i>,6<i>R</i>)-2,6-dimethylmorpholino)-7-fluorobenzo[<i>d</i>]isoxazol-3-yl)-1<i>H</i>-1,2,4-triazol-5-amine (<b>6c</b>, R<sub>5</sub> = NH<sub>2</sub>, Y = Dimethoxymethyl)</h3><div class="NLM_p last">A mixture of 1.26 g (2.96 mmol) of 3-(5-chloro-1<i>H</i>-1,2,4-triazol-1-yl)-5-(dimethoxymethyl)-6-((2<i>R</i>,6<i>R</i>)-2,6-dimethylmorpholino)-7-fluorobenzo[<i>d</i>]isoxazole (<b>6c</b>, Y = dimethoxymethyl) and 29% aqueous ammonium hydroxide (7 mL, 59 mmol) in THF (20 mL) was heated at rt for 2 d. Additional 29% aqueous ammonium hydroxide (7 mL, 59 mmol) was added, and stirring at rt was continued for 3 d. The mixture was partitioned between EtOAc and water. The EtOAc layer was separated, and the aqueous layer was extracted with additional EtOAc. The combined EtOAc extracts were washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated to afford a residue that was purified on silica gel (15–45% gradient elution with EtOAc in CH<sub>2</sub>Cl<sub>2</sub>) to afford the title compound (853 mg, 71%) as a white solid. LCMS (ES): MH<sup>+</sup> 407.2 for C<sub>18</sub>H<sub>23</sub>FN<sub>6</sub>O<sub>4</sub>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.22 (s, 1H), 7.9 (s, 1H), 7.38 (s, 2H), 5.79 (s, 1H), 4.05–4.2 (m, 2H), 3.3 (s, 6H), 3.2–3.3 (m, 2H), 2.6–2.9 (m, 2H), 1.25 (d, <i>J</i> = 6 Hz, 6H); <sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>): δ −143.9.</div></div><div id="sec4_42" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> (2<i>R</i>,4<i>S</i>,4a<i>S</i>)-8-(5-Amino-1<i>H</i>-1,2,4-triazol-1-yl)-11-fluoro-2,4-dimethyl-1,2,4,4a-tetrahydro-2′<i>H</i>,6<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-2′,4′,6′(1′<i>H</i>,3′<i>H</i>)-trione (<b>11n</b>)</h3><div class="NLM_p last">The general T-reaction procedure was used with 833 mg (2.05 mmol) of the preceding compound and heating in 100% acetic acid for 7 h. The solvent was removed, and the residue was taken up in THF. The insoluble material was removed by filtration, and the filtrate was concentrated to afford a residue that was purified by SFC, a Chiralpak IC column, and a gradient of 25% EtOH in CO<sub>2</sub> to afford 296 mg (66%) of the title compound. LCMS rt = 2.44 min, (ES): MH<sup>+</sup> 471.1 for C<sub>20</sub>H<sub>19</sub>FN<sub>8</sub>O<sub>5</sub>; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.8 (br s, 1H), 11.5 (br s, 1H), 7.80 (s, 1H), 7.65 (s, 1H), 7.28 (s, 2H), 4.13 (d, <i>J</i> = 12 Hz, 1H), 3.98 (d, <i>J</i> = 9 Hz, 1H), 3.7–3.9 (m, 2H), 3.65–3.7 (m, 1H), 3.10–3.20 (m, 1H), 2.92 (d, <i>J</i> = 15 Hz, 1H), 1.1 (d, <i>J</i> = 6 Hz, 3H), 0.90 (d, <i>J</i> = 6 Hz, 3H); <sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>): δ −157.37.</div></div><div id="sec4_43" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> 1-(6-((2<i>R</i>,6<i>R</i>)-2,6-Dimethylmorpholino)-5-(1,3-dioxolan-2-yl)-7-fluorobenzo[<i>d</i>]isoxazol-3-yl)-<i>N</i>-methyl-1<i>H</i>-1,2,4-triazol-5-amine (<b>6d</b>, R<sub>5</sub> = −NHCH<sub>3</sub>, Y = 1,3-Dioxolanyl)</h3><div class="NLM_p last">A slurried mixture of 3.2 g (7.55 mmol) of 3-(5-chloro-1<i>H</i>-1,2,4-triazol-1-yl)-6-((2<i>R</i>,6<i>R</i>)-2,6-dimethylmorpholino)-5-(1,3-dioxolan-2-yl)-7-fluorobenzo[<i>d</i>]isoxazole (<b>6c</b>, Y = 1,3-dioxolanyl), methylamine hydrochloride (2.55 g, 37.8 mmol), and Et<sub>3</sub>N (1.05 mL, 7.55 mmol) in THF (40 mL) was heated at 70 °C for 6 h. After cooling to rt and quenching with saturated aqueous NH<sub>4</sub>Cl, the mixture was extracted twice with EtOAc. The combined EtOAc extracts were washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated to afford a residue that was purified on silica gel (20% CH<sub>2</sub>Cl<sub>2</sub> in EtOAc) to afford the title compound (2.62 g, 83%) as a white solid. LCMS (ES): MH<sup>+</sup> 419.2 for C<sub>19</sub>H<sub>24</sub>FN<sub>6</sub>O<sub>4</sub>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.41 (d, <i>J</i> = 0.8 Hz, 1H), 7.76 (d, <i>J</i> = 0.4 Hz, 1H), 6.67 (q, <i>J</i> = 4.7 Hz, 1H), 6.32 (s, 1H), 4.12–4.32 (m, 4H), 3.91–4.12 (m, 2H), 3.32 (br s, 2H), 3.25 (d, <i>J</i> = 4.9 Hz, 3H), 3.00 (dd, <i>J</i> = 11.1, 5.7 Hz, 2H), 1.35 (d, <i>J</i> = 6 Hz, 6H); <sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>): δ −143.3.</div></div><div id="sec4_44" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> (2<i>R</i>,4<i>S</i>,4a<i>S</i>)-11-Fluoro-2,4-dimethyl-8-(5-(methylamino)-1<i>H</i>-1,2,4-triazol-1-yl)-2,4,4a,6-tetrahydro-1<i>H</i>,1′<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-2′,4′,6′(3′<i>H</i>)-trione (<b>11o</b>)</h3><div class="NLM_p last">The general T-reaction procedure was used with 2.62 g (6.26 mmol) of the preceding compound. Purification by SFC, a Chiralpak IC column, and a gradient of 25% EtOH in CO<sub>2</sub> affords 2.0 g (66%) of the title compound. LCMS rt = 2.44 min, (ES) MH<sup>+</sup>: 485.1 for C<sub>21</sub>H<sub>22</sub>FN<sub>8</sub>O<sub>5</sub>; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.93 (br s, 1H), 7.89 (s, 1H), 7.66 (br s, 1H), 7.62 (s, 1H), 7.19 (br s, 1H, methylamine NH), 4.23 (d, <i>J</i> = 13.1 Hz, 1H), 4.16 (d, <i>J</i> = 8.8 Hz, 1H), 3.90–4.06 (m, 2H), 3.74–3.90 (m, 2H), 3.40 (d, <i>J</i> = 5.0 Hz, 2H), 3.10–3.35 (m, 3H), 1.27 (d, <i>J</i> = 6.15 Hz, 3H), 1.05 (d, <i>J</i> = 6.3 Hz, 3H); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.85 (br s, 1H), 11.50 (br s, 1H), 7.86 (s, 1H), 7.66 (s, 1H), 7.10 (q, <i>J</i> = 4.6 Hz, 1H, methylamine NH), 4.14 (d, <i>J</i> = 12.9 Hz, 1H), 3.98 (d, <i>J</i> = 8.8 Hz, 1H), 3.77–3.88 (m, 2H), 3.62–3.75 (m, 1H), 3.10–3.20 (m, 1H), 3.03 (d, <i>J</i> = 4.73 Hz, 3H), 2.92 (d, <i>J</i> = 14.19 Hz, 1H), 1.16 (d, <i>J</i> = 6.15 Hz, 3H), 0.90 (d, <i>J</i> = 6.3 Hz, 3H); <sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>): δ −157.37; <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): δ 170.8, 167.7, 156.3, 152.4 (d, <i>J</i><sub>CF</sub> = 13.2 Hz), 152.3, 152.1, 149.4, 135.8, 133.3 (d, <i>J</i><sub>CF</sub> = 239.3 Hz), 124.1, 117.1, 106.1, 72.1, 71.7, 64.5, 56.3 (d, <i>J</i><sub>CF</sub> = 9.9 Hz), 53.0, 38.2, 30.3, 18.2, 18.1; HRMS (ES): MH<sup>+</sup> calcd for C<sub>21</sub>H<sub>22</sub>FN<sub>8</sub>O<sub>5</sub>, 485.1692; found, 485.1711; [α]<sub class="stack">D</sub><sup class="stack">20</sup> −264 (<i>c</i> 0.1; DMSO).</div></div><div id="sec4_45" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> 1-(6-((2<i>R</i>,6<i>R</i>)-2,6-Dimethylmorpholino)-5-(1,3-dioxolan-2-yl)-7-fluorobenzo[<i>d</i>]isoxazol-3-yl)-<i>N</i>-ethyl-1<i>H</i>-1,2,4-triazol-5-amine (<b>6d</b>, R<sub>3</sub> = NHCH<sub>2</sub>CH<sub>3</sub>, Y = 1,3-Dioxolanyl)</h3><div class="NLM_p last">A solution of 0.23 g (0.54 mmol) of 3-(5-chloro-1<i>H</i>-1,2,4-triazol-1-yl)-6-((2<i>R</i>,6<i>R</i>)-2,6-dimethylmorpholino)-5-(1,3-dioxolan-2-yl)-7-fluorobenzo[<i>d</i>]isoxazole (<b>6c</b>, Y = 1,3-dioxolanyl) in 4 mL of THF and 2.0 M ethylamine in THF (1.0 mL, 2.00 mmol) was heated in a microwave at 100 °C for 60 min. The reaction mixture was diluted with EtOAc and washed with aqueous NaHCO<sub>3</sub> and brine. The organic solution was dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated. The residue was chromatographed on silica gel (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford 155 mg (66%) of the title compound as a white solid. LC–MS (ES): MH<sup>+</sup> 433.2 for C<sub>20</sub>H<sub>26</sub>FN<sub>6</sub>O<sub>4</sub>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.42 (d, <i>J</i> = 0.75 Hz, 1H), 7.79 (s, 1H), 6.78 (br s, 1H), 6.33 (s, 1H), 4.16–4.29 (m, 4H), 4.03–4.12 (m, 2H), 3.63–3.76 (m, 2H), 3.34 (br s, 2H), 3.02 (dd, <i>J</i> = 5.5, 11.1 Hz, 2H), 1.40 (t, <i>J</i> = 7.3 Hz, 3H), 1.35 (d, <i>J</i> = 4.9 Hz, 6H); <sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>): δ −143.30.</div></div><div id="sec4_46" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> (2<i>R</i>,4<i>S</i>,4a<i>S</i>)-8-(5-(Ethylamino)-1<i>H</i>-1,2,4-triazol-1-yl)-11-fluoro-2,4-dimethyl-2,4,4a,6-tetrahydro-1<i>H</i>,1′<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-2′,4′,6′(3′<i>H</i>)-trione (<b>11p</b>)</h3><div class="NLM_p last">The general T-reaction procedure was used with 226 mg (0.44 mmol) of the preceding compound. Purification by SFC, a Chiralpak IC column, and 35% CH<sub>3</sub>CN/MeOH (85:15) in CO<sub>2</sub> affords 130 mg (69%) of the title compound. LC–MS rt = 2.76 min, (ES): MH<sup>+</sup> 499.1 for C<sub>22</sub>H<sub>24</sub>FN<sub>8</sub>O<sub>5</sub>; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.63 (br s, 2H), 7.85 (br s, 1H), 7.65 (br s, 1H), 7.11 (br s, 1H), 4.13 (d, <i>J</i> = 10.9 Hz, 1H), 3.96 (br s, 1H), 3.62–3.89 (m, 3H), 3.48 (m, 3H), 3.15 (d, <i>J</i> = 8.7 Hz, 2H), 2.91 (d, <i>J</i> = 12.2 Hz, 1H), 1.19 (m, 6H), 0.89 (br s, 3H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 170.9, 167.7, 155.6, 152.4 (d, <i>J</i><sub>CF</sub> = 12.8 Hz), 152.3, 152.1, 149.5, 135.8, 133.3 (d, <i>J</i><sub>CF</sub> = 240.1 Hz),124.2, 117.1, 106.1, 72.1, 71.7, 64.5, 56.3 (d, <i>J</i> = 10.8 Hz), 52.9, 38.3, 38.2, 18.2, 18.1, 14.8; <sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>): δ −157.35; HRMS (ES): MH<sup>+</sup> calcd for C<sub>22</sub>H<sub>24</sub>FN<sub>8</sub>O<sub>5</sub>, 499.1848; found, 499.1852.</div></div><div id="sec4_47" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> 2-(1-(6-((2<i>R</i>,6<i>R</i>)-2,6-Dimethylmorpholino)-5-(1,3-dioxolan-2-yl)-7-fluorobenzo[<i>d</i>]isoxazol-3-yl)-1<i>H</i>-1,2,4-triazol-5-ylamino)ethanol (<b>6d</b>, R<sub>3</sub> = NHCH<sub>2</sub>CH<sub>2</sub>OH, Y = 1,3-Dioxolanyl)</h3><div class="NLM_p last">A mixture of 215 mg (0.51 mmol) of 3-(5-chloro-1<i>H</i>-1,2,4-triazol-1-yl)-6-((2<i>R</i>,6<i>R</i>)-2,6-dimethylmorpholino)-5-(1,3-dioxolan-2-yl)-7-fluorobenzo[<i>d</i>]isoxazole (<b>6c</b>, Y = 1,3-dioxolanyl), Et<sub>3</sub>N (0.71 mL, 5.1 mmol), and 2-aminoethanol (62 mg, 1.02 mmol) in THF (40 mL) was heated at 70 °C for 6 h. After cooling to rt and quenching with saturated aqueous NH<sub>4</sub>Cl, the mixture was extracted twice with EtOAc. The combined EtOAc extracts were washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated to afford a residue that was chromatographed on silica gel (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford 206 mg (90%) of the title compound. LC–MS (ES): MH<sup>+</sup> 449.1 for C<sub>20</sub>H<sub>25</sub>FN<sub>6</sub>O<sub>5</sub>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.40 (s, 1H), 7.78 (s, 1H), 7.08–7.24 (m, 1H), 6.33 (s, 1H), 4.16–4.28 (m, 4H), 4.03–4.12 (m, 2H), 3.94–3.99 (m, 2H), 3.78–3.88 (m, 2H), 3.34 (br s, 2H), 3.02 (dd, <i>J</i> = 5.4, 11.4 Hz, 2H), 1.35 (br s, 6H); <sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>): δ −143.15.</div></div><div id="sec4_48" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> (2<i>R</i>,4<i>S</i>,4a<i>S</i>)-11-Fluoro-8-(5-(2-hydroxyethylamino)-1<i>H</i>-1,2,4-triazol-1-yl)-2,4-dimethyl-2,4,4a,6-tetrahydro-1<i>H</i>,1′<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-2′,4′,6′(3′<i>H</i>)-trione (<b>11q</b>)</h3><div class="NLM_p last">The general T-reaction procedure was used with 200 mg (0.446 mmol) of the preceding compound. Purification by SFC, a Chiralpak IC column, and 30% MeOH in CO<sub>2</sub> affords 92 mg (38%) of the title compound. LC–MS rt = 2.20 min, (ES): MH<sup>+</sup> 515.2 for C<sub>22</sub>H<sub>24</sub>FN<sub>8</sub>O<sub>6</sub>; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.76 (br s, 1H), 11.57 (br s, 1H), 7.86 (s, 1H), 7.66 (s, 1H), 7.08 (br s, 1H), 4.88 (br s, 1H), 4.14 (d, <i>J</i> = 13.75 Hz, 1H), 3.98 (d, <i>J</i> = 8.7 Hz, 1H), 3.79 (d, <i>J</i> = 13.4 Hz, 2H), 3.65–3.73 (m, 1H), 3.61 (d, <i>J</i> = 4.9 Hz, 2H), 3.53 (d, <i>J</i> = 5.5 Hz, 2H), 3.12 (m, 1H), 2.92 (d, <i>J</i> = 13.9 Hz, 1H), 1.15 (d, <i>J</i> = 5.8 Hz, 4H), 0.90 (d, <i>J</i> = 6.0 Hz, 3H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 170.8, 167.7, 155.8, 152.4 (d, <i>J</i><sub>CF</sub> = 14.7 Hz), 152.3, 152.1, 149.4, 135.9, 133.3 (d, <i>J</i><sub>CF</sub> = 239.2 Hz), 124.2, 117.1, 106.0, 72.1, 71.7, 64.5, 59.2, 56.3 (d, <i>J</i><sub>CF</sub> = 9.2 Hz), 52.9, 45.8, 38.2, 18.2, 18.1; <sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>): δ −157.29; HRMS (ES): MH<sup>+</sup> calcd for C<sub>22</sub>H<sub>24</sub>FN<sub>8</sub>O<sub>6</sub>, 515.1797; found, 515.1815; [α]<sub class="stack">D</sub><sup class="stack">20</sup> −238 (<i>c</i> 0.1; DMSO).</div></div><div id="sec4_49" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> 1-(6-((2<i>R</i>,6<i>R</i>)-2,6-Dimethylmorpholino)-5-(1,3-dioxolan-2-yl)-7-fluorobenzo[<i>d</i>]isoxazol-3-yl)-<i>N</i>-(2-methoxyethyl)-1<i>H</i>-1,2,4-triazol-5-amine (<b>6d</b>, R<sub>3</sub> = NHCH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub>, Y = 1,3-Dioxolanyl)</h3><div class="NLM_p last">A mixture of 215 mg (0.51 mmol) of 3-(5-chloro-1<i>H</i>-1,2,4-triazol-1-yl)-6-((2<i>R</i>,6<i>R</i>)-2,6-dimethylmorpholino)-5-(1,3-dioxolan-2-yl)-7-fluorobenzo[<i>d</i>]isoxazole (<b>6c</b>, Y = 1,3-dioxolanyl), Et<sub>3</sub>N (0.71 mL, 5.1 mmol), and 2-methoxyethanamine (76 mg, 1.02 mmol) in THF (40 mL) was heated at 70 °C for 6 h. After cooling to rt and quenching with saturated aqueous NH<sub>4</sub>Cl, the mixture was extracted twice with EtOAc. The combined EtOAc extracts were washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated to afford a residue that was chromatographed on silica gel (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford 215 mg (91%) of the title compound. LC–MS (ES) MH<sup>+</sup>: 463.1 for C<sub>21</sub>H<sub>27</sub>FN<sub>6</sub>O<sub>5</sub>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.42 (d, <i>J</i> = 0.75 Hz, 1H), 7.79 (s, 1H), 6.78 (br s, 1H), 6.33 (s, 1H), 4.16–4.29 (m, 4H), 4.03–4.12 (m, 2H), 3.63–3.76 (m, 2H), 3.34 (br s, 2H), 3.02 (dd, <i>J</i> = 5.5, 11.1 Hz, 2H), 1.40 (t, <i>J</i> = 7.3 Hz, 3H), 1.35 (d, <i>J</i> = 4.9 Hz, 6H); <sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>): δ −143.34.</div></div><div id="sec4_50" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> (2<i>R</i>,4<i>S</i>,4a<i>S</i>)-11-Fluoro-8-(5-(2-methoxyethylamino)-1<i>H</i>-1,2,4-triazol-1-yl)-2,4-dimethyl-2,4,4a,6-tetrahydro-1<i>H</i>,1′<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-2′,4′,6′(3′<i>H</i>)-trione (<b>11r</b>)</h3><div class="NLM_p last">The general T-reaction procedure was used with 216 mg (0.454 mmol) of the preceding compound. Purification by SFC, a Chiralpak IC column, and 30% MeOH in CO<sub>2</sub> affords 167 mg (66%) of the title compound. LC–MS rt = 2.55 min, (ES): MH<sup>+</sup> 529.2 for C<sub>23</sub>H<sub>26</sub>FN<sub>8</sub>O<sub>6</sub>; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.64 (br s, 2H), 7.87 (s, 1H), 7.65 (s, 1H), 7.07 (t, <i>J</i> = 5.4 Hz, 1H), 4.13 (d, <i>J</i> = 13.4 Hz, 1H), 3.98 (d, <i>J</i> = 8.85 Hz, 1H), 3.78 (d, <i>J</i> = 13.75 Hz, 2H), 3.59–3.72 (m, 3H), 3.57 (d, <i>J</i> = 4.7 Hz, 2H), 3.30 (s, 3H), 3.04–3.15 (m, 1H), 2.91 (d, <i>J</i> = 14.1 Hz, 1H), 1.15 (d, <i>J</i> = 6.0 Hz, 3H), 0.90 (d, <i>J</i> = 6.2 Hz, 3H); <sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>): δ −157.33; <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 170.9, 167.7, 155.7, 152.4 (d, <i>J</i><sub>CF</sub> = 12.8 Hz), 152.2, 149.5, 135.9, 133.3 (d, <i>J</i><sub>CF</sub> = 239.2 Hz), 117.1, 105.9, 72.1, 71.7, 70.0, 64.5, 58.0, 56.3 (d, <i>J</i><sub>CF</sub> = 9.2 Hz), 52.9, 42.8, 38.2, 18.2, 18.1; HRMS (ES): MH<sup>+</sup> calcd for C<sub>21</sub>H<sub>27</sub>FN<sub>6</sub>O<sub>5</sub>, 529.1954; found, 529.1974; [α]<sub class="stack">D</sub><sup class="stack">20</sup> −239 (<i>c</i> 1; DMSO).</div></div><div id="sec4_51" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> (2<i>R</i>,4<i>S</i>,4a<i>S</i>)-8-(5-((2-(Dimethylamino)ethyl)amino)-1<i>H</i>-1,2,4-triazol-1-yl)-11-fluoro-2,4-dimethyl-2,4,4a,6-tetrahydro-1<i>H</i>,1′<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-2′,4′,6′(3′<i>H</i>)-trione (<b>11s</b>)</h3><div class="NLM_p last">A solution of (300 mg, 0.71 mmol) of 3-(5-chloro-1<i>H</i>-1,2,4-triazol-1-yl)-6-((2<i>R</i>,6<i>R</i>)-2,6-dimethylmorpholino)-5-(1,3-dioxolan-2-yl)-7-fluorobenzo[<i>d</i>]isoxazole (<b>6c</b>, Y = dimethoxymethyl) and <i>N</i>1,<i>N</i>1-dimethylethane-1,2-diamine (0.16 mL, 1.6 mmol) in 5 mL of THF was stirred at rt overnight. The solvent was removed, and the residue was taken up in acetic acid (3.00 mL) and water (0.5 mL). Pyrimidine-2,4,6(1<i>H</i>,3<i>H</i>,5<i>H</i>)-trione (91 mg, 0.71 mmol) was added and the mixture was heated at 120 °C for 1 h. The solvent was removed, and the residue was purified by SFC, a Chiralpak IC column, and a 0–35% gradient of <i>i</i>-PrOH (with 0.1% dimethylethylamine) in CO<sub>2</sub> to afford 170 mg (44%) of the title compound as well as 770 mg of the corresponding enantiomer. UPLC rt = 0.67 min, (ES): MH<sup>+</sup> 541.8 for C<sub>24</sub>H<sub>29</sub>FN<sub>9</sub>O<sub>5</sub>; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.7 (br s, 1H), 11.45 (br s, 1H), 7.80 (s, 1H), 7.59 (s, 1H), 7.04 (t, <i>J</i> = 5.5 Hz, 1H), 4.07 (d, <i>J</i> = 13.0 Hz, 1H), 3.91 (d, <i>J</i> = 8.7 Hz, 1H), 3.72 (d, <i>J</i> = 13.4 Hz, 2H), 3.55–3.66 (m, 1H), 3.47 (q, <i>J</i> = 6.15 Hz, 2H), 3.09 (d, <i>J</i> = 13.0 Hz, 1H), 2.85 (d, <i>J</i> = 14.1 Hz, 1H), 2.47 (br s, 2H), 1.09 (d, <i>J</i> = 6.0 Hz, 3H), 0.83 (d, <i>J</i> = 6.2 Hz, 3H); <sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>): δ −157.33; <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 170.8, 167.7, 155.6, 152.4 (d, <i>J</i><sub>CF</sub> = 13.2 Hz), 152.3, 152.0, 149.4, 135.8, 133.3 (d, <i>J</i><sub>CF</sub> = 240.0 Hz), 124.2, 117.1, 106.0, 72.1, 71.7, 62.0, 57.2, 56.3 (d, <i>J</i><sub>CF</sub> = 9.5 Hz), 52.9, 44.6, 38.2, 25.5, 18.2, 18.1; HRMS (ES): MH<sup>+</sup> calcd for C<sub>24</sub>H<sub>29</sub>FN<sub>9</sub>O<sub>5</sub>, 542.2270; found, 542.2270.</div></div><div id="sec4_52" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> (2<i>R</i>,4<i>S</i>,4a<i>S</i>)-11-Fluoro-2,4-dimethyl-8-(5-(2-morpholinoethylamino)-1<i>H</i>-1,2,4-triazol-1-yl)-2,4,4a,6-tetrahydro-1<i>H</i>,1′<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-2′,4′,6′(3′<i>H</i>)-trione (<b>11t</b>)</h3><div class="NLM_p last">A mixture of 250 mg (0.59 mmol) of 3-(5-chloro-1<i>H</i>-1,2,4-triazol-1-yl)-6-((2<i>R</i>,6<i>R</i>)-2,6-dimethylmorpholino)-5-(1,3-dioxolan-2-yl)-7-fluorobenzo[<i>d</i>]isoxazole (<b>6c</b>, Y = 1,3-dioxolanyl), Et<sub>3</sub>N (0.76 mL, 5.4 mmol), and 2-morpholinoethan-1-amine (230 mg, 1.77 mmol) in THF (40 mL) was heated at 70 °C for 6 h. After cooling to rt and quenching with saturated aqueous NH<sub>4</sub>Cl, the mixture was extracted twice with EtOAc. The combined EtOAc extracts were washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated to afford a residue that was used in the next step without further purification. The general T-reaction procedure was used with the 1.77 mmol of product. Purification by reverse-phase HPLC and 10–50% CH<sub>3</sub>CN gradient in water with 0.1% TFA affords 135 mg (43%) of the title compound as the TFA salt. UPLC rt = 0.68 min, 584.2 for C<sub>26</sub>H<sub>31</sub>FN<sub>9</sub>O<sub>6</sub>; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.84 (s, 1H), 11.46 (s, 1H), 9.53 (br s, 1H), 7.94 (s, 1H), 7.66 (s, 1H), 7.52 (t, <i>J</i> = 5.8 Hz, 1H), 4.13 (d, <i>J</i> = 13.0 Hz, 2H), 3.99 (d, <i>J</i> = 8.9 Hz, 2H), 3.90–4.07 (m, 4H), 3.75–3.87 (m, 5H), 3.67 (dd, <i>J</i> = 6.4, 8.9 Hz, 2H), 3.50–3.73 (m, 5H), 3.44 (m, 2H), 3.09–3.20 (m, 2H), 2.93 (d, <i>J</i> = 14.2 Hz, 1H), 1.16 (d, <i>J</i> = 6.2 Hz, 3H), 0.90 (d, <i>J</i> = 6.2 Hz, 3H); <sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>): δ −73.97 (TFA salt), −157.28; <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 170.8, 167.6, 157.9 (q, <i>J</i><sub>CF</sub> = 33.0 Hz, TFA), 155.4, 152.6 (d, <i>J</i><sub>CF</sub> = 12.8 Hz), 152.1, 151.8, 149.5, 135.9, 133.3 (d, <i>J</i><sub>CF</sub> = 240.1 Hz), 124.4, 116.9, 116.7 (q, <i>J</i><sub>CF</sub> = 296.9 Hz, TFA), 106.0, 72.1, 71.7, 64.5, 63.3, 56.3 (d, <i>J</i><sub>CF</sub> = 10.1 Hz), 55.3, 52.9, 51.4, 38.2, 37.9, 18.2, 18.1; HRMS (ES) MH<sup>+</sup> calcd for C<sub>26</sub>H<sub>31</sub>FN<sub>9</sub>O<sub>6</sub>, 584.2376; found, 584.2393; [α]<sub class="stack">D</sub><sup class="stack">20</sup> −164 (<i>c</i> = 0.1; DMF).</div></div><div id="sec4_53" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> 1-(1-(6-((2<i>R</i>,6<i>R</i>)-2,6-Dimethylmorpholino)-5-(1,3-dioxolan-2-yl)-7-fluorobenzo[<i>d</i>]isoxazol-3-yl)-1<i>H</i>-1,2,4-triazol-5-yl)ethanone (<b>6a</b>, R<sub>5</sub> = C(═O)CH<sub>3</sub>, Y = 1,3-Dioxolanyl)</h3><div class="NLM_p last">LDA (1.8 M in heptane/THF/ethylbenzene, 4.31 mL, 10.79 mmol) was added to 1.4 g (3.60 mmol) of 6-((2<i>R</i>,6<i>R</i>)-2,6-dimethylmorpholino)-5-(1,3-dioxolan-2-yl)-7-fluoro-3-(1<i>H</i>-1,2,4-triazol-1-yl)benzo[<i>d</i>]isoxazole (<b>6</b>, azole = 1<i>H</i>-1,2,4-triazole, X = F, Y = 1,3-dioxolanyl) dissolved in THF (20 mL). This solution was cooled down to −78 °C, allowed to stir for 20 min at −78, and then <i>N</i>-methoxy-<i>N</i>-methylacetamide (1.135 g, 10.79 mmol) (predissolved in 3 mL of dry THF) was added. The mixture was stirred at −78 °C for 1 h before being quenched with saturated aqueous NH<sub>4</sub>Cl and extracted with EtOAc. The organic layer was washed with brine and dried over Na<sub>2</sub>SO<sub>4</sub>. The residue was purified on silica gel (DCM/EtOAc) to afford 936 mg (60%) of the title compound. LC–MS (ES): MH<sup>+</sup> 432.2 for C<sub>20</sub>H<sub>23</sub>FN<sub>5</sub>O<sub>5</sub>; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.68 (s, 1H), 7.74 (s, 1H), 6.19 (s, 1H), 3.8–4.2 (m, 8H), 3.27 (m, 1H), 2.94 (dd, <i>J</i> = 11.5, 4.9 Hz, 1H), 2.70 (s, 1H), 1.23 (d, <i>J</i> = 6.2 Hz, 6H).</div></div><div id="sec4_54" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> 1-(1-(6-((2<i>R</i>,6<i>R</i>)-2,6-Dimethylmorpholino)-5-(1,3-dioxolan-2-yl)-7-fluorobenzo[<i>d</i>]isoxazol-3-yl)-1<i>H</i>-1,2,4-triazol-5-yl)ethanol (<b>6a</b>, R<sub>5</sub> = CH(OH)CH<sub>3</sub>, Y = 1,3-Dioxolanyl)</h3><div class="NLM_p last">A solution of the preceding compound (120 mg, 0.28 mmol) in ethanol (3 mL) was cooled in ice water and sodium borohydride (10.52 mg, 0.28 mmol) was added. The mixture was allowed to warm to rt. After 2 h of stirring, the mixture was treated with aqueous NH<sub>4</sub>Cl and diluted with water and EtOAc. The EtOAc was separated and washed with brine. The combined aqueous layers were extracted with additional EtOAc that was washed with brine. The combined EtOAc layers were dried (MgSO<sub>4</sub>) and concentrated to afford the title compound (121 mg, 100%) as a white solid. LC–MS. LC–MS (ES): MH<sup>+</sup> 434.2 for C<sub>20</sub>H<sub>25</sub>FN<sub>5</sub>O<sub>5</sub>.</div></div><div id="sec4_55" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> (2<i>R</i>,4<i>S</i>,4a<i>S</i>)-11-Fluoro-8-(5-((<i>S</i>)-1-hydroxyethyl)-1<i>H</i>-1,2,4-triazol-1-yl)-2,4-dimethyl-2,4,4a,6-tetrahydro-1<i>H</i>,1′<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-2′,4′,6′(3′<i>H</i>)-trione (<b>11u-A</b>) and (2<i>R</i>,4<i>S</i>,4a<i>S</i>)-11-Fluoro-8-(5-((<i>R</i>)-1-hydroxyethyl)-1<i>H</i>-1,2,4-triazol-1-yl)-2,4-dimethyl-2,4,4a,6-tetrahydro-1<i>H</i>,1′<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-2′,4′,6′(3′<i>H</i>)-trione (<b>11u-B</b>)</h3><div class="NLM_p last">The general T-reaction procedure was used with 121 mg (0.28 mmol) of the preceding compound. Purification by reverse-phase HPLC on an XBridge C18 OBD column eluting with 30–55% MeOH gradient in H<sub>2</sub>O containing 0.2% NH<sub>4</sub>OH affords 38 mg (27%) of diastereomer A as the first eluting material and 40 mg (29%) of diastereomer B as the second eluting material. Diastereomer A: LC–MS rt = 2.09 min, (ES): MH<sup>+</sup> 500.2 for C<sub>22</sub>H<sub>23</sub>FN<sub>7</sub>O<sub>6</sub>; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.60 (br s, 2H), 8.35 (s, 1H), 7.48 (s, 1H), 5.58 (d, <i>J</i> = 6.0 Hz, 1H), 5.44 (m, 1H), 4.15 (d, <i>J</i> = 13.0 Hz, 1H), 3.99 (d, <i>J</i> = 8.9 Hz, 1H), 3.75–3.85 (m, 1 H), 3.6–3.85 (m, 2H), 3.15 (t, <i>J</i> = 12.3 Hz, 1H), 2.92 (d, <i>J</i> = 14.2 Hz, 1H), 1.54 (d, <i>J</i> = 6.4 Hz, 3H); 1.16 (d, <i>J</i> = 6.0 Hz, 3H), 0.90 (d, <i>J</i> = 6.4 Hz, 3H); <sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>): δ −157.50; <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 171.0, 167.9, 160.9, 153.2 (d, <i>J</i><sub>CF</sub> = 12.8 Hz), 152.5, 152.3, 149.7, 135.8, 133.2 (d, <i>J</i><sub>CF</sub> = 240.1 Hz), 125.0, 116.0, 106.9, 72.1, 71.7, 64.5, 60.4, 56.3 (d, <i>J</i><sub>CF</sub> = 9.2 Hz), 52.8, 38.2, 21.6, 18.2, 18.1; HRMS (ES) MH<sup>+</sup> calcd for C<sub>22</sub>H<sub>23</sub>FN<sub>7</sub>O<sub>6</sub>, 500.1688; found, 500.1669. Diastereomer B: LC–MS rt = 2.18 min, (ES): MH<sup>+</sup> 500.2 for C<sub>22</sub>H<sub>23</sub>FN<sub>7</sub>O<sub>6</sub>; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.83 (s, 1H), 11.45 (s, 1H), 8.36 (s, 1H), 7.48 (s, 1H), 5.60 (d, <i>J</i> = 6.0 Hz, 1H), 5.44 (m, 1H), 4.15 (d, <i>J</i> = 13.0 Hz, 1H), 3.97 (d, <i>J</i> = 8.9 Hz, 1H), 3.85–3.95 (m, 1 H), 3.6–3.85 (m, 2H), 3.15 (t, <i>J</i> = 12.3 Hz, 1H), 2.97 (d, <i>J</i> = 14.2 Hz, 1H), 1.53 (d, <i>J</i> = 6.4 Hz, 3H); 1.16 (d, <i>J</i> = 6.0 Hz, 3H), 0.90 (d, <i>J</i> = 6.4 Hz, 3H); <sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>): δ −157.38 (s, 1F); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 170.8, 167.6, 160.9, 153.2, 152.5, 152.3, 149.4, 135.8, 133.2 (d, <i>J</i><sub>CF</sub> = 240.1 Hz), 124.9, 116.0, 107.0, 72.1, 71.7, 64.5, 60.4, 56.3 (d, <i>J</i><sub>CF</sub> = 9.2 Hz), 52.9, 38.2, 21.6, 18.2, 18.1; HRMS (ES): MH<sup>+</sup> calcd for C<sub>22</sub>H<sub>23</sub>FN<sub>7</sub>O<sub>6</sub>, 500.1688; found, 500.1682; [α]<sub class="stack">D</sub><sup class="stack">20</sup> −205 (<i>c</i> 0.1; DMSO).</div></div><div id="sec4_56" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> (<i>S</i>)-1-(1-(6-((2<i>R</i>,6<i>R</i>)-2,6-Dimethylmorpholino)-5-(1,3-dioxolan-2-yl)-7-fluorobenzo[<i>d</i>]isoxazol-3-yl)-1<i>H</i>-1,2,4-triazol-5-ylamino)propan-2-ol (<b>6d</b>, R<sub>3</sub> = <i>S</i>-NHCH<sub>2</sub>CH(OH)CH<sub>3</sub>, Y = 1,3-Dioxolanyl)</h3><div class="NLM_p last">A mixture of 215 mg (0.51 mmol) of 3-(5-chloro-1<i>H</i>-1,2,4-triazol-1-yl)-6-((2<i>R</i>,6<i>R</i>)-2,6-dimethylmorpholino)-5-(1,3-dioxolan-2-yl)-7-fluorobenzo[<i>d</i>]isoxazole (<b>6c</b>, Y = 1,3-dioxolanyl), Et<sub>3</sub>N (0.71 mL, 5.1 mmol), and (<i>S</i>)-1-aminopropan-2-ol (77 mg, 1.02 mmol) in THF (40 mL) was heated at 70 °C for 6 h. After cooling to rt and quenching with saturated aqueous NH<sub>4</sub>Cl, the mixture was extracted twice with EtOAc. The combined EtOAc extracts were washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated to afford a residue that was chromatographed on silica gel (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford 236 mg (100%) of the title compound. LC–MS (ES): MH<sup>+</sup> 463.1 for C<sub>21</sub>H<sub>28</sub>FN<sub>6</sub>O<sub>5</sub>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.41 (s, 1H), 7.76 (s, 1H), 7.13 (br s, 1H), 6.33 (s, 1H), 4.12–4.29 (m, 5H), 4.03–4.12 (m, 2H), 3.70–3.85 (m, 1H), 3.49–3.64 (m, 1H), 3.34 (br s, 2H), 3.02 (dd, <i>J</i> = 5.6, 11.1 Hz, 2H), 1.35 (br s, 6H), 1.32 (d, <i>J</i> = 6.4 Hz, 3H); <sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>): δ −143.21.</div></div><div id="sec4_57" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> (2<i>R</i>,4<i>S</i>,4aS)-11-Fluoro-8-(5-((<i>S</i>)-2-hydroxypropylamino)-1<i>H</i>-1,2,4-triazol-1-yl)-2,4-dimethyl-2,4,4a,6-tetrahydro-1<i>H</i>,1′<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-2′,4′,6′(3′<i>H</i>)-trione (<b>11v-<i>S</i></b>)</h3><div class="NLM_p last">The general T-reaction procedure was used with 230 mg (0.497 mmol) of the preceding compound. Purification by SFC, a Chiralpak IC column, and 25% MeOH in CO<sub>2</sub> affords 137 mg (50%) of the title compound. LC–MS rt = 2.29 min, (ES): MH<sup>+</sup> 529.1 for C<sub>23</sub>H<sub>26</sub>FN<sub>8</sub>O<sub>6</sub>; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.63 (br s, 2H), 7.85 (s, 1H), 7.66 (s, 1H), 7.04 (t, <i>J</i> = 5.7 Hz, 1H), 4.94 (d, <i>J</i> = 3.6 Hz, 1H), 4.13 (d, <i>J</i> = 13.0 Hz, 1H), 3.97 (d, <i>J</i> = 8.9 Hz, 1H), 3.89 (m, 1H), 3.74–3.83 (m, 2H), 3.62–3.73 (m, 1H), 3.50 (ddd, <i>J</i> = 4.25, 6.4, 13.0 Hz, 1H), 3.20–3.43 (m, 1H), 3.07–3.19 (m, 1H), 2.91 (d, <i>J</i> = 14.0 Hz, 1H), 1.15 (d, <i>J</i> = 6.2 Hz, 3H), 1.11 (d, <i>J</i> = 6.23 Hz, 3H), 0.90 (d, <i>J</i> = 6.4 Hz, 3H); <sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>): δ −157.39; <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): δ 170.9, 167.7, 155.9, 152.41 (d, <i>J</i><sub>CF</sub> = 13.2 Hz), 152.40 (d, <i>J</i><sub>CF</sub> = 2.8 Hz), 152.0, 149.5, 135.9, 133.3 (d, <i>J</i><sub>CF</sub> = 239.9 Hz), 124.2 (d, <i>J</i><sub>CF</sub> = 2.2 Hz), 117.1, 106.0, 72.1, 71.7, 64.5, 64.5, 56.3 (d, <i>J</i><sub>CF</sub> = 9.9 Hz), 52.9, 50.6, 38.2, 20.9, 18.1, 18.1; HRMS (ES): MH<sup>+</sup> calcd for C<sub>23</sub>H<sub>26</sub>FN<sub>8</sub>O<sub>6</sub>, 529.1954; found, 529.1973; [α]<sub class="stack">D</sub><sup class="stack">20</sup> −254 (<i>c</i> 0.1; DMSO).</div></div><div id="sec4_58" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> (<i>R</i>)-1-(1-(6-((2<i>R</i>,6<i>R</i>)-2,6-Dimethylmorpholino)-5-(1,3-dioxolan-2-yl)-7-fluorobenzo[<i>d</i>]isoxazol-3-yl)-1<i>H</i>-1,2,4-triazol-5-ylamino)propan-2-ol (<b>6d</b>, R<sub>3</sub> = <i>R</i>-NHCH<sub>2</sub>CH(OH)CH<sub>3</sub>, Y = 1,3-Dioxolanyl)</h3><div class="NLM_p last">A mixture of 215 mg (0.51 mmol) of 3-(5-chloro-1<i>H</i>-1,2,4-triazol-1-yl)-6-((2<i>R</i>,6<i>R</i>)-2,6-dimethylmorpholino)-5-(1,3-dioxolan-2-yl)-7-fluorobenzo[<i>d</i>]isoxazole (<b>6c</b>, Y = 1,3-dioxolanyl), Et<sub>3</sub>N (0.71 μL, 5.1 mmol), and (<i>R</i>)-1-aminopropan-2-ol (77 mg, 1.02 mmol) in THF (40 mL) was heated at 70 °C for 6 h. After cooling to rt and quenching with saturated aqueous NH<sub>4</sub>Cl, the mixture was extracted twice with EtOAc. The combined EtOAc extracts were washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated to afford a residue that was chromatographed on silica gel (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford 227 mg (96%) of the title compound. LC–MS (ES): MH<sup>+</sup> 463.1 for C<sub>21</sub>H<sub>28</sub>FN<sub>6</sub>O<sub>5</sub>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.41 (d, <i>J</i> = 0.9 Hz, 1H), 7.75 (s, 1H), 7.10 (t, <i>J</i> = 5.75 Hz, 1H), 6.33 (s, 1H), 4.13–4.28 (m, 5H), 4.04–4.12 (m, 2H), 3.68–3.80 (m, 1H), 3.54 (ddd, <i>J</i> = 5.6, 7.4, 13.9 Hz, 1H), 3.35 (br s, 2H), 3.02 (dd, <i>J</i> = 5.4, 11.0 Hz, 2H), 1.35 (br s, 6H), 1.31 (d, <i>J</i> = 6.2 Hz, 3H); <sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>): δ −143.24.</div></div><div id="sec4_59" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> (2<i>R</i>,4<i>S</i>,4a<i>S</i>)-11-Fluoro-8-(5-((<i>R</i>)-2-hydroxypropylamino)-1<i>H</i>-1,2,4-triazol-1-yl)-2,4-dimethyl-2,4,4a,6-tetrahydro-1<i>H</i>,1′<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-2′,4′,6′(3′<i>H</i>)-trione (<b>11v-<i>R</i></b>)</h3><div class="NLM_p last">The general T-reaction procedure was used with 220 mg (0.476 mmol) of the preceding compound. Purification by SFC, a Chiralpak IC column, and 25% MeOH in CO<sub>2</sub> affords 130 mg (49%) of the title compound. LC–MS rt = 2.41 min, (ES): MH<sup>+</sup> 529.2 for C<sub>23</sub>H<sub>26</sub>FN<sub>8</sub>O<sub>6</sub>; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.78 (br s, 1H), 11.48 (br s, 1H), 7.86 (s, 1H), 7.67 (s, 1H), 7.05 (t, <i>J</i> = 5.5 Hz, 1H), 4.96 (d, <i>J</i> = 4.7 Hz, 1H), 4.03–4.21 (m, 1H), 3.98 (d, <i>J</i> = 8.85 Hz, 1H), 3.74–3.94 (m, 3H), 3.61–3.74 (m, 1H), 3.41–3.57 (m, 1H), 3.06–3.24 (m, 2H), 2.92 (d, <i>J</i> = 14.13 Hz, 1H), 1.16 (d, <i>J</i> = 6.0 Hz, 3H), 1.10 (d, <i>J</i> = 6.2 Hz, 3H), 0.90 (d, <i>J</i> = 6.2 Hz, 3H) <sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>): δ −157.33; <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 170.9, 167.7, 155.9, 152.5, 152.4 (d, <i>J</i><sub>CF</sub> = 4.6 Hz), 152.1, 149.5, 135.9, 133.3 (d, <i>J</i><sub>CF</sub> = 240.1 Hz), 124.2, 117.1, 106.0, 72.1, 71.7, 64.5, 64.4, 56.3 (d, <i>J</i><sub>CF</sub> = 9.2 Hz), 52.9, 50.6, 38.2, 20.9, 18.2, 18.1; HRMS (ES) MH<sup>+</sup> calcd for C<sub>23</sub>H<sub>26</sub>FN<sub>8</sub>O<sub>6</sub>, 529.1954; found, 529.1955; [α]<sub class="stack">D</sub><sup class="stack">20</sup> −228 (<i>c</i> 0.1; DMSO).</div></div><div id="sec4_60" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> Methyl 2-(1-(6-((2<i>R</i>,6<i>R</i>)-2,6-Dimethylmorpholino)-5-(1,3-dioxolan-2-yl)-7-fluorobenzo[<i>d</i>]isoxazol-3-yl)-1<i>H</i>-1,2,4-triazol-5-ylamino)acetate (<b>6d</b>, R<sub>5</sub> = CH<sub>2</sub>CO<sub>2</sub>CH<sub>3</sub>, Y = 1,3-Dioxolanyl)</h3><div class="NLM_p last">A mixture of 2 g (4.72 mmol) of 3-(5-chloro-1<i>H</i>-1,2,4-triazol-1-yl)-6-((2<i>R</i>,6<i>R</i>)-2,6-dimethylmorpholino)-5-(1,3-dioxolan-2-yl)-7-fluorobenzo[<i>d</i>]isoxazole (<b>6c</b>, Y = 1,3-dioxolanyl), 10 g (99 mmol) of Et<sub>3</sub>N, and glycine methyl ester hydrochloride (2.95 g, 23.6 mmol) in THF (200 mL) was heated at 70 °C for 6 h. After cooling to rt and quenching with saturated aqueous NH<sub>4</sub>Cl, the mixture was extracted twice with EtOAc. The combined EtOAc extracts were washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated to afford a residue that was chromatographed on silica gel (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford 2.02 g (90%) of the title compound. LC–MS (ES): MH<sup>+</sup> 477.2 for C<sub>21</sub>H<sub>26</sub>FN<sub>6</sub>O<sub>6</sub>.</div></div><div id="sec4_61" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> 1-((<i>S</i>)-3-(Dimethylamino)pyrrolidin-1-yl)-2-(1-(6-((2<i>R</i>,6<i>R</i>)-2,6-dimethylmorpholino)-5-(1,3-dioxolan-2-yl)-7-fluorobenzo[<i>d</i>]isoxazol-3-yl)-1<i>H</i>-1,2,4-triazol-5-ylamino)ethanone (<b>6b</b>, R<sub>5</sub> = <i>S</i>-3-(Dimethylamino)pyrrolidin-1-yl, Y = 1,3-Dioxolanyl)</h3><div class="NLM_p last">Me<sub>3</sub>Al (2.0 M in toluene, 1.26 mL, 2.52 mmol) was added over 5 min to a solution of (<i>S</i>)-(+)-3-(dimethylamino)-pyrrolidine (0.288 g, 2.52 mmol) in 10 mL of toluene (10 mL) at 0 °C. After warming to rt, a solution of the preceding compound (0.40 g, 0.84 mmol) in 5 mL toluene was added, and the resultant solution was heated at 80 °C for 2 h. After cooling to rt, the mixture was quenched with aqueous NH<sub>4</sub>Cl and extracted twice with EtOAc. The combined organic layers were washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated. The residue was chromatographed on silica gel (10% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) to afford 400 mg (85%) of the title compound as a white solid. LC–MS (ES) MH<sup>+</sup>: 559.2 for C<sub>26</sub>H<sub>36</sub>FN<sub>8</sub>O<sub>5</sub>; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.29 (s, 1H), 7.98 (s, 1H), 7.46 (d, <i>J</i> = 2.45 Hz, 1H), 6.18 (s, 1H), 4.19–4.31 (m, 2H), 3.93–4.17 (m, 6H), 3.38–3.80 (m, 3H), 3.15–3.28 (m, 2H), 3.05 (dd, <i>J</i> = 8.2, 11.4 Hz, 1H), 2.93 (dd, <i>J</i> = 5.3, 10.8 Hz, 2H), 2.56–2.84 (m, 1H), 2.19 (s, 3H), 2.17 (s, 3H), 1.95–2.13 (m, 1H), 1.54–1.88 (m, 1H), 1.23 (d, <i>J</i> = 6.2 Hz, 6H).</div></div><div id="sec4_62" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> (2<i>R</i>,4<i>S</i>,4a<i>S</i>)-8-(5-(2-((<i>S</i>)-3-(Dimethylamino)pyrrolidin-1-yl)-2-oxoethylamino)-1<i>H</i>-1,2,4-triazol-1-yl)-11-fluoro-2,4-dimethyl-2,4,4a,6-tetrahydro-1<i>H</i>,1′<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-2′,4′,6′(3′H)-trione (<b>11w-<i>S</i></b>)</h3><div class="NLM_p last">The general T-reaction procedure was used with 400 mg (0.72 mmol) of the preceding compound. Purification by reverse-phase HPLC and 10–50% CH<sub>3</sub>CN gradient in water with 0.1% NH<sub>4</sub>OAc buffer affords 125 mg (28%) of the title compound. LC–MS rt = 2.09 min, (ES): MH<sup>+</sup> 625.23 for C<sub>28</sub>H<sub>34</sub>FN<sub>10</sub>O<sub>6</sub>; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.59 (br s, 2H), 7.87 (d, <i>J</i> = 0.8 Hz, 1H), 7.66 (s, 1H), 7.28–7.50 (m, 1H), 4.18–4.27 (m, 2H), 4.14 (d, <i>J</i> = 12.8 Hz, 1H), 3.97 (d, <i>J</i> = 8.9 Hz, 1H), 3.53–3.86 (m, 5H), 3.00–3.52 (m, 10H), 2.91 (d, <i>J</i> = 14.2 Hz, 1H), 2.56–2.83 (m, 1H), 2.19 (s, 3H), 2.17 (s, 3H), 1.96–2.14 (m, 1H), 1.91 (s, 1H), 1.59–1.87 (m, 1H), 1.15 (d, <i>J</i> = 6.2 Hz, 3H), 0.90 (d, <i>J</i> = 6.2 Hz, 3H); <sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>): δ −157.30; <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): δ 170.8, 167.7, 165.9, 155.2, 152.5 (d, <i>J</i><sub>CF</sub> = 13.2 Hz), 152.3, 152.1, 149.4, 135.9, 133.3 (d, <i>J</i><sub>CF</sub> = 239.3 Hz), 124.3, 117.0, 105.9, 72.1, 71.7, 65.2, 64.5, 63.5, 56.2, 52.9, 49.7, 48.9, 45.4, 45.1, 44.7, 44.0, 43.8, 43.7, 38.2, 29.9, 28.1, 21.0, 18.2, 18.1; HRMS (ES): MH<sup>+</sup> calcd for C<sub>28</sub>H<sub>34</sub>FN<sub>10</sub>O<sub>6</sub>, 625.2641; found, 625.2672; [α]<sub class="stack">D</sub><sup class="stack">20</sup> −212 (<i>c</i> 0.1; DMSO).</div></div><div id="sec4_63" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> 1-((<i>R</i>)-3-(Dimethylamino)pyrrolidin-1-yl)-2-(1-(6-((2<i>R</i>,6<i>R</i>)-2,6-dimethylmorpholino)-5-(1,3-dioxolan-2-yl)-7-fluorobenzo[<i>d</i>]isoxazol-3-yl)-1<i>H</i>-1,2,4-triazol-5-ylamino)ethanone (<b>6b</b>, R<sub>5</sub> = <i>R</i>-3-(Dimethylamino)pyrrolidin-1-yl, Y = 1,3-Dioxolanyl)</h3><div class="NLM_p last">Me<sub>3</sub>Al (2.0 M in toluene, 1.26 mL, 2.52 mmol) was added over 5 min to a solution of (<i>R</i>)-(+)-3-(dimethylamino)-pyrrolidine (0.288 g, 2.52 mmol) in 10 mL of toluene (10 mL) at 0 °C. After warming to rt, a solution of methyl 2-(1-(6-((2<i>R</i>,6<i>R</i>)-2,6-dimethylmorpholino)-5-(1,3-dioxolan-2-yl)-7-fluorobenzo[<i>d</i>]isoxazol-3-yl)-1<i>H</i>-1,2,4-triazol-5-ylamino)acetate (0.40 g, 0.84 mmol) in 5 mL of toluene was added, and the resultant solution was heated at 80 °C for 2 h. After cooling to rt, the mixture was quenched with aqueous NH<sub>4</sub>Cl and extracted twice with EtOAc. The combined organic layers were washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated. The residue was chromatographed on silica gel (10% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) to afford 425 mg (91%) of the title compound as a white solid. LC–MS (ES): MH<sup>+</sup> 559.2 for C<sub>26</sub>H<sub>36</sub>FN<sub>8</sub>O<sub>5</sub>; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.29 (s, 1H), 7.98 (s, 1H), 7.47 (d, <i>J</i> = 2.6 Hz, 1H), 6.18 (s, 1H), 4.25 (q, <i>J</i> = 5.6 Hz, 2H), 3.98–4.18 (m, 6H), 3.40–3.78 (m, 3H), 3.24 (d, <i>J</i> = 2.46 Hz, 2H), 2.99–3.22 (m, 1H), 2.93 (dd, <i>J</i> = 5.3, 10.8 Hz, 2H), 2.59–2.83 (m, 1H), 2.19 (s, 3H), 2.17 (s, 3H), 1.96–2.12 (m, 1H), 1.56–1.86 (m, 1H), 1.23 (d, <i>J</i> = 6.2 Hz, 6H).</div></div><div id="sec4_64" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> (2<i>R</i>,4<i>S</i>,4a<i>S</i>)-8-(5-(2-((<i>R</i>)-3-(Dimethylamino)pyrrolidin-1-yl)-2-oxoethylamino)-1<i>H</i>-1,2,4-triazol-1-yl)-11-fluoro-2,4-dimethyl-2,4,4a,6-tetrahydro-1<i>H</i>,1′<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-2′,4′,6′(3′<i>H</i>)-trione (<b>11w-<i>R</i></b>)</h3><div class="NLM_p last">The general T-reaction procedure was used with 425 mg (0.76 mmol) of the preceding compound. Purification by reverse-phase HPLC and 10–50% CH<sub>3</sub>CN gradient in water with 0.1% NH<sub>4</sub>OAc buffer affords 135 mg (43%) of the title compound. LC–MS rt = 2.91 min, (ES): MH<sup>+</sup> 625.24 for C<sub>28</sub>H<sub>34</sub>FN<sub>10</sub>O<sub>6</sub>; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.59 (br s, 2H), 7.87 (s, 1H), 7.66 (s, 1H), 7.41 (d, <i>J</i> = 3.0 Hz, 1H), 4.08–4.28 (m, 3H), 3.97 (d, <i>J</i> = 8.7 Hz, 1H), 3.53–3.85 (m, 5H), 2.99–3.50 (m, 7H), 2.91 (d, <i>J</i> = 14.2 Hz, 1H), 2.58–2.83 (m, 1H), 2.19 (s, 3H), 2.17 (br s, 3H), 1.93–2.12 (m, 1H), 1.55–1.89 (m, 1H), 1.15 (d, <i>J</i> = 6.0 Hz, 3H), 0.90 (d, <i>J</i> = 6.2 Hz, 3H); <sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>): δ −157.31; <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 170.8, 167.7, 165.9, 155.2, 152.5 (d, <i>J</i><sub>CF</sub> = 12.8 Hz), 152.2, 149.4, 135.9, 133.3 (d, <i>J</i><sub>CF</sub> = 240.1 Hz), 124.3, 117.0, 105.9, 84.4, 72.1, 71.7, 65.2, 64.5, 63.5, 56.3 (d, <i>J</i><sub>CF</sub> = 9.2 Hz), 52.9, 49.8, 48.9, 45.4, 45.1, 44.7, 44.0, 43.8, 43.8, 38.2, 29.9, 28.2, 18.2, 18.1; HRMS (ES) MH<sup>+</sup> calcd for C<sub>28</sub>H<sub>34</sub>FN<sub>10</sub>O<sub>6</sub>, 625.2641; found, 625.2669; [α]<sub class="stack">D</sub><sup class="stack">20</sup> −188 (<i>c</i> 0.1; DMSO).</div></div><div id="sec4_65" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> 6,7-Difluoro-5-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)-3-(1<i>H</i>-1,2,4-triazol-1-yl)benzo[<i>d</i>]isoxazole (<b>14a</b>, Major Product) and 6,7-Difluoro-5-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)-3-(4<i>H</i>-1,2,4-triazol-4-yl)benzo[<i>d</i>]isoxazole (<b>14b</b>, Minor Product)</h3><div class="NLM_p last">A mixture of 6,7-difluoro-5-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)-1,2-benzoxazol-3-one (75 g, 0.25 mol),<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> 1<i>H</i>-1,2,4-triazole (132.5 g 1.88 mol), and DIPEA (349.6 mL, 2.0 mol) in 750 mL of CH<sub>3</sub>CN was cooled to 10 °C before adding POCl<sub>3</sub> (46.6 mL, 0.50 mol) dropwise over 15 min during which an exotherm ensued. The temperature was maintained below 25 °C throughout the addition. After stirring at ambient temperature for another 30 min, the mixture was heated to reflux for 16 h before cooling to rt. The mixture was warmed to 70 °C, and 750 mL of water was added slowly over 30 min at a rate to maintain a temperature between 60 and 70 °C. After cooling to 0 °C over 2 h, allowing the mixture to set over 30 min led to the precipitation of solids, which were then collected by vacuum filtration. The solids were rinsed with 3.5 L 1:1 water–acetonitrile and dried in vacuo to afford 59.1 g (67%) of the material consistent with <b>14a</b>. LC–MS (ES) MH<sup>+</sup>: 246.9 for C<sub>16</sub>H<sub>17</sub>F<sub>2</sub>N<sub>4</sub>O<sub>3</sub>; <sup>1</sup>H NMR 400 MHz, CDCl<sub>3</sub>): δ 9.01 (s, 1H), 8.35 (m, 1H), 8.27 (s, 1), 7.72 (s, 1H), 6.24 (s, 1H), 1.35 (s, 6H) 1.28 (s, 6H). The mother liquors were concentrated in vacuo to remove the bulk of CH<sub>3</sub>CN to afford an aqueous residue that was extracted three times with EtOAc. The combined organic extracts were washed with brine, dried (MgSO<sub>4</sub>), filtered, and concentrated. The residue was chromatographed on silica gel (gradient elution with 100% isohexane to 100% EtOAc. The fourth eluting major component proved to be consistent with <b>14b</b>. The material was triturated with a 5:1 mixture of <i>n</i>-heptane–EtOAc to afford the second title compound (2.95 g, 3.4%) after drying in vacuo. LC–MS (ES): MH<sup>+</sup> 246.9 for C<sub>16</sub>H<sub>17</sub>F<sub>2</sub>N<sub>4</sub>O<sub>3</sub>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.85 (s, 2H), 7.79 (dd, <i>J</i><sub>CF</sub> = 5.2, 1 Hz, 1H), 6.21 (s, 1H), 1.33 (s, 6H), 1.23 (s, 6H).</div></div><div id="sec4_66" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> 6-((2<i>R</i>,6<i>R</i>)-2,6-Dimethylmorpholino)-7-fluoro-3-(4<i>H</i>-1,2,4-triazol-4-yl)benzo[<i>d</i>]isoxazole-5-carbaldehyde (<b>15</b>)</h3><div class="NLM_p last">A mixture of 6,7-difluoro-5-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)-3-(4<i>H</i>-1,2,4-triazol-4-yl)benzo[<i>d</i>]isoxazole (100 mg, 0.29 mmol) and 2 N HCl (4.28 mL, 8.56 mmol) in 9:1 CH<sub>3</sub>CN/H<sub>2</sub>O (10 mL) was stirred at rt for 1 h before being heated at 85 °C overnight. After basifying with 2 N NaOH and solid K<sub>2</sub>CO<sub>3</sub>, the mixture was extracted with EtOAc. The organic layer was concentrated, and the residue was dissolved in 10 mL of CH<sub>3</sub>CN. K<sub>2</sub>CO<sub>3</sub> (237 mg, 1.71 mmol) and (2<i>R</i>,6<i>R</i>)-2,6-dimethylmorpholine (66 mg, 0.57 mmol) were added, and the mixture was heated at reflux for 2 h. After cooling to rt, the mixture was diluted with EtOAc and washed with water and brine. EtOAc was dried (MgSO<sub>4</sub>) and concentrated. The residue was purified by reverse-phase HPLC 15% MeCN in H<sub>2</sub>O containing 0.5% TFA to afford 35 mg (18%) of the title compound as an off-white solid. LC–MS (ES): MH<sup>+</sup> 346.1 for C<sub>16</sub>H<sub>17</sub>FN<sub>5</sub>O<sub>3</sub>; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.23 (s, 1H), 9.41 (s, 2H), 8.34 (d, <i>J</i> = 0.9 Hz, 1H), 4.09 (dt, <i>J</i> = 3.3, 6.1 Hz, 2H), 3.36 (td, <i>J</i> = 2.55, 12.1 Hz, 2H), 2.97 (ddd, <i>J</i> = 1.6, 5.7, 12.1 Hz, 2H), 1.15 (d, <i>J</i> = 6.4 Hz, 6H).</div></div><div id="sec4_67" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> (2<i>R</i>,4<i>S</i>,4a<i>S</i>)-11-Fluoro-2,4-dimethyl-8-(4<i>H</i>-1,2,4-triazol-4-yl)-2,4,4a,6-tetrahydro-1<i>H</i>,1′<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-2′,4′,6′(3′<i>H</i>)-trione (<b>12</b>)</h3><div class="NLM_p last">A mixture of the preceding compound (30 mg, 0.09 mmol) and pyrimidine-2,4,6(1<i>H</i>,3<i>H</i>,5<i>H</i>)-trione (13.4 mg, 0.10 mmol) in 3 mL of EtOH/H<sub>2</sub>O (10:1) and a drop of acetic acid was heated in a microwave reactor at 120 °C for 2 h. The solvent was removed, and the residue was purified by reverse-phase HPLC and 10–35% CH<sub>3</sub>CN gradient in H<sub>2</sub>O containing 0.5% TFA to afford 32 mg (81%) of the title compound as an off-white solid as the TFA salt. LC–MS rt = 2.0 min, (ES): MH<sup>+</sup> 456.1.0 for C<sub>20</sub>H<sub>18</sub>FN<sub>7</sub>O<sub>5</sub>; UPLC rt = 0.79 min, (ES) MH<sup>+</sup>: 455.9 for C<sub>20</sub>H<sub>19</sub>FN<sub>7</sub>O<sub>5</sub>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.93 (s, 1H), 11.55 (s, 1H), 9.31 (s, 2H), 7.63 (s, 1H), 4.15 (d, <i>J</i> = 12.8 Hz, 1H), 4.00 (d, <i>J</i> = 8.8 Hz, 1H), 3.76–3.91 (m, 1H), 3.63–3.75 (m, 1H), 3.51 (d, <i>J</i> = 13.8 Hz, 1H), 3.10–3.21 (m, 1H), 3.07 (d, <i>J</i> = 14.05 Hz, 1H), 1.16 (d, <i>J</i> = 6.3 Hz, 3H), 0.92 (d, <i>J</i> = 6.3 Hz, 3H); <sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>): δ −75.54, −156.84; <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 170.7, 167.5, 153.7 (d, <i>J</i><sub>CF</sub> = 13.2 Hz), 149.4, 141.0, 136.0, 133.3 (d, <i>J</i><sub>CF</sub> = 240.8 Hz), 124.5, 114.6, 105.5, 72.1, 71.7, 64.3, 56.3 (d, <i>J</i> = 8.8 Hz), 52.7, 38.6, 18.2, 18.1; HRMS (ES): MH<sup>+</sup> calcd for C<sub>20</sub>H<sub>19</sub>FN<sub>9</sub>O<sub>5</sub>, 456.1426; found, 456.1426; [α]<sub class="stack">D</sub><sup class="stack">20</sup> −149 (<i>c</i> 0.1; DMSO).</div></div><div id="sec4_68" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83"> Computational Chemistry</h3><div class="NLM_p last">The crystal structure of <i>S. aureus</i> DNA gyrase with pyrimidinetrione QPT-1 (PDID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CDM">5CDM</a>)<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> was prepared for modeling calculations using the Protein Preparation Wizard tool in Schrodinger’s Maestro program version 2019-4. Waters involved in hydrogen bonding to the pyrimidinetrione scaffold were kept as part of the binding site. Three-dimensional models for aminotriazole inhibitors were built by modifying QPT-1 and minimized in the <i>S. aureus</i> gyrase binding site using Prime minimization of the inhibitor as well as gyrase residues and DNA bases within 6 Å of the inhibitor. The minimizations were performed using the OPLS2005 force field with the variable dielectric generalized Born solvation model for water and a dielectric constant of 80, over 40 iterations of 200 steps each. Figures of the resulting binding models were produced using PyMOL version 1.8.6.2, Schrodinger, LLC.</div></div><div id="sec4_69" class="NLM_sec NLM_sec_level_2"><div id="ac_i84" class="anchor-spacer"></div><h3 class="article-section__title" id="_i84"> Fluorescence Polarization Assay for Inhibition of DNA Topoisomerase Activity</h3><div class="NLM_p last">IC<sub>50</sub> values against <i>E. coli</i> DNA gyrase were determined using literature procedures.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></div></div><div id="sec4_70" class="NLM_sec NLM_sec_level_2"><div id="ac_i85" class="anchor-spacer"></div><h3 class="article-section__title" id="_i85"> Minimum Inhibitory Concentration</h3><div class="NLM_p last">The bacterial strains included in these studies are maintained in the AstraZeneca Research Collection (ARC) and designated as <i>S. aureus</i> MSSA, ARC516; <i>S. aureus</i> MRQR, ARC517; <i>S. pneumoniae</i>, ARC548; <i>S. pyogenes</i>, ARC838; <i>H. influenzae</i>, ARC737; and <i>E. coli</i>, ARC523. The MIC against each isolate was determined following the guidelines of the Clinical Laboratory Standards Institute (CLSI).<a onclick="showRef(event, 'ref46 ref47'); return false;" href="javascript:void(0);" class="ref ref46 ref47">(46,47)</a> Susceptibility testing against all species was performed using the broth microdilution method; the influence of serum on MSSA MIC values was determined by adding human serum to the culture broths to afford a final concentration of 50%. For more potent compounds with MIC values <6 μM, the reported data represents the averages of 3 or more replications.</div></div><div id="sec4_71" class="NLM_sec NLM_sec_level_2"><div id="ac_i86" class="anchor-spacer"></div><h3 class="article-section__title" id="_i86"> In Vitro Micronucleus Assay, in Vitro MLMA, and Ames mutagenicity</h3><div class="NLM_p last">Experiments for assessing micronucleation in mouse lymphoma cells, the MLMA, were performed as described in the literature.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a></div></div><div id="sec4_72" class="NLM_sec NLM_sec_level_2"><div id="ac_i87" class="anchor-spacer"></div><h3 class="article-section__title" id="_i87"> log <i>D</i> Determination</h3><div class="NLM_p last">The partition coefficient (log <i>D</i>) was measured by a shake flask method, using 10 mM phosphate buffer at pH 7.4 and <i>n</i>-octanol. The samples were allowed to reach equilibrium by shaking for 1 h by inversions, and sample analysis of both the <i>n</i>-octanol and buffer phases was done by LC/UV, with MS for mass confirmation. log <i>D</i> = log((octanol peak area/octanol injection volume)/(buffer peak area/buffer injection volume)).</div></div><div id="sec4_73" class="NLM_sec NLM_sec_level_2"><div id="ac_i88" class="anchor-spacer"></div><h3 class="article-section__title" id="_i88"> PPB Determination</h3><div class="NLM_p last">PPB was determined by equilibrium dialysis from a 10 μM compound solution in a Dianorm plasma well incubating at 37 °C for 16 h. Free fractions were calculated from ratios of drug concentration in buffer and plasma wells were determined by LC–MS/MS. The fraction unbound (fu) = peak area ratio (buffer sample/IS)/peak area ratio (plasma sample/IS).</div></div><div id="sec4_74" class="NLM_sec NLM_sec_level_2"><div id="ac_i89" class="anchor-spacer"></div><h3 class="article-section__title" id="_i89"> Animal Studies</h3><div class="NLM_p last">Mice and rats were maintained in accordance with the American Association for Accreditation of Laboratory Animal Care, and studies were executed according to IUCAC guidelines under protocols approved by the Institutional Animal Care and Use Committee at AstraZeneca. Compounds in mouse and rat PK studies were formulated in 0.2 M meglumine/20% hydroxypropyl-β-cyclodextrin for oral dosing and DMA/TEG/saline 40/40/20% for iv dosing. Compounds in mouse efficacy models were formulated in 0.2 M meglumine/20% hydroxypropyl-β-cyclodextrin for IP dosing. Wistar Han rats for PK studies were obtained from Charles River Laboratories (Raleigh, NC). CD-1 mice were obtained from Charles River Laboratories (Kingston, NY) for PK and pharmacodynamic studies. Female mice were used for the efficacy models. All animals were housed and acclimated in the animal facility on site before each study.</div></div><div id="sec4_75" class="NLM_sec NLM_sec_level_2"><div id="ac_i90" class="anchor-spacer"></div><h3 class="article-section__title" id="_i90"> PK Studies</h3><div class="NLM_p last">PK properties of selected compounds were studied in male rats and mice of either gender. Plasma PKs were determined from following 15 min iv infusions at 3 mg/kg or PO administration at 10 mg/kg. Serial 200 μL samples of whole blood were taken from the jugular vein of each animal at time intervals 0 to 24 h. The concentration of compound in plasma was determined by LC–MS/MS, and PK parameters were estimated using a noncompartmental model in WinNonLin (Pharsight). Mean results were determined for each experiment with three mice or three rats.</div></div><div id="sec4_76" class="NLM_sec NLM_sec_level_2"><div id="ac_i91" class="anchor-spacer"></div><h3 class="article-section__title" id="_i91"> <i>S. aureus</i> Neutropenic Thigh Infection Model</h3><div class="NLM_p last">Compounds <b>11a</b> and <b>11j</b> were studied in a neutropenic mouse thigh infection model as described previously. Briefly, mice were rendered neutropenic by injecting cyclophosphamide (Sigma-Aldrich, St. Louis MO) IP 4 days (150 mg/kg of body weight) and 1 day (100 mg/kg) before experimental infection. A late-log culture of <i>S. aureus</i> ARC516 was diluted to a concentration of ∼1.4 × 10<sup>7</sup> CFU/mL. The bacterial density was determined by dilution and plating for viable counts. Thigh infections were produced by intramuscular injection of 70 μL of culture into each thigh of mice, anesthetized with isoflurane, to achieve a target inoculum of 1.5 × 10<sup>5</sup> CFU/thigh. Two hours after infection, one group of five mice was euthanized to determine the mean CFU in the infected thighs at the beginning of treatment. Starting 2 h postinoculation, groups of three animals each received IP injections of <b>11a</b> as a single dose of 0 (vehicle control), 10, 25, 50, 75, and 100 mg/kg or groups of five animals each received IP injections of <b>11j</b> as a single dose of 0 (vehicle control), 25, 50, and 150 mg/kg. CFU counts were determined for <b>11a</b> 24 h after starting the treatment and for <b>11j</b> at 2, 4, 8, 12, and 24 h after starting the treatment. Mice were euthanized; thighs were removed, weighed, and homogenized; and aliquots were plated onto tryptic soy agar plates and incubated at 37 °C overnight for CFU determination.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i92"><a href="/doi/suppl/10.1021/acs.jmedchem.0c01100" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25775" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25775" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c01100?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01100</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Correlation between DNA gyrase inhibitor potency and antibacterial activity; Alignment of GyrB inhibitor binding domain; Alignment of GyrB from <i>S. aureus</i>, <i>S. pneumoniae</i>, <i>H. influenzae</i>, <i>S. pyogenes</i>, and <i>E. coli</i>; and LC–MS for lead compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01100/suppl_file/jm0c01100_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">PDB files for the DNA gyrase binding models of <b>11l</b> utilized for <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01100/suppl_file/jm0c01100_si_002.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">PDB files for the DNA gyrase binding models of <b>11r</b> utilized for <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01100/suppl_file/jm0c01100_si_003.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Molecular formula strings and associated biological data (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01100/suppl_file/jm0c01100_si_004.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01100/suppl_file/jm0c01100_si_001.pdf">jm0c01100_si_001.pdf (1.07 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01100/suppl_file/jm0c01100_si_002.pdb">jm0c01100_si_002.pdb (123.41 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01100/suppl_file/jm0c01100_si_003.pdb">jm0c01100_si_003.pdb (123.71 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01100/suppl_file/jm0c01100_si_004.csv">jm0c01100_si_004.csv (4.92 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01100" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34664" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34664" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gregory S. Basarab</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry, Infection Innovative Medicines, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5684-6046" title="Orcid link">http://orcid.org/0000-0001-5684-6046</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#6f081d0a08410d0e1c0e1d0e0d2f1a0c1b410e0c41150e"><span class="__cf_email__" data-cfemail="dabda8bfbdf4b8bba9bba8bbb89aafb9aef4bbb9f4a0bb">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peter Doig</span> - <span class="hlFld-Affiliation affiliation">Department
of Biosciences, Infection Innovative Medicines, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Charles J. Eyermann</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry, Infection Innovative Medicines, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vincent Galullo</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry, Infection Innovative Medicines, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gunther Kern</span> - <span class="hlFld-Affiliation affiliation">Department
of Biosciences, Infection Innovative Medicines, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Amy Kimzey</span> - <span class="hlFld-Affiliation affiliation">Discovery
Safety, Infection Innovative Medicines, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Amy Kutschke</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry, Infection Innovative Medicines, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marshall Morningstar</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry, Infection Innovative Medicines, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Virna Schuck</span> - <span class="hlFld-Affiliation affiliation">Drug
Safety and Metabolism, Infection Innovative Medicines, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Karthick Vishwanathan</span> - <span class="hlFld-Affiliation affiliation">Drug
Safety and Metabolism, Infection Innovative Medicines, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fei Zhou</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry, Infection Innovative Medicines, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Madhusudhan Gowravaram</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry, Infection Innovative Medicines, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sheila Hauck</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry, Infection Innovative Medicines, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i94">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50742" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50742" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank the following individuals from AstraZeneca for their analytical services and helpful advice: Natascha Bezdenejnih, Nancy DeGrace, Dr. Camil Joubran, and Sharon Tentarelli. Dr. Steven Raw provided compound <b>14b</b>. Beth Andrews contributed to the DNA gyrase inhibition assay. Marie-Eve Beaudoin, Dr. Eric Gangl, Erica Manyak, Debora Roaquim, Crystal Brown, and Eric Miele are acknowledged for DMPK work and Lena Grosser and Georg Neckermann for contributing to the in vivo efficacy studies. Dr. Mick Fellows contributed to the genotoxicity studies. We also appreciate the contributions for the synthesis of compounds and intermediates by scientists at Biocon, Inc.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">ABT</td><td class="NLM_def"><p class="first last">aminobenzotriazole</p></td></tr><tr><td class="NLM_term">ARC</td><td class="NLM_def"><p class="first last">AstraZeneca Research Collection</p></td></tr><tr><td class="NLM_term">CFU</td><td class="NLM_def"><p class="first last">colony-forming unit</p></td></tr><tr><td class="NLM_term">Cl<sub>p</sub></td><td class="NLM_def"><p class="first last">plasma clearance</p></td></tr><tr><td class="NLM_term">Cl<sub>u</sub></td><td class="NLM_def"><p class="first last">unbound clearance</p></td></tr><tr><td class="NLM_term"><i>f</i><sub>u</sub></td><td class="NLM_def"><p class="first last">fraction unbound</p></td></tr><tr><td class="NLM_term">MLMA</td><td class="NLM_def"><p class="first last">mouse lymphoma micronucleation assay</p></td></tr><tr><td class="NLM_term">MRQR</td><td class="NLM_def"><p class="first last">methicillin-resistant, quinolone-resistant <i>S. aureus</i></p></td></tr><tr><td class="NLM_term">MSSA</td><td class="NLM_def"><p class="first last">methicillin-sensitive <i>S. aureus</i></p></td></tr><tr><td class="NLM_term">PPB</td><td class="NLM_def"><p class="first last">plasma protein binding</p></td></tr><tr><td class="NLM_term">SFC</td><td class="NLM_def"><p class="first last">supercritical fluid chromatography;</p></td></tr><tr><td class="NLM_term">T-reaction</td><td class="NLM_def"><p class="first last">Tertiary amino effect reaction</p></td></tr><tr><td class="NLM_term">Topo IV</td><td class="NLM_def"><p class="first last">topoisomerase IV</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i96">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60064" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60064" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 47 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boucher, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambrose, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chambers, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebright, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jezek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newland, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostrowsky, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rex, J. H.</span></span> <span> </span><span class="NLM_article-title">White Paper: Developing Antimicrobial Drugs for Resistant Pathogens, Narrow-Spectrum Indications, and Unmet Needs</span>. <i>J. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>216</i></span>,  <span class="NLM_fpage">228</span>– <span class="NLM_lpage">236</span>, <span class="refDoi"> DOI: 10.1093/infdis/jix211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1093%2Finfdis%2Fjix211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=28475768" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFCqs7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=216&publication_year=2017&pages=228-236&author=H.+W.+Boucherauthor=P.+G.+Ambroseauthor=H.+F.+Chambersauthor=R.+H.+Ebrightauthor=A.+Jezekauthor=B.+E.+Murrayauthor=J.+G.+Newlandauthor=B.+Ostrowskyauthor=J.+H.+Rex&title=White+Paper%3A+Developing+Antimicrobial+Drugs+for+Resistant+Pathogens%2C+Narrow-Spectrum+Indications%2C+and+Unmet+Needs&doi=10.1093%2Finfdis%2Fjix211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">White paper: developing antimicrobial drugs for resistant pathogens, narrow-spectrum indications, and unmet needs</span></div><div class="casAuthors">Boucher, Helen W.; Ambrose, Paul G.; Chambers, H. F.; Ebright, Richard H.; Jezek, Amanda; Murray, Barbara E.; Newland, Jason G.; Ostrowsky, Belinda; Rex, John H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Infectious Diseases</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">216</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">228-236</span>CODEN:
                <span class="NLM_cas:coden">JIDIAQ</span>;
        ISSN:<span class="NLM_cas:issn">1537-6613</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Despite progress in antimicrobial drug development, a crit. need persists for new, feasible pathways to develop antibacterial agents to treat people infected with drug-resistant bacteria.  Infections due to resistant gram-neg. bacilli continue to cause unacceptable morbidity and mortality rates.  Antibacterial agents have been historically studied in noninferiority clin. trials that focus on a single site of infection (eg, complicated urinary tract infections, intra-abdominal infections), yet these designs may not be optimal, and often are not feasible, for study of infections caused by drug-resistant bacteria.  Over the past several years, multiple stakeholders have worked to develop consensus regarding paths forward with a goal of facilitating timely conduct of antimicrobial development.  Here we advocate for a novel and pragmatic approach and, toward this end, present feasible trial designs for antibacterial agents that could enable conduct of narrow-spectrum, organism-specific clin. trials and ultimately approval of critically needed new antibacterial agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyVfhQ9V8-67Vg90H21EOLACvtfcHk0lj-9cMhhxInLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFCqs7fI&md5=6325b710ea0846da4949e5695f6f9de6</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1093%2Finfdis%2Fjix211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Finfdis%252Fjix211%26sid%3Dliteratum%253Aachs%26aulast%3DBoucher%26aufirst%3DH.%2BW.%26aulast%3DAmbrose%26aufirst%3DP.%2BG.%26aulast%3DChambers%26aufirst%3DH.%2BF.%26aulast%3DEbright%26aufirst%3DR.%2BH.%26aulast%3DJezek%26aufirst%3DA.%26aulast%3DMurray%26aufirst%3DB.%2BE.%26aulast%3DNewland%26aufirst%3DJ.%2BG.%26aulast%3DOstrowsky%26aufirst%3DB.%26aulast%3DRex%26aufirst%3DJ.%2BH.%26atitle%3DWhite%2520Paper%253A%2520Developing%2520Antimicrobial%2520Drugs%2520for%2520Resistant%2520Pathogens%252C%2520Narrow-Spectrum%2520Indications%252C%2520and%2520Unmet%2520Needs%26jtitle%3DJ.%2520Infect.%2520Dis.%26date%3D2017%26volume%3D216%26spage%3D228%26epage%3D236%26doi%3D10.1093%2Finfdis%2Fjix211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vikesland, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maile-Moskowitz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, N.</span></span> <span> </span><span class="NLM_article-title">Differential Drivers of Antimicrobial Resistance across the World</span>. <i>Acc. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">916</span>– <span class="NLM_lpage">924</span>, <span class="refDoi"> DOI: 10.1021/acs.accounts.8b00643</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.accounts.8b00643" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BC1MXktlOqsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2019&pages=916-924&author=P.+Vikeslandauthor=E.+Garnerauthor=S.+Guptaauthor=S.+Kangauthor=A.+Maile-Moskowitzauthor=N.+Zhu&title=Differential+Drivers+of+Antimicrobial+Resistance+across+the+World&doi=10.1021%2Facs.accounts.8b00643"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Differential Drivers of Antimicrobial Resistance across the World</span></div><div class="casAuthors">Vikesland, Peter; Garner, Emily; Gupta, Suraj; Kang, Seju; Maile-Moskowitz, Ayella; Zhu, Ni</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">916-924</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Antimicrobial resistance (AMR) is one of the greatest threats faced by humankind.  The development of resistance in clin. and hospital settings has been well documented ever since the initial discovery of penicillin and the subsequent introduction of sulfonamides as clin. antibiotics.  In contrast, the environmental (i.e., community-acquired) dimensions of resistance dissemination have been only more recently delineated.  The global spread of antibiotic resistant bacteria (ARB) and antibiotic resistance genes (ARGs) between air, water, soil, and food is now well documented, while the factors that affect ARB and ARG dissemination (e.g., water and air quality, antibiotic fluxes, urbanization, sanitation practices) in these and other environmental matrixes are just now beginning to be more fully appreciated.In this Account, we discuss how the global perpetuation of resistance is dictated by highly interconnected socioeconomic risk factors and illustrate that development status should be more fully considered when developing global strategies to address AMR.  We first differentiate low to middle income countries (LMICs) and high-income countries (HICs), then we summarize the modes of action of com. available antibiotics, and then discuss the four primary mechanisms by which bacteria develop resistance to those antibiotics.  Resistance is disseminated via both vertical gene transfer (VGT; parent to offspring) as well as by horizontal gene transfer (HGT; cell to cell transference of genetic material).  A key challenge hindering attempts to control resistance dissemination is the presence of native, environmental bacteria that can harbor ARGs.  Such environmental "resistomes" have potential to transfer resistance to pathogens via HGT.  Of particular concern is the development of resistance to antibiotics of last-resort such as the cephalosporins, carbapenems, and polymyxins.We then illustrate how antibiotic use differs in LMICs relative to HICs in terms of the vols. of antibiotics used and their fate within local environments.  Antibiotic use in HICs has remained flat over the past 15 years, while in LMICs use over the same period has increased substantially as a result of economic improvements and changes in diet.  These use and fate differences impact local citizens and thus the local dissemination of AMR.  Various phys., social, and economic circumstances within LMICs potentially favor AMR dissemination.  We focus on three phys. factors: changing population d., sanitation infrastructure, and solid-waste disposal.  We show that high population densities in cities within LMICs that suffer from poor sanitation and solid-waste disposal can potentially impact the dissemination of resistance.  In the final section, we discuss potential monitoring approaches to quantify the spread of resistance both within LMICs as well as in HICs.  We posit that culture-based approaches, mol. approaches, and cutting-edge nanotechnol.-based methods for monitoring ARB and ARGs should be considered both within HICs and, as appropriate, within LMICs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRfuY4_Wvzk7Vg90H21EOLACvtfcHk0lj-9cMhhxInLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXktlOqsrs%253D&md5=bec2a3f62b68867760d6eee400681646</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1021%2Facs.accounts.8b00643&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.accounts.8b00643%26sid%3Dliteratum%253Aachs%26aulast%3DVikesland%26aufirst%3DP.%26aulast%3DGarner%26aufirst%3DE.%26aulast%3DGupta%26aufirst%3DS.%26aulast%3DKang%26aufirst%3DS.%26aulast%3DMaile-Moskowitz%26aufirst%3DA.%26aulast%3DZhu%26aufirst%3DN.%26atitle%3DDifferential%2520Drivers%2520of%2520Antimicrobial%2520Resistance%2520across%2520the%2520World%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2019%26volume%3D52%26spage%3D916%26epage%3D924%26doi%3D10.1021%2Facs.accounts.8b00643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Christaki, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tofarides, A.</span></span> <span> </span><span class="NLM_article-title">Antimicrobial Resistance in Bacteria: Mechanisms, Evolution, and Persistence</span>. <i>J. Mol. Evol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">26</span>– <span class="NLM_lpage">40</span>, <span class="refDoi"> DOI: 10.1007/s00239-019-09914-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1007%2Fs00239-019-09914-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=31659373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVCksb7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2020&pages=26-40&author=E.+Christakiauthor=M.+Marcouauthor=A.+Tofarides&title=Antimicrobial+Resistance+in+Bacteria%3A+Mechanisms%2C+Evolution%2C+and+Persistence&doi=10.1007%2Fs00239-019-09914-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Antimicrobial Resistance in Bacteria: Mechanisms, Evolution, and Persistence</span></div><div class="casAuthors">Christaki, Eirini; Marcou, Markella; Tofarides, Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Evolution</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">26-40</span>CODEN:
                <span class="NLM_cas:coden">JMEVAU</span>;
        ISSN:<span class="NLM_cas:issn">0022-2844</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">In recent years, we have seen antimicrobial resistance rapidly emerge at a global scale and spread from one country to the other faster than previously thought.  Superbugs and multidrug-resistant bacteria are endemic in many parts of the world.  There is no question that the widespread use, overuse, and misuse of antimicrobials during the last 80 years have been assocd. with the explosion of antimicrobial resistance.  On the other hand, the mol. pathways behind the emergence of antimicrobial resistance in bacteria were present since ancient times.  Some of these mechanisms are the ancestors of current resistance determinants.  Evidently, there are plenty of putative resistance genes in the environment, however, we cannot yet predict which ones would be able to be expressed as phenotypes in pathogenic bacteria and cause clin. disease.  In addn., in the presence of inhibitory and sub-inhibitory concns. of antibiotics in natural habitats, one could assume that novel resistance mechanisms will arise against antimicrobial compds.  This review presents an overview of antimicrobial resistance mechanisms, and describes how these have evolved and how they continue to emerge.  As antimicrobial strategies able to bypass the development of resistance are urgently needed, a better understanding of the crit. factors that contribute to the persistence and spread of antimicrobial resistance may yield innovative perspectives on the design of such new therapeutic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSau-tlfP1vbVg90H21EOLACvtfcHk0lioee25TeIBlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVCksb7I&md5=a554a32de2403d28b25ff76e98af7815</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1007%2Fs00239-019-09914-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00239-019-09914-3%26sid%3Dliteratum%253Aachs%26aulast%3DChristaki%26aufirst%3DE.%26aulast%3DMarcou%26aufirst%3DM.%26aulast%3DTofarides%26aufirst%3DA.%26atitle%3DAntimicrobial%2520Resistance%2520in%2520Bacteria%253A%2520Mechanisms%252C%2520Evolution%252C%2520and%2520Persistence%26jtitle%3DJ.%2520Mol.%2520Evol.%26date%3D2020%26volume%3D88%26spage%3D26%26epage%3D40%26doi%3D10.1007%2Fs00239-019-09914-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Theuretzbacher, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottwalt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beyer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czaplewski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lienhardt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenzo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rex, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silver, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spigel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thwaites, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paccaud, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harbarth, S.</span></span> <span> </span><span class="NLM_article-title">Analysis of the Clinical Antibacterial and Antituberculosis Pipeline</span>. <i>Lancet Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">e40</span>– <span class="NLM_lpage">e50</span>, <span class="refDoi"> DOI: 10.1016/S1473-3099(18)30513-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1016%2FS1473-3099%2818%2930513-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=30337260" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFejtbvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=e40-e50&author=U.+Theuretzbacherauthor=S.+Gottwaltauthor=P.+Beyerauthor=M.+Butlerauthor=L.+Czaplewskiauthor=C.+Lienhardtauthor=M.+Lorenzoauthor=M.+Paulauthor=S.+Paulinauthor=J.+H.+Rexauthor=L.+L.+Silverauthor=M.+Spigelauthor=G.+E.+Thwaitesauthor=J.-P.+Paccaudauthor=S.+Harbarth&title=Analysis+of+the+Clinical+Antibacterial+and+Antituberculosis+Pipeline&doi=10.1016%2FS1473-3099%2818%2930513-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of the clinical antibacterial and antituberculosis pipeline</span></div><div class="casAuthors">Theuretzbacher, Ursula; Gottwalt, Simon; Beyer, Peter; Butler, Mark; Czaplewski, Lloyd; Lienhardt, Christian; Moja, Lorenzo; Paul, Mical; Paulin, Sarah; Rex, John H.; Silver, Lynn L.; Spigelman, Melvin; Thwaites, Guy E.; Paccaud, Jean-Pierre; Harbarth, Stephan</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Infectious Diseases</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e40-e50</span>CODEN:
                <span class="NLM_cas:coden">LIDABP</span>;
        ISSN:<span class="NLM_cas:issn">1473-3099</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">This anal. of the global clin. antibacterial pipeline was done in support of the Global Action Plan on Antimicrobial Resistance.  The study analyzed to what extent antibacterial and antimycobacterial drugs for systemic human use as well as oral non-systemic antibacterial drugs for Clostridium difficile infections were active against pathogens included in the WHO priority pathogen list and their innovativeness measured by their absence of cross-resistance (new class, target, mode of action).  As of July 1, 2018, 30 new chem. entity (NCE) antibacterial drugs, ten biologics, ten NCEs against Mycobacterium tuberculosis, and four NCEs against C difficile were identified.  Of the 30 NCEs, 11 are expected to have some activity against at least one crit. priority pathogen expressing carbapenem resistance.  The clin. pipeline is dominated by derivs. of established classes and most development candidates display limited innovation.  New antibacterial drugs without pre-existing cross-resistance are under-represented and are urgently needed, esp. for geog. regions with high resistance rates among Gram-neg. bacteria and M tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWapn7G_qKT7Vg90H21EOLACvtfcHk0lioee25TeIBlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFejtbvP&md5=38cf1c2a98bc2e353a6fa0fc01acce8d</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2818%2930513-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252818%252930513-9%26sid%3Dliteratum%253Aachs%26aulast%3DTheuretzbacher%26aufirst%3DU.%26aulast%3DGottwalt%26aufirst%3DS.%26aulast%3DBeyer%26aufirst%3DP.%26aulast%3DButler%26aufirst%3DM.%26aulast%3DCzaplewski%26aufirst%3DL.%26aulast%3DLienhardt%26aufirst%3DC.%26aulast%3DLorenzo%26aufirst%3DM.%26aulast%3DPaul%26aufirst%3DM.%26aulast%3DPaulin%26aufirst%3DS.%26aulast%3DRex%26aufirst%3DJ.%2BH.%26aulast%3DSilver%26aufirst%3DL.%2BL.%26aulast%3DSpigel%26aufirst%3DM.%26aulast%3DThwaites%26aufirst%3DG.%2BE.%26aulast%3DPaccaud%26aufirst%3DJ.-P.%26aulast%3DHarbarth%26aufirst%3DS.%26atitle%3DAnalysis%2520of%2520the%2520Clinical%2520Antibacterial%2520and%2520Antituberculosis%2520Pipeline%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2019%26volume%3D19%26spage%3De40%26epage%3De50%26doi%3D10.1016%2FS1473-3099%2818%2930513-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span> </span><span class="NLM_article-title">Global Priority List of Antibiotic-Resistant
Bacteria to Guide Research,
Discovery, and Development of New Antibiotics</span>. <a href="http://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf?ua=1" class="extLink">http://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf?ua=1</a> (accessed Sept 9, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Global+Priority+List+of+Antibiotic-Resistant%0ABacteria+to+Guide+Research%2C%0ADiscovery%2C+and+Development+of+New+Antibiotics.+http%3A%2F%2Fwww.who.int%2Fmedicines%2Fpublications%2FWHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf%3Fua%3D1+%28accessed+Sept+9%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DGlobal%2520Priority%2520List%2520of%2520Antibiotic-Resistant%250ABacteria%2520to%2520Guide%2520Research%252C%250ADiscovery%252C%2520and%2520Development%2520of%2520New%2520Antibiotics" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basarab, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brassil, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doig, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galullo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haimes, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kern, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutschke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mcnulty, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuck, V. J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gowravaram, M.</span></span> <span> </span><span class="NLM_article-title">Novel DNA Gyrase Inhibiting Spiropyrimidinetriones with a Benzisoxazole Scaffold: SAR and in Vivo Characterization</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">9078</span>– <span class="NLM_lpage">9095</span>, <span class="refDoi"> DOI: 10.1021/jm501174m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501174m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1yju7bE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=9078-9095&author=G.+S.+Basarabauthor=P.+Brassilauthor=P.+Doigauthor=V.+Galulloauthor=H.+B.+Haimesauthor=G.+Kernauthor=A.+Kutschkeauthor=J.+Mcnultyauthor=V.+J.+A.+Schuckauthor=G.+Stoneauthor=M.+Gowravaram&title=Novel+DNA+Gyrase+Inhibiting+Spiropyrimidinetriones+with+a+Benzisoxazole+Scaffold%3A+SAR+and+in+Vivo+Characterization&doi=10.1021%2Fjm501174m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Novel DNA Gyrase Inhibiting Spiropyrimidinetriones with a Benzisoxazole Scaffold: SAR and in Vivo Characterization</span></div><div class="casAuthors">Basarab, Gregory S.; Brassil, Patrick; Doig, Peter; Galullo, Vincent; Haimes, Howard B.; Kern, Gunther; Kutschke, Amy; McNulty, John; Schuck, Virna J. A.; Stone, Gregory; Gowravaram, Madhusudhan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9078-9095</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The compds. described herein with a spirocyclic architecture fused to a benzisoxazole ring represent a new class of antibacterial agents that operate by inhibition of DNA gyrase as corroborated in an enzyme assay and by the inhibition of precursor thymidine into DNA during cell growth.  Activity resided in the configurationally lowest energy (2S,4R,4aR) diastereomer.  Highly active compds. against Staphylococcus aureus had sufficiently high soly., high plasma protein free fraction, and favorable pharmacokinetics to suggest that in vivo efficacy could be demonstrated, which was realized with compd. I in S. aureus mouse infection models.  A high drug exposure NOEL on oral dosing in the rat suggested that a high therapeutic margin could be achieved.  Importantly, I was not cross-resistant with other DNA gyrase inhibitors such as fluoroquinolone and aminocoumarin antibacterials.  Hence, this class shows considerable promise for the treatment of infections caused by multidrug resistant bacteria, including S. aureus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpvqD0DFpAALVg90H21EOLACvtfcHk0lioee25TeIBlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1yju7bE&md5=7eccef41b07e14842d79665591364050</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Fjm501174m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501174m%26sid%3Dliteratum%253Aachs%26aulast%3DBasarab%26aufirst%3DG.%2BS.%26aulast%3DBrassil%26aufirst%3DP.%26aulast%3DDoig%26aufirst%3DP.%26aulast%3DGalullo%26aufirst%3DV.%26aulast%3DHaimes%26aufirst%3DH.%2BB.%26aulast%3DKern%26aufirst%3DG.%26aulast%3DKutschke%26aufirst%3DA.%26aulast%3DMcnulty%26aufirst%3DJ.%26aulast%3DSchuck%26aufirst%3DV.%2BJ.%2BA.%26aulast%3DStone%26aufirst%3DG.%26aulast%3DGowravaram%26aufirst%3DM.%26atitle%3DNovel%2520DNA%2520Gyrase%2520Inhibiting%2520Spiropyrimidinetriones%2520with%2520a%2520Benzisoxazole%2520Scaffold%253A%2520SAR%2520and%2520in%2520Vivo%2520Characterization%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D9078%26epage%3D9095%26doi%3D10.1021%2Fjm501174m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basarab, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kern, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNulty, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vishwanathan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alm, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barvian, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doig, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galullo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gowravaram, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huband, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimzey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morningstar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutschke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lahiri, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perros, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuck, V. J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tommasi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walkup, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, J. V.</span></span> <span> </span><span class="NLM_article-title">Responding to the Challenge of Untreatable Gonorrhea: ETX0914, a First-in-Class Agent with a Distinct Mechanism-of-Action against Bacterial Type II Topoisomerases</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">11827</span>, <span class="refDoi"> DOI: 10.1038/srep11827</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1038%2Fsrep11827" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=26168713" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlCjsLvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=11827&author=G.+S.+Basarabauthor=G.+H.+Kernauthor=J.+McNultyauthor=J.+P.+Muellerauthor=K.+Lawrenceauthor=K.+Vishwanathanauthor=R.+A.+Almauthor=K.+Barvianauthor=P.+Doigauthor=V.+Galulloauthor=H.+Gardnerauthor=M.+Gowravaramauthor=M.+Hubandauthor=A.+Kimzeyauthor=M.+Morningstarauthor=A.+Kutschkeauthor=S.+D.+Lahiriauthor=M.+Perrosauthor=R.+Singhauthor=V.+J.+A.+Schuckauthor=R.+Tommasiauthor=G.+Walkupauthor=J.+V.+Newman&title=Responding+to+the+Challenge+of+Untreatable+Gonorrhea%3A+ETX0914%2C+a+First-in-Class+Agent+with+a+Distinct+Mechanism-of-Action+against+Bacterial+Type+II+Topoisomerases&doi=10.1038%2Fsrep11827"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases</span></div><div class="casAuthors">Basarab, Gregory S.; Kern, Gunther H.; McNulty, John; Mueller, John P.; Lawrence, Kenneth; Vishwanathan, Karthick; Alm, Richard A.; Barvian, Kevin; Doig, Peter; Galullo, Vincent; Gardner, Humphrey; Gowravaram, Madhusudhan; Huband, Michael; Kimzey, Amy; Morningstar, Marshall; Kutschke, Amy; Lahiri, Sushmita D.; Perros, Manos; Singh, Renu; Schuck, Virna J. A.; Tommasi, Ruben; Walkup, Grant; Newman, Joseph V.</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">11827</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">With the diminishing effectiveness of current antibacterial therapies, it is critically important to discover agents that operate by a mechanism that circumvents existing resistance.  ETX0914, the first of a new class of antibacterial agent targeted for the treatment of gonorrhea, operates by a novel mode-of-inhibition against bacterial type II topoisomerases.  Incorporating an oxazolidinone on the scaffold mitigated toxicol. issues often seen with topoisomerase inhibitors.  Organisms resistant to other topoisomerase inhibitors were not cross-resistant with ETX0914 nor were spontaneous resistant mutants to ETX0914 cross-resistant with other topoisomerase inhibitor classes, including the widely used fluoroquinolone class.  Preclin. evaluation of ETX0914 pharmacokinetics and pharmacodynamics showed distribution into vascular tissues and efficacy in a murine Staphylococcus aureus infection model that served as a surrogate for predicting efficacious exposures for the treatment of Neisseria gonorrhoeae infections.  A wide safety margin to the efficacious exposure in toxicol. evaluations supported progression to Phase 1.  Dosing ETX0914 in human volunteers showed sufficient exposure and minimal adverse effects to expect a highly efficacious anti-gonorrhea therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCpiUrCSFU1rVg90H21EOLACvtfcHk0liNvrA7WJ2peg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlCjsLvE&md5=0a681c2bd92414d798b03a9c712e138e</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fsrep11827&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep11827%26sid%3Dliteratum%253Aachs%26aulast%3DBasarab%26aufirst%3DG.%2BS.%26aulast%3DKern%26aufirst%3DG.%2BH.%26aulast%3DMcNulty%26aufirst%3DJ.%26aulast%3DMueller%26aufirst%3DJ.%2BP.%26aulast%3DLawrence%26aufirst%3DK.%26aulast%3DVishwanathan%26aufirst%3DK.%26aulast%3DAlm%26aufirst%3DR.%2BA.%26aulast%3DBarvian%26aufirst%3DK.%26aulast%3DDoig%26aufirst%3DP.%26aulast%3DGalullo%26aufirst%3DV.%26aulast%3DGardner%26aufirst%3DH.%26aulast%3DGowravaram%26aufirst%3DM.%26aulast%3DHuband%26aufirst%3DM.%26aulast%3DKimzey%26aufirst%3DA.%26aulast%3DMorningstar%26aufirst%3DM.%26aulast%3DKutschke%26aufirst%3DA.%26aulast%3DLahiri%26aufirst%3DS.%2BD.%26aulast%3DPerros%26aufirst%3DM.%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DSchuck%26aufirst%3DV.%2BJ.%2BA.%26aulast%3DTommasi%26aufirst%3DR.%26aulast%3DWalkup%26aufirst%3DG.%26aulast%3DNewman%26aufirst%3DJ.%2BV.%26atitle%3DResponding%2520to%2520the%2520Challenge%2520of%2520Untreatable%2520Gonorrhea%253A%2520ETX0914%252C%2520a%2520First-in-Class%2520Agent%2520with%2520a%2520Distinct%2520Mechanism-of-Action%2520against%2520Bacterial%2520Type%2520II%2520Topoisomerases%26jtitle%3DSci.%2520Rep.%26date%3D2015%26volume%3D5%26spage%3D11827%26doi%3D10.1038%2Fsrep11827" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kern, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehmann, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basarab, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doig, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sriram, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thresher, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walkup, G. K.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Neisseria Gonorrhoeae Type II Topoisomerases by the Novel Spiropyrimidinetrione AZD0914</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>290</i></span>,  <span class="NLM_fpage">20984</span>– <span class="NLM_lpage">20994</span>, <span class="refDoi"> DOI: 10.1074/jbc.m115.663534</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1074%2Fjbc.M115.663534" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=26149691" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlOrt77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=2015&pages=20984-20994&author=G.+Kernauthor=T.+Palmerauthor=D.+E.+Ehmannauthor=A.+B.+Shapiroauthor=B.+Andrewsauthor=G.+S.+Basarabauthor=P.+Doigauthor=J.+Fanauthor=N.+Gaoauthor=S.+D.+Millsauthor=J.+Muellerauthor=S.+Sriramauthor=J.+Thresherauthor=G.+K.+Walkup&title=Inhibition+of+Neisseria+Gonorrhoeae+Type+II+Topoisomerases+by+the+Novel+Spiropyrimidinetrione+AZD0914&doi=10.1074%2Fjbc.m115.663534"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Neisseria gonorrhoeae Type II Topoisomerases by the Novel Spiropyrimidinetrione AZD0914</span></div><div class="casAuthors">Kern, Gunther; Palmer, Tiffany; Ehmann, David E.; Shapiro, Adam B.; Andrews, Beth; Basarab, Gregory S.; Doig, Peter; Fan, Jun; Gao, Ning; Mills, Scott D.; Mueller, John; Sriram, Shubha; Thresher, Jason; Walkup, Grant K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">290</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">20984-20994</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">We characterized the inhibition of Neisseria gonorrhoeae type II topoisomerases gyrase and topoisomerase IV by AZD0914 (AZD0914 will be henceforth known as ETX0914 (Entasis Therapeutics)), a novel spiropyrimidinetrione antibacterial compd. that is currently in clin. trials for treatment of drug-resistant gonorrhea.  AZD0914 has potent bactericidal activity against N. gonorrhoeae, including multidrug-resistant strains and key Gram-pos., fastidious Gram-neg., atypical, and anaerobic bacterial species (Huband, M. D., Bradford, P. A., Otterson, L. G., Basrab, G. S., Giacobe, R. A., Patey, S. A., Kutschke, A. C., Johnstone, M. R., Potter, M. E., Miller, P. F., and Mueller, J. P. (2014) In Vitro Antibacterial Activity of AZD0914: A New Spiropyrimidinetrione DNA Gyrase/Topoisomerase Inhibitor with Potent Activity against Gram-pos., Fastidious Gram-neg., and Atypical Bacteria. Antimicrob. Agents Chemother. 59, 467-474).  AZD0914 inhibited DNA biosynthesis preferentially to other macromols. in Escherichia coli and induced the SOS response to DNA damage in E. coli.  AZD0914 stabilized the enzyme-DNA cleaved complex for N. gonorrhoeae gyrase and topoisomerase IV.  The potency of AZD0914 for inhibition of supercoiling and the stabilization of cleaved complex by N. gonorrhoeae gyrase increased in a fluoroquinolone-resistant mutant enzyme.  When a mutation, conferring mild resistance to AZD0914, was present in the fluoroquinolone-resistant mutant, the potency of ciprofloxacin for inhibition of supercoiling and stabilization of cleaved complex was increased greater than 20-fold.  In contrast to ciprofloxacin, religation of the cleaved DNA did not occur in the presence of AZD0914 upon removal of magnesium from the DNA-gyrase-inhibitor complex.  AZD0914 had relatively low potency for inhibition of human type II topoisomerases α and β.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5NwS9lT225rVg90H21EOLACvtfcHk0liNvrA7WJ2peg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlOrt77F&md5=9288c211345bd1fd09d0cff247e8e341</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M115.663534&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M115.663534%26sid%3Dliteratum%253Aachs%26aulast%3DKern%26aufirst%3DG.%26aulast%3DPalmer%26aufirst%3DT.%26aulast%3DEhmann%26aufirst%3DD.%2BE.%26aulast%3DShapiro%26aufirst%3DA.%2BB.%26aulast%3DAndrews%26aufirst%3DB.%26aulast%3DBasarab%26aufirst%3DG.%2BS.%26aulast%3DDoig%26aufirst%3DP.%26aulast%3DFan%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DN.%26aulast%3DMills%26aufirst%3DS.%2BD.%26aulast%3DMueller%26aufirst%3DJ.%26aulast%3DSriram%26aufirst%3DS.%26aulast%3DThresher%26aufirst%3DJ.%26aulast%3DWalkup%26aufirst%3DG.%2BK.%26atitle%3DInhibition%2520of%2520Neisseria%2520Gonorrhoeae%2520Type%2520II%2520Topoisomerases%2520by%2520the%2520Novel%2520Spiropyrimidinetrione%2520AZD0914%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2015%26volume%3D290%26spage%3D20984%26epage%3D20994%26doi%3D10.1074%2Fjbc.m115.663534" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Biedenbach, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huband, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hackel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jonge, B. L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahm, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradford, P. A.</span></span> <span> </span><span class="NLM_article-title">In Vitro Activity of AZD0914, a Novel Bacterial DNA Gyrase/Topoisomerase IV Inhibitor, Against Clinically Relevant Gram-Positive and Fastidious Gram-Negative Pathogens</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">6053</span>– <span class="NLM_lpage">6063</span>, <span class="refDoi"> DOI: 10.1128/aac.01016-15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1128%2FAAC.01016-15" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=26195518" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVajs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=6053-6063&author=D.+J.+Biedenbachauthor=M.+D.+Hubandauthor=M.+Hackelauthor=B.+L.+M.+de+Jongeauthor=D.+F.+Sahmauthor=P.+A.+Bradford&title=In+Vitro+Activity+of+AZD0914%2C+a+Novel+Bacterial+DNA+Gyrase%2FTopoisomerase+IV+Inhibitor%2C+Against+Clinically+Relevant+Gram-Positive+and+Fastidious+Gram-Negative+Pathogens&doi=10.1128%2Faac.01016-15"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro activity of AZD0914, a novel bacterial DNA gyrase/topoisomerase IV inhibitor, against clinically relevant Gram-positive and fastidious Gram-negative pathogens</span></div><div class="casAuthors">Biedenbach, Douglas J.; Huband, Michael D.; Hackel, Meredith; de Jonge, Boudewijn L. M.; Sahm, Daniel F.; Bradford, Patricia A.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">6053-6063</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">AZD0914, a new spiropyrimidinetrione bacterial DNA gyrase inhibitor with a novel mode of inhibition, has activity against bacterial species commonly cultured from patient infection specimens, including fluoroquinolone-resistant isolates.  This study assessed the in vitro activity of AZD0914 against key Gram-pos. and fastidious Gram-neg. clin. isolates collected globally in 2013.  AZD0914 demonstrated potent activity, with MIC90s for AZD0914 of 0.25 mg/L against Staphylococcus aureus (n = 11,680), coagulase-neg. staphylococci (n = 1923), streptococci (n = 4380), and Moraxella catarrhalis (n = 145), 0.5 mg/L against Staphylococcus lugdunensis (n = 120) and Haemophilus influenzae (n = 352), 1 mg/L against Enterococcus faecalis (n = 1241), and 2 mg/L against Haemophilus parainfluenzae (n = 70).  The activity against Enterococcus faecium was more limited (MIC90, 8 mg/L).  The spectrum and potency of AZD0914 included fluoroquinolone-resistant isolates in each species group, including methicillin-resistant staphylococci, penicillin-resistant streptococci, vancomycin-resistant enterococci, β-lactamase-producing Haemophilus spp., and M. catarrhalis.  Based on these in vitro findings, AZD0914 warrants further study for its utility against a variety of Gram-pos. and fastidious Gram-neg. bacterial species.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIorJR-vAyIbVg90H21EOLACvtfcHk0ljGRtSBgkbYWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVajs7c%253D&md5=8eefc4607d197f9f3ca782502b1b4bfa</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1128%2FAAC.01016-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01016-15%26sid%3Dliteratum%253Aachs%26aulast%3DBiedenbach%26aufirst%3DD.%2BJ.%26aulast%3DHuband%26aufirst%3DM.%2BD.%26aulast%3DHackel%26aufirst%3DM.%26aulast%3Dde%2BJonge%26aufirst%3DB.%2BL.%2BM.%26aulast%3DSahm%26aufirst%3DD.%2BF.%26aulast%3DBradford%26aufirst%3DP.%2BA.%26atitle%3DIn%2520Vitro%2520Activity%2520of%2520AZD0914%252C%2520a%2520Novel%2520Bacterial%2520DNA%2520Gyrase%252FTopoisomerase%2520IV%2520Inhibitor%252C%2520Against%2520Clinically%2520Relevant%2520Gram-Positive%2520and%2520Fastidious%2520Gram-Negative%2520Pathogens%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2015%26volume%3D59%26spage%3D6053%26epage%3D6063%26doi%3D10.1128%2Faac.01016-15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Papp, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkcaldy, R. D.</span></span> <span> </span><span class="NLM_article-title">In <i>Vitro</i> Growth of Multidrug-Resistant Neisseria Gonorrhoeae Isolates Is Inhibited by ETX0914, a Novel Spiropyrimidinetrione</span>. <i>Int. J. Antimicrob. Agents</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">328</span>– <span class="NLM_lpage">330</span>, <span class="refDoi"> DOI: 10.1016/j.ijantimicag.2016.05.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1016%2Fj.ijantimicag.2016.05.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=27499432" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFyhsr7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2016&pages=328-330&author=J.+R.+Pappauthor=K.+Lawrenceauthor=S.+Sharpeauthor=J.+Muellerauthor=R.+D.+Kirkcaldy&title=In+Vitro+Growth+of+Multidrug-Resistant+Neisseria+Gonorrhoeae+Isolates+Is+Inhibited+by+ETX0914%2C+a+Novel+Spiropyrimidinetrione&doi=10.1016%2Fj.ijantimicag.2016.05.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro growth of multidrug-resistant Neisseria gonorrhoeae isolates is inhibited by ETX0914, a novel spiropyrimidinetrione</span></div><div class="casAuthors">Papp, John R.; Lawrence, Kenneth; Sharpe, Samera; Mueller, John; Kirkcaldy, Robert D.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Antimicrobial Agents</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">328-330</span>CODEN:
                <span class="NLM_cas:coden">IAAGEA</span>;
        ISSN:<span class="NLM_cas:issn">0924-8579</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Antimicrobial resistance in Neisseria gonorrhoeae has severely limited the no. of treatment options, and the emergence of extended-spectrum cephalosporin resistance threatens the effectiveness of the last remaining recommended treatment regimen.  This study assessed the in vitro susceptibility of N. gonorrhoeae to ETX0914, a novel spiropyrimidinetrione that inhibits DNA biosynthesis.  In vitro activity was detd. by agar diln. against 100 N. gonorrhoeae isolates collected from men presenting with urethritis in the USA during 2012-2013 through the Gonococcal Isolate Surveillance Project.  The min. inhibitory concn. (MIC) that inhibited growth in 50% (MIC50) and 90% (MIC90) of isolates was calcd. for each antimicrobial agent.  ETX0914 demonstrated a high level of antimicrobial activity against N. gonorrhoeae, including isolates with decreased susceptibility or resistance to currently available agents.  The ability of ETX0914 to inhibit the growth of N. gonorrhoeae was similar to ceftriaxone, which is currently recommended in combination with azithromycin to treat gonorrhoea.  The data strongly suggest that ETX0914 should be evaluated in a clin. trial for the treatment of N. gonorrhoeae.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4IQ_dAbaNIrVg90H21EOLACvtfcHk0ljGRtSBgkbYWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFyhsr7N&md5=3e4dbb4bc287bffcadb1205d87f7d795</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.ijantimicag.2016.05.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijantimicag.2016.05.018%26sid%3Dliteratum%253Aachs%26aulast%3DPapp%26aufirst%3DJ.%2BR.%26aulast%3DLawrence%26aufirst%3DK.%26aulast%3DSharpe%26aufirst%3DS.%26aulast%3DMueller%26aufirst%3DJ.%26aulast%3DKirkcaldy%26aufirst%3DR.%2BD.%26atitle%3DIn%2520Vitro%2520Growth%2520of%2520Multidrug-Resistant%2520Neisseria%2520Gonorrhoeae%2520Isolates%2520Is%2520Inhibited%2520by%2520ETX0914%252C%2520a%2520Novel%2520Spiropyrimidinetrione%26jtitle%3DInt.%2520J.%2520Antimicrob.%2520Agents%26date%3D2016%26volume%3D48%26spage%3D328%26epage%3D330%26doi%3D10.1016%2Fj.ijantimicag.2016.05.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrazzo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batteiger, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hook, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seña, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierzbicki, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwak, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, J.</span></span> <span> </span><span class="NLM_article-title">Single-Dose Zoliflodacin (ETX0914) for Treatment of Urogenital Gonorrhea</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>379</i></span>,  <span class="NLM_fpage">1835</span>– <span class="NLM_lpage">1845</span>, <span class="refDoi"> DOI: 10.1056/nejmoa1706988</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1056%2FNEJMoa1706988" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=30403954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1GktbzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=379&publication_year=2018&pages=1835-1845&author=S.+N.+Taylorauthor=J.+Marrazzoauthor=B.+E.+Batteigerauthor=E.+W.+Hookauthor=A.+C.+Se%C3%B1aauthor=J.+Longauthor=M.+R.+Wierzbickiauthor=H.+Kwakauthor=S.+M.+Johnsonauthor=K.+Lawrenceauthor=J.+Mueller&title=Single-Dose+Zoliflodacin+%28ETX0914%29+for+Treatment+of+Urogenital+Gonorrhea&doi=10.1056%2Fnejmoa1706988"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Single-Dose zoliflodacin (ETX0914) for treatment of urogenital gonorrhea</span></div><div class="casAuthors">Taylor, Stephanie N.; Marrazzo, Jeanne; Batteiger, Byron E.; Hook, Edward W.; Sena, Arlene C.; Long, Jill; Wierzbicki, Michael R.; Kwak, Hannah; Johnson, Shacondra M.; Lawrence, Kenneth; Mueller, John</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">379</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1835-1845</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Antibiotic-resistant Neisseria gonorrhoeae has prompted the development of new therapies.  Zoliflodacin is a new antibiotic that inhibits DNA biosynthesis.  In this multi-center, phase 2 trial, zoliflodacin was evaluated for the treatment of uncomplicated gonorrhea.  METHODS We randomly assigned eligible men and women who had signs or symptoms of uncomplicated urogenital gonorrhea or untreated urogenital gonorrhea or who had had sexual contact in the preceding 14 days with a person who had gonorrhea to receive a single oral dose of zoliflodacin (2 g or 3 g) or a single 500-mg i.m. dose of ceftriaxone in a ratio of approx. 70:70:40.  A test of cure occurred within 6±2 days after treatment, followed by a safety visit 31±2 days after treatment.  The primary efficacy outcome measure was the proportion of urogenital microbiol. cure in the microbiol. intention-to-treat (micro-ITT) population.  RESULTS From Nov. 2014 through Dec. 2015, a total of 179 participants (167 men and 12 women) were enrolled.  Among the 141 participants in the micro-ITT population who could be evaluated, microbiol. cure at urogenital sites was documented in 55 of 57 (96%) who received 2 g of zoliflodacin, 54 of 56 (96%) who received 3 g of zoliflodacin, and 28 of 28 (100%) who received ceftriaxone.  All rectal infections were cured in all 5 participants who received 2 g of zoliflodacin and all 7 who received 3 g, and in all 3 participants in the group that received ceftriaxone.  Pharyngeal infections were cured in 4 of 8 participants (50%), 9 of 11 participants (82%), and 4 of 4 participants (100%) in the groups that received 2 g of zoliflodacin, 3 g of zoliflodacin, and ceftriaxone, resp.  A total of 84 adverse events were reported: 24 in the group that received 2 g of zoliflodacin, 37 in the group that received 3 g of zoliflodacin, and 23 in the group that received ceftriaxone.  According to investigators, a total of 21 adverse events were thought to be related to zoliflodacin, and most such events were gastrointestinal.  CONCLUSIONS The majority of uncomplicated urogenital and rectal gonococcal infections were successfully treated with oral zoliflodacin, but this agent was less efficacious in the treatment of pharyngeal infections. (Funded by the National Institutes of Health and Entasis Therapeutics; ClinicalTrials.gov no., NCT02257918.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrohoirIrYFf7Vg90H21EOLACvtfcHk0ljGRtSBgkbYWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1GktbzN&md5=f26717391c8d3764114c8fee2a359b8b</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1706988&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1706988%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DS.%2BN.%26aulast%3DMarrazzo%26aufirst%3DJ.%26aulast%3DBatteiger%26aufirst%3DB.%2BE.%26aulast%3DHook%26aufirst%3DE.%2BW.%26aulast%3DSe%25C3%25B1a%26aufirst%3DA.%2BC.%26aulast%3DLong%26aufirst%3DJ.%26aulast%3DWierzbicki%26aufirst%3DM.%2BR.%26aulast%3DKwak%26aufirst%3DH.%26aulast%3DJohnson%26aufirst%3DS.%2BM.%26aulast%3DLawrence%26aufirst%3DK.%26aulast%3DMueller%26aufirst%3DJ.%26atitle%3DSingle-Dose%2520Zoliflodacin%2520%2528ETX0914%2529%2520for%2520Treatment%2520of%2520Urogenital%2520Gonorrhea%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D379%26spage%3D1835%26epage%3D1845%26doi%3D10.1056%2Fnejmoa1706988" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bundy, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mott, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skepner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyle, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hromockyj, a. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marotti, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zurenko, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munzner, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bammert, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamel, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, W.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graber, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolak, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seest, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruble, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamilar, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banitt, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurd, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbachyn, M. R.</span></span> <span> </span><span class="NLM_article-title">Discovery and Characterization of QPT-1, the Progenitor of a New Class of Bacterial Topoisomerase Inhibitors</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">2806</span>– <span class="NLM_lpage">2812</span>, <span class="refDoi"> DOI: 10.1128/aac.00247-08</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1128%2FAAC.00247-08" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=18519725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BD1cXps1Ogt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2008&pages=2806-2812&author=A.+A.+Millerauthor=G.+L.+Bundyauthor=J.+E.+Mottauthor=J.+E.+Skepnerauthor=T.+P.+Boyleauthor=D.+W.+Harrisauthor=a.+E.+Hromockyjauthor=K.+R.+Marottiauthor=G.+E.+Zurenkoauthor=J.+B.+Munznerauthor=M.+T.+Sweeneyauthor=G.+F.+Bammertauthor=J.+C.+Hamelauthor=C.+W.+Fordauthor=W.-Z.+Zhongauthor=D.+R.+Graberauthor=G.+E.+Martinauthor=F.+Hanauthor=L.+A.+Dolakauthor=E.+P.+Seestauthor=J.+C.+Rubleauthor=G.+M.+Kamilarauthor=J.+R.+Palmerauthor=L.+S.+Banittauthor=A.+R.+Hurdauthor=M.+R.+Barbachyn&title=Discovery+and+Characterization+of+QPT-1%2C+the+Progenitor+of+a+New+Class+of+Bacterial+Topoisomerase+Inhibitors&doi=10.1128%2Faac.00247-08"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and characterization of QPT-1, the progenitor of a new class of bacterial topoisomerase inhibitors</span></div><div class="casAuthors">Miller, Alita A.; Bundy, Gordon L.; Mott, John E.; Skepner, Jill E.; Boyle, Timothy P.; Harris, Douglas W.; Hromockyj, Alexander E.; Marotti, Keith R.; Zurenko, Gary E.; Munzner, Jennifer B.; Sweeney, Michael T.; Bammert, Gary F.; Hamel, Judith C.; Ford, Charles W.; Zhong, Wei-Zhu; Graber, David R.; Martin, Gary E.; Han, Fusen; Dolak, Lester A.; Seest, Eric P.; Ruble, J. Craig; Kamilar, Gregg M.; Palmer, John R.; Banitt, Lee S.; Hurd, Alexander R.; Barbachyn, Michael R.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2806-2812</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">QPT-1 was discovered in a compd. library by high-throughput screening and triage for substances with whole-cell antibacterial activity.  This totally synthetic compd. is an unusual barbituric acid deriv. whose activity resides in the (-)-enantiomer.  QPT-1 had activity against a broad spectrum of pathogenic, antibiotic-resistant bacteria, was nontoxic to eukaryotic cells, and showed oral efficacy in a murine infection model, all before any medicinal chem. optimization.  Biochem. and genetic characterization showed that the QPT-1 targets the β subunit of bacterial type II topoisomerases via a mechanism of inhibition distinct from the mechanisms of fluoroquinolones and novobiocin.  Given these attributes, this compd. represents a promising new class of antibacterial agents.  The success of this reverse genomics effort demonstrates the utility of exploring strategies that are alternatives to target-based screens in antibacterial drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoPSHAUxaaj7Vg90H21EOLACvtfcHk0lhjmuTp4xzrSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXps1Ogt7c%253D&md5=c459d15b895768ec27648222ad03d20d</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1128%2FAAC.00247-08&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00247-08%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DA.%2BA.%26aulast%3DBundy%26aufirst%3DG.%2BL.%26aulast%3DMott%26aufirst%3DJ.%2BE.%26aulast%3DSkepner%26aufirst%3DJ.%2BE.%26aulast%3DBoyle%26aufirst%3DT.%2BP.%26aulast%3DHarris%26aufirst%3DD.%2BW.%26aulast%3DHromockyj%26aufirst%3Da.%2BE.%26aulast%3DMarotti%26aufirst%3DK.%2BR.%26aulast%3DZurenko%26aufirst%3DG.%2BE.%26aulast%3DMunzner%26aufirst%3DJ.%2BB.%26aulast%3DSweeney%26aufirst%3DM.%2BT.%26aulast%3DBammert%26aufirst%3DG.%2BF.%26aulast%3DHamel%26aufirst%3DJ.%2BC.%26aulast%3DFord%26aufirst%3DC.%2BW.%26aulast%3DZhong%26aufirst%3DW.-Z.%26aulast%3DGraber%26aufirst%3DD.%2BR.%26aulast%3DMartin%26aufirst%3DG.%2BE.%26aulast%3DHan%26aufirst%3DF.%26aulast%3DDolak%26aufirst%3DL.%2BA.%26aulast%3DSeest%26aufirst%3DE.%2BP.%26aulast%3DRuble%26aufirst%3DJ.%2BC.%26aulast%3DKamilar%26aufirst%3DG.%2BM.%26aulast%3DPalmer%26aufirst%3DJ.%2BR.%26aulast%3DBanitt%26aufirst%3DL.%2BS.%26aulast%3DHurd%26aufirst%3DA.%2BR.%26aulast%3DBarbachyn%26aufirst%3DM.%2BR.%26atitle%3DDiscovery%2520and%2520Characterization%2520of%2520QPT-1%252C%2520the%2520Progenitor%2520of%2520a%2520New%2520Class%2520of%2520Bacterial%2520Topoisomerase%2520Inhibitors%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2008%26volume%3D52%26spage%3D2806%26epage%3D2812%26doi%3D10.1128%2Faac.00247-08" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baltz, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrigley, S. K.</span></span> <span> </span><span class="NLM_article-title">Natural Products to Drugs: Daptomycin and Related Lipopeptide Antibiotics</span>. <i>Nat. Prod. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">717</span>– <span class="NLM_lpage">741</span>, <span class="refDoi"> DOI: 10.1039/b416648p</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1039%2Fb416648p" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=16311632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BD28XjslCrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2005&pages=717-741&author=R.+H.+Baltzauthor=V.+Miaoauthor=S.+K.+Wrigley&title=Natural+Products+to+Drugs%3A+Daptomycin+and+Related+Lipopeptide+Antibiotics&doi=10.1039%2Fb416648p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Natural products to drugs: Daptomycin and related lipopeptide antibiotics</span></div><div class="casAuthors">Baltz, Richard H.; Miao, Vivian; Wrigley, Stephen K.</div><div class="citationInfo"><span class="NLM_cas:title">Natural Product Reports</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">717-741</span>CODEN:
                <span class="NLM_cas:coden">NPRRDF</span>;
        ISSN:<span class="NLM_cas:issn">0265-0568</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review focuses on daptomycin and related lippeptide antibiotics from 1953 to 2005, discussing their recent studies with particular emphasis on the interplay between structural features and antibacterial activities.  Topics discussed include chem. modifications to improve activity; the genetic organization and biosynthesis of lipopeptides; and the genetic engineering of the daptomycin biosynthetic pathway to produce novel derivs. for further chem. modification to develop candidates for clin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZY8U3HyAKhrVg90H21EOLACvtfcHk0lhjmuTp4xzrSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjslCrtg%253D%253D&md5=4f56cba788816c08f12ef5c2d847019a</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1039%2Fb416648p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb416648p%26sid%3Dliteratum%253Aachs%26aulast%3DBaltz%26aufirst%3DR.%2BH.%26aulast%3DMiao%26aufirst%3DV.%26aulast%3DWrigley%26aufirst%3DS.%2BK.%26atitle%3DNatural%2520Products%2520to%2520Drugs%253A%2520Daptomycin%2520and%2520Related%2520Lipopeptide%2520Antibiotics%26jtitle%3DNat.%2520Prod.%2520Rep.%26date%3D2005%26volume%3D22%26spage%3D717%26epage%3D741%26doi%3D10.1039%2Fb416648p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Livermore, D. M.</span></span> <span> </span><span class="NLM_article-title">Linezolid in Vitro: Mechanism and Antibacterial Spectrum</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">ii9</span>– <span class="NLM_lpage">ii16</span>, <span class="refDoi"> DOI: 10.1093/jac/dkg249</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1093%2Fjac%2Fdkg249" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=12730138" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BD3sXktlOqur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2003&pages=ii9-ii16&author=D.+M.+Livermore&title=Linezolid+in+Vitro%3A+Mechanism+and+Antibacterial+Spectrum&doi=10.1093%2Fjac%2Fdkg249"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Linezolid in vitro: Mechanism and antibacterial spectrum</span></div><div class="casAuthors">Livermore, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">Suppl. S2</span>),
    <span class="NLM_cas:pages">ii9-ii16</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Oxazolidinones are prominent among the new Gram-pos. antimicrobial agents now becoming available.  They were discovered by DuPont Pharmaceuticals in the late 1980s but linezolid, the first analog suitable for development, was found only when the family was re-examd. by Pharmacia in the 1990s.  Oxazolidinones bind to the 50S subunit of the prokaryotic ribosome, preventing formation of the initiation complex for protein synthesis.  This is a novel mode of action; other protein synthesis inhibitors either block polypeptide extension or cause misreading of mRNA.  Linezolid MICs vary slightly with the test method, lab., and significance attributed to thin hazes of bacterial survival, but all workers find that the susceptibility distributions are narrow and unimodal, with MIC values between 0.5 and 4 mg/L for streptococci, enterococci and staphylococci.  Fully activity is retained against Gram-pos. cocci resistant to other antibiotics, including methicillin-resistant staphylococci and vancomycin-resistant enterococci.  MICs are 4-8 mg/L for Moraxella, Pasteurella and Bacteroides spp. but other Gram-neg. bacteria are resistant as a result of endogenous efflux activity.  Resistance is difficult to select in vitro but has been reported during therapy in a few enterococcal infections and in two MRSA cases to date; the mechanism entails mutation of the 23S rRNA that forms the binding site for linezolid.  Risk factors for selection of resistance include indwelling devices, undrained foci, protracted therapy and underdosage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMQ0myE42NT7Vg90H21EOLACvtfcHk0lhjmuTp4xzrSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXktlOqur0%253D&md5=c7c7ae8354e0ef29ebf23b7da4bccd8e</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdkg249&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdkg249%26sid%3Dliteratum%253Aachs%26aulast%3DLivermore%26aufirst%3DD.%2BM.%26atitle%3DLinezolid%2520in%2520Vitro%253A%2520Mechanism%2520and%2520Antibacterial%2520Spectrum%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2003%26volume%3D51%26spage%3Dii9%26epage%3Dii16%26doi%3D10.1093%2Fjac%2Fdkg249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diacon, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pym, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grobusch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patientia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rustomjee, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page-Shipp, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pistorius, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krause, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogoshi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Churchyard, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palomino, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Marez, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Heeswijk, R. P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyvisch, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verbeeck, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parys, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Beule, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neeley, D. F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNeeley, D. F.</span></span> <span> </span><span class="NLM_article-title">The Diarylquinoline TMC207 for Multidrug-Resistant Tuberculosis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>360</i></span>,  <span class="NLM_fpage">2397</span>– <span class="NLM_lpage">2405</span>, <span class="refDoi"> DOI: 10.1056/nejmoa0808427</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1056%2FNEJMoa0808427" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=19494215" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BD1MXntVKqsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=360&publication_year=2009&pages=2397-2405&author=A.+H.+Diaconauthor=A.+Pymauthor=M.+Grobuschauthor=R.+Patientiaauthor=R.+Rustomjeeauthor=L.+Page-Shippauthor=C.+Pistoriusauthor=R.+Krauseauthor=M.+Bogoshiauthor=G.+Churchyardauthor=A.+Venterauthor=J.+Allenauthor=J.+C.+Palominoauthor=T.+De+Marezauthor=R.+P.+G.+van+Heeswijkauthor=P.+Meyvischauthor=J.+Verbeeckauthor=W.+Parysauthor=K.+de+Beuleauthor=K.+Andriesauthor=D.+F.+M.+Neeleyauthor=D.+F.+McNeeley&title=The+Diarylquinoline+TMC207+for+Multidrug-Resistant+Tuberculosis&doi=10.1056%2Fnejmoa0808427"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The diarylquinoline TMC207 for multidrug-resistant tuberculosis</span></div><div class="casAuthors">Diacon, Andreas H.; Pym, Alexander; Grobusch, Martin; Patientia, Ramonde; Rustomjee, Roxana; Page-Shipp, Liesl; Pistorius, Christoffel; Krause, Rene; Bogoshi, Mampedi; Churchyard, Gavin; Venter, Amour; Allen, Jenny; Palomino, Juan Carlos; De Marez, Tine; van Heeswijk, Rolf P. G.; Lounis, Nacer; Meyvisch, Paul; Verbeeck, Johan; Parys, Wim; de Beule, Karel; Andries, Koen; McNeeley, David F.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">360</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2397-2405</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND; The diarylquinoline TMC207 offers a new mechanism of antituberculosis action by inhibiting mycobacterial ATP synthase.  TMC207 potently inhibits drug-sensitive and drug-resistant Mycobacterium tuberculosis in vitro and shows bactericidal activity in patients who have drug-susceptible pulmonary tuberculosis.  METHODS: In the first stage of a two-stage, phase 2, randomized, controlled trial, we randomly assigned 47 patients who had newly diagnosed multidrug-resistant pulmonary tuberculosis to receive either TMC207 (400 mg daily for 2 wk, followed by 200 mg three times a week for 6 wk) (23 patients) or placebo (24 patients) in combination with a std. five-drug, second-line antituberculosis regimen.  The primary efficacy end point was the conversion of sputum cultures, in liq. broth, from pos. to neg.  RESULTS: The addn. of TMC207 to std. therapy for multidrug-resistant tuberculosis reduced the time to conversion to a neg. sputum culture, as compared with placebo (hazard ratio, 11.8; 95% confidence interval, 2.3 to 61.3; P = 0.003 by Cox regression anal.) and increased the proportion of patients with conversion of sputum culture (48% vs. 9%).  The mean log10 count of colony-forming units in the sputum declined more rapidly in the TMC207 group than in the placebo group.  No significant differences in av. plasma TMC207 concns. were noted between patients with and those without culture conversion.  Most adverse events were mild to moderate, and only nausea occurred significantly more frequently among patients in the TMC207 group than among patients in the placebo group (26% vs. 4%, P = 0.04).  CONCLUSIONS: The clin. activity of TMC207 validates ATP synthase as a viable target for the treatment of tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGra39rie2VZP7Vg90H21EOLACvtfcHk0lh82xD5_-eZJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXntVKqsrs%253D&md5=76bdbf7f0263a168e58532addaf90a0a</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0808427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0808427%26sid%3Dliteratum%253Aachs%26aulast%3DDiacon%26aufirst%3DA.%2BH.%26aulast%3DPym%26aufirst%3DA.%26aulast%3DGrobusch%26aufirst%3DM.%26aulast%3DPatientia%26aufirst%3DR.%26aulast%3DRustomjee%26aufirst%3DR.%26aulast%3DPage-Shipp%26aufirst%3DL.%26aulast%3DPistorius%26aufirst%3DC.%26aulast%3DKrause%26aufirst%3DR.%26aulast%3DBogoshi%26aufirst%3DM.%26aulast%3DChurchyard%26aufirst%3DG.%26aulast%3DVenter%26aufirst%3DA.%26aulast%3DAllen%26aufirst%3DJ.%26aulast%3DPalomino%26aufirst%3DJ.%2BC.%26aulast%3DDe%2BMarez%26aufirst%3DT.%26aulast%3Dvan%2BHeeswijk%26aufirst%3DR.%2BP.%2BG.%26aulast%3DMeyvisch%26aufirst%3DP.%26aulast%3DVerbeeck%26aufirst%3DJ.%26aulast%3DParys%26aufirst%3DW.%26aulast%3Dde%2BBeule%26aufirst%3DK.%26aulast%3DAndries%26aufirst%3DK.%26aulast%3DNeeley%26aufirst%3DD.%2BF.%2BM.%26aulast%3DMcNeeley%26aufirst%3DD.%2BF.%26atitle%3DThe%2520Diarylquinoline%2520TMC207%2520for%2520Multidrug-Resistant%2520Tuberculosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2009%26volume%3D360%26spage%3D2397%26epage%3D2405%26doi%3D10.1056%2Fnejmoa0808427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Unemo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ringlander, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiggins, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fredlund, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobsson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, M.</span></span> <span> </span><span class="NLM_article-title">High in Vitro Susceptibility to the Novel Spiropyrimidinetrione ETX0914 (Also Known as AZD0914) among 873 Contemporary Clinical Neisseria Gonorrhoeae Isolates in 21 European Countries during 2012-2014</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">5220</span>– <span class="NLM_lpage">5225</span>, <span class="refDoi"> DOI: 10.1128/aac.00786-15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1128%2FAAC.00786-15" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=26077246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlyit7rE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=5220-5225&author=M.+Unemoauthor=J.+Ringlanderauthor=C.+Wigginsauthor=H.+Fredlundauthor=S.+Jacobssonauthor=M.+Cole&title=High+in+Vitro+Susceptibility+to+the+Novel+Spiropyrimidinetrione+ETX0914+%28Also+Known+as+AZD0914%29+among+873+Contemporary+Clinical+Neisseria+Gonorrhoeae+Isolates+in+21+European+Countries+during+2012-2014&doi=10.1128%2Faac.00786-15"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">High in vitro susceptibility to the novel spiropyrimidinetrione ETX0914 (AZD0914) among 873 contemporary clinical Neisseria gonorrhoeae isolates from 21 European countries from 2012 to 2014</span></div><div class="casAuthors">Unemo, Magnus; Ringlander, Johan; Wiggins, Catherine; Fredlund, Hans; Jacobsson, Susanne; Cole, Michelle</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">5220-5225</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Resistance in Neisseria gonorrhoeae against all antimicrobials available for the treatment of gonorrhea has emerged.  The first gonococcal strains with high-level resistance to ceftriaxone, the last option for first-line empirical antimicrobial monotherapy, were recently described.  Consequently, new treatment options are essential.  In this study, the in vitro activity of the novel spiropyrimidinetrione ETX0914 (AZD0914), a DNA topoisomerase II inhibitor, was investigated among contemporary consecutive clin. N. gonorrhoeae isolates obtained in 21 European countries and compared to the activities of antimicrobials currently or previously recommended for treatment.  Consecutive clin. N. gonorrhoeae isolates (n = 873) cultured in 21 European countries from 2012 to 2014 were examd. for their susceptibility to ETX0914.  The MICs of ETX0914 were detd. using the agar diln. method.  For comparison, the MICs of ceftriaxone, cefixime, azithromycin, and ciprofloxacin were detd. using Etest or the agar diln. method.  For ETX0914, the MIC range, modal MIC, MIC50, and MIC90 were ≤0.002 to 0.25 mg/L, 0.125 mg/L, 0.064 mg/L, and 0.125 mg/L, resp.  The MIC values were substantially lower than those of the fluoroquinolone ciprofloxacin and most other antimicrobials examd.  No cross-resistance with any other examd. antimicrobial was obsd.  In conclusion, the in vitro susceptibility to the novel spiropyrimidinetrione ETX0914 (AZD0914) among 873 contemporary clin. isolates from 21 European countries was high, and no cross-resistance to antimicrobials currently or previously used for gonorrhea treatment was indicated.  Addnl. studies investigating the in vitro and in vivo induction and mechanisms of ETX0914 resistance in gonococci, pharmacokinetics/pharmacodynamics in modeling/simulations and in humans, and performance in randomized controlled gonorrhea treatment trials are essential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYWVFFyOWAVbVg90H21EOLACvtfcHk0lh82xD5_-eZJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlyit7rE&md5=8bc15f5d9ff4ba62390d9be5c01e8509</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1128%2FAAC.00786-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00786-15%26sid%3Dliteratum%253Aachs%26aulast%3DUnemo%26aufirst%3DM.%26aulast%3DRinglander%26aufirst%3DJ.%26aulast%3DWiggins%26aufirst%3DC.%26aulast%3DFredlund%26aufirst%3DH.%26aulast%3DJacobsson%26aufirst%3DS.%26aulast%3DCole%26aufirst%3DM.%26atitle%3DHigh%2520in%2520Vitro%2520Susceptibility%2520to%2520the%2520Novel%2520Spiropyrimidinetrione%2520ETX0914%2520%2528Also%2520Known%2520as%2520AZD0914%2529%2520among%2520873%2520Contemporary%2520Clinical%2520Neisseria%2520Gonorrhoeae%2520Isolates%2520in%252021%2520European%2520Countries%2520during%25202012-2014%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2015%26volume%3D59%26spage%3D5220%26epage%3D5225%26doi%3D10.1128%2Faac.00786-15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waites, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crabb, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huband, M. D.</span></span> <span> </span><span class="NLM_article-title">In Vitro Antibacterial Activity of AZD0914 against Human Mycoplasmas and Ureaplasmas</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">3627</span>– <span class="NLM_lpage">3629</span>, <span class="refDoi"> DOI: 10.1128/aac.04945-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1128%2FAAC.04945-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=25824220" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpsFGjuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=3627-3629&author=K.+B.+Waitesauthor=D.+M.+Crabbauthor=L.+B.+Duffyauthor=M.+D.+Huband&title=In+Vitro+Antibacterial+Activity+of+AZD0914+against+Human+Mycoplasmas+and+Ureaplasmas&doi=10.1128%2Faac.04945-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">In Vitro antibacterial activity of AZD0914 against human Mycoplasmas and Ureaplasmas</span></div><div class="casAuthors">Waites, Ken B.; Crabb, Donna M.; Duffy, Lynn B.; Huband, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3627-3629</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Susceptibilities were detd. for AZD0914, a spiropyrimidinetrione DNA gyrase inhibitor, azithromycin, doxycycline, and levofloxacin against Mycoplasma and Ureaplasma species.  The activity of AZD0914 was comparable to that of levofloxacin and doxycycline against Mycoplasma genitalium and Mycoplasma pneumoniae.  The AZD0914 MIC90 against Mycoplasma hominis was 8-fold greater than that for levofloxacin.  The AZD0914 MIC90 against Ureaplasma species was 4-fold less than that for azithromycin and 8-fold less than that for levofloxacin and doxycycline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrW8CtV-uoxC7Vg90H21EOLACvtfcHk0lh82xD5_-eZJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpsFGjuro%253D&md5=b28d0375d052f18529ed993b15e24e13</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1128%2FAAC.04945-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.04945-14%26sid%3Dliteratum%253Aachs%26aulast%3DWaites%26aufirst%3DK.%2BB.%26aulast%3DCrabb%26aufirst%3DD.%2BM.%26aulast%3DDuffy%26aufirst%3DL.%2BB.%26aulast%3DHuband%26aufirst%3DM.%2BD.%26atitle%3DIn%2520Vitro%2520Antibacterial%2520Activity%2520of%2520AZD0914%2520against%2520Human%2520Mycoplasmas%2520and%2520Ureaplasmas%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2015%26volume%3D59%26spage%3D3627%26epage%3D3629%26doi%3D10.1128%2Faac.04945-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Su, X.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, W.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alm, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, P. A.</span></span> <span> </span><span class="NLM_article-title">Multidrug-Resistant Neisseria Gonorrhoeae Isolates from Nanjing, China, Are Sensitive to Killing by a Novel DNA Gyrase Inhibitor, ETX0914 (AZD0914)</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">621</span>– <span class="NLM_lpage">623</span>, <span class="refDoi"> DOI: 10.1128/aac.01211-15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1128%2FAAC.01211-15" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=26482313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVCit7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2016&pages=621-623&author=X.-H.+Suauthor=B.-X.+Wangauthor=W.-J.+Leauthor=Y.-R.+Liuauthor=C.+Wanauthor=S.+Liauthor=R.+A.+Almauthor=J.+P.+Muellerauthor=P.+A.+Rice&title=Multidrug-Resistant+Neisseria+Gonorrhoeae+Isolates+from+Nanjing%2C+China%2C+Are+Sensitive+to+Killing+by+a+Novel+DNA+Gyrase+Inhibitor%2C+ETX0914+%28AZD0914%29&doi=10.1128%2Faac.01211-15"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Multidrug-resistant Neisseria gonorrhoeae isolates from Nanjing, China, are sensitive to killing by a novel DNA gyrase inhibitor, ETX0914 (AZD0914)</span></div><div class="casAuthors">Su, Xiao-Hong; Wang, Bao-Xi; Le, Wen-Jing; Liu, Yu-Rong; Wan, Chuan; Li, Sai; Alm, Richard A.; Mueller, John P.; Rice, Peter A.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">621-623</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">We tested the activity of ETX0914 against 187 Neisseria gonorrhoeae isolates from men with urethritis in Nanjing, China, in 2013.  The MIC50, MIC90, and MIC range for ETX0914 were 0.03 μg/mL, 0.06 μg/mL, and ≤0.002 to 0.125 μg/mL, resp.  All isolates were resistant to ciprofloxacin, and 36.9% (69/187) were resistant to azithromycin.  Of the isolates, 46.5% were penicillinase-producing N. gonorrhoeae (PPNG), 36% were tetracycline-resistant N. gonorrhoeae (TRNG), and 13% (24 isolates) had an MIC of 0.125 μg/mL for ceftriaxone.  ETX0914 may be an effective treatment option for gonorrhea.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9QF6jhy6LWbVg90H21EOLACvtfcHk0liikMtNjI7XWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVCit7%252FJ&md5=56d12ebf6d67d6f3875f1180d32f357c</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1128%2FAAC.01211-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01211-15%26sid%3Dliteratum%253Aachs%26aulast%3DSu%26aufirst%3DX.-H.%26aulast%3DWang%26aufirst%3DB.-X.%26aulast%3DLe%26aufirst%3DW.-J.%26aulast%3DLiu%26aufirst%3DY.-R.%26aulast%3DWan%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DAlm%26aufirst%3DR.%2BA.%26aulast%3DMueller%26aufirst%3DJ.%2BP.%26aulast%3DRice%26aufirst%3DP.%2BA.%26atitle%3DMultidrug-Resistant%2520Neisseria%2520Gonorrhoeae%2520Isolates%2520from%2520Nanjing%252C%2520China%252C%2520Are%2520Sensitive%2520to%2520Killing%2520by%2520a%2520Novel%2520DNA%2520Gyrase%2520Inhibitor%252C%2520ETX0914%2520%2528AZD0914%2529%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2016%26volume%3D60%26spage%3D621%26epage%3D623%26doi%3D10.1128%2Faac.01211-15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jacobsson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golparian, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alm, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huband, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohnishi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unemo, M.</span></span> <span> </span><span class="NLM_article-title">High in Vitro Activity of the Novel Spiropyrimidinetrione AZD0914, a DNA Gyrase Inhibitor, against Multidrug-Resistant Neisseria Gonorrhoeae Isolates Suggests a New Effective Option for Oral Treatment of Gonorrhea</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">5585</span>– <span class="NLM_lpage">5588</span>, <span class="refDoi"> DOI: 10.1128/aac.03090-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1128%2FAAC.03090-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=24982070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1eqtbjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2014&pages=5585-5588&author=S.+Jacobssonauthor=D.+Golparianauthor=R.+A.+Almauthor=M.+Hubandauthor=J.+Muellerauthor=J.+S.+Jensenauthor=M.+Ohnishiauthor=M.+Unemo&title=High+in+Vitro+Activity+of+the+Novel+Spiropyrimidinetrione+AZD0914%2C+a+DNA+Gyrase+Inhibitor%2C+against+Multidrug-Resistant+Neisseria+Gonorrhoeae+Isolates+Suggests+a+New+Effective+Option+for+Oral+Treatment+of+Gonorrhea&doi=10.1128%2Faac.03090-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">High in vitro activity of the novel spiropyrimidinetrione AZD0914, a DNA gyrase inhibitor, against multidrug-resistant Neisseria gonorrhoeae isolates suggests a new effective option for oral treatment of gonorrhea</span></div><div class="casAuthors">Jacobsson, Susanne; Golparian, Daniel; Alm, Richard A.; Huband, Michael; Mueller, John; Jensen, Jorgen Skov; Ohnishi, Makoto; Unemo, Magnus</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">5585-5588, 5 pp.</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">We evaluated the activity of the novel spiropyrimidinetrione AZD0914 (DNA gyrase inhibitor) against clin. gonococcal isolates and international ref. strains (n = 250), including strains with diverse multidrug resistance and extensive drug resistance.  The AZD0914 MICs were substantially lower than those of most other currently or previously recommended antimicrobials.  AZD0914 should be further evaluated, including in vitro selection, in vivo emergence and mechanisms of resistance, pharmacokinetics/pharmacodynamics in humans, optimal dosing, and performance, in appropriate randomized and controlled clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqX-jSLaLHHsrVg90H21EOLACvtfcHk0liikMtNjI7XWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1eqtbjK&md5=b33312a55ea3ba89313153735068d19c</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1128%2FAAC.03090-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.03090-14%26sid%3Dliteratum%253Aachs%26aulast%3DJacobsson%26aufirst%3DS.%26aulast%3DGolparian%26aufirst%3DD.%26aulast%3DAlm%26aufirst%3DR.%2BA.%26aulast%3DHuband%26aufirst%3DM.%26aulast%3DMueller%26aufirst%3DJ.%26aulast%3DJensen%26aufirst%3DJ.%2BS.%26aulast%3DOhnishi%26aufirst%3DM.%26aulast%3DUnemo%26aufirst%3DM.%26atitle%3DHigh%2520in%2520Vitro%2520Activity%2520of%2520the%2520Novel%2520Spiropyrimidinetrione%2520AZD0914%252C%2520a%2520DNA%2520Gyrase%2520Inhibitor%252C%2520against%2520Multidrug-Resistant%2520Neisseria%2520Gonorrhoeae%2520Isolates%2520Suggests%2520a%2520New%2520Effective%2520Option%2520for%2520Oral%2520Treatment%2520of%2520Gonorrhea%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2014%26volume%3D58%26spage%3D5585%26epage%3D5588%26doi%3D10.1128%2Faac.03090-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Damião
Gouveia, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unemo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, J. S.</span></span> <span> </span><span class="NLM_article-title">In Vitro Activity of Zoliflodacin (ETX0914) against Macrolide-Resistant, Fluoroquinolone-Resistant and Antimicrobial-Susceptible Mycoplasma Genitalium Strains</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">1291</span>– <span class="NLM_lpage">1294</span>, <span class="refDoi"> DOI: 10.1093/jac/dky022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1093%2Fjac%2Fdky022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=29444242" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A280%3ADC%252BC1Mrhs12rtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2018&pages=1291-1294&author=A.+C.+Dami%C3%A3o%0AGouveiaauthor=M.+Unemoauthor=J.+S.+Jensen&title=In+Vitro+Activity+of+Zoliflodacin+%28ETX0914%29+against+Macrolide-Resistant%2C+Fluoroquinolone-Resistant+and+Antimicrobial-Susceptible+Mycoplasma+Genitalium+Strains&doi=10.1093%2Fjac%2Fdky022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro activity of zoliflodacin (ETX0914) against macrolide-resistant, fluoroquinolone-resistant and antimicrobial-susceptible Mycoplasma genitalium strains</span></div><div class="casAuthors">Damiao Gouveia A C; Jensen J S; Unemo M</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of antimicrobial chemotherapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1291-1294</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Background:  Mycoplasma genitalium is estimated to be the second most common cause of bacterial sexually transmitted infection in Europe.  It is of increasing public health concern due to the rapid development of resistance to different antimicrobial classes, including the preferred first- and second-line treatments azithromycin and moxifloxacin.  Thus, new antimicrobial agents are urgently needed, especially for the treatment of MDR strains.  Methods:  The in vitro activity of the new spiropyrimidinetrione zoliflodacin against 47 M. genitalium strains was assessed by growing M. genitalium in Vero cell culture and measuring growth by quantitative PCR.  The collection included 34 moxifloxacin-susceptible (MIC <1 mg/L) and 13 moxifloxacin-resistant (MIC ≥1 mg/L) strains.  Twenty-three of the strains were azithromycin resistant (MIC ≥16 mg/L) and 12 of these strains were MDR.  Results:  Only one (2.1%) strain with substantially increased MIC (4 mg/L) and potential resistance to zoliflodacin was found.  Zoliflodacin was overall more potent than moxifloxacin (P = 0.009) and no cross-resistance was observed between the two drug classes of topoisomerase II inhibitors.  Differences in the MICs of zoliflodacin and azithromycin were not statistically significant; however, 23 (48.9%) compared with potentially 1 (2.1%) of the strains were resistant to azithromycin and zoliflodacin, respectively.  Conclusions:  Zoliflodacin is a promising candidate for the treatment of M. genitalium and it is important to further develop and evaluate this drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRXvQhLvVEpggpJitSxOdIlfW6udTcc2ea7_UasGp1B67ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mrhs12rtw%253D%253D&md5=b784d7783cab5d176287d9690748168e</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdky022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdky022%26sid%3Dliteratum%253Aachs%26aulast%3DDami%25C3%25A3o%2BGouveia%26aufirst%3DA.%2BC.%26aulast%3DUnemo%26aufirst%3DM.%26aulast%3DJensen%26aufirst%3DJ.%2BS.%26atitle%3DIn%2520Vitro%2520Activity%2520of%2520Zoliflodacin%2520%2528ETX0914%2529%2520against%2520Macrolide-Resistant%252C%2520Fluoroquinolone-Resistant%2520and%2520Antimicrobial-Susceptible%2520Mycoplasma%2520Genitalium%2520Strains%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2018%26volume%3D73%26spage%3D1291%26epage%3D1294%26doi%3D10.1093%2Fjac%2Fdky022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basarab, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doig, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galullo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kern, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimzey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutschke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morningstar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otterson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vishwanathan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gowravaram, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of Novel DNA Gyrase Inhibiting Spiropyrimidinetriones - Benzisoxazole Fusion with N-Linked Oxazolidinone Substituents Leading to a Clinical Candidate (ETX0914)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">6264</span>– <span class="NLM_lpage">6282</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00863</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00863" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFCrurvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6264-6282&author=G.+S.+Basarabauthor=P.+Doigauthor=V.+Galulloauthor=G.+Kernauthor=A.+Kimzeyauthor=A.+Kutschkeauthor=J.+P.+Newmanauthor=M.+Morningstarauthor=J.+Muellerauthor=L.+Ottersonauthor=K.+Vishwanathanauthor=F.+Zhouauthor=M.+Gowravaram&title=Discovery+of+Novel+DNA+Gyrase+Inhibiting+Spiropyrimidinetriones+-+Benzisoxazole+Fusion+with+N-Linked+Oxazolidinone+Substituents+Leading+to+a+Clinical+Candidate+%28ETX0914%29&doi=10.1021%2Facs.jmedchem.5b00863"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel DNA Gyrase Inhibiting Spiropyrimidinetriones: Benzisoxazole Fusion with N-Linked Oxazolidinone Substituents Leading to a Clinical Candidate (ETX0914)</span></div><div class="casAuthors">Basarab, Gregory S.; Doig, Peter; Galullo, Vincent; Kern, Gunther; Kimzey, Amy; Kutschke, Amy; Newman, Joseph P.; Morningstar, Marshall; Mueller, John; Otterson, Linda; Vishwanathan, Karthick; Zhou, Fei; Gowravaram, Madhusudhan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6264-6282</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel class of bacterial type-II topoisomerase inhibitor displaying a spiropyrimidinetrione architecture fused to a benzisoxazole scaffold shows potent activity against Gram-pos. and fastidious Gram-neg. bacteria.  Here, the authors describe a series of N-linked oxazolidinone substituents on the benzisoxazole that improve upon the antibacterial activity of initially described compds. of the class, show favorable PK properties, and demonstrate efficacy in an in vivo Staphylococcus aureus infection model.  Inhibition of the topoisomerases DNA gyrase and topoisomerase IV from both Gram-pos. and a Gram-neg. organisms was demonstrated.  Compds. showed a clean in vitro toxicity profile, including no genotoxicity and no bone marrow toxicity at the highest evaluated concns. or other issues that have been problematic for some fluoroquinolones.  Compd. I was identified for advancement into human clin. trials for treatment of uncomplicated gonorrhea based on a variety of beneficial attributes including the potent activity and the favorable safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoo8zOqBRUJg7Vg90H21EOLACvtfcHk0lg5XlwxjvPB_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFCrurvL&md5=67b21b269a0dfdf74b7e93196d8dfc4e</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00863&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00863%26sid%3Dliteratum%253Aachs%26aulast%3DBasarab%26aufirst%3DG.%2BS.%26aulast%3DDoig%26aufirst%3DP.%26aulast%3DGalullo%26aufirst%3DV.%26aulast%3DKern%26aufirst%3DG.%26aulast%3DKimzey%26aufirst%3DA.%26aulast%3DKutschke%26aufirst%3DA.%26aulast%3DNewman%26aufirst%3DJ.%2BP.%26aulast%3DMorningstar%26aufirst%3DM.%26aulast%3DMueller%26aufirst%3DJ.%26aulast%3DOtterson%26aufirst%3DL.%26aulast%3DVishwanathan%26aufirst%3DK.%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DGowravaram%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520Novel%2520DNA%2520Gyrase%2520Inhibiting%2520Spiropyrimidinetriones%2520-%2520Benzisoxazole%2520Fusion%2520with%2520N-Linked%2520Oxazolidinone%2520Substituents%2520Leading%2520to%2520a%2520Clinical%2520Candidate%2520%2528ETX0914%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D6264%26epage%3D6282%26doi%3D10.1021%2Facs.jmedchem.5b00863" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Okumura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maya, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onishi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izawa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanifuji, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arano, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, H.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, and Preliminary Evaluation of SPECT Probes for Imaging β-Amyloid in Alzheimer’s Disease Affected Brain</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1503</span>– <span class="NLM_lpage">1514</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.8b00064</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.8b00064" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlvFGls7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1503-1514&author=Y.+Okumuraauthor=Y.+Mayaauthor=T.+Onishiauthor=Y.+Shoyamaauthor=A.+Izawaauthor=D.+Nakamuraauthor=S.+Tanifujiauthor=A.+Tanakaauthor=Y.+Aranoauthor=H.+Matsumoto&title=Design%2C+Synthesis%2C+and+Preliminary+Evaluation+of+SPECT+Probes+for+Imaging+%CE%B2-Amyloid+in+Alzheimer%E2%80%99s+Disease+Affected+Brain&doi=10.1021%2Facschemneuro.8b00064"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Preliminary Evaluation of SPECT Probes for Imaging β-Amyloid in Alzheimer's Disease Affected Brain</span></div><div class="casAuthors">Okumura, Yuki; Maya, Yoshifumi; Onishi, Takako; Shoyama, Yoshinari; Izawa, Akihiro; Nakamura, Daisaku; Tanifuji, Shigeyuki; Tanaka, Akihiro; Arano, Yasushi; Matsumoto, Hiroki</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1503-1514</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this study, we synthesized of a series of 2-phenyl- and 2-pyridyl-imidazo[1,2-a]pyridine derivs. and examine their suitability as novel probes for single-photon emission computed tomog. (SPECT)-based imaging of β-amyloid (Aβ).  Among the 11 evaluated compds., 10 showed moderate affinity to Aβ(1-42) aggregates, exhibiting half-maximal inhibitory concns. (IC50) of 14.7 ± 6.07-87.6 ± 39.8 nM.  In vitro autoradiog. indicated that 123I-labeled triazole-substituted derivs. displayed highly selective binding to Aβ plaques in the hippocampal region of Alzheimer's disease (AD)-affected brain.  Moreover, biodistribution studies performed on normal rats demonstrated that all 123I-labeled probes featured high initial uptake into the brain followed by a rapid washout and were thus well suited for imaging Aβ plaques, with the highest selectivity obsd. for a 1H-1,2,3-triazole-substituted 2-pyridyl-imidazopyridine deriv., [123I]ABC577.  This compd. showed good kinetics in rat brain as well as moderate in vivo stability in rats and is thus a promising SPECT imaging probe for AD in clin. settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp207EWuPGnp7Vg90H21EOLACvtfcHk0lg5XlwxjvPB_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlvFGls7o%253D&md5=b4e388a4a281769468a884982f6f233e</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.8b00064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.8b00064%26sid%3Dliteratum%253Aachs%26aulast%3DOkumura%26aufirst%3DY.%26aulast%3DMaya%26aufirst%3DY.%26aulast%3DOnishi%26aufirst%3DT.%26aulast%3DShoyama%26aufirst%3DY.%26aulast%3DIzawa%26aufirst%3DA.%26aulast%3DNakamura%26aufirst%3DD.%26aulast%3DTanifuji%26aufirst%3DS.%26aulast%3DTanaka%26aufirst%3DA.%26aulast%3DArano%26aufirst%3DY.%26aulast%3DMatsumoto%26aufirst%3DH.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Preliminary%2520Evaluation%2520of%2520SPECT%2520Probes%2520for%2520Imaging%2520%25CE%25B2-Amyloid%2520in%2520Alzheimer%25E2%2580%2599s%2520Disease%2520Affected%2520Brain%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2018%26volume%3D9%26spage%3D1503%26epage%3D1514%26doi%3D10.1021%2Facschemneuro.8b00064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Temburnikar, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelbmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salomon, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seley-Radtke, K. L.</span></span> <span> </span><span class="NLM_article-title">Antiproliferative Activities of Halogenated Thieno[3,2-d]Pyrimidines</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">2113</span>– <span class="NLM_lpage">2122</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2014.02.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1016%2Fj.bmc.2014.02.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=24631358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktlWgsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=2113-2122&author=K.+W.+Temburnikarauthor=S.+C.+Zimmermannauthor=N.+T.+Kimauthor=C.+R.+Rossauthor=C.+Gelbmannauthor=C.+E.+Salomonauthor=G.+M.+Wilsonauthor=J.+Balzariniauthor=K.+L.+Seley-Radtke&title=Antiproliferative+Activities+of+Halogenated+Thieno%5B3%2C2-d%5DPyrimidines&doi=10.1016%2Fj.bmc.2014.02.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Antiproliferative activities of halogenated thieno[3,2-d]pyrimidines</span></div><div class="casAuthors">Temburnikar, Kartik W.; Zimmermann, Sarah C.; Kim, Nathaniel T.; Ross, Christina R.; Gelbmann, Christopher; Salomon, Christine E.; Wilson, Gerald M.; Balzarini, Jan; Seley-Radtke, Katherine L.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2113-2122</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The in vitro evaluation of thieno[3,2-d]pyrimidines identified halogenated compds. 1 and 2 with antiproliferative activity against three different cancer cell lines.  A structure activity relation study indicated the necessity of the chlorine at the C4-position for biol. activity.  The two most active compds. 1 and 2 were found to induce apoptosis in the leukemia L1210 cell line.  Addnl., the compds. were screened against a variety of other microbial targets and as a result, selective activity against several fungi was also obsd.  The synthesis and preliminary biol. results are reported herein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5MFfw6R0CKLVg90H21EOLACvtfcHk0lg5XlwxjvPB_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktlWgsr4%253D&md5=d436cc1f43c71dfd258adbace4ea3468</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.02.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.02.033%26sid%3Dliteratum%253Aachs%26aulast%3DTemburnikar%26aufirst%3DK.%2BW.%26aulast%3DZimmermann%26aufirst%3DS.%2BC.%26aulast%3DKim%26aufirst%3DN.%2BT.%26aulast%3DRoss%26aufirst%3DC.%2BR.%26aulast%3DGelbmann%26aufirst%3DC.%26aulast%3DSalomon%26aufirst%3DC.%2BE.%26aulast%3DWilson%26aufirst%3DG.%2BM.%26aulast%3DBalzarini%26aufirst%3DJ.%26aulast%3DSeley-Radtke%26aufirst%3DK.%2BL.%26atitle%3DAntiproliferative%2520Activities%2520of%2520Halogenated%2520Thieno%255B3%252C2-d%255DPyrimidines%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D2113%26epage%3D2122%26doi%3D10.1016%2Fj.bmc.2014.02.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruble, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurd, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherry, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbachyn, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toogood, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bundy, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graber, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamilar, G. M.</span></span> <span> </span><span class="NLM_article-title">Synthesis of (-)-PNU-286607 by Asymmetric Cyclization of Alkylidene Barbiturates</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">3991</span>– <span class="NLM_lpage">3997</span>, <span class="refDoi"> DOI: 10.1021/ja808014h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja808014h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivVeisL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2009&pages=3991-3997&author=J.+C.+Rubleauthor=A.+R.+Hurdauthor=T.+A.+Johnsonauthor=D.+A.+Sherryauthor=M.+R.+Barbachynauthor=P.+L.+Toogoodauthor=G.+L.+Bundyauthor=D.+R.+Graberauthor=G.+M.+Kamilar&title=Synthesis+of+%28-%29-PNU-286607+by+Asymmetric+Cyclization+of+Alkylidene+Barbiturates&doi=10.1021%2Fja808014h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of (-)-PNU-286607 by Asymmetric Cyclization of Alkylidene Barbiturates</span></div><div class="casAuthors">Ruble, J. Craig; Hurd, Alexander R.; Johnson, Timothy A.; Sherry, Debra A.; Barbachyn, Michael R.; Toogood, Peter L.; Bundy, Gordon L.; Graber, David R.; Kamilar, Gregg M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3991-3997</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">PNU 286607 I, a oxazinoquinolinespiropyrimidinetrione inhibitor of bacterial DNA gyrase for potential use as an antibacterial agent against antibiotic-resistant bacterial strains, is prepd. in two steps from 2-fluoro-5-nitrobenzaldehyde and (R,R)-2,6-dimethylmorpholine by nucleophilic arom. substitution followed by condensation with barbituric acid and a concomitant stereoselective cyclization of the benzylidenepyrimidinetrione.  The stereoselectivities and mechanism of the condensation and cyclization reactions (based on the rearrangements of vinyl anilines, known in the literature as the "tert-amino effect") are investigated using the NMR spectroscopic anal. of the reactions of racemic substrates and the reactions of racemic and nonracemic deuterated substrates; based on the data obtained, the asym. synthesis of I is developed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYwZZhoPHBHrVg90H21EOLACvtfcHk0ljOa0jE_1Waww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivVeisL4%253D&md5=f837986da667a40ce19753baa9d58125</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fja808014h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja808014h%26sid%3Dliteratum%253Aachs%26aulast%3DRuble%26aufirst%3DJ.%2BC.%26aulast%3DHurd%26aufirst%3DA.%2BR.%26aulast%3DJohnson%26aufirst%3DT.%2BA.%26aulast%3DSherry%26aufirst%3DD.%2BA.%26aulast%3DBarbachyn%26aufirst%3DM.%2BR.%26aulast%3DToogood%26aufirst%3DP.%2BL.%26aulast%3DBundy%26aufirst%3DG.%2BL.%26aulast%3DGraber%26aufirst%3DD.%2BR.%26aulast%3DKamilar%26aufirst%3DG.%2BM.%26atitle%3DSynthesis%2520of%2520%2528-%2529-PNU-286607%2520by%2520Asymmetric%2520Cyclization%2520of%2520Alkylidene%2520Barbiturates%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2009%26volume%3D131%26spage%3D3991%26epage%3D3997%26doi%3D10.1021%2Fja808014h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basarab, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galullo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degrace, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauck, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joubran, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wesolowski, S. S.</span></span> <span> </span><span class="NLM_article-title">Synthesis of a Tetrahydronaphthyridine Spiropyrimidinetrione DNA Gyrase Inhibiting Antibacterial Agent - Differential Substitution at All Five Carbon Atoms of Pyridine</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">6456</span>– <span class="NLM_lpage">6459</span>, <span class="refDoi"> DOI: 10.1021/ol503256h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol503256h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVamsrzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2014&pages=6456-6459&author=G.+S.+Basarabauthor=V.+Galulloauthor=N.+Degraceauthor=S.+Hauckauthor=C.+Joubranauthor=S.+S.+Wesolowski&title=Synthesis+of+a+Tetrahydronaphthyridine+Spiropyrimidinetrione+DNA+Gyrase+Inhibiting+Antibacterial+Agent+-+Differential+Substitution+at+All+Five+Carbon+Atoms+of+Pyridine&doi=10.1021%2Fol503256h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of a Tetrahydronaphthyridine Spiropyrimidinetrione DNA Gyrase Inhibiting Antibacterial Agent - Differential Substitution at all Five Carbon Atoms of Pyridine.</span></div><div class="casAuthors">Basarab, Gregory S.; Galullo, Vincent; DeGrace, Nancy; Hauck, Sheila; Joubran, Camil; Wesolowski, Steven S.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6456-6459</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7052</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis of I, a potent antibacterial agent, was achieved stereoselectively in nine steps from readily available starting materials.  Directed metalations were developed to assemble a pentasubstituted pyridine with appropriately positioned aldehyde and dimethylmorpholine substituents for a key tertiary amino effect reaction (T-reaction) that led to the spirocyclic architecture.  Ultimately, I was isolated as the thermodynamically most favored stereoisomer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWsTrK9RkPp7Vg90H21EOLACvtfcHk0ljOa0jE_1Waww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVamsrzN&md5=d593296ffc77a54b3157e5641001d1a8</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fol503256h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol503256h%26sid%3Dliteratum%253Aachs%26aulast%3DBasarab%26aufirst%3DG.%2BS.%26aulast%3DGalullo%26aufirst%3DV.%26aulast%3DDegrace%26aufirst%3DN.%26aulast%3DHauck%26aufirst%3DS.%26aulast%3DJoubran%26aufirst%3DC.%26aulast%3DWesolowski%26aufirst%3DS.%2BS.%26atitle%3DSynthesis%2520of%2520a%2520Tetrahydronaphthyridine%2520Spiropyrimidinetrione%2520DNA%2520Gyrase%2520Inhibiting%2520Antibacterial%2520Agent%2520-%2520Differential%2520Substitution%2520at%2520All%2520Five%2520Carbon%2520Atoms%2520of%2520Pyridine%26jtitle%3DOrg.%2520Lett.%26date%3D2014%26volume%3D16%26spage%3D6456%26epage%3D6459%26doi%3D10.1021%2Fol503256h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raw, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Kearney-McMullan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, M. A.</span></span> <span> </span><span class="NLM_article-title">Unexpected Ring-Expansion of 1,2-Benzisoxazol-3-Ones</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">6775</span>– <span class="NLM_lpage">6778</span>, <span class="refDoi"> DOI: 10.1016/j.tetlet.2011.10.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1016%2Fj.tetlet.2011.10.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVOjt7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2011&pages=6775-6778&author=S.+A.+Rawauthor=A.+M.+O%E2%80%99Kearney-McMullanauthor=M.+A.+Graham&title=Unexpected+Ring-Expansion+of+1%2C2-Benzisoxazol-3-Ones&doi=10.1016%2Fj.tetlet.2011.10.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Unexpected ring-expansion of 1,2-benzisoxazol-3-ones</span></div><div class="casAuthors">Raw, Steven A.; O'Kearney-McMullan, Anne M.; Graham, Mark A.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">50</span>),
    <span class="NLM_cas:pages">6775-6778</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A novel and unexpected ring-expansion reaction of 1,2-benzisoxazol-3-ones is identified.  The scope of this reaction is exemplified and the proposed mechanism is also implicated in another degrdn. process.  This reaction also represents a new method for accessing the 4H-1,3-benzoxazin-4-one, e.g., I, skeleton.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjWZHjxa7V3rVg90H21EOLACvtfcHk0ljOa0jE_1Waww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVOjt7fM&md5=117620d39bc7d24edacb0bdae121e152</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2011.10.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2011.10.027%26sid%3Dliteratum%253Aachs%26aulast%3DRaw%26aufirst%3DS.%2BA.%26aulast%3DO%25E2%2580%2599Kearney-McMullan%26aufirst%3DA.%2BM.%26aulast%3DGraham%26aufirst%3DM.%2BA.%26atitle%3DUnexpected%2520Ring-Expansion%2520of%25201%252C2-Benzisoxazol-3-Ones%26jtitle%3DTetrahedron%2520Lett.%26date%3D2011%26volume%3D52%26spage%3D6775%26epage%3D6778%26doi%3D10.1016%2Fj.tetlet.2011.10.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sikorski, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reitz, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilla, L. T.</span></span> <span> </span><span class="NLM_article-title">Triazole Phosphonates. Electrophilic Substitution of 1-Substituted-1<i>H</i>-1,2,4-Triazoles <i>via</i> Lithiated Triazole Intermediates</span>. <i>J. Heterocycl. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1257</span>– <span class="NLM_lpage">1262</span>, <span class="refDoi"> DOI: 10.1002/jhet.5570230457</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1002%2Fjhet.5570230457" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADyaL2sXitFertrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1986&pages=1257-1262&author=D.+K.+Andersonauthor=J.+A.+Sikorskiauthor=D.+B.+Reitzauthor=L.+T.+Pilla&title=Triazole+Phosphonates.+Electrophilic+Substitution+of+1-Substituted-1H-1%2C2%2C4-Triazoles+via+Lithiated+Triazole+Intermediates&doi=10.1002%2Fjhet.5570230457"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Triazole phosphonates.  Electrophilic substitution of 1-substituted 1H-1,2,4-triazoles via lithiated triazole intermediates</span></div><div class="casAuthors">Anderson, D. Keith; Sikorski, James A.; Reitz, David B.; Pilla, Linda T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Heterocyclic Chemistry</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1257-62</span>CODEN:
                <span class="NLM_cas:coden">JHTCAD</span>;
        ISSN:<span class="NLM_cas:issn">0022-152X</span>.
    </div><div class="casAbstract">Lithiation of triazoles I (R = Ph, R1 = CH2Ph; R = H, R1 = Me, CPh3, CH2Ph) and II with BuLi in THF proceeded exclusively at C-5.  Li salts of I were stable at -78° and on treatment with electrophiles gave triazoles III [R2 = P(O)(OEt)2, SPh, Me3CSiMe2, D, C(OH)Ph2, Me, Cl, CO2Me].  Deesterification of III [R = H, R1 = CH2Ph, Me, R2 = P(O)(OEt)2] with Me3SiBr gave III (R2 = PO3H2).  The crystal structure of III (R = H, R1 = CH2Ph, R2 = PO3H2) is reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfxo1o7O8Ks7Vg90H21EOLACvtfcHk0ljOa0jE_1Waww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXitFertrk%253D&md5=d612f2fb93a47076e983b9168b04ec81</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1002%2Fjhet.5570230457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjhet.5570230457%26sid%3Dliteratum%253Aachs%26aulast%3DAnderson%26aufirst%3DD.%2BK.%26aulast%3DSikorski%26aufirst%3DJ.%2BA.%26aulast%3DReitz%26aufirst%3DD.%2BB.%26aulast%3DPilla%26aufirst%3DL.%2BT.%26atitle%3DTriazole%2520Phosphonates.%2520Electrophilic%2520Substitution%2520of%25201-Substituted-1H-1%252C2%252C4-Triazoles%2520via%2520Lithiated%2520Triazole%2520Intermediates%26jtitle%3DJ.%2520Heterocycl.%2520Chem.%26date%3D1986%26volume%3D23%26spage%3D1257%26epage%3D1262%26doi%3D10.1002%2Fjhet.5570230457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lakshmireddy, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naga Veera, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">China
Raju, B.</span></span> <span> </span><span class="NLM_article-title">A Green and Sustainable Approach for Selective Halogenation of Anilides, Benzanilides, Sulphonamides and Heterocycles</span>. <i>Asian J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1380</span>– <span class="NLM_lpage">1384</span>, <span class="refDoi"> DOI: 10.1002/ajoc.201900296</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1002%2Fajoc.201900296" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1ensbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2019&pages=1380-1384&author=V.+M.+Lakshmireddyauthor=Y.+Naga+Veeraauthor=T.+J.+Reddyauthor=V.+J.+Raoauthor=B.+China%0ARaju&title=A+Green+and+Sustainable+Approach+for+Selective+Halogenation+of+Anilides%2C+Benzanilides%2C+Sulphonamides+and+Heterocycles&doi=10.1002%2Fajoc.201900296"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">A Green and Sustainable Approach for Selective Halogenation of Anilides, Benzanilides, Sulphonamides and Heterocycles</span></div><div class="casAuthors">Lakshmireddy, V. M.; Naga Veera, Y.; Reddy, T. J.; Rao, V. J.; China Raju, B.</div><div class="citationInfo"><span class="NLM_cas:title">Asian Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1380-1384</span>CODEN:
                <span class="NLM_cas:coden">AJOCC7</span>;
        ISSN:<span class="NLM_cas:issn">2193-5807</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">An efficient green and sustainable protocol was devised for the selective oxidative halogenation of acetanilides, benzanilides, sulfonamides and heterocyclic compds. to afford haloanilides and halosulfonamides I [R = COMe, COPh, SO2Ph; R1 = Cl, Br; R2 = H, F; R3 = H, i-Pr, CF3, etc.; R4 = H, F, Br, etc.], haloimidazoles, haloindoles, halothiazoles and 1,2,4-triazole e.g. II and halopyridines III [R5 = NH2, NHCOMe, Br, etc.; R6 = NH2, Cl, Br, etc.; R7 = H, NH2, NH(Me)2, NHCOMe; R8 = H, Cl, Br] using easily available NaX as a halogen source and oxone as a powerful oxidant.  The present protocol was simple and environmentally benign to conduct the lab. scale halogenations and could be extended to prep. industrially important compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-hRjC5UB_vrVg90H21EOLACvtfcHk0ljSgeaBqugxew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1ensbvI&md5=e55c9ba30e8eb39b32382458ae852143</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2Fajoc.201900296&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fajoc.201900296%26sid%3Dliteratum%253Aachs%26aulast%3DLakshmireddy%26aufirst%3DV.%2BM.%26aulast%3DNaga%2BVeera%26aufirst%3DY.%26aulast%3DReddy%26aufirst%3DT.%2BJ.%26aulast%3DRao%26aufirst%3DV.%2BJ.%26aulast%3DChina%2BRaju%26aufirst%3DB.%26atitle%3DA%2520Green%2520and%2520Sustainable%2520Approach%2520for%2520Selective%2520Halogenation%2520of%2520Anilides%252C%2520Benzanilides%252C%2520Sulphonamides%2520and%2520Heterocycles%26jtitle%3DAsian%2520J.%2520Org.%2520Chem.%26date%3D2019%26volume%3D8%26spage%3D1380%26epage%3D1384%26doi%3D10.1002%2Fajoc.201900296" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannecouque, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span> <span> </span><span class="NLM_article-title">Arylazolylthioacetanilide. Part 8: Design, Synthesis and Biological Evaluation of Novel 2-(2-(2,4-Dichlorophenyl)-2H-1,2,4-Triazol-3-Ylthio)-N-Arylacetamides as Potent HIV-1 Inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">5039</span>– <span class="NLM_lpage">5045</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2011.08.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1016%2Fj.ejmech.2011.08.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=21872971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1amt7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2011&pages=5039-5045&author=P.+Zhanauthor=X.+Chenauthor=X.+Liauthor=D.+Liauthor=Y.+Tianauthor=W.+Chenauthor=C.+Pannecouqueauthor=E.+De+Clercqauthor=X.+Liu&title=Arylazolylthioacetanilide.+Part+8%3A+Design%2C+Synthesis+and+Biological+Evaluation+of+Novel+2-%282-%282%2C4-Dichlorophenyl%29-2H-1%2C2%2C4-Triazol-3-Ylthio%29-N-Arylacetamides+as+Potent+HIV-1+Inhibitors&doi=10.1016%2Fj.ejmech.2011.08.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of Novel 2-(2-(2,4-Dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides As Potent HIV-1 inhibitors</span></div><div class="casAuthors">Zhan, Peng; Chen, Xu-Wang; Li, Xiao; Li, Dong-Yue; Tian, Ye; Chen, Wen-Wen; Pannecouque, Christophe; De Clercq, Erik; Liu, Xin-Yong</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5039-5045</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The development of novel HIV-1 NNRTIs offers the possibility of generating novel structures with increased potency.  Based on the bioisosteric principle, a novel series of 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamide derivs., e.g., I, were designed, synthesized using a simple and efficient synthetic route, structurally confirmed by spectral anal., evaluated for their anti-HIV activity in MT-4 cells and their inhibitory effect on HIV-1 RT.  The results showed that some of the new compds. displayed low micromolar potency for inhibiting HIV-1 replication and promising activities against several selected resistant strains that confer resistance to current NNRTIs.  However, all newly synthesized derivs. were not active against HIV-2 replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpP0yww0QTfUrVg90H21EOLACvtfcHk0ljSgeaBqugxew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1amt7rF&md5=35ac87ec7d91d1853041e3a4069c6226</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2011.08.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2011.08.011%26sid%3Dliteratum%253Aachs%26aulast%3DZhan%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DTian%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DPannecouque%26aufirst%3DC.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DX.%26atitle%3DArylazolylthioacetanilide.%2520Part%25208%253A%2520Design%252C%2520Synthesis%2520and%2520Biological%2520Evaluation%2520of%2520Novel%25202-%25282-%25282%252C4-Dichlorophenyl%2529-2H-1%252C2%252C4-Triazol-3-Ylthio%2529-N-Arylacetamides%2520as%2520Potent%2520HIV-1%2520Inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2011%26volume%3D46%26spage%3D5039%26epage%3D5045%26doi%3D10.1016%2Fj.ejmech.2011.08.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span>; <span class="NLM_string-name">Yohi, P. W.</span>; <span class="NLM_string-name">Michael, X.</span>; <span class="NLM_string-name">Cruise, D.</span></span> <span> </span><span class="NLM_article-title">Synthesis of PARP Inhibitor Talazoparb</span>. U.S. Patent <span class="NLM_patent">US 9,708,319 B1</span>, July 18, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=Y.+Xu&author=P.+W.+Yohi&author=X.+Michael&author=D.+Cruise&title=Synthesis+of+PARP+Inhibitor+Talazoparb"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DY.%26atitle%3DSynthesis%2520of%2520PARP%2520Inhibitor%2520Talazoparb%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blaquiere, N.</span>; <span class="NLM_string-name">Do, S.</span>; <span class="NLM_string-name">Dudley, D.</span>; <span class="NLM_string-name">Fokes, A. J.</span>; <span class="NLM_string-name">Heald, R.</span>; <span class="NLM_string-name">Heffron, T.</span>; <span class="NLM_string-name">Jones, M.</span>; <span class="NLM_string-name">Kolesnikov, A.</span>; <span class="NLM_string-name">Ndubaku, C.</span>; <span class="NLM_string-name">Olivero, A. G.</span>; <span class="NLM_string-name">Price, S.</span>; <span class="NLM_string-name">Staben, S.</span>; <span class="NLM_string-name">Wang, L.</span></span> <span> </span><span class="NLM_article-title">Benzoxazepin PI3K Inhibitor Compounds and Methods of Use</span>. <span class="NLM_patent">WO 2011036280 A1</span>, March 6, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=N.+Blaquiere&author=S.+Do&author=D.+Dudley&author=A.+J.+Fokes&author=R.+Heald&author=T.+Heffron&author=M.+Jones&author=A.+Kolesnikov&author=C.+Ndubaku&author=A.+G.+Olivero&author=S.+Price&author=S.+Staben&author=L.+Wang&title=Benzoxazepin+PI3K+Inhibitor+Compounds+and+Methods+of+Use"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBlaquiere%26aufirst%3DN.%26atitle%3DBenzoxazepin%2520PI3K%2520Inhibitor%2520Compounds%2520and%2520Methods%2520of%2520Use%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srikannathasan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fosberry, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hann, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hibbs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Homes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingraham, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizzollo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shillings, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitsfaden, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiobald, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stavenger, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bax, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gwynn, M. N.</span></span> <span> </span><span class="NLM_article-title">Structural Basis of DNA Gyrase Inhibition by Antibacterial QPT-1, Anticancer Drug Etoposide and Moxifloxacin</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">10048</span>, <span class="refDoi"> DOI: 10.1038/ncomms10048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1038%2Fncomms10048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=26640131" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFyks7jL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=10048&author=P.+F.+Chanauthor=V.+Srikannathasanauthor=J.+Huangauthor=H.+Cuiauthor=A.+P.+Fosberryauthor=M.+Guauthor=M.+M.+Hannauthor=M.+Hibbsauthor=P.+Homesauthor=K.+Ingrahamauthor=J.+Pizzolloauthor=C.+Shenauthor=A.+J.+Shillingsauthor=C.+E.+Spitsfadenauthor=R.+Tannerauthor=A.+J.+Thiobaldauthor=R.+A.+Stavengerauthor=B.+D.+Baxauthor=M.+N.+Gwynn&title=Structural+Basis+of+DNA+Gyrase+Inhibition+by+Antibacterial+QPT-1%2C+Anticancer+Drug+Etoposide+and+Moxifloxacin&doi=10.1038%2Fncomms10048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis of DNA gyrase inhibition by antibacterial QPT-1, anticancer drug etoposide and moxifloxacin</span></div><div class="casAuthors">Chan, Pan F.; Srikannathasan, Velupillai; Huang, Jianzhong; Cui, Haifeng; Fosberry, Andrew P.; Gu, Minghua; Hann, Michael M.; Hibbs, Martin; Homes, Paul; Ingraham, Karen; Pizzollo, Jason; Shen, Carol; Shillings, Anthony J.; Spitzfaden, Claus E.; Tanner, Robert; Theobald, Andrew J.; Stavenger, Robert A.; Bax, Benjamin D.; Gwynn, Michael N.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10048</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">New antibacterials are needed to tackle antibiotic-resistant bacteria.  Type IIA topoisomerases (topo2As), the targets of fluoroquinolones, regulate DNA topol. by creating transient double-strand DNA breaks.  Here we report the first co-crystal structures of the antibacterial QPT-1 and the anticancer drug etoposide with Staphylococcus aureus DNA gyrase, showing binding at the same sites in the cleaved DNA as the fluoroquinolone moxifloxacin.  Unlike moxifloxacin, QPT-1 and etoposide interact with conserved GyrB TOPRIM residues rationalizing why QPT-1 can overcome fluoroquinolone resistance.  Our data show etoposide's antibacterial activity is due to DNA gyrase inhibition and suggests other anticancer agents act similarly.  Anal. of multiple DNA gyrase co-crystal structures, including asym. cleavage complexes, led to a 'pair of swing-doors' hypothesis in which the movement of one DNA segment regulates cleavage and religation of the second DNA duplex.  This mechanism can explain QPT-1's bacterial specificity.  Structure-based strategies for developing topo2A antibacterials are suggested.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoY_mF0ShDkkbVg90H21EOLACvtfcHk0ljSgeaBqugxew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFyks7jL&md5=1e358e6e0e9454967cf2aa2e01a0306b</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fncomms10048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms10048%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DP.%2BF.%26aulast%3DSrikannathasan%26aufirst%3DV.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DCui%26aufirst%3DH.%26aulast%3DFosberry%26aufirst%3DA.%2BP.%26aulast%3DGu%26aufirst%3DM.%26aulast%3DHann%26aufirst%3DM.%2BM.%26aulast%3DHibbs%26aufirst%3DM.%26aulast%3DHomes%26aufirst%3DP.%26aulast%3DIngraham%26aufirst%3DK.%26aulast%3DPizzollo%26aufirst%3DJ.%26aulast%3DShen%26aufirst%3DC.%26aulast%3DShillings%26aufirst%3DA.%2BJ.%26aulast%3DSpitsfaden%26aufirst%3DC.%2BE.%26aulast%3DTanner%26aufirst%3DR.%26aulast%3DThiobald%26aufirst%3DA.%2BJ.%26aulast%3DStavenger%26aufirst%3DR.%2BA.%26aulast%3DBax%26aufirst%3DB.%2BD.%26aulast%3DGwynn%26aufirst%3DM.%2BN.%26atitle%3DStructural%2520Basis%2520of%2520DNA%2520Gyrase%2520Inhibition%2520by%2520Antibacterial%2520QPT-1%252C%2520Anticancer%2520Drug%2520Etoposide%2520and%2520Moxifloxacin%26jtitle%3DNat.%2520Commun.%26date%3D2015%26volume%3D6%26spage%3D10048%26doi%3D10.1038%2Fncomms10048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laponogov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, X.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veselkov, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAuley, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanderson, M. R.</span></span> <span> </span><span class="NLM_article-title">Structural Basis of Gate-DNA Breakage and Resealing by Type II Topoisomerases</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">e11338</span>, <span class="refDoi"> DOI: 10.1371/annotation/deacc2fd-665b-4736-b668-dc69a38bb4f9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1371%2Fjournal.pone.0011338" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=20596531" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A280%3ADC%252BC3cnksVagsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=e11338&author=I.+Laponogovauthor=X.-S.+Panauthor=D.+A.+Veselkovauthor=K.+E.+McAuleyauthor=L.+M.+Fisherauthor=M.+R.+Sanderson&title=Structural+Basis+of+Gate-DNA+Breakage+and+Resealing+by+Type+II+Topoisomerases&doi=10.1371%2Fannotation%2Fdeacc2fd-665b-4736-b668-dc69a38bb4f9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis of gate-DNA breakage and resealing by type II topoisomerases</span></div><div class="casAuthors">Laponogov Ivan; Pan Xiao-Su; Veselkov Dennis A; McAuley Katherine E; Fisher L Mark; Sanderson Mark R</div><div class="citationInfo"><span class="NLM_cas:title">PloS one</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e11338</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Type II DNA topoisomerases are ubiquitous enzymes with essential functions in DNA replication, recombination and transcription.  They change DNA topology by forming a transient covalent cleavage complex with a gate-DNA duplex that allows transport of a second duplex though the gate.  Despite its biological importance and targeting by anticancer and antibacterial drugs, cleavage complex formation and reversal is not understood for any type II enzyme.  To address the mechanism, we have used X-ray crystallography to study sequential states in the formation and reversal of a DNA cleavage complex by topoisomerase IV from Streptococcus pneumoniae, the bacterial type II enzyme involved in chromosome segregation.  A high resolution structure of the complex captured by a novel antibacterial dione reveals two drug molecules intercalated at a cleaved B-form DNA gate and anchored by drug-specific protein contacts.  Dione release generated drug-free cleaved and resealed DNA complexes in which the DNA gate instead adopts an unusual A/B-form helical conformation with a Mg(2+) ion repositioned to coordinate each scissile phosphodiester group and promote reversible cleavage by active-site tyrosines.  These structures, the first for putative reaction intermediates of a type II topoisomerase, suggest how a type II enzyme reseals DNA during its normal reaction cycle and illuminate aspects of drug arrest important for the development of new topoisomerase-targeting therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcShiG7Hb50Ehd0Q2ypr7jHkfW6udTcc2eYEmsRvOP519bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cnksVagsA%253D%253D&md5=fcddd6c8ad69c0bc09137d484aad638d</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0011338&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0011338%26sid%3Dliteratum%253Aachs%26aulast%3DLaponogov%26aufirst%3DI.%26aulast%3DPan%26aufirst%3DX.-S.%26aulast%3DVeselkov%26aufirst%3DD.%2BA.%26aulast%3DMcAuley%26aufirst%3DK.%2BE.%26aulast%3DFisher%26aufirst%3DL.%2BM.%26aulast%3DSanderson%26aufirst%3DM.%2BR.%26atitle%3DStructural%2520Basis%2520of%2520Gate-DNA%2520Breakage%2520and%2520Resealing%2520by%2520Type%2520II%2520Topoisomerases%26jtitle%3DPLoS%2520One%26date%3D2010%26volume%3D5%26spage%3De11338%26doi%3D10.1371%2Fannotation%2Fdeacc2fd-665b-4736-b668-dc69a38bb4f9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laponogov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sohi, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veselkov, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, X.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawhney, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAuley, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanderson, M. R.</span></span> <span> </span><span class="NLM_article-title">Structural Insight into the Quinolone-DNA Cleavage Complex of Type IIA Topoisomerases</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">667</span>– <span class="NLM_lpage">669</span>, <span class="refDoi"> DOI: 10.1038/nsmb.1604</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1038%2Fnsmb.1604" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=19448616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtVOqsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=667-669&author=I.+Laponogovauthor=M.+K.+Sohiauthor=D.+A.+Veselkovauthor=X.-S.+Panauthor=R.+Sawhneyauthor=A.+W.+Thompsonauthor=K.+E.+McAuleyauthor=L.+M.+Fisherauthor=M.+R.+Sanderson&title=Structural+Insight+into+the+Quinolone-DNA+Cleavage+Complex+of+Type+IIA+Topoisomerases&doi=10.1038%2Fnsmb.1604"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases</span></div><div class="casAuthors">Laponogov, Ivan; Sohi, Maninder K.; Veselkov, Dennis A.; Pan, Xiao-Su; Sawhney, Ritica; Thompson, Andrew W.; McAuley, Katherine E.; Fisher, L. Mark; Sanderson, Mark R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">667-669</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Type II topoisomerases alter DNA topol. by forming a covalent DNA-cleavage complex that allows DNA transport through a double-stranded DNA break.  We present the structures of cleavage complexes formed by the Streptococcus pneumoniae ParC breakage-reunion and ParE TOPRIM domains of topoisomerase IV stabilized by moxifloxacin and clinafloxacin, two antipneumococcal fluoroquinolones.  These structures reveal two drug mols. intercalated at the highly bent DNA gate and help explain antibacterial quinolone action and resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDXhjTPq1GlrVg90H21EOLACvtfcHk0lhPy-g2kuZyHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtVOqsrc%253D&md5=cd4c757dbb5d50c8113e658837d44a34</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.1604&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.1604%26sid%3Dliteratum%253Aachs%26aulast%3DLaponogov%26aufirst%3DI.%26aulast%3DSohi%26aufirst%3DM.%2BK.%26aulast%3DVeselkov%26aufirst%3DD.%2BA.%26aulast%3DPan%26aufirst%3DX.-S.%26aulast%3DSawhney%26aufirst%3DR.%26aulast%3DThompson%26aufirst%3DA.%2BW.%26aulast%3DMcAuley%26aufirst%3DK.%2BE.%26aulast%3DFisher%26aufirst%3DL.%2BM.%26aulast%3DSanderson%26aufirst%3DM.%2BR.%26atitle%3DStructural%2520Insight%2520into%2520the%2520Quinolone-DNA%2520Cleavage%2520Complex%2520of%2520Type%2520IIA%2520Topoisomerases%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2009%26volume%3D16%26spage%3D667%26epage%3D669%26doi%3D10.1038%2Fnsmb.1604" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blower, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williamson, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerns, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, J. M.</span></span> <span> </span><span class="NLM_article-title">Crystal Structure and Stability of Gyrase-Fluoroquinolone Cleaved Complexes from Mycobacterium Tuberculosis</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">1706</span>– <span class="NLM_lpage">1713</span>, <span class="refDoi"> DOI: 10.1073/pnas.1525047113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1073%2Fpnas.1525047113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=26792525" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFWjsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2016&pages=1706-1713&author=T.+R.+Blowerauthor=B.+H.+Williamsonauthor=R.+J.+Kernsauthor=J.+M.+Berger&title=Crystal+Structure+and+Stability+of+Gyrase-Fluoroquinolone+Cleaved+Complexes+from+Mycobacterium+Tuberculosis&doi=10.1073%2Fpnas.1525047113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure and stability of gyrase-fluoroquinolone cleaved complexes from Mycobacterium tuberculosis</span></div><div class="casAuthors">Blower, Tim R.; Williamson, Benjamin H.; Kerns, Robert J.; Berger, James M.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1706-1713</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Mycobacterium tuberculosis (Mtb) infects one-third of the world's population and in 2013 accounted for 1.5 million deaths.  Fluoroquinolone antibacterials, which target DNA gyrase, are crit. agents used to halt the progression from multidrug-resistant tuberculosis to extensively resistant disease; however, fluoroquinolone resistance is emerging and new ways to bypass resistance are required.  To better explain known differences in fluoroquinolone action, the crystal structures of the WT Mtb DNA gyrase cleavage core and a fluoroquinolone-sensitized mutant were detd. in complex with DNA and five fluoroquinolones.  The structures, ranging from 2.4- to 2.6-Å resoln., show that the intrinsically low susceptibility of Mtb to fluoroquinolones correlates with a redn. in contacts to the water shell of an assocd. magnesium ion, which bridges fluoroquinolone-gyrase interactions.  Surprisingly, the structural data revealed few differences in fluoroquinolone-enzyme contacts from drugs that have very different activities against Mtb.  By contrast, a stability assay using purified components showed a clear relationship between ternary complex reversibility and inhibitory activities reported with cultured cells.  Collectively, our data indicate that the stability of fluoroquinolone/DNA interactions is a major determinant of fluoroquinolone activity and that moieties that have been appended to the C7 position of different quinolone scaffolds do not take advantage of specific contacts that might be made with the enzyme.  These concepts point to new approaches for developing quinolone-class compds. that have increased potency against Mtb and the ability to overcome resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotyAfeeRgSebVg90H21EOLACvtfcHk0lhPy-g2kuZyHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFWjsr8%253D&md5=bde8e79ead3566a890d7e970de8c3292</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1525047113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1525047113%26sid%3Dliteratum%253Aachs%26aulast%3DBlower%26aufirst%3DT.%2BR.%26aulast%3DWilliamson%26aufirst%3DB.%2BH.%26aulast%3DKerns%26aufirst%3DR.%2BJ.%26aulast%3DBerger%26aufirst%3DJ.%2BM.%26atitle%3DCrystal%2520Structure%2520and%2520Stability%2520of%2520Gyrase-Fluoroquinolone%2520Cleaved%2520Complexes%2520from%2520Mycobacterium%2520Tuberculosis%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2016%26volume%3D113%26spage%3D1706%26epage%3D1713%26doi%3D10.1073%2Fpnas.1525047113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahic, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thresher, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hajec, L.</span></span> <span> </span><span class="NLM_article-title">A Homogeneous, High-Throughput Fluorescence Anisotropy-Based DNA Supercoiling Assay</span>. <i>J. Biomol. Screen.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1088</span>– <span class="NLM_lpage">1098</span>, <span class="refDoi"> DOI: 10.1177/1087057110378624</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1177%2F1087057110378624" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=20930214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVajsLrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2010&pages=1088-1098&author=A.+Shapiroauthor=H.+Jahicauthor=S.+Prasadauthor=D.+Ehmannauthor=J.+Thresherauthor=N.+Gaoauthor=L.+Hajec&title=A+Homogeneous%2C+High-Throughput+Fluorescence+Anisotropy-Based+DNA+Supercoiling+Assay&doi=10.1177%2F1087057110378624"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">A homogeneous, high-throughput fluorescence anisotropy-based DNA supercoiling assay</span></div><div class="casAuthors">Shapiro, Adam; Jahic, Haris; Prasad, Swati; Ehmann, David; Thresher, Jason; Gao, Ning; Hajec, Laurel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Screening</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1088-1098</span>CODEN:
                <span class="NLM_cas:coden">JBISF3</span>;
        ISSN:<span class="NLM_cas:issn">1087-0571</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">The degree of supercoiling of DNA is vital for cellular processes, such as replication and transcription.  DNA topol. is controlled by the action of DNA topoisomerase enzymes.  Topoisomerases, because of their importance in cellular replication, are the targets of several anticancer and antibacterial drugs.  In the search for new drugs targeting topoisomerases, a biochem. assay compatible with automated high-throughput screening (HTS) would be valuable.  Gel electrophoresis is the std. method for measuring changes in the extent of supercoiling of plasmid DNA when acted upon by topoisomerases, but this is a low-throughput and laborious method.  A medium-throughput method was described previously that quant. distinguishes relaxed and supercoiled plasmids by the difference in their abilities to form triplex structures with an immobilized oligonucleotide.  In this article, the authors describe a homogeneous supercoiling assay based on triplex formation in which the oligonucleotide strand is labeled with a fluorescent dye and the readout is fluorescence anisotropy.  The new assay requires no immobilization, filtration, or plate washing steps and is therefore well suited to HTS for inhibitors of topoisomerases.  The utility of this assay is demonstrated with relaxation of supercoiled plasmid by Escherichia coli topoisomerase I, supercoiling of relaxed plasmid by E. coli DNA gyrase, and inhibition of gyrase by fluoroquinolones and nalidixic acid.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLPydgbbQi2bVg90H21EOLACvtfcHk0lg8pUqlpJebgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVajsLrN&md5=51191c534eaf19b3e198866d0c68e14a</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1177%2F1087057110378624&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057110378624%26sid%3Dliteratum%253Aachs%26aulast%3DShapiro%26aufirst%3DA.%26aulast%3DJahic%26aufirst%3DH.%26aulast%3DPrasad%26aufirst%3DS.%26aulast%3DEhmann%26aufirst%3DD.%26aulast%3DThresher%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DN.%26aulast%3DHajec%26aufirst%3DL.%26atitle%3DA%2520Homogeneous%252C%2520High-Throughput%2520Fluorescence%2520Anisotropy-Based%2520DNA%2520Supercoiling%2520Assay%26jtitle%3DJ.%2520Biomol.%2520Screen.%26date%3D2010%26volume%3D15%26spage%3D1088%26epage%3D1098%26doi%3D10.1177%2F1087057110378624" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lahiri, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutschke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormack, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alm, R. A.</span></span> <span> </span><span class="NLM_article-title">Insights into the Mechanism of Inhibition of Novel Bacteria Topoisomerase Inhibitors from Characterization of Resistant Mutants of Staphylococcus Aureus</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">5278</span>– <span class="NLM_lpage">5287</span>, <span class="refDoi"> DOI: 10.1128/aac.00571-15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1128%2FAAC.00571-15" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=26077256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlyitrfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=5278-5287&author=S.+D.+Lahiriauthor=A.+Kutschkeauthor=K.+McCormackauthor=R.+A.+Alm&title=Insights+into+the+Mechanism+of+Inhibition+of+Novel+Bacteria+Topoisomerase+Inhibitors+from+Characterization+of+Resistant+Mutants+of+Staphylococcus+Aureus&doi=10.1128%2Faac.00571-15"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into the mechanism of inhibition of novel bacterial topoisomerase inhibitors from characterization of resistant mutants of Staphylococcus aureus</span></div><div class="casAuthors">Lahiri, Sushmita D.; Kutschke, Amy; McCormack, Kathy; Alm, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">5278-5287</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The type II topoisomerases DNA gyrase and topoisomerase IV are clin. validated bacterial targets that catalyze the modulation of DNA topol. that is vital to DNA replication, repair, and decatenation.  Increasing resistance to fluoroquinolones, which trap the topoisomerase-DNA complex, has led to significant efforts in the discovery of novel inhibitors of these targets.  AZ6142 is a member of the class of novel bacterial topoisomerase inhibitors (NBTIs) that utilizes a distinct mechanism to trap the protein- DNA complex.  AZ6142 has very potent activity against Gram-pos. organisms, including Staphylococcus aureus, Streptococcus pneumoniae, and Streptococcus pyogenes.  In this study, we detd. the frequencies of resistance to AZ6142 and other representative NBTI compds. in S. aureus and S. pneumoniae.  The frequencies of selection of resistant mutants at 4× the MIC were 1.7 × 10-8 for S. aureus and <5.5 × 10-10 for S. pneumoniae.  To improve our understanding of the NBTI mechanism of inhibition, the resistant S. aureus mutants were characterized and 20 unique substitutions in the topoisomerase subunits were identified.  Many of these substitutions were located outside the NBTI binding pocket and impact the susceptibility of AZ6142, resulting in a 4- to 32-fold elevation in the MIC over the wild-type parent strain.  Data on cross-resistance with other NBTIs and fluoroquinolones enabled the differentiation of scaffold-specific changes from compd.-specific variations.  Our results suggest that AZ6142 inhibits both type II topoisomerases in S. aureus but that DNA gyrase is the primary target.  Further, the genotype of the resistant mutants suggests that domain conformations and DNA interactions may uniquely impact NBTIs compared to fluoroquinolones.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoh17EyyLZqWLVg90H21EOLACvtfcHk0lg8pUqlpJebgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlyitrfF&md5=ed718068b6189445b6161bf3811af97a</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1128%2FAAC.00571-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00571-15%26sid%3Dliteratum%253Aachs%26aulast%3DLahiri%26aufirst%3DS.%2BD.%26aulast%3DKutschke%26aufirst%3DA.%26aulast%3DMcCormack%26aufirst%3DK.%26aulast%3DAlm%26aufirst%3DR.%2BA.%26atitle%3DInsights%2520into%2520the%2520Mechanism%2520of%2520Inhibition%2520of%2520Novel%2520Bacteria%2520Topoisomerase%2520Inhibitors%2520from%2520Characterization%2520of%2520Resistant%2520Mutants%2520of%2520Staphylococcus%2520Aureus%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2015%26volume%3D59%26spage%3D5278%26epage%3D5287%26doi%3D10.1128%2Faac.00571-15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acree, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aliev, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leo, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whaley, W. L.</span></span> <span> </span><span class="NLM_article-title">An NMR Method for the Quantitative Assessment of Intramolecular Hydrogen Bonding; Application to Physicochemical, Environmental, and Biochemical Properties</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">11075</span>– <span class="NLM_lpage">11083</span>, <span class="refDoi"> DOI: 10.1021/jo502080p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo502080p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVensLrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2014&pages=11075-11083&author=M.+H.+Abrahamauthor=R.+J.+Abrahamauthor=W.+E.+Acreeauthor=A.+E.+Alievauthor=A.+J.+Leoauthor=W.+L.+Whaley&title=An+NMR+Method+for+the+Quantitative+Assessment+of+Intramolecular+Hydrogen+Bonding%3B+Application+to+Physicochemical%2C+Environmental%2C+and+Biochemical+Properties&doi=10.1021%2Fjo502080p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">An NMR Method for the Quantitative Assessment of Intramolecular Hydrogen Bonding; Application to Physicochemical, Environmental, and Biochemical Properties</span></div><div class="casAuthors">Abraham, Michael H.; Abraham, Raymond J.; Acree, William E.; Aliev, Abil E.; Leo, Al J.; Whaley, William L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">11075-11083</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">1H NMR chem. shifts have been obtained in the solvents deuterochloroform and DMSO.  The difference in the chem. shifts of an OH or NH group in these two solvents, Δδ = δ(DMSO) - δ(CDCl3), can be converted into the hydrogen bond acidity, A, of the group using the equation A = 0.0065 + 0.133Δδ.  The NMR A value, ANMR, can be used as a quant. assessment of intramol. hydrogen bonding.  We list values of Δδ and ANMR for 55 compds. contg. an OH group and 60 compds. with an NH group.  For the hydroxy compds., if A > 0.5 then the OH group is not part of an intramol. hydrogen bond, but if A < 0.1 then the OH group forms part of an intramol. hydrogen bond.  For NH compds., if A > 0.16 the NH group is not part of an intramol. hydrogen bond, and if A < 0.05 the NH group is part of an intramol. hydrogen bond.  No comparison compds. are needed, and the method is extremely simple.  We further show how it is possible to relate intramol. hydrogen bonding to the actual effect on values of a no. of physicochem., environmental, and biochem. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpS3GZXQi7robVg90H21EOLACvtfcHk0lg8pUqlpJebgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVensLrM&md5=b5e9948a04237fadb3b4fc3237bde8b1</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjo502080p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo502080p%26sid%3Dliteratum%253Aachs%26aulast%3DAbraham%26aufirst%3DM.%2BH.%26aulast%3DAbraham%26aufirst%3DR.%2BJ.%26aulast%3DAcree%26aufirst%3DW.%2BE.%26aulast%3DAliev%26aufirst%3DA.%2BE.%26aulast%3DLeo%26aufirst%3DA.%2BJ.%26aulast%3DWhaley%26aufirst%3DW.%2BL.%26atitle%3DAn%2520NMR%2520Method%2520for%2520the%2520Quantitative%2520Assessment%2520of%2520Intramolecular%2520Hydrogen%2520Bonding%253B%2520Application%2520to%2520Physicochemical%252C%2520Environmental%252C%2520and%2520Biochemical%2520Properties%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2014%26volume%3D79%26spage%3D11075%26epage%3D11083%26doi%3D10.1021%2Fjo502080p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alm, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lahiri, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutschke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otterson, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whiteaker, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huband, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, J. P.</span></span> <span> </span><span class="NLM_article-title">Characterization of the Novel DNA Gyrase Inhibitor AZD0914: Low Resistance Potential and Lack of Cross-Resistance in Neisseria Gonorrhoeae</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1478</span>– <span class="NLM_lpage">1486</span>, <span class="refDoi"> DOI: 10.1128/aac.04456-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1128%2FAAC.04456-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=25534723" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtFajtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=1478-1486&author=R.+A.+Almauthor=S.+D.+Lahiriauthor=A.+Kutschkeauthor=L.+G.+Ottersonauthor=R.+E.+McLaughlinauthor=J.+D.+Whiteakerauthor=L.+A.+Lewisauthor=X.+Suauthor=M.+D.+Hubandauthor=H.+Gardnerauthor=J.+P.+Mueller&title=Characterization+of+the+Novel+DNA+Gyrase+Inhibitor+AZD0914%3A+Low+Resistance+Potential+and+Lack+of+Cross-Resistance+in+Neisseria+Gonorrhoeae&doi=10.1128%2Faac.04456-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the novel DNA gyrase inhibitor AZD0914: low resistance potential and lack of cross-resistance in Neisseria gonorrhoeae</span></div><div class="casAuthors">Alm, Richard A.; Lahiri, Sushmita D.; Kutschke, Amy; Otterson, Linda G.; McLaughlin, Robert E.; Whiteaker, James D.; Lewis, Lisa A.; Su, Xiaohong; Huband, Michael D.; Gardner, Humphrey; Mueller, John P.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1478-1486</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The unmet medical need for novel intervention strategies to treat Neisseria gonorrhoeae infections is significant and increasing, as rapidly emerging resistance in this pathogen is threatening to eliminate the currently available treatment options.  AZD0914 is a novel bacterial gyrase inhibitor that possesses potent in vitro activities against isolates with high-level resistance to ciprofloxacin and extended-spectrum cephalosporins, and it is currently in clin. development for the treatment of N. gonorrhoeae infections.  The propensity to develop resistance against AZD0914 was examd. in N. gonorrhoeae and found to be extremely low, a finding supported by similar studies with Staphylococcus aureus.  The genetic characterization of both first-step and second-step mutants that exhibited decreased susceptibilities to AZD0914 identified substitutions in the conserved GyrB TOPRIM domain, confirming DNA gyrase as the primary target of AZD0914 and providing differentiation from fluoroquinolones.  The anal. of available bacterial gyrase and topoisomerase IV structures, including those bound to fluoroquinolone and nonfluoroquinolone inhibitors, has allowed the rationalization of the lack of cross-resistance that AZD0914 shares with fluoroquinolones.  Microbiol. susceptibility data also indicate that the topoisomerase inhibition mechanisms are subtly different between N. gonorrhoeae and other bacterial species.  Taken together, these data support the progression of AZD0914 as a novel treatment option for the oral treatment of N. gonorrhoeae infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmr5nuUGnvorVg90H21EOLACvtfcHk0lgPrXtTKmOMLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtFajtrs%253D&md5=6d6f73ded98cf4895bb1019f8de28681</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1128%2FAAC.04456-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.04456-14%26sid%3Dliteratum%253Aachs%26aulast%3DAlm%26aufirst%3DR.%2BA.%26aulast%3DLahiri%26aufirst%3DS.%2BD.%26aulast%3DKutschke%26aufirst%3DA.%26aulast%3DOtterson%26aufirst%3DL.%2BG.%26aulast%3DMcLaughlin%26aufirst%3DR.%2BE.%26aulast%3DWhiteaker%26aufirst%3DJ.%2BD.%26aulast%3DLewis%26aufirst%3DL.%2BA.%26aulast%3DSu%26aufirst%3DX.%26aulast%3DHuband%26aufirst%3DM.%2BD.%26aulast%3DGardner%26aufirst%3DH.%26aulast%3DMueller%26aufirst%3DJ.%2BP.%26atitle%3DCharacterization%2520of%2520the%2520Novel%2520DNA%2520Gyrase%2520Inhibitor%2520AZD0914%253A%2520Low%2520Resistance%2520Potential%2520and%2520Lack%2520of%2520Cross-Resistance%2520in%2520Neisseria%2520Gonorrhoeae%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2015%26volume%3D59%26spage%3D1478%26epage%3D1486%26doi%3D10.1128%2Faac.04456-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bax, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eggleston, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fosberry, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gentry, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorrec, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordano, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hann, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennessy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hibbs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">May, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitzfaden, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shillings, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theobald, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wohlkonig, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gwynn, M. N.</span></span> <span> </span><span class="NLM_article-title">Type IIA Topoisomerase Inhibition by a New Class of Antibacterial Agents</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>466</i></span>,  <span class="NLM_fpage">935</span>– <span class="NLM_lpage">940</span>, <span class="refDoi"> DOI: 10.1038/nature09197</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1038%2Fnature09197" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=20686482" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A280%3ADC%252BC3cjmtFaktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=466&publication_year=2010&pages=935-940&author=B.+D.+Baxauthor=P.+F.+Chanauthor=D.+S.+Egglestonauthor=A.+Fosberryauthor=D.+R.+Gentryauthor=F.+Gorrecauthor=I.+Giordanoauthor=M.+M.+Hannauthor=A.+Hennessyauthor=M.+Hibbsauthor=J.+Huangauthor=E.+Jonesauthor=J.+Jonesauthor=K.+K.+Brownauthor=C.+J.+Lewisauthor=E.+W.+Mayauthor=M.+R.+Saundersauthor=O.+Singhauthor=C.+E.+Spitzfadenauthor=C.+Shenauthor=A.+Shillingsauthor=A.+J.+Theobaldauthor=A.+Wohlkonigauthor=N.+D.+Pearsonauthor=M.+N.+Gwynn&title=Type+IIA+Topoisomerase+Inhibition+by+a+New+Class+of+Antibacterial+Agents&doi=10.1038%2Fnature09197"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Type IIA topoisomerase inhibition by a new class of antibacterial agents</span></div><div class="casAuthors">Bax Benjamin D; Chan Pan F; Eggleston Drake S; Fosberry Andrew; Gentry Daniel R; Gorrec Fabrice; Giordano Ilaria; Hann Michael M; Hennessy Alan; Hibbs Martin; Huang Jianzhong; Jones Emma; Jones Jo; Brown Kristin Koretke; Lewis Ceri J; May Earl W; Saunders Martin R; Singh Onkar; Spitzfaden Claus E; Shen Carol; Shillings Anthony; Theobald Andrew J; Wohlkonig Alexandre; Pearson Neil D; Gwynn Michael N</div><div class="citationInfo"><span class="NLM_cas:title">Nature</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">466</span>
        (<span class="NLM_cas:issue">7309</span>),
    <span class="NLM_cas:pages">935-40</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Despite the success of genomics in identifying new essential bacterial genes, there is a lack of sustainable leads in antibacterial drug discovery to address increasing multidrug resistance.  Type IIA topoisomerases cleave and religate DNA to regulate DNA topology and are a major class of antibacterial and anticancer drug targets, yet there is no well developed structural basis for understanding drug action.  Here we report the 2.1 A crystal structure of a potent, new class, broad-spectrum antibacterial agent in complex with Staphylococcus aureus DNA gyrase and DNA, showing a new mode of inhibition that circumvents fluoroquinolone resistance in this clinically important drug target.  The inhibitor 'bridges' the DNA and a transient non-catalytic pocket on the two-fold axis at the GyrA dimer interface, and is close to the active sites and fluoroquinolone binding sites.  In the inhibitor complex the active site seems poised to cleave the DNA, with a single metal ion observed between the TOPRIM (topoisomerase/primase) domain and the scissile phosphate.  This work provides new insights into the mechanism of topoisomerase action and a platform for structure-based drug design of a new class of antibacterial agents against a clinically proven, but conformationally flexible, enzyme class.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTzBPk2FYUX-kBuFdjgVNKSfW6udTcc2eY-D-qOYA0887ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cjmtFaktA%253D%253D&md5=006fef200c7a44f0671829b2a5fbddef</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fnature09197&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09197%26sid%3Dliteratum%253Aachs%26aulast%3DBax%26aufirst%3DB.%2BD.%26aulast%3DChan%26aufirst%3DP.%2BF.%26aulast%3DEggleston%26aufirst%3DD.%2BS.%26aulast%3DFosberry%26aufirst%3DA.%26aulast%3DGentry%26aufirst%3DD.%2BR.%26aulast%3DGorrec%26aufirst%3DF.%26aulast%3DGiordano%26aufirst%3DI.%26aulast%3DHann%26aufirst%3DM.%2BM.%26aulast%3DHennessy%26aufirst%3DA.%26aulast%3DHibbs%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DJones%26aufirst%3DE.%26aulast%3DJones%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DK.%2BK.%26aulast%3DLewis%26aufirst%3DC.%2BJ.%26aulast%3DMay%26aufirst%3DE.%2BW.%26aulast%3DSaunders%26aufirst%3DM.%2BR.%26aulast%3DSingh%26aufirst%3DO.%26aulast%3DSpitzfaden%26aufirst%3DC.%2BE.%26aulast%3DShen%26aufirst%3DC.%26aulast%3DShillings%26aufirst%3DA.%26aulast%3DTheobald%26aufirst%3DA.%2BJ.%26aulast%3DWohlkonig%26aufirst%3DA.%26aulast%3DPearson%26aufirst%3DN.%2BD.%26aulast%3DGwynn%26aufirst%3DM.%2BN.%26atitle%3DType%2520IIA%2520Topoisomerase%2520Inhibition%2520by%2520a%2520New%2520Class%2520of%2520Antibacterial%2520Agents%26jtitle%3DNature%26date%3D2010%26volume%3D466%26spage%3D935%26epage%3D940%26doi%3D10.1038%2Fnature09197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basarab, G. S.</span></span> <span> </span><span class="NLM_article-title">Four Ways to Skin a Cat: Inhibition of Bacterial Topoisomerases Leading to the Clinic</span>. In  <i>Topics in Medicinal Chemistry 25 Antibacterials Volume 1</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, J. F.</span>, <span class="NLM_string-name">Miller, M. J.</span>, <span class="NLM_string-name">Mobashery, S.</span></span>, Eds.; <span class="NLM_publisher-name">Springer International Publishing</span>: <span class="NLM_publisher-loc">Cham, Switzerland</span>, <span class="NLM_year">2018</span>; pp  <span class="NLM_fpage">165</span>– <span class="NLM_lpage">188</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&pages=165-188&author=G.+S.+Basarabauthor=J.+F.+Fisher&author=M.+J.+Miller&author=S.+Mobashery&title=Topics+in+Medicinal+Chemistry+25+Antibacterials+Volume+1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DBasarab%26aufirst%3DG.%2BS.%26atitle%3DFour%2520Ways%2520to%2520Skin%2520a%2520Cat%253A%2520Inhibition%2520of%2520Bacterial%2520Topoisomerases%2520Leading%2520to%2520the%2520Clinic%26btitle%3DTopics%2520in%2520Medicinal%2520Chemistry%252025%2520Antibacterials%2520Volume%25201%26aulast%3DFisher%26aufirst%3DJ.%2BF.%26pub%3DSpringer%2520International%2520Publishing%26date%3D2018%26spage%3D165%26epage%3D188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerns, E. H.</span></span> <span> </span><span class="NLM_article-title">The Effect of Plasma Protein Binding on in Vivo Efficacy: Misconceptions in Drug Discovery</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">929</span>– <span class="NLM_lpage">939</span>, <span class="refDoi"> DOI: 10.1038/nrd3287</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1038%2Fnrd3287" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=21119731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsV2jurfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=929-939&author=D.+A.+Smithauthor=L.+Diauthor=E.+H.+Kerns&title=The+Effect+of+Plasma+Protein+Binding+on+in+Vivo+Efficacy%3A+Misconceptions+in+Drug+Discovery&doi=10.1038%2Fnrd3287"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery</span></div><div class="casAuthors">Smith, Dennis A.; Di, Li; Kerns, Edward H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">929-939</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Data from in vitro plasma protein binding expts. that det. the fraction of protein-bound drug are frequently used in drug discovery to guide structure design and to prioritize compds. for in vivo studies.  However, we consider that these practices are usually misleading, because in vivo efficacy is detd. by the free (unbound) drug concn. surrounding the therapeutic target, not by the free drug fraction.  These practices yield no enhancement of the in vivo free drug concn.  So, decisions based on free drug fraction could result in the wrong compds. being advanced through drug discovery programs.  This Perspective provides guidance on the application of plasma protein binding information in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOa3ippodhGbVg90H21EOLACvtfcHk0lgPrXtTKmOMLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsV2jurfI&md5=a45d00f68ab44580fa38a6acef49493a</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1038%2Fnrd3287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3287%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DDi%26aufirst%3DL.%26aulast%3DKerns%26aufirst%3DE.%2BH.%26atitle%3DThe%2520Effect%2520of%2520Plasma%2520Protein%2520Binding%2520on%2520in%2520Vivo%2520Efficacy%253A%2520Misconceptions%2520in%2520Drug%2520Discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26spage%3D929%26epage%3D939%26doi%3D10.1038%2Fnrd3287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van
den Bergh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilissen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Straetemans, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wuyts, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bijnens, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackie, C.</span></span> <span> </span><span class="NLM_article-title">Prediction of Human Oral Plasma Concentration-Time Profiles Using Preclinical Data</span>. <i>Clin. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">505</span>– <span class="NLM_lpage">517</span>, <span class="refDoi"> DOI: 10.2165/11587230-000000000-00000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.2165%2F11587230-000000000-00000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=21740074" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1WmtbbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2011&pages=505-517&author=A.+Van%0Aden+Berghauthor=V.+Sinhaauthor=R.+Gilissenauthor=R.+Straetemansauthor=K.+Wuytsauthor=D.+Morrisonauthor=L.+Bijnensauthor=C.+Mackie&title=Prediction+of+Human+Oral+Plasma+Concentration-Time+Profiles+Using+Preclinical+Data&doi=10.2165%2F11587230-000000000-00000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of human oral plasma concentration-time profiles using preclinical data: Comparative evaluation of prediction approaches in early pharmaceutical discovery</span></div><div class="casAuthors">Van den Bergh, An; Sinha, Vikash; Gilissen, Ron; Straetemans, Roel; Wuyts, Koen; Morrison, Denise; Bijnens, Luc; Mackie, Claire</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">505-517</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Wolters Kluwer Health</span>)
        </div><div class="casAbstract">Background and Objectives: Empirically based methods remain one of our tools in human pharmacokinetic predictions.  The Dedrick approach and the steady-state plasma drug concn. (Css)-mean residence time (MRT) approach are based on the assumption that concn.-time profiles are similar among species, including man, and that curves derived from a variety of animal species can be superimposed after math. transformation.  In the Dedrick approach the transformation is based on the slope and intercept of the allometric relationship.  The Css-MRT approach is based on the implementation of measured animal and predicted human MRT and dose/vol. of distribution at steady state (Vss).  The aims of the present study were to compare the predictive performance of concn.-time profiles obtained by these approaches, to evaluate the prediction of individual pharmacokinetic parameters by these approaches and to further refine these approaches incorporating the experience from our previous work.  Methods: A retrospective anal. using 35 proprietary compds. developed at Johnson & Johnson Pharmaceutical Research and Development was conducted to compare the accuracies of the Dedrick and Css-MRT approaches for predicting oral concn.-time profiles and pharmacokinetic parameters in man.  In the first step, input for the transformation was based on simple allometry.  Then we assessed whether both methods could be fine-tuned by systematically incorporating correction factors (max. life span potential, brain wt. and plasma protein binding), depending on the interspecies relationship.  In addn., for the Css-MRT approach, we used formulas based on multivariate regression anal. as input for the transformation.  Results: Inclusion of correction factors significantly improved the profile predictability for the Dedrick and Css-MRT approaches.  This was mainly linked to an improved prediction of terminal elimination half-life (t1/2), MRT and the ratio between the max. plasma concn. and the concn. at the last obsd. time point (Cmax/Clast).  No significant differences were obsd. between the Dedrick approach with correction factors, the Css-MRT approach with correction factors and the Css-MRT approach, based on the regression equations.  Conclusions: Based on the dataset evaluated in this study, we demonstrated that human plasma concn.-time profiles and pharmacokinetic parameters could be predicted with the Dedrick and Css-MRT approaches and that if correction factors were implemented, the predictions improved significantly.  With the requirement of only a limited preclin. in vivo pharmacokinetic dataset, these empirical methods could offer potential in the early stages of drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKYttKxUygj7Vg90H21EOLACvtfcHk0lhyFcXq9Zv7tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1WmtbbP&md5=31a5bf80ffb713d74c87787deccba085</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.2165%2F11587230-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F11587230-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2Bden%2BBergh%26aufirst%3DA.%26aulast%3DSinha%26aufirst%3DV.%26aulast%3DGilissen%26aufirst%3DR.%26aulast%3DStraetemans%26aufirst%3DR.%26aulast%3DWuyts%26aufirst%3DK.%26aulast%3DMorrison%26aufirst%3DD.%26aulast%3DBijnens%26aufirst%3DL.%26aulast%3DMackie%26aufirst%3DC.%26atitle%3DPrediction%2520of%2520Human%2520Oral%2520Plasma%2520Concentration-Time%2520Profiles%2520Using%2520Preclinical%2520Data%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2011%26volume%3D50%26spage%3D505%26epage%3D517%26doi%3D10.2165%2F11587230-000000000-00000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peters, S. A.</span></span> <i>Physiologically-Based Pharmacokinetic (PBPK) Modeling and Simulations: Principles, Methods, and Applications in the Pharmaceutical Industry</i>, <span class="NLM_edition">1</span>st ed.; <span class="NLM_publisher-name">John Wiley & Sons, Inc.</span>: <span class="NLM_publisher-loc">Hoboken, NJ</span>, <span class="NLM_year">2012</span>; pp  <span class="NLM_fpage">407</span>– <span class="NLM_lpage">421</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1002%2F9781118140291.app1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=407-421&author=S.+A.+Peters&title=Physiologically-Based+Pharmacokinetic+%28PBPK%29+Modeling+and+Simulations%3A+Principles%2C+Methods%2C+and+Applications+in+the+Pharmaceutical+Industry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1002%2F9781118140291.app1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9781118140291.app1%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DS.%2BA.%26btitle%3DPhysiologically-Based%2520Pharmacokinetic%2520%2528PBPK%2529%2520Modeling%2520and%2520Simulations%253A%2520Principles%252C%2520Methods%252C%2520and%2520Applications%2520in%2520the%2520Pharmaceutical%2520Industry%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26date%3D2012%26spage%3D407%26epage%3D421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doherty, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fellows, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donovan, M.</span></span> <span> </span><span class="NLM_article-title">A Rapid, Semi-Automated Method for Scoring Micronuclei in Mononucleated Mouse Lymphoma Cells</span>. <i>Mutat. Res. Genet. Toxicol. Environ. Mutagen</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>726</i></span>,  <span class="NLM_fpage">36</span>– <span class="NLM_lpage">41</span>, <span class="refDoi"> DOI: 10.1016/j.mrgentox.2011.08.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1016%2Fj.mrgentox.2011.08.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht12rurvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=726&publication_year=2011&pages=36-41&author=A.+T.+Dohertyauthor=J.+Hayesauthor=M.+Fellowsauthor=S.+Kirkauthor=M.+O%E2%80%99Donovan&title=A+Rapid%2C+Semi-Automated+Method+for+Scoring+Micronuclei+in+Mononucleated+Mouse+Lymphoma+Cells&doi=10.1016%2Fj.mrgentox.2011.08.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">A rapid, semi-automated method for scoring micronuclei in mononucleated mouse lymphoma cells</span></div><div class="casAuthors">Doherty, Ann T.; Hayes, Julie; Fellows, Mick; Kirk, Sarah; O'Donovan, Mike</div><div class="citationInfo"><span class="NLM_cas:title">Mutation Research, Genetic Toxicology and Environmental Mutagenesis</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">726</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">36-41</span>CODEN:
                <span class="NLM_cas:coden">MRGMFI</span>;
        ISSN:<span class="NLM_cas:issn">1383-5718</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A semi-automated scoring system has been developed to provide rapid, accurate assessment of micronuclei in prepns. of mononuclear mouse lymphoma L5178Y cells.  Following exposure to a range of test agents, flat, single-cell prepns. were produced from exponentially growing cultures by cytocentrifugation.  Following staining with 4'-6-diamidino-2-phenylindole (DAPI), cells were scanned by use of the MicroNuc module of Metafer 4 v 3.4.102, after modifying the classifier developed for selecting micronuclei in binucleate cells to increase its sensitivity.  The image gallery of all cells was then sorted to bring aberrant cells to the top of the gallery to assess visually the nos. of cells with micronuclei, as distinct from other debris.  Slide quality was shown to be paramount in obtaining accurate results from an automated scan and the data obtained compared very well with the incidence of micronuclei scored conventionally by microscopy.  Compared with manual scoring the time saving is considerable, as more than 2000 images are captured in approx. 2 min, with subsequent visual assessment of aberrant cells in the image gallery taking about 1-2 min/slide.  By scanning all aberrant cells, the system also captures addnl. information on necrotic, apoptotic and fragmented cells.  Although optimized for mouse lymphoma cells, it should be simple to adapt the method for any cell type growing in suspension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVN4Bt_LDuxbVg90H21EOLACvtfcHk0lhyFcXq9Zv7tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht12rurvI&md5=0e85329ca1060c131ed364bdcfa00d2d</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.mrgentox.2011.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mrgentox.2011.08.002%26sid%3Dliteratum%253Aachs%26aulast%3DDoherty%26aufirst%3DA.%2BT.%26aulast%3DHayes%26aufirst%3DJ.%26aulast%3DFellows%26aufirst%3DM.%26aulast%3DKirk%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Donovan%26aufirst%3DM.%26atitle%3DA%2520Rapid%252C%2520Semi-Automated%2520Method%2520for%2520Scoring%2520Micronuclei%2520in%2520Mononucleated%2520Mouse%2520Lymphoma%2520Cells%26jtitle%3DMutat.%2520Res.%2520Genet.%2520Toxicol.%2520Environ.%2520Mutagen%26date%3D2011%26volume%3D726%26spage%3D36%26epage%3D41%26doi%3D10.1016%2Fj.mrgentox.2011.08.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Clinical
and Laboratory Standards
Institute</span>.  <i>M07 Methods for Dilution
Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically;
Approved Standard</i>, <span class="NLM_edition">42</span>nd ed.; <span class="NLM_publisher-name">Clinical and Laboratory Standards Institute</span>: <span class="NLM_publisher-loc">Wayne, PA</span>, <span class="NLM_year">2012</span>; p  <span class="NLM_fpage">88</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=Clinical%0Aand+Laboratory+Standards%0AInstitute&title=M07+Methods+for+Dilution%0AAntimicrobial+Susceptibility+Tests+for+Bacteria+That+Grow+Aerobically%3B%0AApproved+Standard"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DM07%2520Methods%2520for%2520Dilution%250AAntimicrobial%2520Susceptibility%2520Tests%2520for%2520Bacteria%2520That%2520Grow%2520Aerobically%253B%250AApproved%2520Standard%26pub%3DClinical%2520and%2520Laboratory%2520Standards%2520Institute%26date%3D2012%26spage%3D88" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Clinical
and Laboratory Standards
Institute</span>.  <i>Performance Standards for
Antimicrobial Susceptibility Testing; Twenty-Fourth Informational
Supplement (M100-S24)</i>; <span class="NLM_publisher-name">Clinical and Laboratory
Standards Institute</span>: <span class="NLM_publisher-loc">Wayne, PA</span>, <span class="NLM_year">2014</span>; p  <span class="NLM_fpage">10</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=Clinical%0Aand+Laboratory+Standards%0AInstitute&title=Performance+Standards+for%0AAntimicrobial+Susceptibility+Testing%3B+Twenty-Fourth+Informational%0ASupplement+%28M100-S24%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DPerformance%2520Standards%2520for%250AAntimicrobial%2520Susceptibility%2520Testing%253B%2520Twenty-Fourth%2520Informational%250ASupplement%2520%2528M100-S24%2529%26pub%3DClinical%2520and%2520Laboratory%250AStandards%2520Institute%26date%3D2014%26spage%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 1 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Hang Sun, Mohammad Fawad Ansari, Bo Fang, <span class="NLM_string-name hlFld-ContribAuthor">Cheng-He Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Natural Berberine-Hybridized Benzimidazoles as Novel Unique Bactericides against Staphylococcus aureus. </span><span class="cited-content_cbyCitation_journal-name">Journal of Agricultural and Food Chemistry</span><span> <strong>2021,</strong> <em>69 </em>
                                    (28)
                                     , 7831-7840. <a href="https://doi.org/10.1021/acs.jafc.1c02545" title="DOI URL">https://doi.org/10.1021/acs.jafc.1c02545</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jafc.1c02545&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jafc.1c02545%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Agricultural%2520and%2520Food%2520Chemistry%26atitle%3DNatural%252BBerberine-Hybridized%252BBenzimidazoles%252Bas%252BNovel%252BUnique%252BBactericides%252Bagainst%252BStaphylococcus%252Baureus%26aulast%3DSun%26aufirst%3DHang%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D29042021%26date%3D24062021%26date%3D23062021%26date%3D06072021%26volume%3D69%26issue%3D28%26spage%3D7831%26epage%3D7840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/medium/jm0c01100_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/large/jm0c01100_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01100&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/medium/jm0c01100_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/large/jm0c01100_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of zoliflodacin <b>1</b>, QPT-1 <b>2</b>, linezolid <b>3</b>, and ciprofloxacin <b>4</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/large/jm0c01100_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01100&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/medium/jm0c01100_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/large/jm0c01100_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Route for the Synthesis of SPTs with a Variety of Azole Substituents</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/large/jm0c01100_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01100&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/medium/jm0c01100_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/large/jm0c01100_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. : Synthesis of Symmetrical 1,2,4-Triazole Derivative <b>12</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/large/jm0c01100_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01100&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) DIPEA, POCl<sub>3</sub>, 1,2,4-triazole, and reflux; (b) HCl, H<sub>2</sub>O, CH<sub>3</sub>CN, and 85 °C; (c) K<sub>2</sub>CO<sub>3</sub>, (2<i>R</i>,6<i>R</i>)-2,6-dimethylmorpholine CH<sub>3</sub>CN, and reflux; and (d) barbituric acid; 90% aqueous EtOH, AcOH, 120 °C, and 2 h.</p></p></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/medium/jm0c01100_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/large/jm0c01100_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds with N-Linked Triazole Benzisoxazole Substituents<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/large/jm0c01100_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01100&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaH, DMF, rt, and 16 h; (b) LDA or <i>n</i>-BuLi, THF, E<sup>+</sup>, and −70 °C; (c) LDA, THF, Cl<sub>3</sub>CCCl<sub>3</sub>, and −70 °C; (d) functional group transformations on R<sub>5</sub>; (e) Nuc-H, base, and rt; and (f) AcOH, H<sub>2</sub>O, 120 °C, and 1 h.</p></p></figure><figure data-id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/medium/jm0c01100_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/large/jm0c01100_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Views of QPT-1 from <i>S. aureus</i> crystal structure (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CDM">5CDM</a>) (A). Hydrogen bond array and bridging water molecules surrounding pyrimidinetrione. (B) Morpholine chair conformation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/large/jm0c01100_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01100&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/medium/jm0c01100_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/large/jm0c01100_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Correlation between PPB and log <i>D</i>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/large/jm0c01100_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01100&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/medium/jm0c01100_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/large/jm0c01100_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Intramolecular hydrogen bond from the triazole amine substituent to the benzisoxazole nitrogen.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/large/jm0c01100_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01100&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/medium/jm0c01100_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/large/jm0c01100_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Models derived from the DNA gyrase crystal structure of <i>S. aureus</i> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CDM">5CDM</a>) showing the triazoles of <b>11r</b> (<b>A</b>) and <b>11l</b> (<b>B</b>) attached to the SPT scaffold that is intercalated between stacking DNA bases.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/large/jm0c01100_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01100&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/medium/jm0c01100_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/large/jm0c01100_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Neutropenic mouse thigh models of <i>S. aureus</i> infection. Left: CFU time course dosing <b>11j</b>; right: CFU counts after 24 h postdose of <b>11a</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-20/acs.jmedchem.0c01100/20201019/images/large/jm0c01100_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01100&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i96">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14521" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14521" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 47 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boucher, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambrose, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chambers, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebright, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jezek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newland, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostrowsky, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rex, J. H.</span></span> <span> </span><span class="NLM_article-title">White Paper: Developing Antimicrobial Drugs for Resistant Pathogens, Narrow-Spectrum Indications, and Unmet Needs</span>. <i>J. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>216</i></span>,  <span class="NLM_fpage">228</span>– <span class="NLM_lpage">236</span>, <span class="refDoi"> DOI: 10.1093/infdis/jix211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1093%2Finfdis%2Fjix211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=28475768" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFCqs7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=216&publication_year=2017&pages=228-236&author=H.+W.+Boucherauthor=P.+G.+Ambroseauthor=H.+F.+Chambersauthor=R.+H.+Ebrightauthor=A.+Jezekauthor=B.+E.+Murrayauthor=J.+G.+Newlandauthor=B.+Ostrowskyauthor=J.+H.+Rex&title=White+Paper%3A+Developing+Antimicrobial+Drugs+for+Resistant+Pathogens%2C+Narrow-Spectrum+Indications%2C+and+Unmet+Needs&doi=10.1093%2Finfdis%2Fjix211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">White paper: developing antimicrobial drugs for resistant pathogens, narrow-spectrum indications, and unmet needs</span></div><div class="casAuthors">Boucher, Helen W.; Ambrose, Paul G.; Chambers, H. F.; Ebright, Richard H.; Jezek, Amanda; Murray, Barbara E.; Newland, Jason G.; Ostrowsky, Belinda; Rex, John H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Infectious Diseases</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">216</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">228-236</span>CODEN:
                <span class="NLM_cas:coden">JIDIAQ</span>;
        ISSN:<span class="NLM_cas:issn">1537-6613</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Despite progress in antimicrobial drug development, a crit. need persists for new, feasible pathways to develop antibacterial agents to treat people infected with drug-resistant bacteria.  Infections due to resistant gram-neg. bacilli continue to cause unacceptable morbidity and mortality rates.  Antibacterial agents have been historically studied in noninferiority clin. trials that focus on a single site of infection (eg, complicated urinary tract infections, intra-abdominal infections), yet these designs may not be optimal, and often are not feasible, for study of infections caused by drug-resistant bacteria.  Over the past several years, multiple stakeholders have worked to develop consensus regarding paths forward with a goal of facilitating timely conduct of antimicrobial development.  Here we advocate for a novel and pragmatic approach and, toward this end, present feasible trial designs for antibacterial agents that could enable conduct of narrow-spectrum, organism-specific clin. trials and ultimately approval of critically needed new antibacterial agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyVfhQ9V8-67Vg90H21EOLACvtfcHk0lhX3AOYM2q0BA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFCqs7fI&md5=6325b710ea0846da4949e5695f6f9de6</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1093%2Finfdis%2Fjix211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Finfdis%252Fjix211%26sid%3Dliteratum%253Aachs%26aulast%3DBoucher%26aufirst%3DH.%2BW.%26aulast%3DAmbrose%26aufirst%3DP.%2BG.%26aulast%3DChambers%26aufirst%3DH.%2BF.%26aulast%3DEbright%26aufirst%3DR.%2BH.%26aulast%3DJezek%26aufirst%3DA.%26aulast%3DMurray%26aufirst%3DB.%2BE.%26aulast%3DNewland%26aufirst%3DJ.%2BG.%26aulast%3DOstrowsky%26aufirst%3DB.%26aulast%3DRex%26aufirst%3DJ.%2BH.%26atitle%3DWhite%2520Paper%253A%2520Developing%2520Antimicrobial%2520Drugs%2520for%2520Resistant%2520Pathogens%252C%2520Narrow-Spectrum%2520Indications%252C%2520and%2520Unmet%2520Needs%26jtitle%3DJ.%2520Infect.%2520Dis.%26date%3D2017%26volume%3D216%26spage%3D228%26epage%3D236%26doi%3D10.1093%2Finfdis%2Fjix211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vikesland, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maile-Moskowitz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, N.</span></span> <span> </span><span class="NLM_article-title">Differential Drivers of Antimicrobial Resistance across the World</span>. <i>Acc. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">916</span>– <span class="NLM_lpage">924</span>, <span class="refDoi"> DOI: 10.1021/acs.accounts.8b00643</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.accounts.8b00643" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BC1MXktlOqsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2019&pages=916-924&author=P.+Vikeslandauthor=E.+Garnerauthor=S.+Guptaauthor=S.+Kangauthor=A.+Maile-Moskowitzauthor=N.+Zhu&title=Differential+Drivers+of+Antimicrobial+Resistance+across+the+World&doi=10.1021%2Facs.accounts.8b00643"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Differential Drivers of Antimicrobial Resistance across the World</span></div><div class="casAuthors">Vikesland, Peter; Garner, Emily; Gupta, Suraj; Kang, Seju; Maile-Moskowitz, Ayella; Zhu, Ni</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">916-924</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Antimicrobial resistance (AMR) is one of the greatest threats faced by humankind.  The development of resistance in clin. and hospital settings has been well documented ever since the initial discovery of penicillin and the subsequent introduction of sulfonamides as clin. antibiotics.  In contrast, the environmental (i.e., community-acquired) dimensions of resistance dissemination have been only more recently delineated.  The global spread of antibiotic resistant bacteria (ARB) and antibiotic resistance genes (ARGs) between air, water, soil, and food is now well documented, while the factors that affect ARB and ARG dissemination (e.g., water and air quality, antibiotic fluxes, urbanization, sanitation practices) in these and other environmental matrixes are just now beginning to be more fully appreciated.In this Account, we discuss how the global perpetuation of resistance is dictated by highly interconnected socioeconomic risk factors and illustrate that development status should be more fully considered when developing global strategies to address AMR.  We first differentiate low to middle income countries (LMICs) and high-income countries (HICs), then we summarize the modes of action of com. available antibiotics, and then discuss the four primary mechanisms by which bacteria develop resistance to those antibiotics.  Resistance is disseminated via both vertical gene transfer (VGT; parent to offspring) as well as by horizontal gene transfer (HGT; cell to cell transference of genetic material).  A key challenge hindering attempts to control resistance dissemination is the presence of native, environmental bacteria that can harbor ARGs.  Such environmental "resistomes" have potential to transfer resistance to pathogens via HGT.  Of particular concern is the development of resistance to antibiotics of last-resort such as the cephalosporins, carbapenems, and polymyxins.We then illustrate how antibiotic use differs in LMICs relative to HICs in terms of the vols. of antibiotics used and their fate within local environments.  Antibiotic use in HICs has remained flat over the past 15 years, while in LMICs use over the same period has increased substantially as a result of economic improvements and changes in diet.  These use and fate differences impact local citizens and thus the local dissemination of AMR.  Various phys., social, and economic circumstances within LMICs potentially favor AMR dissemination.  We focus on three phys. factors: changing population d., sanitation infrastructure, and solid-waste disposal.  We show that high population densities in cities within LMICs that suffer from poor sanitation and solid-waste disposal can potentially impact the dissemination of resistance.  In the final section, we discuss potential monitoring approaches to quantify the spread of resistance both within LMICs as well as in HICs.  We posit that culture-based approaches, mol. approaches, and cutting-edge nanotechnol.-based methods for monitoring ARB and ARGs should be considered both within HICs and, as appropriate, within LMICs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRfuY4_Wvzk7Vg90H21EOLACvtfcHk0lgkG78qnLW1NA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXktlOqsrs%253D&md5=bec2a3f62b68867760d6eee400681646</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1021%2Facs.accounts.8b00643&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.accounts.8b00643%26sid%3Dliteratum%253Aachs%26aulast%3DVikesland%26aufirst%3DP.%26aulast%3DGarner%26aufirst%3DE.%26aulast%3DGupta%26aufirst%3DS.%26aulast%3DKang%26aufirst%3DS.%26aulast%3DMaile-Moskowitz%26aufirst%3DA.%26aulast%3DZhu%26aufirst%3DN.%26atitle%3DDifferential%2520Drivers%2520of%2520Antimicrobial%2520Resistance%2520across%2520the%2520World%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2019%26volume%3D52%26spage%3D916%26epage%3D924%26doi%3D10.1021%2Facs.accounts.8b00643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Christaki, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tofarides, A.</span></span> <span> </span><span class="NLM_article-title">Antimicrobial Resistance in Bacteria: Mechanisms, Evolution, and Persistence</span>. <i>J. Mol. Evol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">26</span>– <span class="NLM_lpage">40</span>, <span class="refDoi"> DOI: 10.1007/s00239-019-09914-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1007%2Fs00239-019-09914-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=31659373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVCksb7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2020&pages=26-40&author=E.+Christakiauthor=M.+Marcouauthor=A.+Tofarides&title=Antimicrobial+Resistance+in+Bacteria%3A+Mechanisms%2C+Evolution%2C+and+Persistence&doi=10.1007%2Fs00239-019-09914-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Antimicrobial Resistance in Bacteria: Mechanisms, Evolution, and Persistence</span></div><div class="casAuthors">Christaki, Eirini; Marcou, Markella; Tofarides, Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Evolution</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">26-40</span>CODEN:
                <span class="NLM_cas:coden">JMEVAU</span>;
        ISSN:<span class="NLM_cas:issn">0022-2844</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">In recent years, we have seen antimicrobial resistance rapidly emerge at a global scale and spread from one country to the other faster than previously thought.  Superbugs and multidrug-resistant bacteria are endemic in many parts of the world.  There is no question that the widespread use, overuse, and misuse of antimicrobials during the last 80 years have been assocd. with the explosion of antimicrobial resistance.  On the other hand, the mol. pathways behind the emergence of antimicrobial resistance in bacteria were present since ancient times.  Some of these mechanisms are the ancestors of current resistance determinants.  Evidently, there are plenty of putative resistance genes in the environment, however, we cannot yet predict which ones would be able to be expressed as phenotypes in pathogenic bacteria and cause clin. disease.  In addn., in the presence of inhibitory and sub-inhibitory concns. of antibiotics in natural habitats, one could assume that novel resistance mechanisms will arise against antimicrobial compds.  This review presents an overview of antimicrobial resistance mechanisms, and describes how these have evolved and how they continue to emerge.  As antimicrobial strategies able to bypass the development of resistance are urgently needed, a better understanding of the crit. factors that contribute to the persistence and spread of antimicrobial resistance may yield innovative perspectives on the design of such new therapeutic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSau-tlfP1vbVg90H21EOLACvtfcHk0lgkG78qnLW1NA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVCksb7I&md5=a554a32de2403d28b25ff76e98af7815</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1007%2Fs00239-019-09914-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00239-019-09914-3%26sid%3Dliteratum%253Aachs%26aulast%3DChristaki%26aufirst%3DE.%26aulast%3DMarcou%26aufirst%3DM.%26aulast%3DTofarides%26aufirst%3DA.%26atitle%3DAntimicrobial%2520Resistance%2520in%2520Bacteria%253A%2520Mechanisms%252C%2520Evolution%252C%2520and%2520Persistence%26jtitle%3DJ.%2520Mol.%2520Evol.%26date%3D2020%26volume%3D88%26spage%3D26%26epage%3D40%26doi%3D10.1007%2Fs00239-019-09914-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Theuretzbacher, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottwalt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beyer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czaplewski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lienhardt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenzo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rex, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silver, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spigel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thwaites, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paccaud, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harbarth, S.</span></span> <span> </span><span class="NLM_article-title">Analysis of the Clinical Antibacterial and Antituberculosis Pipeline</span>. <i>Lancet Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">e40</span>– <span class="NLM_lpage">e50</span>, <span class="refDoi"> DOI: 10.1016/S1473-3099(18)30513-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1016%2FS1473-3099%2818%2930513-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=30337260" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFejtbvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=e40-e50&author=U.+Theuretzbacherauthor=S.+Gottwaltauthor=P.+Beyerauthor=M.+Butlerauthor=L.+Czaplewskiauthor=C.+Lienhardtauthor=M.+Lorenzoauthor=M.+Paulauthor=S.+Paulinauthor=J.+H.+Rexauthor=L.+L.+Silverauthor=M.+Spigelauthor=G.+E.+Thwaitesauthor=J.-P.+Paccaudauthor=S.+Harbarth&title=Analysis+of+the+Clinical+Antibacterial+and+Antituberculosis+Pipeline&doi=10.1016%2FS1473-3099%2818%2930513-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of the clinical antibacterial and antituberculosis pipeline</span></div><div class="casAuthors">Theuretzbacher, Ursula; Gottwalt, Simon; Beyer, Peter; Butler, Mark; Czaplewski, Lloyd; Lienhardt, Christian; Moja, Lorenzo; Paul, Mical; Paulin, Sarah; Rex, John H.; Silver, Lynn L.; Spigelman, Melvin; Thwaites, Guy E.; Paccaud, Jean-Pierre; Harbarth, Stephan</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Infectious Diseases</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e40-e50</span>CODEN:
                <span class="NLM_cas:coden">LIDABP</span>;
        ISSN:<span class="NLM_cas:issn">1473-3099</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">This anal. of the global clin. antibacterial pipeline was done in support of the Global Action Plan on Antimicrobial Resistance.  The study analyzed to what extent antibacterial and antimycobacterial drugs for systemic human use as well as oral non-systemic antibacterial drugs for Clostridium difficile infections were active against pathogens included in the WHO priority pathogen list and their innovativeness measured by their absence of cross-resistance (new class, target, mode of action).  As of July 1, 2018, 30 new chem. entity (NCE) antibacterial drugs, ten biologics, ten NCEs against Mycobacterium tuberculosis, and four NCEs against C difficile were identified.  Of the 30 NCEs, 11 are expected to have some activity against at least one crit. priority pathogen expressing carbapenem resistance.  The clin. pipeline is dominated by derivs. of established classes and most development candidates display limited innovation.  New antibacterial drugs without pre-existing cross-resistance are under-represented and are urgently needed, esp. for geog. regions with high resistance rates among Gram-neg. bacteria and M tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWapn7G_qKT7Vg90H21EOLACvtfcHk0lgkG78qnLW1NA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFejtbvP&md5=38cf1c2a98bc2e353a6fa0fc01acce8d</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2818%2930513-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252818%252930513-9%26sid%3Dliteratum%253Aachs%26aulast%3DTheuretzbacher%26aufirst%3DU.%26aulast%3DGottwalt%26aufirst%3DS.%26aulast%3DBeyer%26aufirst%3DP.%26aulast%3DButler%26aufirst%3DM.%26aulast%3DCzaplewski%26aufirst%3DL.%26aulast%3DLienhardt%26aufirst%3DC.%26aulast%3DLorenzo%26aufirst%3DM.%26aulast%3DPaul%26aufirst%3DM.%26aulast%3DPaulin%26aufirst%3DS.%26aulast%3DRex%26aufirst%3DJ.%2BH.%26aulast%3DSilver%26aufirst%3DL.%2BL.%26aulast%3DSpigel%26aufirst%3DM.%26aulast%3DThwaites%26aufirst%3DG.%2BE.%26aulast%3DPaccaud%26aufirst%3DJ.-P.%26aulast%3DHarbarth%26aufirst%3DS.%26atitle%3DAnalysis%2520of%2520the%2520Clinical%2520Antibacterial%2520and%2520Antituberculosis%2520Pipeline%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2019%26volume%3D19%26spage%3De40%26epage%3De50%26doi%3D10.1016%2FS1473-3099%2818%2930513-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span> </span><span class="NLM_article-title">Global Priority List of Antibiotic-Resistant
Bacteria to Guide Research,
Discovery, and Development of New Antibiotics</span>. <a href="http://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf?ua=1" class="extLink">http://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf?ua=1</a> (accessed Sept 9, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Global+Priority+List+of+Antibiotic-Resistant%0ABacteria+to+Guide+Research%2C%0ADiscovery%2C+and+Development+of+New+Antibiotics.+http%3A%2F%2Fwww.who.int%2Fmedicines%2Fpublications%2FWHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf%3Fua%3D1+%28accessed+Sept+9%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DGlobal%2520Priority%2520List%2520of%2520Antibiotic-Resistant%250ABacteria%2520to%2520Guide%2520Research%252C%250ADiscovery%252C%2520and%2520Development%2520of%2520New%2520Antibiotics" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basarab, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brassil, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doig, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galullo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haimes, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kern, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutschke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mcnulty, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuck, V. J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gowravaram, M.</span></span> <span> </span><span class="NLM_article-title">Novel DNA Gyrase Inhibiting Spiropyrimidinetriones with a Benzisoxazole Scaffold: SAR and in Vivo Characterization</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">9078</span>– <span class="NLM_lpage">9095</span>, <span class="refDoi"> DOI: 10.1021/jm501174m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501174m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1yju7bE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=9078-9095&author=G.+S.+Basarabauthor=P.+Brassilauthor=P.+Doigauthor=V.+Galulloauthor=H.+B.+Haimesauthor=G.+Kernauthor=A.+Kutschkeauthor=J.+Mcnultyauthor=V.+J.+A.+Schuckauthor=G.+Stoneauthor=M.+Gowravaram&title=Novel+DNA+Gyrase+Inhibiting+Spiropyrimidinetriones+with+a+Benzisoxazole+Scaffold%3A+SAR+and+in+Vivo+Characterization&doi=10.1021%2Fjm501174m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Novel DNA Gyrase Inhibiting Spiropyrimidinetriones with a Benzisoxazole Scaffold: SAR and in Vivo Characterization</span></div><div class="casAuthors">Basarab, Gregory S.; Brassil, Patrick; Doig, Peter; Galullo, Vincent; Haimes, Howard B.; Kern, Gunther; Kutschke, Amy; McNulty, John; Schuck, Virna J. A.; Stone, Gregory; Gowravaram, Madhusudhan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9078-9095</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The compds. described herein with a spirocyclic architecture fused to a benzisoxazole ring represent a new class of antibacterial agents that operate by inhibition of DNA gyrase as corroborated in an enzyme assay and by the inhibition of precursor thymidine into DNA during cell growth.  Activity resided in the configurationally lowest energy (2S,4R,4aR) diastereomer.  Highly active compds. against Staphylococcus aureus had sufficiently high soly., high plasma protein free fraction, and favorable pharmacokinetics to suggest that in vivo efficacy could be demonstrated, which was realized with compd. I in S. aureus mouse infection models.  A high drug exposure NOEL on oral dosing in the rat suggested that a high therapeutic margin could be achieved.  Importantly, I was not cross-resistant with other DNA gyrase inhibitors such as fluoroquinolone and aminocoumarin antibacterials.  Hence, this class shows considerable promise for the treatment of infections caused by multidrug resistant bacteria, including S. aureus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpvqD0DFpAALVg90H21EOLACvtfcHk0liLLvh8ON6-7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1yju7bE&md5=7eccef41b07e14842d79665591364050</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Fjm501174m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501174m%26sid%3Dliteratum%253Aachs%26aulast%3DBasarab%26aufirst%3DG.%2BS.%26aulast%3DBrassil%26aufirst%3DP.%26aulast%3DDoig%26aufirst%3DP.%26aulast%3DGalullo%26aufirst%3DV.%26aulast%3DHaimes%26aufirst%3DH.%2BB.%26aulast%3DKern%26aufirst%3DG.%26aulast%3DKutschke%26aufirst%3DA.%26aulast%3DMcnulty%26aufirst%3DJ.%26aulast%3DSchuck%26aufirst%3DV.%2BJ.%2BA.%26aulast%3DStone%26aufirst%3DG.%26aulast%3DGowravaram%26aufirst%3DM.%26atitle%3DNovel%2520DNA%2520Gyrase%2520Inhibiting%2520Spiropyrimidinetriones%2520with%2520a%2520Benzisoxazole%2520Scaffold%253A%2520SAR%2520and%2520in%2520Vivo%2520Characterization%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D9078%26epage%3D9095%26doi%3D10.1021%2Fjm501174m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basarab, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kern, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNulty, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vishwanathan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alm, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barvian, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doig, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galullo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gowravaram, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huband, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimzey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morningstar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutschke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lahiri, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perros, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuck, V. J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tommasi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walkup, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, J. V.</span></span> <span> </span><span class="NLM_article-title">Responding to the Challenge of Untreatable Gonorrhea: ETX0914, a First-in-Class Agent with a Distinct Mechanism-of-Action against Bacterial Type II Topoisomerases</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">11827</span>, <span class="refDoi"> DOI: 10.1038/srep11827</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1038%2Fsrep11827" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=26168713" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlCjsLvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=11827&author=G.+S.+Basarabauthor=G.+H.+Kernauthor=J.+McNultyauthor=J.+P.+Muellerauthor=K.+Lawrenceauthor=K.+Vishwanathanauthor=R.+A.+Almauthor=K.+Barvianauthor=P.+Doigauthor=V.+Galulloauthor=H.+Gardnerauthor=M.+Gowravaramauthor=M.+Hubandauthor=A.+Kimzeyauthor=M.+Morningstarauthor=A.+Kutschkeauthor=S.+D.+Lahiriauthor=M.+Perrosauthor=R.+Singhauthor=V.+J.+A.+Schuckauthor=R.+Tommasiauthor=G.+Walkupauthor=J.+V.+Newman&title=Responding+to+the+Challenge+of+Untreatable+Gonorrhea%3A+ETX0914%2C+a+First-in-Class+Agent+with+a+Distinct+Mechanism-of-Action+against+Bacterial+Type+II+Topoisomerases&doi=10.1038%2Fsrep11827"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases</span></div><div class="casAuthors">Basarab, Gregory S.; Kern, Gunther H.; McNulty, John; Mueller, John P.; Lawrence, Kenneth; Vishwanathan, Karthick; Alm, Richard A.; Barvian, Kevin; Doig, Peter; Galullo, Vincent; Gardner, Humphrey; Gowravaram, Madhusudhan; Huband, Michael; Kimzey, Amy; Morningstar, Marshall; Kutschke, Amy; Lahiri, Sushmita D.; Perros, Manos; Singh, Renu; Schuck, Virna J. A.; Tommasi, Ruben; Walkup, Grant; Newman, Joseph V.</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">11827</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">With the diminishing effectiveness of current antibacterial therapies, it is critically important to discover agents that operate by a mechanism that circumvents existing resistance.  ETX0914, the first of a new class of antibacterial agent targeted for the treatment of gonorrhea, operates by a novel mode-of-inhibition against bacterial type II topoisomerases.  Incorporating an oxazolidinone on the scaffold mitigated toxicol. issues often seen with topoisomerase inhibitors.  Organisms resistant to other topoisomerase inhibitors were not cross-resistant with ETX0914 nor were spontaneous resistant mutants to ETX0914 cross-resistant with other topoisomerase inhibitor classes, including the widely used fluoroquinolone class.  Preclin. evaluation of ETX0914 pharmacokinetics and pharmacodynamics showed distribution into vascular tissues and efficacy in a murine Staphylococcus aureus infection model that served as a surrogate for predicting efficacious exposures for the treatment of Neisseria gonorrhoeae infections.  A wide safety margin to the efficacious exposure in toxicol. evaluations supported progression to Phase 1.  Dosing ETX0914 in human volunteers showed sufficient exposure and minimal adverse effects to expect a highly efficacious anti-gonorrhea therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCpiUrCSFU1rVg90H21EOLACvtfcHk0liLLvh8ON6-7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlCjsLvE&md5=0a681c2bd92414d798b03a9c712e138e</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fsrep11827&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep11827%26sid%3Dliteratum%253Aachs%26aulast%3DBasarab%26aufirst%3DG.%2BS.%26aulast%3DKern%26aufirst%3DG.%2BH.%26aulast%3DMcNulty%26aufirst%3DJ.%26aulast%3DMueller%26aufirst%3DJ.%2BP.%26aulast%3DLawrence%26aufirst%3DK.%26aulast%3DVishwanathan%26aufirst%3DK.%26aulast%3DAlm%26aufirst%3DR.%2BA.%26aulast%3DBarvian%26aufirst%3DK.%26aulast%3DDoig%26aufirst%3DP.%26aulast%3DGalullo%26aufirst%3DV.%26aulast%3DGardner%26aufirst%3DH.%26aulast%3DGowravaram%26aufirst%3DM.%26aulast%3DHuband%26aufirst%3DM.%26aulast%3DKimzey%26aufirst%3DA.%26aulast%3DMorningstar%26aufirst%3DM.%26aulast%3DKutschke%26aufirst%3DA.%26aulast%3DLahiri%26aufirst%3DS.%2BD.%26aulast%3DPerros%26aufirst%3DM.%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DSchuck%26aufirst%3DV.%2BJ.%2BA.%26aulast%3DTommasi%26aufirst%3DR.%26aulast%3DWalkup%26aufirst%3DG.%26aulast%3DNewman%26aufirst%3DJ.%2BV.%26atitle%3DResponding%2520to%2520the%2520Challenge%2520of%2520Untreatable%2520Gonorrhea%253A%2520ETX0914%252C%2520a%2520First-in-Class%2520Agent%2520with%2520a%2520Distinct%2520Mechanism-of-Action%2520against%2520Bacterial%2520Type%2520II%2520Topoisomerases%26jtitle%3DSci.%2520Rep.%26date%3D2015%26volume%3D5%26spage%3D11827%26doi%3D10.1038%2Fsrep11827" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kern, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehmann, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basarab, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doig, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sriram, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thresher, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walkup, G. K.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Neisseria Gonorrhoeae Type II Topoisomerases by the Novel Spiropyrimidinetrione AZD0914</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>290</i></span>,  <span class="NLM_fpage">20984</span>– <span class="NLM_lpage">20994</span>, <span class="refDoi"> DOI: 10.1074/jbc.m115.663534</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1074%2Fjbc.M115.663534" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=26149691" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlOrt77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=2015&pages=20984-20994&author=G.+Kernauthor=T.+Palmerauthor=D.+E.+Ehmannauthor=A.+B.+Shapiroauthor=B.+Andrewsauthor=G.+S.+Basarabauthor=P.+Doigauthor=J.+Fanauthor=N.+Gaoauthor=S.+D.+Millsauthor=J.+Muellerauthor=S.+Sriramauthor=J.+Thresherauthor=G.+K.+Walkup&title=Inhibition+of+Neisseria+Gonorrhoeae+Type+II+Topoisomerases+by+the+Novel+Spiropyrimidinetrione+AZD0914&doi=10.1074%2Fjbc.m115.663534"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Neisseria gonorrhoeae Type II Topoisomerases by the Novel Spiropyrimidinetrione AZD0914</span></div><div class="casAuthors">Kern, Gunther; Palmer, Tiffany; Ehmann, David E.; Shapiro, Adam B.; Andrews, Beth; Basarab, Gregory S.; Doig, Peter; Fan, Jun; Gao, Ning; Mills, Scott D.; Mueller, John; Sriram, Shubha; Thresher, Jason; Walkup, Grant K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">290</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">20984-20994</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">We characterized the inhibition of Neisseria gonorrhoeae type II topoisomerases gyrase and topoisomerase IV by AZD0914 (AZD0914 will be henceforth known as ETX0914 (Entasis Therapeutics)), a novel spiropyrimidinetrione antibacterial compd. that is currently in clin. trials for treatment of drug-resistant gonorrhea.  AZD0914 has potent bactericidal activity against N. gonorrhoeae, including multidrug-resistant strains and key Gram-pos., fastidious Gram-neg., atypical, and anaerobic bacterial species (Huband, M. D., Bradford, P. A., Otterson, L. G., Basrab, G. S., Giacobe, R. A., Patey, S. A., Kutschke, A. C., Johnstone, M. R., Potter, M. E., Miller, P. F., and Mueller, J. P. (2014) In Vitro Antibacterial Activity of AZD0914: A New Spiropyrimidinetrione DNA Gyrase/Topoisomerase Inhibitor with Potent Activity against Gram-pos., Fastidious Gram-neg., and Atypical Bacteria. Antimicrob. Agents Chemother. 59, 467-474).  AZD0914 inhibited DNA biosynthesis preferentially to other macromols. in Escherichia coli and induced the SOS response to DNA damage in E. coli.  AZD0914 stabilized the enzyme-DNA cleaved complex for N. gonorrhoeae gyrase and topoisomerase IV.  The potency of AZD0914 for inhibition of supercoiling and the stabilization of cleaved complex by N. gonorrhoeae gyrase increased in a fluoroquinolone-resistant mutant enzyme.  When a mutation, conferring mild resistance to AZD0914, was present in the fluoroquinolone-resistant mutant, the potency of ciprofloxacin for inhibition of supercoiling and stabilization of cleaved complex was increased greater than 20-fold.  In contrast to ciprofloxacin, religation of the cleaved DNA did not occur in the presence of AZD0914 upon removal of magnesium from the DNA-gyrase-inhibitor complex.  AZD0914 had relatively low potency for inhibition of human type II topoisomerases α and β.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5NwS9lT225rVg90H21EOLACvtfcHk0lh8cbg2iCkn2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlOrt77F&md5=9288c211345bd1fd09d0cff247e8e341</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M115.663534&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M115.663534%26sid%3Dliteratum%253Aachs%26aulast%3DKern%26aufirst%3DG.%26aulast%3DPalmer%26aufirst%3DT.%26aulast%3DEhmann%26aufirst%3DD.%2BE.%26aulast%3DShapiro%26aufirst%3DA.%2BB.%26aulast%3DAndrews%26aufirst%3DB.%26aulast%3DBasarab%26aufirst%3DG.%2BS.%26aulast%3DDoig%26aufirst%3DP.%26aulast%3DFan%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DN.%26aulast%3DMills%26aufirst%3DS.%2BD.%26aulast%3DMueller%26aufirst%3DJ.%26aulast%3DSriram%26aufirst%3DS.%26aulast%3DThresher%26aufirst%3DJ.%26aulast%3DWalkup%26aufirst%3DG.%2BK.%26atitle%3DInhibition%2520of%2520Neisseria%2520Gonorrhoeae%2520Type%2520II%2520Topoisomerases%2520by%2520the%2520Novel%2520Spiropyrimidinetrione%2520AZD0914%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2015%26volume%3D290%26spage%3D20984%26epage%3D20994%26doi%3D10.1074%2Fjbc.m115.663534" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Biedenbach, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huband, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hackel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jonge, B. L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahm, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradford, P. A.</span></span> <span> </span><span class="NLM_article-title">In Vitro Activity of AZD0914, a Novel Bacterial DNA Gyrase/Topoisomerase IV Inhibitor, Against Clinically Relevant Gram-Positive and Fastidious Gram-Negative Pathogens</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">6053</span>– <span class="NLM_lpage">6063</span>, <span class="refDoi"> DOI: 10.1128/aac.01016-15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1128%2FAAC.01016-15" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=26195518" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVajs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=6053-6063&author=D.+J.+Biedenbachauthor=M.+D.+Hubandauthor=M.+Hackelauthor=B.+L.+M.+de+Jongeauthor=D.+F.+Sahmauthor=P.+A.+Bradford&title=In+Vitro+Activity+of+AZD0914%2C+a+Novel+Bacterial+DNA+Gyrase%2FTopoisomerase+IV+Inhibitor%2C+Against+Clinically+Relevant+Gram-Positive+and+Fastidious+Gram-Negative+Pathogens&doi=10.1128%2Faac.01016-15"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro activity of AZD0914, a novel bacterial DNA gyrase/topoisomerase IV inhibitor, against clinically relevant Gram-positive and fastidious Gram-negative pathogens</span></div><div class="casAuthors">Biedenbach, Douglas J.; Huband, Michael D.; Hackel, Meredith; de Jonge, Boudewijn L. M.; Sahm, Daniel F.; Bradford, Patricia A.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">6053-6063</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">AZD0914, a new spiropyrimidinetrione bacterial DNA gyrase inhibitor with a novel mode of inhibition, has activity against bacterial species commonly cultured from patient infection specimens, including fluoroquinolone-resistant isolates.  This study assessed the in vitro activity of AZD0914 against key Gram-pos. and fastidious Gram-neg. clin. isolates collected globally in 2013.  AZD0914 demonstrated potent activity, with MIC90s for AZD0914 of 0.25 mg/L against Staphylococcus aureus (n = 11,680), coagulase-neg. staphylococci (n = 1923), streptococci (n = 4380), and Moraxella catarrhalis (n = 145), 0.5 mg/L against Staphylococcus lugdunensis (n = 120) and Haemophilus influenzae (n = 352), 1 mg/L against Enterococcus faecalis (n = 1241), and 2 mg/L against Haemophilus parainfluenzae (n = 70).  The activity against Enterococcus faecium was more limited (MIC90, 8 mg/L).  The spectrum and potency of AZD0914 included fluoroquinolone-resistant isolates in each species group, including methicillin-resistant staphylococci, penicillin-resistant streptococci, vancomycin-resistant enterococci, β-lactamase-producing Haemophilus spp., and M. catarrhalis.  Based on these in vitro findings, AZD0914 warrants further study for its utility against a variety of Gram-pos. and fastidious Gram-neg. bacterial species.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIorJR-vAyIbVg90H21EOLACvtfcHk0lh8cbg2iCkn2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVajs7c%253D&md5=8eefc4607d197f9f3ca782502b1b4bfa</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1128%2FAAC.01016-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01016-15%26sid%3Dliteratum%253Aachs%26aulast%3DBiedenbach%26aufirst%3DD.%2BJ.%26aulast%3DHuband%26aufirst%3DM.%2BD.%26aulast%3DHackel%26aufirst%3DM.%26aulast%3Dde%2BJonge%26aufirst%3DB.%2BL.%2BM.%26aulast%3DSahm%26aufirst%3DD.%2BF.%26aulast%3DBradford%26aufirst%3DP.%2BA.%26atitle%3DIn%2520Vitro%2520Activity%2520of%2520AZD0914%252C%2520a%2520Novel%2520Bacterial%2520DNA%2520Gyrase%252FTopoisomerase%2520IV%2520Inhibitor%252C%2520Against%2520Clinically%2520Relevant%2520Gram-Positive%2520and%2520Fastidious%2520Gram-Negative%2520Pathogens%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2015%26volume%3D59%26spage%3D6053%26epage%3D6063%26doi%3D10.1128%2Faac.01016-15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Papp, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkcaldy, R. D.</span></span> <span> </span><span class="NLM_article-title">In <i>Vitro</i> Growth of Multidrug-Resistant Neisseria Gonorrhoeae Isolates Is Inhibited by ETX0914, a Novel Spiropyrimidinetrione</span>. <i>Int. J. Antimicrob. Agents</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">328</span>– <span class="NLM_lpage">330</span>, <span class="refDoi"> DOI: 10.1016/j.ijantimicag.2016.05.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1016%2Fj.ijantimicag.2016.05.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=27499432" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFyhsr7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2016&pages=328-330&author=J.+R.+Pappauthor=K.+Lawrenceauthor=S.+Sharpeauthor=J.+Muellerauthor=R.+D.+Kirkcaldy&title=In+Vitro+Growth+of+Multidrug-Resistant+Neisseria+Gonorrhoeae+Isolates+Is+Inhibited+by+ETX0914%2C+a+Novel+Spiropyrimidinetrione&doi=10.1016%2Fj.ijantimicag.2016.05.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro growth of multidrug-resistant Neisseria gonorrhoeae isolates is inhibited by ETX0914, a novel spiropyrimidinetrione</span></div><div class="casAuthors">Papp, John R.; Lawrence, Kenneth; Sharpe, Samera; Mueller, John; Kirkcaldy, Robert D.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Antimicrobial Agents</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">328-330</span>CODEN:
                <span class="NLM_cas:coden">IAAGEA</span>;
        ISSN:<span class="NLM_cas:issn">0924-8579</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Antimicrobial resistance in Neisseria gonorrhoeae has severely limited the no. of treatment options, and the emergence of extended-spectrum cephalosporin resistance threatens the effectiveness of the last remaining recommended treatment regimen.  This study assessed the in vitro susceptibility of N. gonorrhoeae to ETX0914, a novel spiropyrimidinetrione that inhibits DNA biosynthesis.  In vitro activity was detd. by agar diln. against 100 N. gonorrhoeae isolates collected from men presenting with urethritis in the USA during 2012-2013 through the Gonococcal Isolate Surveillance Project.  The min. inhibitory concn. (MIC) that inhibited growth in 50% (MIC50) and 90% (MIC90) of isolates was calcd. for each antimicrobial agent.  ETX0914 demonstrated a high level of antimicrobial activity against N. gonorrhoeae, including isolates with decreased susceptibility or resistance to currently available agents.  The ability of ETX0914 to inhibit the growth of N. gonorrhoeae was similar to ceftriaxone, which is currently recommended in combination with azithromycin to treat gonorrhoea.  The data strongly suggest that ETX0914 should be evaluated in a clin. trial for the treatment of N. gonorrhoeae.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4IQ_dAbaNIrVg90H21EOLACvtfcHk0lh8cbg2iCkn2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFyhsr7N&md5=3e4dbb4bc287bffcadb1205d87f7d795</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.ijantimicag.2016.05.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijantimicag.2016.05.018%26sid%3Dliteratum%253Aachs%26aulast%3DPapp%26aufirst%3DJ.%2BR.%26aulast%3DLawrence%26aufirst%3DK.%26aulast%3DSharpe%26aufirst%3DS.%26aulast%3DMueller%26aufirst%3DJ.%26aulast%3DKirkcaldy%26aufirst%3DR.%2BD.%26atitle%3DIn%2520Vitro%2520Growth%2520of%2520Multidrug-Resistant%2520Neisseria%2520Gonorrhoeae%2520Isolates%2520Is%2520Inhibited%2520by%2520ETX0914%252C%2520a%2520Novel%2520Spiropyrimidinetrione%26jtitle%3DInt.%2520J.%2520Antimicrob.%2520Agents%26date%3D2016%26volume%3D48%26spage%3D328%26epage%3D330%26doi%3D10.1016%2Fj.ijantimicag.2016.05.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrazzo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batteiger, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hook, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seña, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierzbicki, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwak, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, J.</span></span> <span> </span><span class="NLM_article-title">Single-Dose Zoliflodacin (ETX0914) for Treatment of Urogenital Gonorrhea</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>379</i></span>,  <span class="NLM_fpage">1835</span>– <span class="NLM_lpage">1845</span>, <span class="refDoi"> DOI: 10.1056/nejmoa1706988</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1056%2FNEJMoa1706988" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=30403954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1GktbzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=379&publication_year=2018&pages=1835-1845&author=S.+N.+Taylorauthor=J.+Marrazzoauthor=B.+E.+Batteigerauthor=E.+W.+Hookauthor=A.+C.+Se%C3%B1aauthor=J.+Longauthor=M.+R.+Wierzbickiauthor=H.+Kwakauthor=S.+M.+Johnsonauthor=K.+Lawrenceauthor=J.+Mueller&title=Single-Dose+Zoliflodacin+%28ETX0914%29+for+Treatment+of+Urogenital+Gonorrhea&doi=10.1056%2Fnejmoa1706988"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Single-Dose zoliflodacin (ETX0914) for treatment of urogenital gonorrhea</span></div><div class="casAuthors">Taylor, Stephanie N.; Marrazzo, Jeanne; Batteiger, Byron E.; Hook, Edward W.; Sena, Arlene C.; Long, Jill; Wierzbicki, Michael R.; Kwak, Hannah; Johnson, Shacondra M.; Lawrence, Kenneth; Mueller, John</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">379</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1835-1845</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Antibiotic-resistant Neisseria gonorrhoeae has prompted the development of new therapies.  Zoliflodacin is a new antibiotic that inhibits DNA biosynthesis.  In this multi-center, phase 2 trial, zoliflodacin was evaluated for the treatment of uncomplicated gonorrhea.  METHODS We randomly assigned eligible men and women who had signs or symptoms of uncomplicated urogenital gonorrhea or untreated urogenital gonorrhea or who had had sexual contact in the preceding 14 days with a person who had gonorrhea to receive a single oral dose of zoliflodacin (2 g or 3 g) or a single 500-mg i.m. dose of ceftriaxone in a ratio of approx. 70:70:40.  A test of cure occurred within 6±2 days after treatment, followed by a safety visit 31±2 days after treatment.  The primary efficacy outcome measure was the proportion of urogenital microbiol. cure in the microbiol. intention-to-treat (micro-ITT) population.  RESULTS From Nov. 2014 through Dec. 2015, a total of 179 participants (167 men and 12 women) were enrolled.  Among the 141 participants in the micro-ITT population who could be evaluated, microbiol. cure at urogenital sites was documented in 55 of 57 (96%) who received 2 g of zoliflodacin, 54 of 56 (96%) who received 3 g of zoliflodacin, and 28 of 28 (100%) who received ceftriaxone.  All rectal infections were cured in all 5 participants who received 2 g of zoliflodacin and all 7 who received 3 g, and in all 3 participants in the group that received ceftriaxone.  Pharyngeal infections were cured in 4 of 8 participants (50%), 9 of 11 participants (82%), and 4 of 4 participants (100%) in the groups that received 2 g of zoliflodacin, 3 g of zoliflodacin, and ceftriaxone, resp.  A total of 84 adverse events were reported: 24 in the group that received 2 g of zoliflodacin, 37 in the group that received 3 g of zoliflodacin, and 23 in the group that received ceftriaxone.  According to investigators, a total of 21 adverse events were thought to be related to zoliflodacin, and most such events were gastrointestinal.  CONCLUSIONS The majority of uncomplicated urogenital and rectal gonococcal infections were successfully treated with oral zoliflodacin, but this agent was less efficacious in the treatment of pharyngeal infections. (Funded by the National Institutes of Health and Entasis Therapeutics; ClinicalTrials.gov no., NCT02257918.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrohoirIrYFf7Vg90H21EOLACvtfcHk0liZysILVfIBhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1GktbzN&md5=f26717391c8d3764114c8fee2a359b8b</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1706988&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1706988%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DS.%2BN.%26aulast%3DMarrazzo%26aufirst%3DJ.%26aulast%3DBatteiger%26aufirst%3DB.%2BE.%26aulast%3DHook%26aufirst%3DE.%2BW.%26aulast%3DSe%25C3%25B1a%26aufirst%3DA.%2BC.%26aulast%3DLong%26aufirst%3DJ.%26aulast%3DWierzbicki%26aufirst%3DM.%2BR.%26aulast%3DKwak%26aufirst%3DH.%26aulast%3DJohnson%26aufirst%3DS.%2BM.%26aulast%3DLawrence%26aufirst%3DK.%26aulast%3DMueller%26aufirst%3DJ.%26atitle%3DSingle-Dose%2520Zoliflodacin%2520%2528ETX0914%2529%2520for%2520Treatment%2520of%2520Urogenital%2520Gonorrhea%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D379%26spage%3D1835%26epage%3D1845%26doi%3D10.1056%2Fnejmoa1706988" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bundy, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mott, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skepner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyle, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hromockyj, a. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marotti, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zurenko, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munzner, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bammert, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamel, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, W.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graber, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolak, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seest, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruble, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamilar, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banitt, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurd, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbachyn, M. R.</span></span> <span> </span><span class="NLM_article-title">Discovery and Characterization of QPT-1, the Progenitor of a New Class of Bacterial Topoisomerase Inhibitors</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">2806</span>– <span class="NLM_lpage">2812</span>, <span class="refDoi"> DOI: 10.1128/aac.00247-08</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1128%2FAAC.00247-08" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=18519725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BD1cXps1Ogt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2008&pages=2806-2812&author=A.+A.+Millerauthor=G.+L.+Bundyauthor=J.+E.+Mottauthor=J.+E.+Skepnerauthor=T.+P.+Boyleauthor=D.+W.+Harrisauthor=a.+E.+Hromockyjauthor=K.+R.+Marottiauthor=G.+E.+Zurenkoauthor=J.+B.+Munznerauthor=M.+T.+Sweeneyauthor=G.+F.+Bammertauthor=J.+C.+Hamelauthor=C.+W.+Fordauthor=W.-Z.+Zhongauthor=D.+R.+Graberauthor=G.+E.+Martinauthor=F.+Hanauthor=L.+A.+Dolakauthor=E.+P.+Seestauthor=J.+C.+Rubleauthor=G.+M.+Kamilarauthor=J.+R.+Palmerauthor=L.+S.+Banittauthor=A.+R.+Hurdauthor=M.+R.+Barbachyn&title=Discovery+and+Characterization+of+QPT-1%2C+the+Progenitor+of+a+New+Class+of+Bacterial+Topoisomerase+Inhibitors&doi=10.1128%2Faac.00247-08"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and characterization of QPT-1, the progenitor of a new class of bacterial topoisomerase inhibitors</span></div><div class="casAuthors">Miller, Alita A.; Bundy, Gordon L.; Mott, John E.; Skepner, Jill E.; Boyle, Timothy P.; Harris, Douglas W.; Hromockyj, Alexander E.; Marotti, Keith R.; Zurenko, Gary E.; Munzner, Jennifer B.; Sweeney, Michael T.; Bammert, Gary F.; Hamel, Judith C.; Ford, Charles W.; Zhong, Wei-Zhu; Graber, David R.; Martin, Gary E.; Han, Fusen; Dolak, Lester A.; Seest, Eric P.; Ruble, J. Craig; Kamilar, Gregg M.; Palmer, John R.; Banitt, Lee S.; Hurd, Alexander R.; Barbachyn, Michael R.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2806-2812</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">QPT-1 was discovered in a compd. library by high-throughput screening and triage for substances with whole-cell antibacterial activity.  This totally synthetic compd. is an unusual barbituric acid deriv. whose activity resides in the (-)-enantiomer.  QPT-1 had activity against a broad spectrum of pathogenic, antibiotic-resistant bacteria, was nontoxic to eukaryotic cells, and showed oral efficacy in a murine infection model, all before any medicinal chem. optimization.  Biochem. and genetic characterization showed that the QPT-1 targets the β subunit of bacterial type II topoisomerases via a mechanism of inhibition distinct from the mechanisms of fluoroquinolones and novobiocin.  Given these attributes, this compd. represents a promising new class of antibacterial agents.  The success of this reverse genomics effort demonstrates the utility of exploring strategies that are alternatives to target-based screens in antibacterial drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoPSHAUxaaj7Vg90H21EOLACvtfcHk0liZysILVfIBhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXps1Ogt7c%253D&md5=c459d15b895768ec27648222ad03d20d</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1128%2FAAC.00247-08&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00247-08%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DA.%2BA.%26aulast%3DBundy%26aufirst%3DG.%2BL.%26aulast%3DMott%26aufirst%3DJ.%2BE.%26aulast%3DSkepner%26aufirst%3DJ.%2BE.%26aulast%3DBoyle%26aufirst%3DT.%2BP.%26aulast%3DHarris%26aufirst%3DD.%2BW.%26aulast%3DHromockyj%26aufirst%3Da.%2BE.%26aulast%3DMarotti%26aufirst%3DK.%2BR.%26aulast%3DZurenko%26aufirst%3DG.%2BE.%26aulast%3DMunzner%26aufirst%3DJ.%2BB.%26aulast%3DSweeney%26aufirst%3DM.%2BT.%26aulast%3DBammert%26aufirst%3DG.%2BF.%26aulast%3DHamel%26aufirst%3DJ.%2BC.%26aulast%3DFord%26aufirst%3DC.%2BW.%26aulast%3DZhong%26aufirst%3DW.-Z.%26aulast%3DGraber%26aufirst%3DD.%2BR.%26aulast%3DMartin%26aufirst%3DG.%2BE.%26aulast%3DHan%26aufirst%3DF.%26aulast%3DDolak%26aufirst%3DL.%2BA.%26aulast%3DSeest%26aufirst%3DE.%2BP.%26aulast%3DRuble%26aufirst%3DJ.%2BC.%26aulast%3DKamilar%26aufirst%3DG.%2BM.%26aulast%3DPalmer%26aufirst%3DJ.%2BR.%26aulast%3DBanitt%26aufirst%3DL.%2BS.%26aulast%3DHurd%26aufirst%3DA.%2BR.%26aulast%3DBarbachyn%26aufirst%3DM.%2BR.%26atitle%3DDiscovery%2520and%2520Characterization%2520of%2520QPT-1%252C%2520the%2520Progenitor%2520of%2520a%2520New%2520Class%2520of%2520Bacterial%2520Topoisomerase%2520Inhibitors%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2008%26volume%3D52%26spage%3D2806%26epage%3D2812%26doi%3D10.1128%2Faac.00247-08" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baltz, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrigley, S. K.</span></span> <span> </span><span class="NLM_article-title">Natural Products to Drugs: Daptomycin and Related Lipopeptide Antibiotics</span>. <i>Nat. Prod. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">717</span>– <span class="NLM_lpage">741</span>, <span class="refDoi"> DOI: 10.1039/b416648p</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1039%2Fb416648p" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=16311632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BD28XjslCrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2005&pages=717-741&author=R.+H.+Baltzauthor=V.+Miaoauthor=S.+K.+Wrigley&title=Natural+Products+to+Drugs%3A+Daptomycin+and+Related+Lipopeptide+Antibiotics&doi=10.1039%2Fb416648p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Natural products to drugs: Daptomycin and related lipopeptide antibiotics</span></div><div class="casAuthors">Baltz, Richard H.; Miao, Vivian; Wrigley, Stephen K.</div><div class="citationInfo"><span class="NLM_cas:title">Natural Product Reports</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">717-741</span>CODEN:
                <span class="NLM_cas:coden">NPRRDF</span>;
        ISSN:<span class="NLM_cas:issn">0265-0568</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review focuses on daptomycin and related lippeptide antibiotics from 1953 to 2005, discussing their recent studies with particular emphasis on the interplay between structural features and antibacterial activities.  Topics discussed include chem. modifications to improve activity; the genetic organization and biosynthesis of lipopeptides; and the genetic engineering of the daptomycin biosynthetic pathway to produce novel derivs. for further chem. modification to develop candidates for clin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZY8U3HyAKhrVg90H21EOLACvtfcHk0liZysILVfIBhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjslCrtg%253D%253D&md5=4f56cba788816c08f12ef5c2d847019a</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1039%2Fb416648p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb416648p%26sid%3Dliteratum%253Aachs%26aulast%3DBaltz%26aufirst%3DR.%2BH.%26aulast%3DMiao%26aufirst%3DV.%26aulast%3DWrigley%26aufirst%3DS.%2BK.%26atitle%3DNatural%2520Products%2520to%2520Drugs%253A%2520Daptomycin%2520and%2520Related%2520Lipopeptide%2520Antibiotics%26jtitle%3DNat.%2520Prod.%2520Rep.%26date%3D2005%26volume%3D22%26spage%3D717%26epage%3D741%26doi%3D10.1039%2Fb416648p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Livermore, D. M.</span></span> <span> </span><span class="NLM_article-title">Linezolid in Vitro: Mechanism and Antibacterial Spectrum</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">ii9</span>– <span class="NLM_lpage">ii16</span>, <span class="refDoi"> DOI: 10.1093/jac/dkg249</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1093%2Fjac%2Fdkg249" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=12730138" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BD3sXktlOqur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2003&pages=ii9-ii16&author=D.+M.+Livermore&title=Linezolid+in+Vitro%3A+Mechanism+and+Antibacterial+Spectrum&doi=10.1093%2Fjac%2Fdkg249"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Linezolid in vitro: Mechanism and antibacterial spectrum</span></div><div class="casAuthors">Livermore, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">Suppl. S2</span>),
    <span class="NLM_cas:pages">ii9-ii16</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Oxazolidinones are prominent among the new Gram-pos. antimicrobial agents now becoming available.  They were discovered by DuPont Pharmaceuticals in the late 1980s but linezolid, the first analog suitable for development, was found only when the family was re-examd. by Pharmacia in the 1990s.  Oxazolidinones bind to the 50S subunit of the prokaryotic ribosome, preventing formation of the initiation complex for protein synthesis.  This is a novel mode of action; other protein synthesis inhibitors either block polypeptide extension or cause misreading of mRNA.  Linezolid MICs vary slightly with the test method, lab., and significance attributed to thin hazes of bacterial survival, but all workers find that the susceptibility distributions are narrow and unimodal, with MIC values between 0.5 and 4 mg/L for streptococci, enterococci and staphylococci.  Fully activity is retained against Gram-pos. cocci resistant to other antibiotics, including methicillin-resistant staphylococci and vancomycin-resistant enterococci.  MICs are 4-8 mg/L for Moraxella, Pasteurella and Bacteroides spp. but other Gram-neg. bacteria are resistant as a result of endogenous efflux activity.  Resistance is difficult to select in vitro but has been reported during therapy in a few enterococcal infections and in two MRSA cases to date; the mechanism entails mutation of the 23S rRNA that forms the binding site for linezolid.  Risk factors for selection of resistance include indwelling devices, undrained foci, protracted therapy and underdosage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMQ0myE42NT7Vg90H21EOLACvtfcHk0liz7UAXuh_BwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXktlOqur0%253D&md5=c7c7ae8354e0ef29ebf23b7da4bccd8e</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdkg249&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdkg249%26sid%3Dliteratum%253Aachs%26aulast%3DLivermore%26aufirst%3DD.%2BM.%26atitle%3DLinezolid%2520in%2520Vitro%253A%2520Mechanism%2520and%2520Antibacterial%2520Spectrum%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2003%26volume%3D51%26spage%3Dii9%26epage%3Dii16%26doi%3D10.1093%2Fjac%2Fdkg249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diacon, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pym, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grobusch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patientia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rustomjee, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page-Shipp, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pistorius, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krause, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogoshi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Churchyard, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palomino, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Marez, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Heeswijk, R. P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyvisch, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verbeeck, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parys, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Beule, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neeley, D. F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNeeley, D. F.</span></span> <span> </span><span class="NLM_article-title">The Diarylquinoline TMC207 for Multidrug-Resistant Tuberculosis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>360</i></span>,  <span class="NLM_fpage">2397</span>– <span class="NLM_lpage">2405</span>, <span class="refDoi"> DOI: 10.1056/nejmoa0808427</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1056%2FNEJMoa0808427" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=19494215" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BD1MXntVKqsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=360&publication_year=2009&pages=2397-2405&author=A.+H.+Diaconauthor=A.+Pymauthor=M.+Grobuschauthor=R.+Patientiaauthor=R.+Rustomjeeauthor=L.+Page-Shippauthor=C.+Pistoriusauthor=R.+Krauseauthor=M.+Bogoshiauthor=G.+Churchyardauthor=A.+Venterauthor=J.+Allenauthor=J.+C.+Palominoauthor=T.+De+Marezauthor=R.+P.+G.+van+Heeswijkauthor=P.+Meyvischauthor=J.+Verbeeckauthor=W.+Parysauthor=K.+de+Beuleauthor=K.+Andriesauthor=D.+F.+M.+Neeleyauthor=D.+F.+McNeeley&title=The+Diarylquinoline+TMC207+for+Multidrug-Resistant+Tuberculosis&doi=10.1056%2Fnejmoa0808427"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The diarylquinoline TMC207 for multidrug-resistant tuberculosis</span></div><div class="casAuthors">Diacon, Andreas H.; Pym, Alexander; Grobusch, Martin; Patientia, Ramonde; Rustomjee, Roxana; Page-Shipp, Liesl; Pistorius, Christoffel; Krause, Rene; Bogoshi, Mampedi; Churchyard, Gavin; Venter, Amour; Allen, Jenny; Palomino, Juan Carlos; De Marez, Tine; van Heeswijk, Rolf P. G.; Lounis, Nacer; Meyvisch, Paul; Verbeeck, Johan; Parys, Wim; de Beule, Karel; Andries, Koen; McNeeley, David F.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">360</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2397-2405</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND; The diarylquinoline TMC207 offers a new mechanism of antituberculosis action by inhibiting mycobacterial ATP synthase.  TMC207 potently inhibits drug-sensitive and drug-resistant Mycobacterium tuberculosis in vitro and shows bactericidal activity in patients who have drug-susceptible pulmonary tuberculosis.  METHODS: In the first stage of a two-stage, phase 2, randomized, controlled trial, we randomly assigned 47 patients who had newly diagnosed multidrug-resistant pulmonary tuberculosis to receive either TMC207 (400 mg daily for 2 wk, followed by 200 mg three times a week for 6 wk) (23 patients) or placebo (24 patients) in combination with a std. five-drug, second-line antituberculosis regimen.  The primary efficacy end point was the conversion of sputum cultures, in liq. broth, from pos. to neg.  RESULTS: The addn. of TMC207 to std. therapy for multidrug-resistant tuberculosis reduced the time to conversion to a neg. sputum culture, as compared with placebo (hazard ratio, 11.8; 95% confidence interval, 2.3 to 61.3; P = 0.003 by Cox regression anal.) and increased the proportion of patients with conversion of sputum culture (48% vs. 9%).  The mean log10 count of colony-forming units in the sputum declined more rapidly in the TMC207 group than in the placebo group.  No significant differences in av. plasma TMC207 concns. were noted between patients with and those without culture conversion.  Most adverse events were mild to moderate, and only nausea occurred significantly more frequently among patients in the TMC207 group than among patients in the placebo group (26% vs. 4%, P = 0.04).  CONCLUSIONS: The clin. activity of TMC207 validates ATP synthase as a viable target for the treatment of tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGra39rie2VZP7Vg90H21EOLACvtfcHk0liz7UAXuh_BwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXntVKqsrs%253D&md5=76bdbf7f0263a168e58532addaf90a0a</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0808427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0808427%26sid%3Dliteratum%253Aachs%26aulast%3DDiacon%26aufirst%3DA.%2BH.%26aulast%3DPym%26aufirst%3DA.%26aulast%3DGrobusch%26aufirst%3DM.%26aulast%3DPatientia%26aufirst%3DR.%26aulast%3DRustomjee%26aufirst%3DR.%26aulast%3DPage-Shipp%26aufirst%3DL.%26aulast%3DPistorius%26aufirst%3DC.%26aulast%3DKrause%26aufirst%3DR.%26aulast%3DBogoshi%26aufirst%3DM.%26aulast%3DChurchyard%26aufirst%3DG.%26aulast%3DVenter%26aufirst%3DA.%26aulast%3DAllen%26aufirst%3DJ.%26aulast%3DPalomino%26aufirst%3DJ.%2BC.%26aulast%3DDe%2BMarez%26aufirst%3DT.%26aulast%3Dvan%2BHeeswijk%26aufirst%3DR.%2BP.%2BG.%26aulast%3DMeyvisch%26aufirst%3DP.%26aulast%3DVerbeeck%26aufirst%3DJ.%26aulast%3DParys%26aufirst%3DW.%26aulast%3Dde%2BBeule%26aufirst%3DK.%26aulast%3DAndries%26aufirst%3DK.%26aulast%3DNeeley%26aufirst%3DD.%2BF.%2BM.%26aulast%3DMcNeeley%26aufirst%3DD.%2BF.%26atitle%3DThe%2520Diarylquinoline%2520TMC207%2520for%2520Multidrug-Resistant%2520Tuberculosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2009%26volume%3D360%26spage%3D2397%26epage%3D2405%26doi%3D10.1056%2Fnejmoa0808427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Unemo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ringlander, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiggins, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fredlund, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobsson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, M.</span></span> <span> </span><span class="NLM_article-title">High in Vitro Susceptibility to the Novel Spiropyrimidinetrione ETX0914 (Also Known as AZD0914) among 873 Contemporary Clinical Neisseria Gonorrhoeae Isolates in 21 European Countries during 2012-2014</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">5220</span>– <span class="NLM_lpage">5225</span>, <span class="refDoi"> DOI: 10.1128/aac.00786-15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1128%2FAAC.00786-15" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=26077246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlyit7rE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=5220-5225&author=M.+Unemoauthor=J.+Ringlanderauthor=C.+Wigginsauthor=H.+Fredlundauthor=S.+Jacobssonauthor=M.+Cole&title=High+in+Vitro+Susceptibility+to+the+Novel+Spiropyrimidinetrione+ETX0914+%28Also+Known+as+AZD0914%29+among+873+Contemporary+Clinical+Neisseria+Gonorrhoeae+Isolates+in+21+European+Countries+during+2012-2014&doi=10.1128%2Faac.00786-15"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">High in vitro susceptibility to the novel spiropyrimidinetrione ETX0914 (AZD0914) among 873 contemporary clinical Neisseria gonorrhoeae isolates from 21 European countries from 2012 to 2014</span></div><div class="casAuthors">Unemo, Magnus; Ringlander, Johan; Wiggins, Catherine; Fredlund, Hans; Jacobsson, Susanne; Cole, Michelle</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">5220-5225</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Resistance in Neisseria gonorrhoeae against all antimicrobials available for the treatment of gonorrhea has emerged.  The first gonococcal strains with high-level resistance to ceftriaxone, the last option for first-line empirical antimicrobial monotherapy, were recently described.  Consequently, new treatment options are essential.  In this study, the in vitro activity of the novel spiropyrimidinetrione ETX0914 (AZD0914), a DNA topoisomerase II inhibitor, was investigated among contemporary consecutive clin. N. gonorrhoeae isolates obtained in 21 European countries and compared to the activities of antimicrobials currently or previously recommended for treatment.  Consecutive clin. N. gonorrhoeae isolates (n = 873) cultured in 21 European countries from 2012 to 2014 were examd. for their susceptibility to ETX0914.  The MICs of ETX0914 were detd. using the agar diln. method.  For comparison, the MICs of ceftriaxone, cefixime, azithromycin, and ciprofloxacin were detd. using Etest or the agar diln. method.  For ETX0914, the MIC range, modal MIC, MIC50, and MIC90 were ≤0.002 to 0.25 mg/L, 0.125 mg/L, 0.064 mg/L, and 0.125 mg/L, resp.  The MIC values were substantially lower than those of the fluoroquinolone ciprofloxacin and most other antimicrobials examd.  No cross-resistance with any other examd. antimicrobial was obsd.  In conclusion, the in vitro susceptibility to the novel spiropyrimidinetrione ETX0914 (AZD0914) among 873 contemporary clin. isolates from 21 European countries was high, and no cross-resistance to antimicrobials currently or previously used for gonorrhea treatment was indicated.  Addnl. studies investigating the in vitro and in vivo induction and mechanisms of ETX0914 resistance in gonococci, pharmacokinetics/pharmacodynamics in modeling/simulations and in humans, and performance in randomized controlled gonorrhea treatment trials are essential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYWVFFyOWAVbVg90H21EOLACvtfcHk0liz7UAXuh_BwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlyit7rE&md5=8bc15f5d9ff4ba62390d9be5c01e8509</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1128%2FAAC.00786-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00786-15%26sid%3Dliteratum%253Aachs%26aulast%3DUnemo%26aufirst%3DM.%26aulast%3DRinglander%26aufirst%3DJ.%26aulast%3DWiggins%26aufirst%3DC.%26aulast%3DFredlund%26aufirst%3DH.%26aulast%3DJacobsson%26aufirst%3DS.%26aulast%3DCole%26aufirst%3DM.%26atitle%3DHigh%2520in%2520Vitro%2520Susceptibility%2520to%2520the%2520Novel%2520Spiropyrimidinetrione%2520ETX0914%2520%2528Also%2520Known%2520as%2520AZD0914%2529%2520among%2520873%2520Contemporary%2520Clinical%2520Neisseria%2520Gonorrhoeae%2520Isolates%2520in%252021%2520European%2520Countries%2520during%25202012-2014%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2015%26volume%3D59%26spage%3D5220%26epage%3D5225%26doi%3D10.1128%2Faac.00786-15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waites, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crabb, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huband, M. D.</span></span> <span> </span><span class="NLM_article-title">In Vitro Antibacterial Activity of AZD0914 against Human Mycoplasmas and Ureaplasmas</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">3627</span>– <span class="NLM_lpage">3629</span>, <span class="refDoi"> DOI: 10.1128/aac.04945-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1128%2FAAC.04945-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=25824220" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpsFGjuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=3627-3629&author=K.+B.+Waitesauthor=D.+M.+Crabbauthor=L.+B.+Duffyauthor=M.+D.+Huband&title=In+Vitro+Antibacterial+Activity+of+AZD0914+against+Human+Mycoplasmas+and+Ureaplasmas&doi=10.1128%2Faac.04945-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">In Vitro antibacterial activity of AZD0914 against human Mycoplasmas and Ureaplasmas</span></div><div class="casAuthors">Waites, Ken B.; Crabb, Donna M.; Duffy, Lynn B.; Huband, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3627-3629</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Susceptibilities were detd. for AZD0914, a spiropyrimidinetrione DNA gyrase inhibitor, azithromycin, doxycycline, and levofloxacin against Mycoplasma and Ureaplasma species.  The activity of AZD0914 was comparable to that of levofloxacin and doxycycline against Mycoplasma genitalium and Mycoplasma pneumoniae.  The AZD0914 MIC90 against Mycoplasma hominis was 8-fold greater than that for levofloxacin.  The AZD0914 MIC90 against Ureaplasma species was 4-fold less than that for azithromycin and 8-fold less than that for levofloxacin and doxycycline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrW8CtV-uoxC7Vg90H21EOLACvtfcHk0ljsqlMHFJqmXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpsFGjuro%253D&md5=b28d0375d052f18529ed993b15e24e13</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1128%2FAAC.04945-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.04945-14%26sid%3Dliteratum%253Aachs%26aulast%3DWaites%26aufirst%3DK.%2BB.%26aulast%3DCrabb%26aufirst%3DD.%2BM.%26aulast%3DDuffy%26aufirst%3DL.%2BB.%26aulast%3DHuband%26aufirst%3DM.%2BD.%26atitle%3DIn%2520Vitro%2520Antibacterial%2520Activity%2520of%2520AZD0914%2520against%2520Human%2520Mycoplasmas%2520and%2520Ureaplasmas%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2015%26volume%3D59%26spage%3D3627%26epage%3D3629%26doi%3D10.1128%2Faac.04945-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Su, X.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, W.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alm, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, P. A.</span></span> <span> </span><span class="NLM_article-title">Multidrug-Resistant Neisseria Gonorrhoeae Isolates from Nanjing, China, Are Sensitive to Killing by a Novel DNA Gyrase Inhibitor, ETX0914 (AZD0914)</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">621</span>– <span class="NLM_lpage">623</span>, <span class="refDoi"> DOI: 10.1128/aac.01211-15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1128%2FAAC.01211-15" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=26482313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVCit7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2016&pages=621-623&author=X.-H.+Suauthor=B.-X.+Wangauthor=W.-J.+Leauthor=Y.-R.+Liuauthor=C.+Wanauthor=S.+Liauthor=R.+A.+Almauthor=J.+P.+Muellerauthor=P.+A.+Rice&title=Multidrug-Resistant+Neisseria+Gonorrhoeae+Isolates+from+Nanjing%2C+China%2C+Are+Sensitive+to+Killing+by+a+Novel+DNA+Gyrase+Inhibitor%2C+ETX0914+%28AZD0914%29&doi=10.1128%2Faac.01211-15"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Multidrug-resistant Neisseria gonorrhoeae isolates from Nanjing, China, are sensitive to killing by a novel DNA gyrase inhibitor, ETX0914 (AZD0914)</span></div><div class="casAuthors">Su, Xiao-Hong; Wang, Bao-Xi; Le, Wen-Jing; Liu, Yu-Rong; Wan, Chuan; Li, Sai; Alm, Richard A.; Mueller, John P.; Rice, Peter A.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">621-623</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">We tested the activity of ETX0914 against 187 Neisseria gonorrhoeae isolates from men with urethritis in Nanjing, China, in 2013.  The MIC50, MIC90, and MIC range for ETX0914 were 0.03 μg/mL, 0.06 μg/mL, and ≤0.002 to 0.125 μg/mL, resp.  All isolates were resistant to ciprofloxacin, and 36.9% (69/187) were resistant to azithromycin.  Of the isolates, 46.5% were penicillinase-producing N. gonorrhoeae (PPNG), 36% were tetracycline-resistant N. gonorrhoeae (TRNG), and 13% (24 isolates) had an MIC of 0.125 μg/mL for ceftriaxone.  ETX0914 may be an effective treatment option for gonorrhea.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9QF6jhy6LWbVg90H21EOLACvtfcHk0ljsqlMHFJqmXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVCit7%252FJ&md5=56d12ebf6d67d6f3875f1180d32f357c</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1128%2FAAC.01211-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01211-15%26sid%3Dliteratum%253Aachs%26aulast%3DSu%26aufirst%3DX.-H.%26aulast%3DWang%26aufirst%3DB.-X.%26aulast%3DLe%26aufirst%3DW.-J.%26aulast%3DLiu%26aufirst%3DY.-R.%26aulast%3DWan%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DAlm%26aufirst%3DR.%2BA.%26aulast%3DMueller%26aufirst%3DJ.%2BP.%26aulast%3DRice%26aufirst%3DP.%2BA.%26atitle%3DMultidrug-Resistant%2520Neisseria%2520Gonorrhoeae%2520Isolates%2520from%2520Nanjing%252C%2520China%252C%2520Are%2520Sensitive%2520to%2520Killing%2520by%2520a%2520Novel%2520DNA%2520Gyrase%2520Inhibitor%252C%2520ETX0914%2520%2528AZD0914%2529%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2016%26volume%3D60%26spage%3D621%26epage%3D623%26doi%3D10.1128%2Faac.01211-15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jacobsson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golparian, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alm, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huband, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohnishi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unemo, M.</span></span> <span> </span><span class="NLM_article-title">High in Vitro Activity of the Novel Spiropyrimidinetrione AZD0914, a DNA Gyrase Inhibitor, against Multidrug-Resistant Neisseria Gonorrhoeae Isolates Suggests a New Effective Option for Oral Treatment of Gonorrhea</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">5585</span>– <span class="NLM_lpage">5588</span>, <span class="refDoi"> DOI: 10.1128/aac.03090-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1128%2FAAC.03090-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=24982070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1eqtbjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2014&pages=5585-5588&author=S.+Jacobssonauthor=D.+Golparianauthor=R.+A.+Almauthor=M.+Hubandauthor=J.+Muellerauthor=J.+S.+Jensenauthor=M.+Ohnishiauthor=M.+Unemo&title=High+in+Vitro+Activity+of+the+Novel+Spiropyrimidinetrione+AZD0914%2C+a+DNA+Gyrase+Inhibitor%2C+against+Multidrug-Resistant+Neisseria+Gonorrhoeae+Isolates+Suggests+a+New+Effective+Option+for+Oral+Treatment+of+Gonorrhea&doi=10.1128%2Faac.03090-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">High in vitro activity of the novel spiropyrimidinetrione AZD0914, a DNA gyrase inhibitor, against multidrug-resistant Neisseria gonorrhoeae isolates suggests a new effective option for oral treatment of gonorrhea</span></div><div class="casAuthors">Jacobsson, Susanne; Golparian, Daniel; Alm, Richard A.; Huband, Michael; Mueller, John; Jensen, Jorgen Skov; Ohnishi, Makoto; Unemo, Magnus</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">5585-5588, 5 pp.</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">We evaluated the activity of the novel spiropyrimidinetrione AZD0914 (DNA gyrase inhibitor) against clin. gonococcal isolates and international ref. strains (n = 250), including strains with diverse multidrug resistance and extensive drug resistance.  The AZD0914 MICs were substantially lower than those of most other currently or previously recommended antimicrobials.  AZD0914 should be further evaluated, including in vitro selection, in vivo emergence and mechanisms of resistance, pharmacokinetics/pharmacodynamics in humans, optimal dosing, and performance, in appropriate randomized and controlled clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqX-jSLaLHHsrVg90H21EOLACvtfcHk0ljsqlMHFJqmXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1eqtbjK&md5=b33312a55ea3ba89313153735068d19c</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1128%2FAAC.03090-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.03090-14%26sid%3Dliteratum%253Aachs%26aulast%3DJacobsson%26aufirst%3DS.%26aulast%3DGolparian%26aufirst%3DD.%26aulast%3DAlm%26aufirst%3DR.%2BA.%26aulast%3DHuband%26aufirst%3DM.%26aulast%3DMueller%26aufirst%3DJ.%26aulast%3DJensen%26aufirst%3DJ.%2BS.%26aulast%3DOhnishi%26aufirst%3DM.%26aulast%3DUnemo%26aufirst%3DM.%26atitle%3DHigh%2520in%2520Vitro%2520Activity%2520of%2520the%2520Novel%2520Spiropyrimidinetrione%2520AZD0914%252C%2520a%2520DNA%2520Gyrase%2520Inhibitor%252C%2520against%2520Multidrug-Resistant%2520Neisseria%2520Gonorrhoeae%2520Isolates%2520Suggests%2520a%2520New%2520Effective%2520Option%2520for%2520Oral%2520Treatment%2520of%2520Gonorrhea%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2014%26volume%3D58%26spage%3D5585%26epage%3D5588%26doi%3D10.1128%2Faac.03090-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Damião
Gouveia, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unemo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, J. S.</span></span> <span> </span><span class="NLM_article-title">In Vitro Activity of Zoliflodacin (ETX0914) against Macrolide-Resistant, Fluoroquinolone-Resistant and Antimicrobial-Susceptible Mycoplasma Genitalium Strains</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">1291</span>– <span class="NLM_lpage">1294</span>, <span class="refDoi"> DOI: 10.1093/jac/dky022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1093%2Fjac%2Fdky022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=29444242" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A280%3ADC%252BC1Mrhs12rtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2018&pages=1291-1294&author=A.+C.+Dami%C3%A3o%0AGouveiaauthor=M.+Unemoauthor=J.+S.+Jensen&title=In+Vitro+Activity+of+Zoliflodacin+%28ETX0914%29+against+Macrolide-Resistant%2C+Fluoroquinolone-Resistant+and+Antimicrobial-Susceptible+Mycoplasma+Genitalium+Strains&doi=10.1093%2Fjac%2Fdky022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro activity of zoliflodacin (ETX0914) against macrolide-resistant, fluoroquinolone-resistant and antimicrobial-susceptible Mycoplasma genitalium strains</span></div><div class="casAuthors">Damiao Gouveia A C; Jensen J S; Unemo M</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of antimicrobial chemotherapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1291-1294</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Background:  Mycoplasma genitalium is estimated to be the second most common cause of bacterial sexually transmitted infection in Europe.  It is of increasing public health concern due to the rapid development of resistance to different antimicrobial classes, including the preferred first- and second-line treatments azithromycin and moxifloxacin.  Thus, new antimicrobial agents are urgently needed, especially for the treatment of MDR strains.  Methods:  The in vitro activity of the new spiropyrimidinetrione zoliflodacin against 47 M. genitalium strains was assessed by growing M. genitalium in Vero cell culture and measuring growth by quantitative PCR.  The collection included 34 moxifloxacin-susceptible (MIC <1 mg/L) and 13 moxifloxacin-resistant (MIC ≥1 mg/L) strains.  Twenty-three of the strains were azithromycin resistant (MIC ≥16 mg/L) and 12 of these strains were MDR.  Results:  Only one (2.1%) strain with substantially increased MIC (4 mg/L) and potential resistance to zoliflodacin was found.  Zoliflodacin was overall more potent than moxifloxacin (P = 0.009) and no cross-resistance was observed between the two drug classes of topoisomerase II inhibitors.  Differences in the MICs of zoliflodacin and azithromycin were not statistically significant; however, 23 (48.9%) compared with potentially 1 (2.1%) of the strains were resistant to azithromycin and zoliflodacin, respectively.  Conclusions:  Zoliflodacin is a promising candidate for the treatment of M. genitalium and it is important to further develop and evaluate this drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRXvQhLvVEpggpJitSxOdIlfW6udTcc2eYDe9DZKoI8a7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mrhs12rtw%253D%253D&md5=b784d7783cab5d176287d9690748168e</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdky022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdky022%26sid%3Dliteratum%253Aachs%26aulast%3DDami%25C3%25A3o%2BGouveia%26aufirst%3DA.%2BC.%26aulast%3DUnemo%26aufirst%3DM.%26aulast%3DJensen%26aufirst%3DJ.%2BS.%26atitle%3DIn%2520Vitro%2520Activity%2520of%2520Zoliflodacin%2520%2528ETX0914%2529%2520against%2520Macrolide-Resistant%252C%2520Fluoroquinolone-Resistant%2520and%2520Antimicrobial-Susceptible%2520Mycoplasma%2520Genitalium%2520Strains%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2018%26volume%3D73%26spage%3D1291%26epage%3D1294%26doi%3D10.1093%2Fjac%2Fdky022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basarab, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doig, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galullo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kern, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimzey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutschke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morningstar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otterson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vishwanathan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gowravaram, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of Novel DNA Gyrase Inhibiting Spiropyrimidinetriones - Benzisoxazole Fusion with N-Linked Oxazolidinone Substituents Leading to a Clinical Candidate (ETX0914)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">6264</span>– <span class="NLM_lpage">6282</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00863</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00863" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFCrurvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6264-6282&author=G.+S.+Basarabauthor=P.+Doigauthor=V.+Galulloauthor=G.+Kernauthor=A.+Kimzeyauthor=A.+Kutschkeauthor=J.+P.+Newmanauthor=M.+Morningstarauthor=J.+Muellerauthor=L.+Ottersonauthor=K.+Vishwanathanauthor=F.+Zhouauthor=M.+Gowravaram&title=Discovery+of+Novel+DNA+Gyrase+Inhibiting+Spiropyrimidinetriones+-+Benzisoxazole+Fusion+with+N-Linked+Oxazolidinone+Substituents+Leading+to+a+Clinical+Candidate+%28ETX0914%29&doi=10.1021%2Facs.jmedchem.5b00863"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel DNA Gyrase Inhibiting Spiropyrimidinetriones: Benzisoxazole Fusion with N-Linked Oxazolidinone Substituents Leading to a Clinical Candidate (ETX0914)</span></div><div class="casAuthors">Basarab, Gregory S.; Doig, Peter; Galullo, Vincent; Kern, Gunther; Kimzey, Amy; Kutschke, Amy; Newman, Joseph P.; Morningstar, Marshall; Mueller, John; Otterson, Linda; Vishwanathan, Karthick; Zhou, Fei; Gowravaram, Madhusudhan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6264-6282</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel class of bacterial type-II topoisomerase inhibitor displaying a spiropyrimidinetrione architecture fused to a benzisoxazole scaffold shows potent activity against Gram-pos. and fastidious Gram-neg. bacteria.  Here, the authors describe a series of N-linked oxazolidinone substituents on the benzisoxazole that improve upon the antibacterial activity of initially described compds. of the class, show favorable PK properties, and demonstrate efficacy in an in vivo Staphylococcus aureus infection model.  Inhibition of the topoisomerases DNA gyrase and topoisomerase IV from both Gram-pos. and a Gram-neg. organisms was demonstrated.  Compds. showed a clean in vitro toxicity profile, including no genotoxicity and no bone marrow toxicity at the highest evaluated concns. or other issues that have been problematic for some fluoroquinolones.  Compd. I was identified for advancement into human clin. trials for treatment of uncomplicated gonorrhea based on a variety of beneficial attributes including the potent activity and the favorable safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoo8zOqBRUJg7Vg90H21EOLACvtfcHk0lhXXsjG290BGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFCrurvL&md5=67b21b269a0dfdf74b7e93196d8dfc4e</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00863&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00863%26sid%3Dliteratum%253Aachs%26aulast%3DBasarab%26aufirst%3DG.%2BS.%26aulast%3DDoig%26aufirst%3DP.%26aulast%3DGalullo%26aufirst%3DV.%26aulast%3DKern%26aufirst%3DG.%26aulast%3DKimzey%26aufirst%3DA.%26aulast%3DKutschke%26aufirst%3DA.%26aulast%3DNewman%26aufirst%3DJ.%2BP.%26aulast%3DMorningstar%26aufirst%3DM.%26aulast%3DMueller%26aufirst%3DJ.%26aulast%3DOtterson%26aufirst%3DL.%26aulast%3DVishwanathan%26aufirst%3DK.%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DGowravaram%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520Novel%2520DNA%2520Gyrase%2520Inhibiting%2520Spiropyrimidinetriones%2520-%2520Benzisoxazole%2520Fusion%2520with%2520N-Linked%2520Oxazolidinone%2520Substituents%2520Leading%2520to%2520a%2520Clinical%2520Candidate%2520%2528ETX0914%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D6264%26epage%3D6282%26doi%3D10.1021%2Facs.jmedchem.5b00863" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Okumura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maya, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onishi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izawa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanifuji, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arano, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, H.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, and Preliminary Evaluation of SPECT Probes for Imaging β-Amyloid in Alzheimer’s Disease Affected Brain</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1503</span>– <span class="NLM_lpage">1514</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.8b00064</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.8b00064" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlvFGls7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1503-1514&author=Y.+Okumuraauthor=Y.+Mayaauthor=T.+Onishiauthor=Y.+Shoyamaauthor=A.+Izawaauthor=D.+Nakamuraauthor=S.+Tanifujiauthor=A.+Tanakaauthor=Y.+Aranoauthor=H.+Matsumoto&title=Design%2C+Synthesis%2C+and+Preliminary+Evaluation+of+SPECT+Probes+for+Imaging+%CE%B2-Amyloid+in+Alzheimer%E2%80%99s+Disease+Affected+Brain&doi=10.1021%2Facschemneuro.8b00064"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Preliminary Evaluation of SPECT Probes for Imaging β-Amyloid in Alzheimer's Disease Affected Brain</span></div><div class="casAuthors">Okumura, Yuki; Maya, Yoshifumi; Onishi, Takako; Shoyama, Yoshinari; Izawa, Akihiro; Nakamura, Daisaku; Tanifuji, Shigeyuki; Tanaka, Akihiro; Arano, Yasushi; Matsumoto, Hiroki</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1503-1514</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this study, we synthesized of a series of 2-phenyl- and 2-pyridyl-imidazo[1,2-a]pyridine derivs. and examine their suitability as novel probes for single-photon emission computed tomog. (SPECT)-based imaging of β-amyloid (Aβ).  Among the 11 evaluated compds., 10 showed moderate affinity to Aβ(1-42) aggregates, exhibiting half-maximal inhibitory concns. (IC50) of 14.7 ± 6.07-87.6 ± 39.8 nM.  In vitro autoradiog. indicated that 123I-labeled triazole-substituted derivs. displayed highly selective binding to Aβ plaques in the hippocampal region of Alzheimer's disease (AD)-affected brain.  Moreover, biodistribution studies performed on normal rats demonstrated that all 123I-labeled probes featured high initial uptake into the brain followed by a rapid washout and were thus well suited for imaging Aβ plaques, with the highest selectivity obsd. for a 1H-1,2,3-triazole-substituted 2-pyridyl-imidazopyridine deriv., [123I]ABC577.  This compd. showed good kinetics in rat brain as well as moderate in vivo stability in rats and is thus a promising SPECT imaging probe for AD in clin. settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp207EWuPGnp7Vg90H21EOLACvtfcHk0lhXXsjG290BGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlvFGls7o%253D&md5=b4e388a4a281769468a884982f6f233e</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.8b00064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.8b00064%26sid%3Dliteratum%253Aachs%26aulast%3DOkumura%26aufirst%3DY.%26aulast%3DMaya%26aufirst%3DY.%26aulast%3DOnishi%26aufirst%3DT.%26aulast%3DShoyama%26aufirst%3DY.%26aulast%3DIzawa%26aufirst%3DA.%26aulast%3DNakamura%26aufirst%3DD.%26aulast%3DTanifuji%26aufirst%3DS.%26aulast%3DTanaka%26aufirst%3DA.%26aulast%3DArano%26aufirst%3DY.%26aulast%3DMatsumoto%26aufirst%3DH.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Preliminary%2520Evaluation%2520of%2520SPECT%2520Probes%2520for%2520Imaging%2520%25CE%25B2-Amyloid%2520in%2520Alzheimer%25E2%2580%2599s%2520Disease%2520Affected%2520Brain%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2018%26volume%3D9%26spage%3D1503%26epage%3D1514%26doi%3D10.1021%2Facschemneuro.8b00064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Temburnikar, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelbmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salomon, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seley-Radtke, K. L.</span></span> <span> </span><span class="NLM_article-title">Antiproliferative Activities of Halogenated Thieno[3,2-d]Pyrimidines</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">2113</span>– <span class="NLM_lpage">2122</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2014.02.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1016%2Fj.bmc.2014.02.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=24631358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktlWgsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=2113-2122&author=K.+W.+Temburnikarauthor=S.+C.+Zimmermannauthor=N.+T.+Kimauthor=C.+R.+Rossauthor=C.+Gelbmannauthor=C.+E.+Salomonauthor=G.+M.+Wilsonauthor=J.+Balzariniauthor=K.+L.+Seley-Radtke&title=Antiproliferative+Activities+of+Halogenated+Thieno%5B3%2C2-d%5DPyrimidines&doi=10.1016%2Fj.bmc.2014.02.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Antiproliferative activities of halogenated thieno[3,2-d]pyrimidines</span></div><div class="casAuthors">Temburnikar, Kartik W.; Zimmermann, Sarah C.; Kim, Nathaniel T.; Ross, Christina R.; Gelbmann, Christopher; Salomon, Christine E.; Wilson, Gerald M.; Balzarini, Jan; Seley-Radtke, Katherine L.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2113-2122</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The in vitro evaluation of thieno[3,2-d]pyrimidines identified halogenated compds. 1 and 2 with antiproliferative activity against three different cancer cell lines.  A structure activity relation study indicated the necessity of the chlorine at the C4-position for biol. activity.  The two most active compds. 1 and 2 were found to induce apoptosis in the leukemia L1210 cell line.  Addnl., the compds. were screened against a variety of other microbial targets and as a result, selective activity against several fungi was also obsd.  The synthesis and preliminary biol. results are reported herein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5MFfw6R0CKLVg90H21EOLACvtfcHk0lgxqwXWFpL0BA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktlWgsr4%253D&md5=d436cc1f43c71dfd258adbace4ea3468</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.02.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.02.033%26sid%3Dliteratum%253Aachs%26aulast%3DTemburnikar%26aufirst%3DK.%2BW.%26aulast%3DZimmermann%26aufirst%3DS.%2BC.%26aulast%3DKim%26aufirst%3DN.%2BT.%26aulast%3DRoss%26aufirst%3DC.%2BR.%26aulast%3DGelbmann%26aufirst%3DC.%26aulast%3DSalomon%26aufirst%3DC.%2BE.%26aulast%3DWilson%26aufirst%3DG.%2BM.%26aulast%3DBalzarini%26aufirst%3DJ.%26aulast%3DSeley-Radtke%26aufirst%3DK.%2BL.%26atitle%3DAntiproliferative%2520Activities%2520of%2520Halogenated%2520Thieno%255B3%252C2-d%255DPyrimidines%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D2113%26epage%3D2122%26doi%3D10.1016%2Fj.bmc.2014.02.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruble, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurd, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherry, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbachyn, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toogood, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bundy, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graber, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamilar, G. M.</span></span> <span> </span><span class="NLM_article-title">Synthesis of (-)-PNU-286607 by Asymmetric Cyclization of Alkylidene Barbiturates</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">3991</span>– <span class="NLM_lpage">3997</span>, <span class="refDoi"> DOI: 10.1021/ja808014h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja808014h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivVeisL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2009&pages=3991-3997&author=J.+C.+Rubleauthor=A.+R.+Hurdauthor=T.+A.+Johnsonauthor=D.+A.+Sherryauthor=M.+R.+Barbachynauthor=P.+L.+Toogoodauthor=G.+L.+Bundyauthor=D.+R.+Graberauthor=G.+M.+Kamilar&title=Synthesis+of+%28-%29-PNU-286607+by+Asymmetric+Cyclization+of+Alkylidene+Barbiturates&doi=10.1021%2Fja808014h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of (-)-PNU-286607 by Asymmetric Cyclization of Alkylidene Barbiturates</span></div><div class="casAuthors">Ruble, J. Craig; Hurd, Alexander R.; Johnson, Timothy A.; Sherry, Debra A.; Barbachyn, Michael R.; Toogood, Peter L.; Bundy, Gordon L.; Graber, David R.; Kamilar, Gregg M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3991-3997</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">PNU 286607 I, a oxazinoquinolinespiropyrimidinetrione inhibitor of bacterial DNA gyrase for potential use as an antibacterial agent against antibiotic-resistant bacterial strains, is prepd. in two steps from 2-fluoro-5-nitrobenzaldehyde and (R,R)-2,6-dimethylmorpholine by nucleophilic arom. substitution followed by condensation with barbituric acid and a concomitant stereoselective cyclization of the benzylidenepyrimidinetrione.  The stereoselectivities and mechanism of the condensation and cyclization reactions (based on the rearrangements of vinyl anilines, known in the literature as the "tert-amino effect") are investigated using the NMR spectroscopic anal. of the reactions of racemic substrates and the reactions of racemic and nonracemic deuterated substrates; based on the data obtained, the asym. synthesis of I is developed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYwZZhoPHBHrVg90H21EOLACvtfcHk0lgxqwXWFpL0BA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivVeisL4%253D&md5=f837986da667a40ce19753baa9d58125</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fja808014h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja808014h%26sid%3Dliteratum%253Aachs%26aulast%3DRuble%26aufirst%3DJ.%2BC.%26aulast%3DHurd%26aufirst%3DA.%2BR.%26aulast%3DJohnson%26aufirst%3DT.%2BA.%26aulast%3DSherry%26aufirst%3DD.%2BA.%26aulast%3DBarbachyn%26aufirst%3DM.%2BR.%26aulast%3DToogood%26aufirst%3DP.%2BL.%26aulast%3DBundy%26aufirst%3DG.%2BL.%26aulast%3DGraber%26aufirst%3DD.%2BR.%26aulast%3DKamilar%26aufirst%3DG.%2BM.%26atitle%3DSynthesis%2520of%2520%2528-%2529-PNU-286607%2520by%2520Asymmetric%2520Cyclization%2520of%2520Alkylidene%2520Barbiturates%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2009%26volume%3D131%26spage%3D3991%26epage%3D3997%26doi%3D10.1021%2Fja808014h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basarab, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galullo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degrace, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauck, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joubran, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wesolowski, S. S.</span></span> <span> </span><span class="NLM_article-title">Synthesis of a Tetrahydronaphthyridine Spiropyrimidinetrione DNA Gyrase Inhibiting Antibacterial Agent - Differential Substitution at All Five Carbon Atoms of Pyridine</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">6456</span>– <span class="NLM_lpage">6459</span>, <span class="refDoi"> DOI: 10.1021/ol503256h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol503256h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVamsrzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2014&pages=6456-6459&author=G.+S.+Basarabauthor=V.+Galulloauthor=N.+Degraceauthor=S.+Hauckauthor=C.+Joubranauthor=S.+S.+Wesolowski&title=Synthesis+of+a+Tetrahydronaphthyridine+Spiropyrimidinetrione+DNA+Gyrase+Inhibiting+Antibacterial+Agent+-+Differential+Substitution+at+All+Five+Carbon+Atoms+of+Pyridine&doi=10.1021%2Fol503256h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of a Tetrahydronaphthyridine Spiropyrimidinetrione DNA Gyrase Inhibiting Antibacterial Agent - Differential Substitution at all Five Carbon Atoms of Pyridine.</span></div><div class="casAuthors">Basarab, Gregory S.; Galullo, Vincent; DeGrace, Nancy; Hauck, Sheila; Joubran, Camil; Wesolowski, Steven S.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6456-6459</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7052</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis of I, a potent antibacterial agent, was achieved stereoselectively in nine steps from readily available starting materials.  Directed metalations were developed to assemble a pentasubstituted pyridine with appropriately positioned aldehyde and dimethylmorpholine substituents for a key tertiary amino effect reaction (T-reaction) that led to the spirocyclic architecture.  Ultimately, I was isolated as the thermodynamically most favored stereoisomer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWsTrK9RkPp7Vg90H21EOLACvtfcHk0lgxqwXWFpL0BA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVamsrzN&md5=d593296ffc77a54b3157e5641001d1a8</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fol503256h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol503256h%26sid%3Dliteratum%253Aachs%26aulast%3DBasarab%26aufirst%3DG.%2BS.%26aulast%3DGalullo%26aufirst%3DV.%26aulast%3DDegrace%26aufirst%3DN.%26aulast%3DHauck%26aufirst%3DS.%26aulast%3DJoubran%26aufirst%3DC.%26aulast%3DWesolowski%26aufirst%3DS.%2BS.%26atitle%3DSynthesis%2520of%2520a%2520Tetrahydronaphthyridine%2520Spiropyrimidinetrione%2520DNA%2520Gyrase%2520Inhibiting%2520Antibacterial%2520Agent%2520-%2520Differential%2520Substitution%2520at%2520All%2520Five%2520Carbon%2520Atoms%2520of%2520Pyridine%26jtitle%3DOrg.%2520Lett.%26date%3D2014%26volume%3D16%26spage%3D6456%26epage%3D6459%26doi%3D10.1021%2Fol503256h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raw, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Kearney-McMullan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, M. A.</span></span> <span> </span><span class="NLM_article-title">Unexpected Ring-Expansion of 1,2-Benzisoxazol-3-Ones</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">6775</span>– <span class="NLM_lpage">6778</span>, <span class="refDoi"> DOI: 10.1016/j.tetlet.2011.10.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1016%2Fj.tetlet.2011.10.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVOjt7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2011&pages=6775-6778&author=S.+A.+Rawauthor=A.+M.+O%E2%80%99Kearney-McMullanauthor=M.+A.+Graham&title=Unexpected+Ring-Expansion+of+1%2C2-Benzisoxazol-3-Ones&doi=10.1016%2Fj.tetlet.2011.10.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Unexpected ring-expansion of 1,2-benzisoxazol-3-ones</span></div><div class="casAuthors">Raw, Steven A.; O'Kearney-McMullan, Anne M.; Graham, Mark A.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">50</span>),
    <span class="NLM_cas:pages">6775-6778</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A novel and unexpected ring-expansion reaction of 1,2-benzisoxazol-3-ones is identified.  The scope of this reaction is exemplified and the proposed mechanism is also implicated in another degrdn. process.  This reaction also represents a new method for accessing the 4H-1,3-benzoxazin-4-one, e.g., I, skeleton.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjWZHjxa7V3rVg90H21EOLACvtfcHk0lgxqwXWFpL0BA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVOjt7fM&md5=117620d39bc7d24edacb0bdae121e152</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2011.10.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2011.10.027%26sid%3Dliteratum%253Aachs%26aulast%3DRaw%26aufirst%3DS.%2BA.%26aulast%3DO%25E2%2580%2599Kearney-McMullan%26aufirst%3DA.%2BM.%26aulast%3DGraham%26aufirst%3DM.%2BA.%26atitle%3DUnexpected%2520Ring-Expansion%2520of%25201%252C2-Benzisoxazol-3-Ones%26jtitle%3DTetrahedron%2520Lett.%26date%3D2011%26volume%3D52%26spage%3D6775%26epage%3D6778%26doi%3D10.1016%2Fj.tetlet.2011.10.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sikorski, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reitz, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilla, L. T.</span></span> <span> </span><span class="NLM_article-title">Triazole Phosphonates. Electrophilic Substitution of 1-Substituted-1<i>H</i>-1,2,4-Triazoles <i>via</i> Lithiated Triazole Intermediates</span>. <i>J. Heterocycl. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1257</span>– <span class="NLM_lpage">1262</span>, <span class="refDoi"> DOI: 10.1002/jhet.5570230457</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1002%2Fjhet.5570230457" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADyaL2sXitFertrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1986&pages=1257-1262&author=D.+K.+Andersonauthor=J.+A.+Sikorskiauthor=D.+B.+Reitzauthor=L.+T.+Pilla&title=Triazole+Phosphonates.+Electrophilic+Substitution+of+1-Substituted-1H-1%2C2%2C4-Triazoles+via+Lithiated+Triazole+Intermediates&doi=10.1002%2Fjhet.5570230457"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Triazole phosphonates.  Electrophilic substitution of 1-substituted 1H-1,2,4-triazoles via lithiated triazole intermediates</span></div><div class="casAuthors">Anderson, D. Keith; Sikorski, James A.; Reitz, David B.; Pilla, Linda T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Heterocyclic Chemistry</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1257-62</span>CODEN:
                <span class="NLM_cas:coden">JHTCAD</span>;
        ISSN:<span class="NLM_cas:issn">0022-152X</span>.
    </div><div class="casAbstract">Lithiation of triazoles I (R = Ph, R1 = CH2Ph; R = H, R1 = Me, CPh3, CH2Ph) and II with BuLi in THF proceeded exclusively at C-5.  Li salts of I were stable at -78° and on treatment with electrophiles gave triazoles III [R2 = P(O)(OEt)2, SPh, Me3CSiMe2, D, C(OH)Ph2, Me, Cl, CO2Me].  Deesterification of III [R = H, R1 = CH2Ph, Me, R2 = P(O)(OEt)2] with Me3SiBr gave III (R2 = PO3H2).  The crystal structure of III (R = H, R1 = CH2Ph, R2 = PO3H2) is reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfxo1o7O8Ks7Vg90H21EOLACvtfcHk0ljsKA3aMPdxwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXitFertrk%253D&md5=d612f2fb93a47076e983b9168b04ec81</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1002%2Fjhet.5570230457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjhet.5570230457%26sid%3Dliteratum%253Aachs%26aulast%3DAnderson%26aufirst%3DD.%2BK.%26aulast%3DSikorski%26aufirst%3DJ.%2BA.%26aulast%3DReitz%26aufirst%3DD.%2BB.%26aulast%3DPilla%26aufirst%3DL.%2BT.%26atitle%3DTriazole%2520Phosphonates.%2520Electrophilic%2520Substitution%2520of%25201-Substituted-1H-1%252C2%252C4-Triazoles%2520via%2520Lithiated%2520Triazole%2520Intermediates%26jtitle%3DJ.%2520Heterocycl.%2520Chem.%26date%3D1986%26volume%3D23%26spage%3D1257%26epage%3D1262%26doi%3D10.1002%2Fjhet.5570230457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lakshmireddy, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naga Veera, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">China
Raju, B.</span></span> <span> </span><span class="NLM_article-title">A Green and Sustainable Approach for Selective Halogenation of Anilides, Benzanilides, Sulphonamides and Heterocycles</span>. <i>Asian J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1380</span>– <span class="NLM_lpage">1384</span>, <span class="refDoi"> DOI: 10.1002/ajoc.201900296</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1002%2Fajoc.201900296" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1ensbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2019&pages=1380-1384&author=V.+M.+Lakshmireddyauthor=Y.+Naga+Veeraauthor=T.+J.+Reddyauthor=V.+J.+Raoauthor=B.+China%0ARaju&title=A+Green+and+Sustainable+Approach+for+Selective+Halogenation+of+Anilides%2C+Benzanilides%2C+Sulphonamides+and+Heterocycles&doi=10.1002%2Fajoc.201900296"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">A Green and Sustainable Approach for Selective Halogenation of Anilides, Benzanilides, Sulphonamides and Heterocycles</span></div><div class="casAuthors">Lakshmireddy, V. M.; Naga Veera, Y.; Reddy, T. J.; Rao, V. J.; China Raju, B.</div><div class="citationInfo"><span class="NLM_cas:title">Asian Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1380-1384</span>CODEN:
                <span class="NLM_cas:coden">AJOCC7</span>;
        ISSN:<span class="NLM_cas:issn">2193-5807</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">An efficient green and sustainable protocol was devised for the selective oxidative halogenation of acetanilides, benzanilides, sulfonamides and heterocyclic compds. to afford haloanilides and halosulfonamides I [R = COMe, COPh, SO2Ph; R1 = Cl, Br; R2 = H, F; R3 = H, i-Pr, CF3, etc.; R4 = H, F, Br, etc.], haloimidazoles, haloindoles, halothiazoles and 1,2,4-triazole e.g. II and halopyridines III [R5 = NH2, NHCOMe, Br, etc.; R6 = NH2, Cl, Br, etc.; R7 = H, NH2, NH(Me)2, NHCOMe; R8 = H, Cl, Br] using easily available NaX as a halogen source and oxone as a powerful oxidant.  The present protocol was simple and environmentally benign to conduct the lab. scale halogenations and could be extended to prep. industrially important compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-hRjC5UB_vrVg90H21EOLACvtfcHk0ljsKA3aMPdxwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1ensbvI&md5=e55c9ba30e8eb39b32382458ae852143</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2Fajoc.201900296&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fajoc.201900296%26sid%3Dliteratum%253Aachs%26aulast%3DLakshmireddy%26aufirst%3DV.%2BM.%26aulast%3DNaga%2BVeera%26aufirst%3DY.%26aulast%3DReddy%26aufirst%3DT.%2BJ.%26aulast%3DRao%26aufirst%3DV.%2BJ.%26aulast%3DChina%2BRaju%26aufirst%3DB.%26atitle%3DA%2520Green%2520and%2520Sustainable%2520Approach%2520for%2520Selective%2520Halogenation%2520of%2520Anilides%252C%2520Benzanilides%252C%2520Sulphonamides%2520and%2520Heterocycles%26jtitle%3DAsian%2520J.%2520Org.%2520Chem.%26date%3D2019%26volume%3D8%26spage%3D1380%26epage%3D1384%26doi%3D10.1002%2Fajoc.201900296" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannecouque, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span> <span> </span><span class="NLM_article-title">Arylazolylthioacetanilide. Part 8: Design, Synthesis and Biological Evaluation of Novel 2-(2-(2,4-Dichlorophenyl)-2H-1,2,4-Triazol-3-Ylthio)-N-Arylacetamides as Potent HIV-1 Inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">5039</span>– <span class="NLM_lpage">5045</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2011.08.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1016%2Fj.ejmech.2011.08.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=21872971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1amt7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2011&pages=5039-5045&author=P.+Zhanauthor=X.+Chenauthor=X.+Liauthor=D.+Liauthor=Y.+Tianauthor=W.+Chenauthor=C.+Pannecouqueauthor=E.+De+Clercqauthor=X.+Liu&title=Arylazolylthioacetanilide.+Part+8%3A+Design%2C+Synthesis+and+Biological+Evaluation+of+Novel+2-%282-%282%2C4-Dichlorophenyl%29-2H-1%2C2%2C4-Triazol-3-Ylthio%29-N-Arylacetamides+as+Potent+HIV-1+Inhibitors&doi=10.1016%2Fj.ejmech.2011.08.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of Novel 2-(2-(2,4-Dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides As Potent HIV-1 inhibitors</span></div><div class="casAuthors">Zhan, Peng; Chen, Xu-Wang; Li, Xiao; Li, Dong-Yue; Tian, Ye; Chen, Wen-Wen; Pannecouque, Christophe; De Clercq, Erik; Liu, Xin-Yong</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5039-5045</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The development of novel HIV-1 NNRTIs offers the possibility of generating novel structures with increased potency.  Based on the bioisosteric principle, a novel series of 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamide derivs., e.g., I, were designed, synthesized using a simple and efficient synthetic route, structurally confirmed by spectral anal., evaluated for their anti-HIV activity in MT-4 cells and their inhibitory effect on HIV-1 RT.  The results showed that some of the new compds. displayed low micromolar potency for inhibiting HIV-1 replication and promising activities against several selected resistant strains that confer resistance to current NNRTIs.  However, all newly synthesized derivs. were not active against HIV-2 replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpP0yww0QTfUrVg90H21EOLACvtfcHk0ljsKA3aMPdxwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1amt7rF&md5=35ac87ec7d91d1853041e3a4069c6226</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2011.08.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2011.08.011%26sid%3Dliteratum%253Aachs%26aulast%3DZhan%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DTian%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DPannecouque%26aufirst%3DC.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DX.%26atitle%3DArylazolylthioacetanilide.%2520Part%25208%253A%2520Design%252C%2520Synthesis%2520and%2520Biological%2520Evaluation%2520of%2520Novel%25202-%25282-%25282%252C4-Dichlorophenyl%2529-2H-1%252C2%252C4-Triazol-3-Ylthio%2529-N-Arylacetamides%2520as%2520Potent%2520HIV-1%2520Inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2011%26volume%3D46%26spage%3D5039%26epage%3D5045%26doi%3D10.1016%2Fj.ejmech.2011.08.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span>; <span class="NLM_string-name">Yohi, P. W.</span>; <span class="NLM_string-name">Michael, X.</span>; <span class="NLM_string-name">Cruise, D.</span></span> <span> </span><span class="NLM_article-title">Synthesis of PARP Inhibitor Talazoparb</span>. U.S. Patent <span class="NLM_patent">US 9,708,319 B1</span>, July 18, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=Y.+Xu&author=P.+W.+Yohi&author=X.+Michael&author=D.+Cruise&title=Synthesis+of+PARP+Inhibitor+Talazoparb"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DY.%26atitle%3DSynthesis%2520of%2520PARP%2520Inhibitor%2520Talazoparb%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blaquiere, N.</span>; <span class="NLM_string-name">Do, S.</span>; <span class="NLM_string-name">Dudley, D.</span>; <span class="NLM_string-name">Fokes, A. J.</span>; <span class="NLM_string-name">Heald, R.</span>; <span class="NLM_string-name">Heffron, T.</span>; <span class="NLM_string-name">Jones, M.</span>; <span class="NLM_string-name">Kolesnikov, A.</span>; <span class="NLM_string-name">Ndubaku, C.</span>; <span class="NLM_string-name">Olivero, A. G.</span>; <span class="NLM_string-name">Price, S.</span>; <span class="NLM_string-name">Staben, S.</span>; <span class="NLM_string-name">Wang, L.</span></span> <span> </span><span class="NLM_article-title">Benzoxazepin PI3K Inhibitor Compounds and Methods of Use</span>. <span class="NLM_patent">WO 2011036280 A1</span>, March 6, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=N.+Blaquiere&author=S.+Do&author=D.+Dudley&author=A.+J.+Fokes&author=R.+Heald&author=T.+Heffron&author=M.+Jones&author=A.+Kolesnikov&author=C.+Ndubaku&author=A.+G.+Olivero&author=S.+Price&author=S.+Staben&author=L.+Wang&title=Benzoxazepin+PI3K+Inhibitor+Compounds+and+Methods+of+Use"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBlaquiere%26aufirst%3DN.%26atitle%3DBenzoxazepin%2520PI3K%2520Inhibitor%2520Compounds%2520and%2520Methods%2520of%2520Use%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srikannathasan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fosberry, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hann, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hibbs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Homes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingraham, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizzollo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shillings, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitsfaden, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiobald, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stavenger, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bax, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gwynn, M. N.</span></span> <span> </span><span class="NLM_article-title">Structural Basis of DNA Gyrase Inhibition by Antibacterial QPT-1, Anticancer Drug Etoposide and Moxifloxacin</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">10048</span>, <span class="refDoi"> DOI: 10.1038/ncomms10048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1038%2Fncomms10048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=26640131" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFyks7jL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=10048&author=P.+F.+Chanauthor=V.+Srikannathasanauthor=J.+Huangauthor=H.+Cuiauthor=A.+P.+Fosberryauthor=M.+Guauthor=M.+M.+Hannauthor=M.+Hibbsauthor=P.+Homesauthor=K.+Ingrahamauthor=J.+Pizzolloauthor=C.+Shenauthor=A.+J.+Shillingsauthor=C.+E.+Spitsfadenauthor=R.+Tannerauthor=A.+J.+Thiobaldauthor=R.+A.+Stavengerauthor=B.+D.+Baxauthor=M.+N.+Gwynn&title=Structural+Basis+of+DNA+Gyrase+Inhibition+by+Antibacterial+QPT-1%2C+Anticancer+Drug+Etoposide+and+Moxifloxacin&doi=10.1038%2Fncomms10048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis of DNA gyrase inhibition by antibacterial QPT-1, anticancer drug etoposide and moxifloxacin</span></div><div class="casAuthors">Chan, Pan F.; Srikannathasan, Velupillai; Huang, Jianzhong; Cui, Haifeng; Fosberry, Andrew P.; Gu, Minghua; Hann, Michael M.; Hibbs, Martin; Homes, Paul; Ingraham, Karen; Pizzollo, Jason; Shen, Carol; Shillings, Anthony J.; Spitzfaden, Claus E.; Tanner, Robert; Theobald, Andrew J.; Stavenger, Robert A.; Bax, Benjamin D.; Gwynn, Michael N.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10048</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">New antibacterials are needed to tackle antibiotic-resistant bacteria.  Type IIA topoisomerases (topo2As), the targets of fluoroquinolones, regulate DNA topol. by creating transient double-strand DNA breaks.  Here we report the first co-crystal structures of the antibacterial QPT-1 and the anticancer drug etoposide with Staphylococcus aureus DNA gyrase, showing binding at the same sites in the cleaved DNA as the fluoroquinolone moxifloxacin.  Unlike moxifloxacin, QPT-1 and etoposide interact with conserved GyrB TOPRIM residues rationalizing why QPT-1 can overcome fluoroquinolone resistance.  Our data show etoposide's antibacterial activity is due to DNA gyrase inhibition and suggests other anticancer agents act similarly.  Anal. of multiple DNA gyrase co-crystal structures, including asym. cleavage complexes, led to a 'pair of swing-doors' hypothesis in which the movement of one DNA segment regulates cleavage and religation of the second DNA duplex.  This mechanism can explain QPT-1's bacterial specificity.  Structure-based strategies for developing topo2A antibacterials are suggested.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoY_mF0ShDkkbVg90H21EOLACvtfcHk0lgb3OM43O4K6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFyks7jL&md5=1e358e6e0e9454967cf2aa2e01a0306b</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fncomms10048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms10048%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DP.%2BF.%26aulast%3DSrikannathasan%26aufirst%3DV.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DCui%26aufirst%3DH.%26aulast%3DFosberry%26aufirst%3DA.%2BP.%26aulast%3DGu%26aufirst%3DM.%26aulast%3DHann%26aufirst%3DM.%2BM.%26aulast%3DHibbs%26aufirst%3DM.%26aulast%3DHomes%26aufirst%3DP.%26aulast%3DIngraham%26aufirst%3DK.%26aulast%3DPizzollo%26aufirst%3DJ.%26aulast%3DShen%26aufirst%3DC.%26aulast%3DShillings%26aufirst%3DA.%2BJ.%26aulast%3DSpitsfaden%26aufirst%3DC.%2BE.%26aulast%3DTanner%26aufirst%3DR.%26aulast%3DThiobald%26aufirst%3DA.%2BJ.%26aulast%3DStavenger%26aufirst%3DR.%2BA.%26aulast%3DBax%26aufirst%3DB.%2BD.%26aulast%3DGwynn%26aufirst%3DM.%2BN.%26atitle%3DStructural%2520Basis%2520of%2520DNA%2520Gyrase%2520Inhibition%2520by%2520Antibacterial%2520QPT-1%252C%2520Anticancer%2520Drug%2520Etoposide%2520and%2520Moxifloxacin%26jtitle%3DNat.%2520Commun.%26date%3D2015%26volume%3D6%26spage%3D10048%26doi%3D10.1038%2Fncomms10048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laponogov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, X.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veselkov, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAuley, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanderson, M. R.</span></span> <span> </span><span class="NLM_article-title">Structural Basis of Gate-DNA Breakage and Resealing by Type II Topoisomerases</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">e11338</span>, <span class="refDoi"> DOI: 10.1371/annotation/deacc2fd-665b-4736-b668-dc69a38bb4f9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1371%2Fjournal.pone.0011338" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=20596531" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A280%3ADC%252BC3cnksVagsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=e11338&author=I.+Laponogovauthor=X.-S.+Panauthor=D.+A.+Veselkovauthor=K.+E.+McAuleyauthor=L.+M.+Fisherauthor=M.+R.+Sanderson&title=Structural+Basis+of+Gate-DNA+Breakage+and+Resealing+by+Type+II+Topoisomerases&doi=10.1371%2Fannotation%2Fdeacc2fd-665b-4736-b668-dc69a38bb4f9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis of gate-DNA breakage and resealing by type II topoisomerases</span></div><div class="casAuthors">Laponogov Ivan; Pan Xiao-Su; Veselkov Dennis A; McAuley Katherine E; Fisher L Mark; Sanderson Mark R</div><div class="citationInfo"><span class="NLM_cas:title">PloS one</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e11338</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Type II DNA topoisomerases are ubiquitous enzymes with essential functions in DNA replication, recombination and transcription.  They change DNA topology by forming a transient covalent cleavage complex with a gate-DNA duplex that allows transport of a second duplex though the gate.  Despite its biological importance and targeting by anticancer and antibacterial drugs, cleavage complex formation and reversal is not understood for any type II enzyme.  To address the mechanism, we have used X-ray crystallography to study sequential states in the formation and reversal of a DNA cleavage complex by topoisomerase IV from Streptococcus pneumoniae, the bacterial type II enzyme involved in chromosome segregation.  A high resolution structure of the complex captured by a novel antibacterial dione reveals two drug molecules intercalated at a cleaved B-form DNA gate and anchored by drug-specific protein contacts.  Dione release generated drug-free cleaved and resealed DNA complexes in which the DNA gate instead adopts an unusual A/B-form helical conformation with a Mg(2+) ion repositioned to coordinate each scissile phosphodiester group and promote reversible cleavage by active-site tyrosines.  These structures, the first for putative reaction intermediates of a type II topoisomerase, suggest how a type II enzyme reseals DNA during its normal reaction cycle and illuminate aspects of drug arrest important for the development of new topoisomerase-targeting therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcShiG7Hb50Ehd0Q2ypr7jHkfW6udTcc2eaJuWELVHMuGrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cnksVagsA%253D%253D&md5=fcddd6c8ad69c0bc09137d484aad638d</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0011338&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0011338%26sid%3Dliteratum%253Aachs%26aulast%3DLaponogov%26aufirst%3DI.%26aulast%3DPan%26aufirst%3DX.-S.%26aulast%3DVeselkov%26aufirst%3DD.%2BA.%26aulast%3DMcAuley%26aufirst%3DK.%2BE.%26aulast%3DFisher%26aufirst%3DL.%2BM.%26aulast%3DSanderson%26aufirst%3DM.%2BR.%26atitle%3DStructural%2520Basis%2520of%2520Gate-DNA%2520Breakage%2520and%2520Resealing%2520by%2520Type%2520II%2520Topoisomerases%26jtitle%3DPLoS%2520One%26date%3D2010%26volume%3D5%26spage%3De11338%26doi%3D10.1371%2Fannotation%2Fdeacc2fd-665b-4736-b668-dc69a38bb4f9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laponogov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sohi, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veselkov, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, X.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawhney, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAuley, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanderson, M. R.</span></span> <span> </span><span class="NLM_article-title">Structural Insight into the Quinolone-DNA Cleavage Complex of Type IIA Topoisomerases</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">667</span>– <span class="NLM_lpage">669</span>, <span class="refDoi"> DOI: 10.1038/nsmb.1604</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1038%2Fnsmb.1604" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=19448616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtVOqsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=667-669&author=I.+Laponogovauthor=M.+K.+Sohiauthor=D.+A.+Veselkovauthor=X.-S.+Panauthor=R.+Sawhneyauthor=A.+W.+Thompsonauthor=K.+E.+McAuleyauthor=L.+M.+Fisherauthor=M.+R.+Sanderson&title=Structural+Insight+into+the+Quinolone-DNA+Cleavage+Complex+of+Type+IIA+Topoisomerases&doi=10.1038%2Fnsmb.1604"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases</span></div><div class="casAuthors">Laponogov, Ivan; Sohi, Maninder K.; Veselkov, Dennis A.; Pan, Xiao-Su; Sawhney, Ritica; Thompson, Andrew W.; McAuley, Katherine E.; Fisher, L. Mark; Sanderson, Mark R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">667-669</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Type II topoisomerases alter DNA topol. by forming a covalent DNA-cleavage complex that allows DNA transport through a double-stranded DNA break.  We present the structures of cleavage complexes formed by the Streptococcus pneumoniae ParC breakage-reunion and ParE TOPRIM domains of topoisomerase IV stabilized by moxifloxacin and clinafloxacin, two antipneumococcal fluoroquinolones.  These structures reveal two drug mols. intercalated at the highly bent DNA gate and help explain antibacterial quinolone action and resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDXhjTPq1GlrVg90H21EOLACvtfcHk0ljBoZAiX4Uf_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtVOqsrc%253D&md5=cd4c757dbb5d50c8113e658837d44a34</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.1604&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.1604%26sid%3Dliteratum%253Aachs%26aulast%3DLaponogov%26aufirst%3DI.%26aulast%3DSohi%26aufirst%3DM.%2BK.%26aulast%3DVeselkov%26aufirst%3DD.%2BA.%26aulast%3DPan%26aufirst%3DX.-S.%26aulast%3DSawhney%26aufirst%3DR.%26aulast%3DThompson%26aufirst%3DA.%2BW.%26aulast%3DMcAuley%26aufirst%3DK.%2BE.%26aulast%3DFisher%26aufirst%3DL.%2BM.%26aulast%3DSanderson%26aufirst%3DM.%2BR.%26atitle%3DStructural%2520Insight%2520into%2520the%2520Quinolone-DNA%2520Cleavage%2520Complex%2520of%2520Type%2520IIA%2520Topoisomerases%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2009%26volume%3D16%26spage%3D667%26epage%3D669%26doi%3D10.1038%2Fnsmb.1604" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blower, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williamson, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerns, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, J. M.</span></span> <span> </span><span class="NLM_article-title">Crystal Structure and Stability of Gyrase-Fluoroquinolone Cleaved Complexes from Mycobacterium Tuberculosis</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">1706</span>– <span class="NLM_lpage">1713</span>, <span class="refDoi"> DOI: 10.1073/pnas.1525047113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1073%2Fpnas.1525047113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=26792525" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFWjsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2016&pages=1706-1713&author=T.+R.+Blowerauthor=B.+H.+Williamsonauthor=R.+J.+Kernsauthor=J.+M.+Berger&title=Crystal+Structure+and+Stability+of+Gyrase-Fluoroquinolone+Cleaved+Complexes+from+Mycobacterium+Tuberculosis&doi=10.1073%2Fpnas.1525047113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure and stability of gyrase-fluoroquinolone cleaved complexes from Mycobacterium tuberculosis</span></div><div class="casAuthors">Blower, Tim R.; Williamson, Benjamin H.; Kerns, Robert J.; Berger, James M.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1706-1713</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Mycobacterium tuberculosis (Mtb) infects one-third of the world's population and in 2013 accounted for 1.5 million deaths.  Fluoroquinolone antibacterials, which target DNA gyrase, are crit. agents used to halt the progression from multidrug-resistant tuberculosis to extensively resistant disease; however, fluoroquinolone resistance is emerging and new ways to bypass resistance are required.  To better explain known differences in fluoroquinolone action, the crystal structures of the WT Mtb DNA gyrase cleavage core and a fluoroquinolone-sensitized mutant were detd. in complex with DNA and five fluoroquinolones.  The structures, ranging from 2.4- to 2.6-Å resoln., show that the intrinsically low susceptibility of Mtb to fluoroquinolones correlates with a redn. in contacts to the water shell of an assocd. magnesium ion, which bridges fluoroquinolone-gyrase interactions.  Surprisingly, the structural data revealed few differences in fluoroquinolone-enzyme contacts from drugs that have very different activities against Mtb.  By contrast, a stability assay using purified components showed a clear relationship between ternary complex reversibility and inhibitory activities reported with cultured cells.  Collectively, our data indicate that the stability of fluoroquinolone/DNA interactions is a major determinant of fluoroquinolone activity and that moieties that have been appended to the C7 position of different quinolone scaffolds do not take advantage of specific contacts that might be made with the enzyme.  These concepts point to new approaches for developing quinolone-class compds. that have increased potency against Mtb and the ability to overcome resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotyAfeeRgSebVg90H21EOLACvtfcHk0ljBoZAiX4Uf_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFWjsr8%253D&md5=bde8e79ead3566a890d7e970de8c3292</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1525047113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1525047113%26sid%3Dliteratum%253Aachs%26aulast%3DBlower%26aufirst%3DT.%2BR.%26aulast%3DWilliamson%26aufirst%3DB.%2BH.%26aulast%3DKerns%26aufirst%3DR.%2BJ.%26aulast%3DBerger%26aufirst%3DJ.%2BM.%26atitle%3DCrystal%2520Structure%2520and%2520Stability%2520of%2520Gyrase-Fluoroquinolone%2520Cleaved%2520Complexes%2520from%2520Mycobacterium%2520Tuberculosis%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2016%26volume%3D113%26spage%3D1706%26epage%3D1713%26doi%3D10.1073%2Fpnas.1525047113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahic, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thresher, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hajec, L.</span></span> <span> </span><span class="NLM_article-title">A Homogeneous, High-Throughput Fluorescence Anisotropy-Based DNA Supercoiling Assay</span>. <i>J. Biomol. Screen.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1088</span>– <span class="NLM_lpage">1098</span>, <span class="refDoi"> DOI: 10.1177/1087057110378624</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1177%2F1087057110378624" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=20930214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVajsLrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2010&pages=1088-1098&author=A.+Shapiroauthor=H.+Jahicauthor=S.+Prasadauthor=D.+Ehmannauthor=J.+Thresherauthor=N.+Gaoauthor=L.+Hajec&title=A+Homogeneous%2C+High-Throughput+Fluorescence+Anisotropy-Based+DNA+Supercoiling+Assay&doi=10.1177%2F1087057110378624"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">A homogeneous, high-throughput fluorescence anisotropy-based DNA supercoiling assay</span></div><div class="casAuthors">Shapiro, Adam; Jahic, Haris; Prasad, Swati; Ehmann, David; Thresher, Jason; Gao, Ning; Hajec, Laurel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Screening</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1088-1098</span>CODEN:
                <span class="NLM_cas:coden">JBISF3</span>;
        ISSN:<span class="NLM_cas:issn">1087-0571</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">The degree of supercoiling of DNA is vital for cellular processes, such as replication and transcription.  DNA topol. is controlled by the action of DNA topoisomerase enzymes.  Topoisomerases, because of their importance in cellular replication, are the targets of several anticancer and antibacterial drugs.  In the search for new drugs targeting topoisomerases, a biochem. assay compatible with automated high-throughput screening (HTS) would be valuable.  Gel electrophoresis is the std. method for measuring changes in the extent of supercoiling of plasmid DNA when acted upon by topoisomerases, but this is a low-throughput and laborious method.  A medium-throughput method was described previously that quant. distinguishes relaxed and supercoiled plasmids by the difference in their abilities to form triplex structures with an immobilized oligonucleotide.  In this article, the authors describe a homogeneous supercoiling assay based on triplex formation in which the oligonucleotide strand is labeled with a fluorescent dye and the readout is fluorescence anisotropy.  The new assay requires no immobilization, filtration, or plate washing steps and is therefore well suited to HTS for inhibitors of topoisomerases.  The utility of this assay is demonstrated with relaxation of supercoiled plasmid by Escherichia coli topoisomerase I, supercoiling of relaxed plasmid by E. coli DNA gyrase, and inhibition of gyrase by fluoroquinolones and nalidixic acid.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLPydgbbQi2bVg90H21EOLACvtfcHk0ljBoZAiX4Uf_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVajsLrN&md5=51191c534eaf19b3e198866d0c68e14a</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1177%2F1087057110378624&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057110378624%26sid%3Dliteratum%253Aachs%26aulast%3DShapiro%26aufirst%3DA.%26aulast%3DJahic%26aufirst%3DH.%26aulast%3DPrasad%26aufirst%3DS.%26aulast%3DEhmann%26aufirst%3DD.%26aulast%3DThresher%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DN.%26aulast%3DHajec%26aufirst%3DL.%26atitle%3DA%2520Homogeneous%252C%2520High-Throughput%2520Fluorescence%2520Anisotropy-Based%2520DNA%2520Supercoiling%2520Assay%26jtitle%3DJ.%2520Biomol.%2520Screen.%26date%3D2010%26volume%3D15%26spage%3D1088%26epage%3D1098%26doi%3D10.1177%2F1087057110378624" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lahiri, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutschke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormack, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alm, R. A.</span></span> <span> </span><span class="NLM_article-title">Insights into the Mechanism of Inhibition of Novel Bacteria Topoisomerase Inhibitors from Characterization of Resistant Mutants of Staphylococcus Aureus</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">5278</span>– <span class="NLM_lpage">5287</span>, <span class="refDoi"> DOI: 10.1128/aac.00571-15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1128%2FAAC.00571-15" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=26077256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlyitrfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=5278-5287&author=S.+D.+Lahiriauthor=A.+Kutschkeauthor=K.+McCormackauthor=R.+A.+Alm&title=Insights+into+the+Mechanism+of+Inhibition+of+Novel+Bacteria+Topoisomerase+Inhibitors+from+Characterization+of+Resistant+Mutants+of+Staphylococcus+Aureus&doi=10.1128%2Faac.00571-15"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into the mechanism of inhibition of novel bacterial topoisomerase inhibitors from characterization of resistant mutants of Staphylococcus aureus</span></div><div class="casAuthors">Lahiri, Sushmita D.; Kutschke, Amy; McCormack, Kathy; Alm, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">5278-5287</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The type II topoisomerases DNA gyrase and topoisomerase IV are clin. validated bacterial targets that catalyze the modulation of DNA topol. that is vital to DNA replication, repair, and decatenation.  Increasing resistance to fluoroquinolones, which trap the topoisomerase-DNA complex, has led to significant efforts in the discovery of novel inhibitors of these targets.  AZ6142 is a member of the class of novel bacterial topoisomerase inhibitors (NBTIs) that utilizes a distinct mechanism to trap the protein- DNA complex.  AZ6142 has very potent activity against Gram-pos. organisms, including Staphylococcus aureus, Streptococcus pneumoniae, and Streptococcus pyogenes.  In this study, we detd. the frequencies of resistance to AZ6142 and other representative NBTI compds. in S. aureus and S. pneumoniae.  The frequencies of selection of resistant mutants at 4× the MIC were 1.7 × 10-8 for S. aureus and <5.5 × 10-10 for S. pneumoniae.  To improve our understanding of the NBTI mechanism of inhibition, the resistant S. aureus mutants were characterized and 20 unique substitutions in the topoisomerase subunits were identified.  Many of these substitutions were located outside the NBTI binding pocket and impact the susceptibility of AZ6142, resulting in a 4- to 32-fold elevation in the MIC over the wild-type parent strain.  Data on cross-resistance with other NBTIs and fluoroquinolones enabled the differentiation of scaffold-specific changes from compd.-specific variations.  Our results suggest that AZ6142 inhibits both type II topoisomerases in S. aureus but that DNA gyrase is the primary target.  Further, the genotype of the resistant mutants suggests that domain conformations and DNA interactions may uniquely impact NBTIs compared to fluoroquinolones.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoh17EyyLZqWLVg90H21EOLACvtfcHk0ljBoZAiX4Uf_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlyitrfF&md5=ed718068b6189445b6161bf3811af97a</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1128%2FAAC.00571-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00571-15%26sid%3Dliteratum%253Aachs%26aulast%3DLahiri%26aufirst%3DS.%2BD.%26aulast%3DKutschke%26aufirst%3DA.%26aulast%3DMcCormack%26aufirst%3DK.%26aulast%3DAlm%26aufirst%3DR.%2BA.%26atitle%3DInsights%2520into%2520the%2520Mechanism%2520of%2520Inhibition%2520of%2520Novel%2520Bacteria%2520Topoisomerase%2520Inhibitors%2520from%2520Characterization%2520of%2520Resistant%2520Mutants%2520of%2520Staphylococcus%2520Aureus%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2015%26volume%3D59%26spage%3D5278%26epage%3D5287%26doi%3D10.1128%2Faac.00571-15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acree, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aliev, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leo, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whaley, W. L.</span></span> <span> </span><span class="NLM_article-title">An NMR Method for the Quantitative Assessment of Intramolecular Hydrogen Bonding; Application to Physicochemical, Environmental, and Biochemical Properties</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">11075</span>– <span class="NLM_lpage">11083</span>, <span class="refDoi"> DOI: 10.1021/jo502080p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo502080p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVensLrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2014&pages=11075-11083&author=M.+H.+Abrahamauthor=R.+J.+Abrahamauthor=W.+E.+Acreeauthor=A.+E.+Alievauthor=A.+J.+Leoauthor=W.+L.+Whaley&title=An+NMR+Method+for+the+Quantitative+Assessment+of+Intramolecular+Hydrogen+Bonding%3B+Application+to+Physicochemical%2C+Environmental%2C+and+Biochemical+Properties&doi=10.1021%2Fjo502080p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">An NMR Method for the Quantitative Assessment of Intramolecular Hydrogen Bonding; Application to Physicochemical, Environmental, and Biochemical Properties</span></div><div class="casAuthors">Abraham, Michael H.; Abraham, Raymond J.; Acree, William E.; Aliev, Abil E.; Leo, Al J.; Whaley, William L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">11075-11083</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">1H NMR chem. shifts have been obtained in the solvents deuterochloroform and DMSO.  The difference in the chem. shifts of an OH or NH group in these two solvents, Δδ = δ(DMSO) - δ(CDCl3), can be converted into the hydrogen bond acidity, A, of the group using the equation A = 0.0065 + 0.133Δδ.  The NMR A value, ANMR, can be used as a quant. assessment of intramol. hydrogen bonding.  We list values of Δδ and ANMR for 55 compds. contg. an OH group and 60 compds. with an NH group.  For the hydroxy compds., if A > 0.5 then the OH group is not part of an intramol. hydrogen bond, but if A < 0.1 then the OH group forms part of an intramol. hydrogen bond.  For NH compds., if A > 0.16 the NH group is not part of an intramol. hydrogen bond, and if A < 0.05 the NH group is part of an intramol. hydrogen bond.  No comparison compds. are needed, and the method is extremely simple.  We further show how it is possible to relate intramol. hydrogen bonding to the actual effect on values of a no. of physicochem., environmental, and biochem. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpS3GZXQi7robVg90H21EOLACvtfcHk0ljHCk93bhPFGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVensLrM&md5=b5e9948a04237fadb3b4fc3237bde8b1</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjo502080p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo502080p%26sid%3Dliteratum%253Aachs%26aulast%3DAbraham%26aufirst%3DM.%2BH.%26aulast%3DAbraham%26aufirst%3DR.%2BJ.%26aulast%3DAcree%26aufirst%3DW.%2BE.%26aulast%3DAliev%26aufirst%3DA.%2BE.%26aulast%3DLeo%26aufirst%3DA.%2BJ.%26aulast%3DWhaley%26aufirst%3DW.%2BL.%26atitle%3DAn%2520NMR%2520Method%2520for%2520the%2520Quantitative%2520Assessment%2520of%2520Intramolecular%2520Hydrogen%2520Bonding%253B%2520Application%2520to%2520Physicochemical%252C%2520Environmental%252C%2520and%2520Biochemical%2520Properties%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2014%26volume%3D79%26spage%3D11075%26epage%3D11083%26doi%3D10.1021%2Fjo502080p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alm, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lahiri, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutschke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otterson, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whiteaker, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huband, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, J. P.</span></span> <span> </span><span class="NLM_article-title">Characterization of the Novel DNA Gyrase Inhibitor AZD0914: Low Resistance Potential and Lack of Cross-Resistance in Neisseria Gonorrhoeae</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1478</span>– <span class="NLM_lpage">1486</span>, <span class="refDoi"> DOI: 10.1128/aac.04456-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1128%2FAAC.04456-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=25534723" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtFajtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=1478-1486&author=R.+A.+Almauthor=S.+D.+Lahiriauthor=A.+Kutschkeauthor=L.+G.+Ottersonauthor=R.+E.+McLaughlinauthor=J.+D.+Whiteakerauthor=L.+A.+Lewisauthor=X.+Suauthor=M.+D.+Hubandauthor=H.+Gardnerauthor=J.+P.+Mueller&title=Characterization+of+the+Novel+DNA+Gyrase+Inhibitor+AZD0914%3A+Low+Resistance+Potential+and+Lack+of+Cross-Resistance+in+Neisseria+Gonorrhoeae&doi=10.1128%2Faac.04456-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the novel DNA gyrase inhibitor AZD0914: low resistance potential and lack of cross-resistance in Neisseria gonorrhoeae</span></div><div class="casAuthors">Alm, Richard A.; Lahiri, Sushmita D.; Kutschke, Amy; Otterson, Linda G.; McLaughlin, Robert E.; Whiteaker, James D.; Lewis, Lisa A.; Su, Xiaohong; Huband, Michael D.; Gardner, Humphrey; Mueller, John P.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1478-1486</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The unmet medical need for novel intervention strategies to treat Neisseria gonorrhoeae infections is significant and increasing, as rapidly emerging resistance in this pathogen is threatening to eliminate the currently available treatment options.  AZD0914 is a novel bacterial gyrase inhibitor that possesses potent in vitro activities against isolates with high-level resistance to ciprofloxacin and extended-spectrum cephalosporins, and it is currently in clin. development for the treatment of N. gonorrhoeae infections.  The propensity to develop resistance against AZD0914 was examd. in N. gonorrhoeae and found to be extremely low, a finding supported by similar studies with Staphylococcus aureus.  The genetic characterization of both first-step and second-step mutants that exhibited decreased susceptibilities to AZD0914 identified substitutions in the conserved GyrB TOPRIM domain, confirming DNA gyrase as the primary target of AZD0914 and providing differentiation from fluoroquinolones.  The anal. of available bacterial gyrase and topoisomerase IV structures, including those bound to fluoroquinolone and nonfluoroquinolone inhibitors, has allowed the rationalization of the lack of cross-resistance that AZD0914 shares with fluoroquinolones.  Microbiol. susceptibility data also indicate that the topoisomerase inhibition mechanisms are subtly different between N. gonorrhoeae and other bacterial species.  Taken together, these data support the progression of AZD0914 as a novel treatment option for the oral treatment of N. gonorrhoeae infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmr5nuUGnvorVg90H21EOLACvtfcHk0ljHCk93bhPFGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtFajtrs%253D&md5=6d6f73ded98cf4895bb1019f8de28681</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1128%2FAAC.04456-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.04456-14%26sid%3Dliteratum%253Aachs%26aulast%3DAlm%26aufirst%3DR.%2BA.%26aulast%3DLahiri%26aufirst%3DS.%2BD.%26aulast%3DKutschke%26aufirst%3DA.%26aulast%3DOtterson%26aufirst%3DL.%2BG.%26aulast%3DMcLaughlin%26aufirst%3DR.%2BE.%26aulast%3DWhiteaker%26aufirst%3DJ.%2BD.%26aulast%3DLewis%26aufirst%3DL.%2BA.%26aulast%3DSu%26aufirst%3DX.%26aulast%3DHuband%26aufirst%3DM.%2BD.%26aulast%3DGardner%26aufirst%3DH.%26aulast%3DMueller%26aufirst%3DJ.%2BP.%26atitle%3DCharacterization%2520of%2520the%2520Novel%2520DNA%2520Gyrase%2520Inhibitor%2520AZD0914%253A%2520Low%2520Resistance%2520Potential%2520and%2520Lack%2520of%2520Cross-Resistance%2520in%2520Neisseria%2520Gonorrhoeae%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2015%26volume%3D59%26spage%3D1478%26epage%3D1486%26doi%3D10.1128%2Faac.04456-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bax, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eggleston, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fosberry, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gentry, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorrec, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordano, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hann, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennessy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hibbs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">May, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitzfaden, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shillings, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theobald, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wohlkonig, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gwynn, M. N.</span></span> <span> </span><span class="NLM_article-title">Type IIA Topoisomerase Inhibition by a New Class of Antibacterial Agents</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>466</i></span>,  <span class="NLM_fpage">935</span>– <span class="NLM_lpage">940</span>, <span class="refDoi"> DOI: 10.1038/nature09197</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1038%2Fnature09197" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=20686482" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A280%3ADC%252BC3cjmtFaktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=466&publication_year=2010&pages=935-940&author=B.+D.+Baxauthor=P.+F.+Chanauthor=D.+S.+Egglestonauthor=A.+Fosberryauthor=D.+R.+Gentryauthor=F.+Gorrecauthor=I.+Giordanoauthor=M.+M.+Hannauthor=A.+Hennessyauthor=M.+Hibbsauthor=J.+Huangauthor=E.+Jonesauthor=J.+Jonesauthor=K.+K.+Brownauthor=C.+J.+Lewisauthor=E.+W.+Mayauthor=M.+R.+Saundersauthor=O.+Singhauthor=C.+E.+Spitzfadenauthor=C.+Shenauthor=A.+Shillingsauthor=A.+J.+Theobaldauthor=A.+Wohlkonigauthor=N.+D.+Pearsonauthor=M.+N.+Gwynn&title=Type+IIA+Topoisomerase+Inhibition+by+a+New+Class+of+Antibacterial+Agents&doi=10.1038%2Fnature09197"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Type IIA topoisomerase inhibition by a new class of antibacterial agents</span></div><div class="casAuthors">Bax Benjamin D; Chan Pan F; Eggleston Drake S; Fosberry Andrew; Gentry Daniel R; Gorrec Fabrice; Giordano Ilaria; Hann Michael M; Hennessy Alan; Hibbs Martin; Huang Jianzhong; Jones Emma; Jones Jo; Brown Kristin Koretke; Lewis Ceri J; May Earl W; Saunders Martin R; Singh Onkar; Spitzfaden Claus E; Shen Carol; Shillings Anthony; Theobald Andrew J; Wohlkonig Alexandre; Pearson Neil D; Gwynn Michael N</div><div class="citationInfo"><span class="NLM_cas:title">Nature</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">466</span>
        (<span class="NLM_cas:issue">7309</span>),
    <span class="NLM_cas:pages">935-40</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Despite the success of genomics in identifying new essential bacterial genes, there is a lack of sustainable leads in antibacterial drug discovery to address increasing multidrug resistance.  Type IIA topoisomerases cleave and religate DNA to regulate DNA topology and are a major class of antibacterial and anticancer drug targets, yet there is no well developed structural basis for understanding drug action.  Here we report the 2.1 A crystal structure of a potent, new class, broad-spectrum antibacterial agent in complex with Staphylococcus aureus DNA gyrase and DNA, showing a new mode of inhibition that circumvents fluoroquinolone resistance in this clinically important drug target.  The inhibitor 'bridges' the DNA and a transient non-catalytic pocket on the two-fold axis at the GyrA dimer interface, and is close to the active sites and fluoroquinolone binding sites.  In the inhibitor complex the active site seems poised to cleave the DNA, with a single metal ion observed between the TOPRIM (topoisomerase/primase) domain and the scissile phosphate.  This work provides new insights into the mechanism of topoisomerase action and a platform for structure-based drug design of a new class of antibacterial agents against a clinically proven, but conformationally flexible, enzyme class.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTzBPk2FYUX-kBuFdjgVNKSfW6udTcc2ebWk3KDcX2TS7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cjmtFaktA%253D%253D&md5=006fef200c7a44f0671829b2a5fbddef</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fnature09197&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09197%26sid%3Dliteratum%253Aachs%26aulast%3DBax%26aufirst%3DB.%2BD.%26aulast%3DChan%26aufirst%3DP.%2BF.%26aulast%3DEggleston%26aufirst%3DD.%2BS.%26aulast%3DFosberry%26aufirst%3DA.%26aulast%3DGentry%26aufirst%3DD.%2BR.%26aulast%3DGorrec%26aufirst%3DF.%26aulast%3DGiordano%26aufirst%3DI.%26aulast%3DHann%26aufirst%3DM.%2BM.%26aulast%3DHennessy%26aufirst%3DA.%26aulast%3DHibbs%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DJones%26aufirst%3DE.%26aulast%3DJones%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DK.%2BK.%26aulast%3DLewis%26aufirst%3DC.%2BJ.%26aulast%3DMay%26aufirst%3DE.%2BW.%26aulast%3DSaunders%26aufirst%3DM.%2BR.%26aulast%3DSingh%26aufirst%3DO.%26aulast%3DSpitzfaden%26aufirst%3DC.%2BE.%26aulast%3DShen%26aufirst%3DC.%26aulast%3DShillings%26aufirst%3DA.%26aulast%3DTheobald%26aufirst%3DA.%2BJ.%26aulast%3DWohlkonig%26aufirst%3DA.%26aulast%3DPearson%26aufirst%3DN.%2BD.%26aulast%3DGwynn%26aufirst%3DM.%2BN.%26atitle%3DType%2520IIA%2520Topoisomerase%2520Inhibition%2520by%2520a%2520New%2520Class%2520of%2520Antibacterial%2520Agents%26jtitle%3DNature%26date%3D2010%26volume%3D466%26spage%3D935%26epage%3D940%26doi%3D10.1038%2Fnature09197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basarab, G. S.</span></span> <span> </span><span class="NLM_article-title">Four Ways to Skin a Cat: Inhibition of Bacterial Topoisomerases Leading to the Clinic</span>. In  <i>Topics in Medicinal Chemistry 25 Antibacterials Volume 1</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, J. F.</span>, <span class="NLM_string-name">Miller, M. J.</span>, <span class="NLM_string-name">Mobashery, S.</span></span>, Eds.; <span class="NLM_publisher-name">Springer International Publishing</span>: <span class="NLM_publisher-loc">Cham, Switzerland</span>, <span class="NLM_year">2018</span>; pp  <span class="NLM_fpage">165</span>– <span class="NLM_lpage">188</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&pages=165-188&author=G.+S.+Basarabauthor=J.+F.+Fisher&author=M.+J.+Miller&author=S.+Mobashery&title=Topics+in+Medicinal+Chemistry+25+Antibacterials+Volume+1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DBasarab%26aufirst%3DG.%2BS.%26atitle%3DFour%2520Ways%2520to%2520Skin%2520a%2520Cat%253A%2520Inhibition%2520of%2520Bacterial%2520Topoisomerases%2520Leading%2520to%2520the%2520Clinic%26btitle%3DTopics%2520in%2520Medicinal%2520Chemistry%252025%2520Antibacterials%2520Volume%25201%26aulast%3DFisher%26aufirst%3DJ.%2BF.%26pub%3DSpringer%2520International%2520Publishing%26date%3D2018%26spage%3D165%26epage%3D188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerns, E. H.</span></span> <span> </span><span class="NLM_article-title">The Effect of Plasma Protein Binding on in Vivo Efficacy: Misconceptions in Drug Discovery</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">929</span>– <span class="NLM_lpage">939</span>, <span class="refDoi"> DOI: 10.1038/nrd3287</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1038%2Fnrd3287" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=21119731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsV2jurfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=929-939&author=D.+A.+Smithauthor=L.+Diauthor=E.+H.+Kerns&title=The+Effect+of+Plasma+Protein+Binding+on+in+Vivo+Efficacy%3A+Misconceptions+in+Drug+Discovery&doi=10.1038%2Fnrd3287"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery</span></div><div class="casAuthors">Smith, Dennis A.; Di, Li; Kerns, Edward H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">929-939</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Data from in vitro plasma protein binding expts. that det. the fraction of protein-bound drug are frequently used in drug discovery to guide structure design and to prioritize compds. for in vivo studies.  However, we consider that these practices are usually misleading, because in vivo efficacy is detd. by the free (unbound) drug concn. surrounding the therapeutic target, not by the free drug fraction.  These practices yield no enhancement of the in vivo free drug concn.  So, decisions based on free drug fraction could result in the wrong compds. being advanced through drug discovery programs.  This Perspective provides guidance on the application of plasma protein binding information in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOa3ippodhGbVg90H21EOLACvtfcHk0lh9sdwf4yQlSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsV2jurfI&md5=a45d00f68ab44580fa38a6acef49493a</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1038%2Fnrd3287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3287%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DDi%26aufirst%3DL.%26aulast%3DKerns%26aufirst%3DE.%2BH.%26atitle%3DThe%2520Effect%2520of%2520Plasma%2520Protein%2520Binding%2520on%2520in%2520Vivo%2520Efficacy%253A%2520Misconceptions%2520in%2520Drug%2520Discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26spage%3D929%26epage%3D939%26doi%3D10.1038%2Fnrd3287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van
den Bergh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilissen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Straetemans, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wuyts, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bijnens, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackie, C.</span></span> <span> </span><span class="NLM_article-title">Prediction of Human Oral Plasma Concentration-Time Profiles Using Preclinical Data</span>. <i>Clin. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">505</span>– <span class="NLM_lpage">517</span>, <span class="refDoi"> DOI: 10.2165/11587230-000000000-00000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.2165%2F11587230-000000000-00000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=21740074" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1WmtbbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2011&pages=505-517&author=A.+Van%0Aden+Berghauthor=V.+Sinhaauthor=R.+Gilissenauthor=R.+Straetemansauthor=K.+Wuytsauthor=D.+Morrisonauthor=L.+Bijnensauthor=C.+Mackie&title=Prediction+of+Human+Oral+Plasma+Concentration-Time+Profiles+Using+Preclinical+Data&doi=10.2165%2F11587230-000000000-00000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of human oral plasma concentration-time profiles using preclinical data: Comparative evaluation of prediction approaches in early pharmaceutical discovery</span></div><div class="casAuthors">Van den Bergh, An; Sinha, Vikash; Gilissen, Ron; Straetemans, Roel; Wuyts, Koen; Morrison, Denise; Bijnens, Luc; Mackie, Claire</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">505-517</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Wolters Kluwer Health</span>)
        </div><div class="casAbstract">Background and Objectives: Empirically based methods remain one of our tools in human pharmacokinetic predictions.  The Dedrick approach and the steady-state plasma drug concn. (Css)-mean residence time (MRT) approach are based on the assumption that concn.-time profiles are similar among species, including man, and that curves derived from a variety of animal species can be superimposed after math. transformation.  In the Dedrick approach the transformation is based on the slope and intercept of the allometric relationship.  The Css-MRT approach is based on the implementation of measured animal and predicted human MRT and dose/vol. of distribution at steady state (Vss).  The aims of the present study were to compare the predictive performance of concn.-time profiles obtained by these approaches, to evaluate the prediction of individual pharmacokinetic parameters by these approaches and to further refine these approaches incorporating the experience from our previous work.  Methods: A retrospective anal. using 35 proprietary compds. developed at Johnson & Johnson Pharmaceutical Research and Development was conducted to compare the accuracies of the Dedrick and Css-MRT approaches for predicting oral concn.-time profiles and pharmacokinetic parameters in man.  In the first step, input for the transformation was based on simple allometry.  Then we assessed whether both methods could be fine-tuned by systematically incorporating correction factors (max. life span potential, brain wt. and plasma protein binding), depending on the interspecies relationship.  In addn., for the Css-MRT approach, we used formulas based on multivariate regression anal. as input for the transformation.  Results: Inclusion of correction factors significantly improved the profile predictability for the Dedrick and Css-MRT approaches.  This was mainly linked to an improved prediction of terminal elimination half-life (t1/2), MRT and the ratio between the max. plasma concn. and the concn. at the last obsd. time point (Cmax/Clast).  No significant differences were obsd. between the Dedrick approach with correction factors, the Css-MRT approach with correction factors and the Css-MRT approach, based on the regression equations.  Conclusions: Based on the dataset evaluated in this study, we demonstrated that human plasma concn.-time profiles and pharmacokinetic parameters could be predicted with the Dedrick and Css-MRT approaches and that if correction factors were implemented, the predictions improved significantly.  With the requirement of only a limited preclin. in vivo pharmacokinetic dataset, these empirical methods could offer potential in the early stages of drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKYttKxUygj7Vg90H21EOLACvtfcHk0lh9sdwf4yQlSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1WmtbbP&md5=31a5bf80ffb713d74c87787deccba085</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.2165%2F11587230-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F11587230-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2Bden%2BBergh%26aufirst%3DA.%26aulast%3DSinha%26aufirst%3DV.%26aulast%3DGilissen%26aufirst%3DR.%26aulast%3DStraetemans%26aufirst%3DR.%26aulast%3DWuyts%26aufirst%3DK.%26aulast%3DMorrison%26aufirst%3DD.%26aulast%3DBijnens%26aufirst%3DL.%26aulast%3DMackie%26aufirst%3DC.%26atitle%3DPrediction%2520of%2520Human%2520Oral%2520Plasma%2520Concentration-Time%2520Profiles%2520Using%2520Preclinical%2520Data%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2011%26volume%3D50%26spage%3D505%26epage%3D517%26doi%3D10.2165%2F11587230-000000000-00000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peters, S. A.</span></span> <i>Physiologically-Based Pharmacokinetic (PBPK) Modeling and Simulations: Principles, Methods, and Applications in the Pharmaceutical Industry</i>, <span class="NLM_edition">1</span>st ed.; <span class="NLM_publisher-name">John Wiley & Sons, Inc.</span>: <span class="NLM_publisher-loc">Hoboken, NJ</span>, <span class="NLM_year">2012</span>; pp  <span class="NLM_fpage">407</span>– <span class="NLM_lpage">421</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1002%2F9781118140291.app1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=407-421&author=S.+A.+Peters&title=Physiologically-Based+Pharmacokinetic+%28PBPK%29+Modeling+and+Simulations%3A+Principles%2C+Methods%2C+and+Applications+in+the+Pharmaceutical+Industry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1002%2F9781118140291.app1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9781118140291.app1%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DS.%2BA.%26btitle%3DPhysiologically-Based%2520Pharmacokinetic%2520%2528PBPK%2529%2520Modeling%2520and%2520Simulations%253A%2520Principles%252C%2520Methods%252C%2520and%2520Applications%2520in%2520the%2520Pharmaceutical%2520Industry%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26date%3D2012%26spage%3D407%26epage%3D421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doherty, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fellows, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donovan, M.</span></span> <span> </span><span class="NLM_article-title">A Rapid, Semi-Automated Method for Scoring Micronuclei in Mononucleated Mouse Lymphoma Cells</span>. <i>Mutat. Res. Genet. Toxicol. Environ. Mutagen</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>726</i></span>,  <span class="NLM_fpage">36</span>– <span class="NLM_lpage">41</span>, <span class="refDoi"> DOI: 10.1016/j.mrgentox.2011.08.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=10.1016%2Fj.mrgentox.2011.08.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht12rurvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=726&publication_year=2011&pages=36-41&author=A.+T.+Dohertyauthor=J.+Hayesauthor=M.+Fellowsauthor=S.+Kirkauthor=M.+O%E2%80%99Donovan&title=A+Rapid%2C+Semi-Automated+Method+for+Scoring+Micronuclei+in+Mononucleated+Mouse+Lymphoma+Cells&doi=10.1016%2Fj.mrgentox.2011.08.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">A rapid, semi-automated method for scoring micronuclei in mononucleated mouse lymphoma cells</span></div><div class="casAuthors">Doherty, Ann T.; Hayes, Julie; Fellows, Mick; Kirk, Sarah; O'Donovan, Mike</div><div class="citationInfo"><span class="NLM_cas:title">Mutation Research, Genetic Toxicology and Environmental Mutagenesis</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">726</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">36-41</span>CODEN:
                <span class="NLM_cas:coden">MRGMFI</span>;
        ISSN:<span class="NLM_cas:issn">1383-5718</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A semi-automated scoring system has been developed to provide rapid, accurate assessment of micronuclei in prepns. of mononuclear mouse lymphoma L5178Y cells.  Following exposure to a range of test agents, flat, single-cell prepns. were produced from exponentially growing cultures by cytocentrifugation.  Following staining with 4'-6-diamidino-2-phenylindole (DAPI), cells were scanned by use of the MicroNuc module of Metafer 4 v 3.4.102, after modifying the classifier developed for selecting micronuclei in binucleate cells to increase its sensitivity.  The image gallery of all cells was then sorted to bring aberrant cells to the top of the gallery to assess visually the nos. of cells with micronuclei, as distinct from other debris.  Slide quality was shown to be paramount in obtaining accurate results from an automated scan and the data obtained compared very well with the incidence of micronuclei scored conventionally by microscopy.  Compared with manual scoring the time saving is considerable, as more than 2000 images are captured in approx. 2 min, with subsequent visual assessment of aberrant cells in the image gallery taking about 1-2 min/slide.  By scanning all aberrant cells, the system also captures addnl. information on necrotic, apoptotic and fragmented cells.  Although optimized for mouse lymphoma cells, it should be simple to adapt the method for any cell type growing in suspension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVN4Bt_LDuxbVg90H21EOLACvtfcHk0ljPMYu0KcZoFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht12rurvI&md5=0e85329ca1060c131ed364bdcfa00d2d</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.mrgentox.2011.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mrgentox.2011.08.002%26sid%3Dliteratum%253Aachs%26aulast%3DDoherty%26aufirst%3DA.%2BT.%26aulast%3DHayes%26aufirst%3DJ.%26aulast%3DFellows%26aufirst%3DM.%26aulast%3DKirk%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Donovan%26aufirst%3DM.%26atitle%3DA%2520Rapid%252C%2520Semi-Automated%2520Method%2520for%2520Scoring%2520Micronuclei%2520in%2520Mononucleated%2520Mouse%2520Lymphoma%2520Cells%26jtitle%3DMutat.%2520Res.%2520Genet.%2520Toxicol.%2520Environ.%2520Mutagen%26date%3D2011%26volume%3D726%26spage%3D36%26epage%3D41%26doi%3D10.1016%2Fj.mrgentox.2011.08.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Clinical
and Laboratory Standards
Institute</span>.  <i>M07 Methods for Dilution
Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically;
Approved Standard</i>, <span class="NLM_edition">42</span>nd ed.; <span class="NLM_publisher-name">Clinical and Laboratory Standards Institute</span>: <span class="NLM_publisher-loc">Wayne, PA</span>, <span class="NLM_year">2012</span>; p  <span class="NLM_fpage">88</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=Clinical%0Aand+Laboratory+Standards%0AInstitute&title=M07+Methods+for+Dilution%0AAntimicrobial+Susceptibility+Tests+for+Bacteria+That+Grow+Aerobically%3B%0AApproved+Standard"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DM07%2520Methods%2520for%2520Dilution%250AAntimicrobial%2520Susceptibility%2520Tests%2520for%2520Bacteria%2520That%2520Grow%2520Aerobically%253B%250AApproved%2520Standard%26pub%3DClinical%2520and%2520Laboratory%2520Standards%2520Institute%26date%3D2012%26spage%3D88" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Clinical
and Laboratory Standards
Institute</span>.  <i>Performance Standards for
Antimicrobial Susceptibility Testing; Twenty-Fourth Informational
Supplement (M100-S24)</i>; <span class="NLM_publisher-name">Clinical and Laboratory
Standards Institute</span>: <span class="NLM_publisher-loc">Wayne, PA</span>, <span class="NLM_year">2014</span>; p  <span class="NLM_fpage">10</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=Clinical%0Aand+Laboratory+Standards%0AInstitute&title=Performance+Standards+for%0AAntimicrobial+Susceptibility+Testing%3B+Twenty-Fourth+Informational%0ASupplement+%28M100-S24%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DPerformance%2520Standards%2520for%250AAntimicrobial%2520Susceptibility%2520Testing%253B%2520Twenty-Fourth%2520Informational%250ASupplement%2520%2528M100-S24%2529%26pub%3DClinical%2520and%2520Laboratory%250AStandards%2520Institute%26date%3D2014%26spage%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CDM" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CDM','PDB','5CDM'); return false;">PDB: 5CDM</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i92"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01100">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_28317"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01100?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01100</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Correlation between DNA gyrase inhibitor potency and antibacterial activity; Alignment of GyrB inhibitor binding domain; Alignment of GyrB from <i>S. aureus</i>, <i>S. pneumoniae</i>, <i>H. influenzae</i>, <i>S. pyogenes</i>, and <i>E. coli</i>; and LC–MS for lead compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01100/suppl_file/jm0c01100_si_001.pdf">PDF</a>)</p></li><li><p class="inline">PDB files for the DNA gyrase binding models of <b>11l</b> utilized for <a id="rightTab-" class=" internalNav" href="#fig5">Figure <a id="rightTab-" class=" internalNav" href="#fig5">5</a></a> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01100/suppl_file/jm0c01100_si_002.pdb">PDB</a>)</p></li><li><p class="inline">PDB files for the DNA gyrase binding models of <b>11r</b> utilized for <a id="rightTab-" class=" internalNav" href="#fig5">Figure <a id="rightTab-" class=" internalNav" href="#fig5">5</a></a> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01100/suppl_file/jm0c01100_si_003.pdb">PDB</a>)</p></li><li><p class="inline">Molecular formula strings and associated biological data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01100/suppl_file/jm0c01100_si_004.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01100/suppl_file/jm0c01100_si_001.pdf">jm0c01100_si_001.pdf (1.07 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01100/suppl_file/jm0c01100_si_002.pdb">jm0c01100_si_002.pdb (123.41 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01100/suppl_file/jm0c01100_si_003.pdb">jm0c01100_si_003.pdb (123.71 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01100/suppl_file/jm0c01100_si_004.csv">jm0c01100_si_004.csv (4.92 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01100&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01100%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-20%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01100" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679978ebacae3cbe","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
